Forside til Testrapporter

596 DMT

Restriction - in use

Pesticide **Dimethoate. -. / Omethoate - 1113,02,6 -**

Subject **Toxicology**

Author **Mellert, W., Deckardt, K., Kaufmann, W., van Ravenzwaay, B. (2003)**

Laboratory **BASF Aktiengesellschaft, Experimental Toxicology and Ecology**

Title: **Omethoate - Acute oral neurotoxicity Study in Wistar Rats; Single administration by Gavage.**

Project No. **'20C0709/01098**

Report No.: **'O-541-004**

Study date: **2003.12.04**

No. of pages/Volumes: **752 / 2**

Other information:

Report Language: **English**

Other Report Languages:

Work print necessary:? **Yes**

Workprint filed:?

MC Necessary:? **Yes**

MC filed:?

Original filed:?

Amendments / Supplements information:

Date

Date received

Submissions:

Country:

Agency:

Date:

MRID:

Status:

MASTERKOPI

STUDY

Report

Omethoate – Acute oral neurotoxicity study in Wistar rats; single administration by gavage

DATA REQUIREMENT

U.S. EPA OPPTS 870.6200
OECD 424

AUTHORS

Dr. W. Mellert (Study Director)
Dr. K. Deckardt
Dr. W. Kaufmann
Dr. B. van Ravenzwaay

STUDY COMPLETED ON

December 4, 2003

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 20C0709/01098

SPONSOR

Dimethoate Task Force (DTF)
c/o P. Hofmann
Wotanstr. 39
D-68305 Mannheim, Germany

VOLUME I OF III
(REPORT SECTION AND SUMMARY TABLES)

Confidentiality Statement
This report is property of the Dimethoate Task Force with its member companies BASF, Cheminova, and Isagro. This report (752 pages) should not be communicated to third parties, reproduced or published in any form without the proprietors' explicit written authorization.

This page is intentionally left blank for statements by the sponsor or submitter

GLP COMPLIANCE STATEMENT

This study was conducted in accordance with the OECD Principles of Good Laboratory Practice as revised in 1997 [ENV/MC/CHEM(98)17] and the GLP Principles of the German "Chemikaliengesetz" [Chemicals Act, "Bundesgesetzblatt", Part I, No. 40 (June 27, 2002)].

There were no circumstances which may have affected the quality or integrity of the data.

Mun, Dec. 04, 2003
.....
Dr. med. vet. W. Mellert
(Study Director)

This page is intentionally left blank for statements by the sponsor or submitter

SIGNATURE PAGE

Study Director: Dec 04, 2003
Dr. med. vet. W. Mellert

Clinical Pathology: Deckardt, Dec 03, 2003
Dr. phil. nat. K. Deckardt

Pathology: , Dec. 03, 2003
Dr. med. vet. W. Kaufmann

Management: 04 Dec 2003
Dr. rer. nat. B. van Ravenzwaay

Study monitor:

SCC Scientific Consulting Company
Chemisch-Wissenschaftliche Beratung GmbH
Mikroforum Ring 1
D-55234 Wendelsheim, Germany

STATEMENT

of the Quality Assurance Unit

The Quality Assurance Unit (QAU) inspected the study and reported any inspection results to the Study Director and to Management.

The final report reflects the raw data.

Phase of study	Date of inspection (mm-dd-yyyy)	Reported to Study Director and to Management (mm-dd-yyyy)
Study Plan:	10-07-2002	10-07-2002
Conduct of study:	10-23-2002	10-23-2002
	10-29-2002	10-29-2002
	11-07-2002	11-07-2002
	12-11-2002	12-11-2002
Report:	05-15-2003	05-15-2003

Ludwigshafen, Dec. 04, 2003

Hajok

RheinlandPfalz

Landesanstalt
für Pflanzenbau und Pflanzenschutz

GLP-Bescheinigung / Statement of GLP Compliance

(gemäß / according to § 19 b Abs. 1 Chemikaliengesetz)

Eine GLP-Inspektion zur Überwachung der Einhaltung der GLP-Grundsätze gemäß Chemikaliengesetz bzw. Richtlinie 88/320/EG wurde durchgeführt in:

Assessment of conformity with GLP according to Chemikaliengesetz and Directive 88/320/EEC at:

☒ Prüfeinrichtung / Test facility ☐ Prüfstandort / Test site

BASF Aktiengesellschaft
Experimentelle Toxikologie und Ökologie
D-67056 Ludwigshafen

Prüfungen nach Kategorien / Areas of Expertise
(gemäß/according ChemVwV-GLP Nr. 5.3/OECD guidance)

.....1,2,3,4,5,8,9.....

Datum der Inspektion / Date of Inspection

.....15.05.2001 und vom 21. bis 26.06.2001.....

Die/Der genannte Prüfeinrichtung/Prüfstandort befindet sich im nationalen GLP-Überwachungsverfahren und wird regelmäßig auf Einhaltung der GLP-Grundsätze überwacht.

Auf der Grundlage des Inspektionsberichtes wird hiermit bestätigt, dass in dieser Prüfeinrichtung/diesem Prüfstandort die oben genannten Prüfungen unter Einhaltung der GLP-Grundsätze durchgeführt werden können.

The above mentioned test facility/test site is included in the national GLP-Compliance Programme and is inspected on a regular basis.

Based on the inspection report it can be confirmed, that this test facility/test site is able to conduct the aforementioned studies in compliance with the Principles of GLP.

Schiestinger 24. Sept. 2001

Unterschrift, Datum / Signature, Date

(Name und Funktion der verantwortlichen Person / Name and function of responsible person)

Landesanstalt für Pflanzenbau und Pflanzenschutz Rheinland-Pfalz 1 (Siegel) Mainz

CONTENTS OF VOLUME I (REPORT SECTION AND SUMMARY TABLES)

Part A:
CLINICAL EXAMINATIONS (MEAN VALUES AND SUMMARY TABLES)

Part B:
CLINICAL PATHOLOGY (MEAN VALUES AND SUMMARY TABLES)

Part C:
PATHOLOGY (MEAN VALUES AND SUMMARY TABLES)

CONTENTS OF VOLUME II (TABLES SECTION; INDIVIDUAL VALUES)

Part B:
CLINCAL PATHOLOGY (INDIVIDUAL VALUES)

Part C:
PATHOLOGY (INDIVIDUAL VALUES)

CONTENTS OF VOLUME III (SUPPLEMENT)

1. SUMMARY

Omethoate was administered to groups of 25 male and 25 female Wistar rats as a single oral administration by gavage at dose levels of 0 (vehicle control), 0.2, 0.25, 0.35 and 5 mg/kg body weight. The vehicle used was doubly distilled water and the administration volume was 5 ml/kg body weight.

The dose groups were split into 3 subsets

- Subset A: 10 animals per sex and dose; cholinesterase determination before administration and about 2.5 h after administration.
- Subset B: 10 animals per sex and dose; cholinesterase determination before administration and on day 15; functional observational battery (FOB) and motor activity measurement on days –7, 0 (about 2 h after administration), 7 and 14
- Subset C: 5 animals per sex and dose; Functional observational battery (FOB) and motor activity measurement on days –7, 0 (about 2 h after administration), 7 and 14; in situ perfusion and neuropathological examinations.

No mortalities and no adverse effects were noted with regard to food consumption, body weight, absolute and relative organ weights, gross lesion, and neuropathology at any time point up to the highest dose tested.

The following substance-related effects were observed on the day of test substance administration on **day 0** (about 2 h after administration, time to peak effect):

Test group 4 (5 mg/kg bw)
Functional observation battery:

- 1 male showed frequent chewing in the home cage
- 1 female showed squatting posture in the home cage
- 1 male showed no resistance against the handling but appears indifferent
- 2 males and 1 female showed urine staining of anogenital region
- 1 male showed accelerated respiration
- 3 males and 2 females showed irregular respiration
- 8 males and 9 females showed slight tremors
- 2 males and 2 females showed frequent chewing
- 1 female showed stiff gait
- 9 males and 11 female showed slight impairment of coordination, unsteady gait
- 1 female showed moderate impairment of coordination, shuffling gait
- 3 males and 2 females showed reduced exploration of the area
- 2 males showed soft feces
- 7 males and 9 females showed retarded adaptation of the pupil to light
- 8 males and 5 females showed no adaptation of the pupils to light, pupils permanently contracted
- rearing was statistically significantly decreased in females
- grip strength of forelimbs and hindlimbs was significantly decreased in females

Motor activity:
- motor activity was decreased in males and females

Clinical pathology:
- marked decrease of serum, erythrocyte and brain-cholinesterase-activity in males (54%, 77% an 81% inhibition) and in females (41%, 75% and 80% inhibition) 2.5 hours after treatment

Test group 3 (0.35 mg/kg bw)
Functional observation battery:
- 1 male showed accelerated respiration
- 1 male showed irregular respiration
- 1 female showed slight impairment of co-ordination, unsteady gait
- 1 male and 2 females showed retarded adaptation of the pupil to light
- 1 male showed no adaptation of the pupil to light, pupils permanently contracted

Clinical pathology:
- slight but biologically relevant decrease of brain cholinesterase activity (27% inhibition) in females 2.5 hours after treatment

Test group 2 (0.25 mg/kg bw)
Functional observation battery:
- 2 males and 2 females showed retarded adaptation of the pupil to light
- 1 male showed no adaptation of the pupil to light, pupils permanently contracted

Test group 1 (0.2 mg/kg bw)
- no substance-related effects

On **days 7 and 14**, no biologically relevant effects were observed with regard to any parameter investigated. Thus, all findings obtained were fully reversible.

In conclusion, administration of 5 mg/kg bw caused abnormal clinical signs and a marked inhibition of cholinesterase activities in serum, erythrocytes and brain of male and female animals. At 0.35 mg/kg bw, a few animals showed abnormal clinical signs with regard to respiration, co-ordination and pupil reflex. At this dose level, a slight but biologically relevant decrease of brain cholinesterase activity was found in females.

No toxicologically relevant effects were observed in the animals of the 0.2 mg/kg bw and 0.25 mg/kg bw groups, but changes of pupil reflex were observed in two females and two males at 0.25 mg/kg bw. The changes of pupil reflex were only noted in a few animals at 0.25 and 0.35 mg/kg bw, but without any dose-relationship. In parallel no biologically relevant cholinesterase inhibition or other relevant clinical signs like effects on respiration or impairment of co-ordination as observed at 0.35 mg/kg bw were noted at 0.25 mg/kg bw. Thus, the **no observed adverse effect level (NOAEL) in this study is 0.25 mg/kg bw.**

2. INTRODUCTION AND DOSE SELECTION

2.1. AIM OF THE STUDY

The aim of the study was to determine a possible neurotoxicity of the test substance after single administration by gavage to Wistar rats. Moreover, the influence on cholinesterase in serum, erythrocytes and brain was examined.

2.2. SELECTION OF DOSES

On request of the sponsor, dose levels of 0, 0.2, 0.25, 0.35 and 5 mg/kg body weight were tested based on the result obtained in dose range-finding studies.

2.3. TEST GUIDELINES

- EPA Health Effects Test Guidelines; OPPTS 870.6200; Neurotoxicity Screening Battery
- OECD Guideline 424: Neurotoxicity study in rodents

As required in the test guidelines, positive control studies have been performed by BASF. Summaries of these studies are given in volume III of this report. The studies demonstrated the ability to detect signs of neurotoxicity and have been assigned MRID numbers by the US-EPA (see Volume III).

3. MATERIALS AND METHODS

3.1. TEST SUBSTANCE

Name of test substance:	Omethoate
Test substance No.:	01/0709-1
CAS No.:	1113-02-6
IUPAC name:	O,O-Dimethyl-S-[2-(methylamino)-2-oxoethyl] phosphorothioate
Batch No.:	676-BSe-74B
Date of production:	Unknown
Expiry date:	10/2004
Physical state/ Appearance:	Liquid/ pale yellow
Purity:	96.5%
Homogeneity:	Homogeneous on account of the high purity
Stability:	Until 10/2004
Storage conditions:	Freezer (≤ -18°C), light protection

The analyses of the test substance were carried out by Cheminova Agro A/S, Lemvig, Denmark. Test substance data sheet and Batch Analytical Certificate can be found in Volume III.

3.2. TEST ANIMALS

3.2.1. Species and strain

Male and female Wistar rats [CrlGlxBrlHan: WI] were supplied by Charles River, Sulzfeld, Germany. Only animals free from clinical signs of disease were used for the study.

3.2.2. Animal identification

The rats were identified clearly by ear tattoo. The animals were tattooed in consecutive order after arrival and before randomization.

3.2.3. Reason for species selection

Rats are frequently used laboratory animals, and there is comprehensive experience with this animal species. Moreover, the rat has been proposed as a suitable animal species by the OECD and the EPA for this type of study. Wistar rats were used as all positive control data for neurotoxicity were performed with this strain.

3.3. HOUSING AND DIET

The rats were housed in a non-barrier animal house singly in type DK III stainless steel wire cages from Becker & Co., Castrop-Rauxel, Germany (floor area about 800 cm^2). Underneath the cages, waste trays were fixed containing absorbent material (type 3/4 dustfree embedding, supplied by SSNIFF, Soest, Germany).

The motor activity measurements were conducted in Polycarbonate cages with wire covers from Ehret, Emmendingen, Germany (floor area about 800 cm^2) and small amounts of absorbent material (see above).

The animals were housed in a completely air-conditioned room in which a central air-conditioner ensured temperatures in the range 20 - 24°C and relative humidities in the range 30 - 70%. The day/night rhythm was 12 hours (12 hours light from 6:00 a.m. - 6:00 p.m., 12 hours dark from 6:00 p.m. - 6:00 a.m.). Deviations from these ranges did not occur. The air exchange was tenfold per hour. The room was completely disinfected using a disinfector ("AUTEX", fully automatic, formalin-ammonia-based terminal disinfector, supplied by Dr. Gruß KG, Neuss, Germany) before the start of the study. The walls and the floor were cleaned once a week, in each case using water containing 0.1% Incidin ® (supplied by Henkel, Düsseldorf, Germany).

The food used was ground Kliba maintenance diet rat/mouse/hamster, pellets, supplied by Provimi Kliba SA, Kaiseraugst, Switzerland. Food and drinking water (from water bottles) were available ad libitum.

3.4. TEST GROUPS AND DOSES / CONCENTRATIONS

The dose groups were split into 3 subsets.

- Subset A: 10 animals per sex and dose; cholinesterase determination before administration and about 2.5 h after administration.
- Subset B: 10 animals per sex and dose; cholinesterase determination before administration and on day 15; functional observational battery (FOB) and motor activity measurement on days –7, 0 (about 2 h after administration), 7 and 14
- Subset C: 5 animals per sex and dose; Functional observational battery (FOB) and motor activity measurement on days –7, 0 (about 2 h after administration), 7 and 14; in situ perfusion and neuropathological examinations.

Table 1: Test groups male animals

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
0 / A	0 [2)] (vehicle control)	10	23	1
			46	2
			17	3
			45	4
			19	5
			51	6
			7	7
			33	8
			14	9
			32	10
0 / B		10	75	11
			65	12
			70	13
			68	14
			69	15
			102	16
			105	17
			86	18
			93	19
			97	20
0 / C		5	239	21
			222	22
			226	23
			228	24
			238	25

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight
[2)] vehicle control: doubly distilled water

Table 1: Test groups male animals (continued)

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
1 / A	0.2	10	3	26
			35	27
			1	28
			5	29
			30	30
			37	31
			25	32
			42	33
			15	34
			41	35
1 / B		10	53	36
			60	37
			63	38
			79	39
			59	40
			95	41
			100	42
			84	43
			101	44
			88	45
1 / C		5	233	46
			216	47
			220	48
			231	49
			219	50
2 / A	0.25	10	43	51
			22	52
			2	53
			48	54
			34	55
			38	56
			52	57
			29	58
			36	59
			44	60
2 / B		10	77	61
			78	62
			55	63
			62	64
			76	65
			81	66
			99	67
			94	68
			90	69
			96	70

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight

Table 1: Test groups male animals (continued)

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
2 / C	0.25	5	215 237 218 213 224	71 72 73 74 75
3 / A	0.35	10	10 4 8 16 50 47 28 24 11 18	76 77 78 79 80 81 82 83 84 85
3 / B	0.35	10	73 57 72 56 74 85 103 83 91 106	86 87 88 89 90 91 92 93 94 95
3 / C		5	225 227 230 232 221	96 97 98 99 100
4 / A	5	10	21 31 12 49 40 13 26 9 20 27	101 102 103 104 105 106 107 108 109 110

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight

Table 1: Test groups male animals (continued)

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
4 / B	5	10	66 64 54 71 58 92 104 87 98 82	111 112 113 114 115 116 117 118 119 120
4 / C	5	5	229 236 235 217 214	121 122 123 124 125

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight

Table 2: Test groups female animals

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
0 / A	0 [2)] (vehicle control)	10	144	126
			110	127
			128	128
			109	129
			157	130
			152	131
			129	132
			126	133
			120	134
			125	135
0 / B		10	181	136
			180	137
			173	138
			162	139
			184	140
			211	141
			201	142
			194	143
			198	144
			202	145
0 / C		5	243	146
			261	147
			264	148
			266	149
			244	150
1 / A	0.2	10	143	151
			150	152
			108	153
			145	154
			131	155
			149	156
			118	157
			136	158
			130	159
			116	160
1 / B		10	167	161
			161	162
			170	163
			175	164
			185	165
			193	166
			186	167
			212	168
			209	169
			188	170

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight
[2)] vehicle control: doubly distilled water

Table 2: Test groups female animals (continued)

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
1 / C	0.2	5	241 242 246 245 257	171 172 173 174 175
2 / A	0.25	10	111 141 140 142 155 153 114 148 113 122	176 177 178 179 180 181 182 183 184 185
2 / B		10	168 159 160 183 177 210 195 196 200 197	186 187 188 189 190 191 192 193 194 195
2 / C		5	240 265 258 254 259	196 197 198 199 200
3 / A	0.35	10	138 115 146 119 134 156 137 154 112 151	201 202 203 204 205 206 207 208 209 210

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight

Table 2: Test groups female animals (continued)

Dose group / Subset	Dose in mg/kg body weight[1)]	Number of animals	Animal No.	Cage No.
3 / B	0.35	10	163	211
			176	212
			174	213
			179	214
			171	215
			204	216
			203	217
			192	218
			191	219
			190	220
3 / C		5	263	221
			248	222
			255	223
			260	224
			250	225
4 / A	5	10	147	226
			107	227
			158	228
			123	229
			124	230
			133	231
			117	232
			139	233
			121	234
			132	235
4 / B		10	165	236
			164	237
			166	238
			178	239
			182	240
			207	241
			208	242
			187	243
			206	244
			205	245
4 / C		5	253	246
			251	247
			247	248
			262	249
			252	250

[1)] The doses refer to the body weight of each individual animal determined on day 0; administration volume was 5 ml/kg body weight

3.5. TEST SUBSTANCE PREPARATION AND ANALYSES

3.5.1. Preparation

The test substance was administered as a solution in doubly distilled water and freshly prepared each time immediately before the administration. The appropriate amount of test substance was weighed, depending on the dose group. Then doubly distilled water was filled up to the desired volume and the preparations were dissolved by shaking the flasks.

3.5.2. Analyses

The analyses of the test substance preparations were carried out at the Analytical Chemistry Laboratory of the Experimental Toxicology and Ecology of BASF Aktiengesellschaft (see Volume III).

Homogeneity analysis of the high and low dose and a concentration control analysis of the mid doses were carried out at the start of the study. The homogeneity analyses served also as concentration control.

The stability of the test substance in doubly distilled water over a period of 4 hours at room temperature was verified before the start of the study (see analytical report, Volume III, Supplement).

3.5.2.1. Analytical methods

The methods used for the analytical investigations of the test substance preparations can be found in VOLUME III (Supplement).

3.5.3. Food analyses

The food used in the study (batch 52/02) was assayed for chemical and microbiological contaminants. The data for the used batch are presented in Volume III.

3.5.4. Drinking water analyses

The drinking water is regularly assayed for chemical contaminants by the municipal authorities of Frankenthal and the Technical Services of BASF Aktiengesellschaft as well as for the presence of microorganisms by a contract laboratory. The respective data are presented in Volume III.

3.5.5. Bedding analyses

The bedding is regularly assayed for contaminants (chlorinated hydrocarbons and heavy metals). The respective data are presented in Volume III. The batch(es) used in this study are covered with these analyses.

3.6. EXPERIMENTAL PROCEDURE AND TIME SCHEDULE

On the day of arrival, an acclimatization period started in which the animals were accustomed to housing and diet. The animals were tattooed in consecutive order after arrival and before randomization. Prior to the first functional observational battery the animals were randomly assigned to the groups based upon body weight and separated by sex. The weight variation of the animals used did not exceed 10 percent of the mean weight of each sex. The randomization list was drawn up by a computer.

In order to balance the groups, the study was conducted with 3 subsets (Subset A males, Subset A females, Subset B males part 1, Subset B females part 1, Subset B males part 2, Subset B females part 2, Subset C males and Subset C females). Within each subset, animals of control and four dose groups were tested again in randomized order. The randomization list was drawn up by a computer (laboratory data processing, Experimental Toxicology and Ecology, BASF Aktiengesellschaft).

Thus it was ensured, that

- all animals were examined within the same time after dosing. Time of testing was therefore identical for all animals;
- for each examination day animals from all test groups (including controls) could be examined in parallel;
- the examinations for all subsets could be performed on the same time of the day, thus diurnal effects could be neglected.

As the study was conducted with 3 Subsets (A, B and C male and female animals respectively) the animals were delivered on Oct. 08, 2002 at an age of 35 days (Subset A males), 34 days (Subset A females), 36 days (Subset B males part 1), 35 days (Subset B females part 1), 34 days (Subset B males part 2), 33 days (Subset B females part 2), and on Nov. 12, 2002 at an age of 35 days (Subset C males) and 34 days (Subset C females), (+/- 1 day) respectively. Thus it was ensured that all animals were 49 days (+/- 1 day) old at the day of the test substance administration (i.e. day 0 for each subset; see time tables below).

The animals of the different groups received the corresponding doses once by gavage. The animals of the control group received the vehicle, only. The administration volume was 5 ml/kg body weight. The doses were administered using syringes (3 cc Syringe; Fa. Becton Dickinson & Co., USA).

Functional observational batteries and motor activity measurements were carried out, in all animals of subsets B and C, prior to the test substance administration (day -7), on the day of administration (day 0, about 2 hours after administration), and 7 and 14 days after dosing. Gavage was performed at about 8.00 a.m., FOBs were performed each time from about 10.00 a.m. and motor activity measurements were conducted each time after the FOBs.

At the end of the study the 5 animals per sex and dose of Subset C were sacrificed by perfusion fixation. The remaining animals of Subset A and B were sacrificed under Isoflo® (Essex GmbH München, Germany) anesthesia. The brain was removed for determination of brain cholinesterase. No further examinations were performed.

Due to the high number of animals, subset C first started after termination of subsets A and B and subset B is divided in 2 parts per sex (first 5 animals and second 5 animals per sex and dose).

The study was performed according to the following time schedules:

Table 3: Time schedules

Subset A (males)	Subset A (females)	Phase of study / examination	Day of study
Oct. 08, 2002	Oct. 08, 2002	Experimental starting date: arrival of the animals and start of acclimatization period. Age of the animals: 35(±1) days 34(±1) days	-14 –15
Oct. 10, 2002	Oct. 10, 2002	Randomization	-12 –13
Oct. 16, 2002	Oct. 17, 2002	Blood sampling	-6
Oct. 22, 2002	Oct. 23, 2002	Test substance administration, blood sampling and necropsy[1] about 2.5h after administration	0

1 = Before necropsy no fasting period

Table 3: Time schedules (continued)

Subset B (males, part 1)	Subset B (females, part 1)	Subset B (males, part 2)	Subset B (females, part 2)	Phase of study / examination	Day of study
Oct. 08, 2002	Oct. 08, 2002	Oct. 08, 2002	Oct. 08, 2002	Arrival of the animals and beginning of the experimental phase: Age of the animals: 36(±1) days 35(±1) days 34(±1) days 33(±1) days	 -13 -14 -15 -16
Oct. 10, 2002	Oct. 10, 2002	Oct. 10, 2002	Oct. 10, 2002	Randomization	-11 -12 -13 -14
Oct. 14, 2002	Oct. 15, 2002	Oct. 16, 2002	Oct. 17, 2002	FOB1; M1/M2 FOB2; M3/M4 FOB3; M5/M6 FOB4; M7/M8	-7
Oct. 18, 2002	Oct. 18, 2002	Oct. 18, 2002	Oct. 18, 2002	Blood sampling	-3 -4 -5 -6
Oct. 21, 2002	Oct. 22, 2002	Oct. 23, 2002	Oct. 24, 2002	Test substance administration	0
Oct. 21, 2002	Oct. 22, 2002	Oct. 23, 2002	Oct. 24, 2002	FOB5; M9/M10 FOB6; M11/M12 FOB7; M13/M14 FOB8; M15/M16	0
Oct. 28, 2002	Oct. 29, 2002	Oct. 30, 2002	Oct. 31, 2002	FOB9; M17/M18 FOB10; M19/M20 FOB11; M21/M22 FOB12; M23/M24	7
Nov. 04, 2002	Nov. 05, 2002	Nov. 06, 2002	Nov. 07, 2002	FOB13; M25/M26 FOB14; M27/M28 FOB15; M29/M30 FOB16; M31/M32	14
Nov. 05, 2002	Nov. 06, 2002	Nov. 07, 2002	Nov. 08, 2002	Blood sampling and necropsy[1]	15

1 = Before necropsy no fasting period
FOB = Functional observational battery
M = Measurement of motor activity
1 ... 32 = Identification No. of the specific examination

Table 3: Time schedules (continued)

Subset C (males)	Subset C (females)	Phase of study / examination	Study day
Nov. 12, 2002	Nov. 12, 2002	Arrival of the animals Age of the animals: 35(±1) days 34(±1) days	 -14 -15
Nov. 14, 2002	Nov. 14, 2002	Randomization	-12 -13
Nov. 19, 2002	Nov. 20, 2002	FOB17; M33/M34 FOB18; M35/M36	-7
Nov. 26, 2002	Nov. 27, 2002	Test substance administration	0
Nov. 26, 2002	Nov. 27, 2002	FOB19; M37/M38 FOB20; M39/M40	0
Dec. 03, 2002	Dec. 04, 2002	FOB21; M41/M42 FOB22; M43/M44	7
Dec. 10, 2002	Dec. 11, 2002	FOB23; M45/M46 FOB24; M47/M48	14
Dec. 11, 2002	Dec. 12, 2002	Perfusion fixation[1]	15
Dec. 2002 – April 2003		Evaluation and reporting	
April 29, 2003		Experimental completion date: Draft report to QAU	

1 = Before necropsy no fasting period

FOB = Functional observational battery
M = Measurement of motor activity
17... 48 = Identification No. of the specific examination

3.7. CLINICAL EXAMINATIONS

3.7.1. General clinical observations

The general state of health of the animals was checked twice a day (Monday to Friday) and once a day (Saturdays, Sundays and public holidays). Furthermore, the animals were examined carefully once each working day, except on the days when functional observational batteries were carried out.

3.7.2. Food consumption

Food consumption was determined weekly and calculated as mean food consumption in grams per animal and day.

3.7.3. Water consumption

Water consumption was observed daily by visual inspection of the water bottles for any overt changes in volume.

3.7.4. Body weight data

The body weight was determined before the first functional observational battery in order to randomize the animals. During the conduct of the study, the body weight was determined weekly and additionally on the days when functional observational batteries were carried out (days –7, 0, 7 and 14) for the relevant animals. The difference between the body weight on the respective day of weighing and the body weight on day 0 was calculated as body weight change.

3.7.5. Functional observational battery (FOB)

FOBs were performed in all animals of subsets B and C once before the administration (day -7), and on day 0 (about 2 hours after dosing) as well as 7 and 14 days after administration. The FOBs started with passive observations without disturbing the animals, followed by removal from the home cage and open field observations in a standard arena. Thereafter, sensorimotor tests and reflex tests were conducted. The examinations were carried out by trained technicians who performed positive control studies as part of their training[1]. The findings were ranked according to the degree of severity, if applicable.

In order to guarantee the blind status of the observer, the cages were randomly distributed in the racks at least 30 minutes before the examinations, and the cage labels

[1] see Volume III

(indicating the dose group) were turned. Thus only the animal number, but not the allocation of the animals to the different dose groups could be identified by the observer. Moreover, the examinations were carried out in randomized order. The findings and values obtained were documented by another technician knowing the identification of the animals. A detailed description of the methods, the ranking and documentation system can be found in Volume III (Supplement).

Home cage observations:

The animals were observed in their closed home cages; any disturbing activities (touching the cage or rack, noise) were avoided during these examinations in order not to influence the behavior of the animals. Besides all other overt abnormal findings, special attention was paid to:

1. posture
2. tremor
3. convulsions
4. abnormal movements
5. impairment of gait

Open field observations:

The animals were transferred to a standard arena (50 x 50 cm with sides of 25 cm high) and observed for at least 2 minutes. Following parameters were examined:

1. behavior when removed from cage
2. fur
3. skin
4. salivation
5. nose discharge
6. lacrimation
7. eyes/pupil size
8. posture
9. palpebral closure
10. respiration
11. tremors
12. convulsions
13. abnormal movements/stereotypics
14. impairment of gait
15. activity/arousal level
16. feces (number of fecal pellets/appearance/consistency) within two minutes
17. urine (volume/color) within two minutes
18. number of rearings within two minutes

Sensorimotor Tests/Reflexes:

The animals were removed from the open field and subjected to following sensorimotor or reflex tests:

1. approach response
2. touch response
3. vision (visual placing response)
4. pupillary reflex
5. pinna reflex
6. audition (startle response)
7. coordination of movements (righting response)
8. behavior during handling
9. vocalization
10. pain perception (tail pinch)
11. grip strength of forelimbs
12. grip strength of hindlimbs
13. landing foot-splay test

3.7.6. Motor activity assessment

Motor activity was measured on the same day as FOB was performed in all animals of subsets B and C. The measurement was performed in the dark using the Multi-Varimex-System (Columbus Instruments Int. Corp., Ohio, USA) with 4 infrared beams per cage (placed on the longer side of the cage at a height of about 5 cm and at equal distances of about 10 cm). During the measurement the animals were kept in Polycarbonate cages with absorbent material. The cages were cleaned prior to each use. The animals were put into the cages in a randomized order. The measurements started immediately after the FOBs and the number of beam interrupts were counted over 12 intervals, each lasting 5 minutes. Measurement did not commence at the same instant for all cages; the period of assessment for each animal started when the first beam was interrupted by pushing the cage into the rack (staggered start). Measurements ended exactly 60 minutes thereafter. During the measurements the animals received no food and no water.

3.7.7. Statistics of clinical examinations

Means and standard deviations of each test group were calculated for several parameters (see tables). Further statistical analyses were performed according to following tables:

Parameters	Statistical test	Markers in the tables	References
Food consumption, body weight and body weight change	A comparison of each group with the control group was performed using DUNNETT's test (two-sided) for the hypothesis of equal means	* for p = 0.050 ** for p = 0.010	DUNNETT, C.W. (1955): A multiple comparison procedure for comparing several treatments with a control. JASA, Vol. 50, 1096 - 1121 DUNNETT, C.W. (1964): New tables for multiple comparisons with a control. Biometrics, Vol. 20, 482 – 491
Feces, rearing, grip strength forelimbs, grip strength hind-limbs, landing foot-splay test, motor activity for the time intervals	Non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pairwise comparison of the dose groups with the control group was performed using WILCOXON-test (two-sided) for the hypothesis equal medians	* for p = 0.050 ** for p = 0.010	SIEGEL, S. (1956): Non-parametric statistics for the behavioural sciences. McGraw-Hill New York

Due to technical reasons, on the tables the following markers are given:
* = 0.050 = * for $p \leq 0.05$
** = 0.010 = ** for $p \leq 0.01$

3.8. CLINICAL PATHOLOGY

Blood samples were taken from the retroorbital venous plexus of non fasted animals before treatment, 2.5 hours after treatment or about two weeks after test substance administration, respectively. For blood sampling the animals were anaesthetized using isoflurane (Isoflo®, Essex GmbH, Munich, Germany) as anesthesia. The blood sampling procedure and the subsequent analysis of the blood and serum samples were carried out in a randomized sequence. The list of randomization instructions was compiled with a computer. The following parameters were examined:

3.8.1. Cholinesterase

- Hematocrit

  In order to calculate red blood cell cholinesterase activity per liter erythrocytes the hematocrit value was determined in blood with EDTA-K_3 as anticoagulant using a particle counter (Technicon H 1 E model; Bayer, Munich, FRG):

  Method:

Parameter	Unit	Method	References
Hematocrit (HCT)	l/l	calculation: MCV x erythrocytes	Operator's Guide for Technicon H 1 E System

- Serum cholinesterase (modified Ellman method with **DTNB** as color reagent):

  Blood was collected in serum gel tubes without anticoagulant and transferred under ice cooling into the clinical-pathology laboratory. To separate the serum, the samples were centrifuged for 2 minutes (3,000 x g, 4 °C). The serum cholinesterase activity was determined within 2 hours after blood sampling.

- Erythrocyte cholinesterase (modified Ellman method with **DTNA** as color reagent):

  50 µl blood was pipetted in 2.5 ml ice-cold isotonic sodium chloride and mixed immediately. Subsequently the samples were transferred under ice cooling to the laboratory. The erythrocytes were isolated by centrifugation (3,000 x g, 4 °C, 15 minutes). The supernatant was discarded and the retained red blood cells were lysated with Triton-buffer (0.1% Triton) for 1 hour under continuous ice cooling. The hemolysate was analyzed for cholinesterase activity within 3 hours after blood sampling.

- Brain cholinesterase (modified Ellman method with **DTNB** as color reagent):

  The left hemisphere was kept on ice directly after necropsy, frozen within 1 hour at approximately -80°C and stored for about a week before analysis. After thawing the samples about 0.2 g cortex was separated from the truncus cerebri and immediately homogenized in Triton-buffer (0.75%) under ice cooling. After centrifugation (1,500 x g, 4 °C, 5 minutes) the cholinesterase activity and protein content was measured in the supernatant at the same day.

  An automatic analyzer (Cobas Fara II; Hoffmann LaRoche, Grenzach, FRG) was used to measure the cholinesterase activities.

  Methods:

Enzyme (systematic name and system number)	**Unit**	**Method, wave-length and measuring temperature**	**References**
Serum-cholinesterase (SCHE) (acylcholinacylhydrolase; EC 3.1.1.7.)	µkat/l	kinetic color test, 412 nm, 37°C	Federal Register. 1996, April 26, 61,18593; Environmental Protection Agency (EPA) [OPP-00432; FRL-5364-5] „Standard operating procedure for measuring cholinesterases in laboratory rats and dogs exposed to non-reversible cholinesterase inhibitors“
Erythrocyte-cholinesterase (ECHE) (acylcholinacyl-hydrolase; EC 3.1.1.7.)	µkat/l eryth-rocytes	kinetic UV test, 343 nm, 37°C	
Brain-cholinesterase (BCHE) (acylcholinacylhydrolase; EC 3.1.1.7.)	µkat/g protein	kinetic color test, 412 nm, 37°C	Wilson, B.W. et al.,J. Toxicol. Env. Health 48, 187-195 (1996), " Factors in standardizing automated cholinesterase assays

- Protein in brain homogenate

  In order to calculate the specific cholinesterase activity in the brain, the protein concentrations were determined in the supernatant of the brain homogenate.

  An automatic analyzer (Hitachi 917; Roche, Mannheim, FRG) was used to examine the protein level.

  Method:

Blood Chemistry Parameter	**Unit**	**Method**	**References**
Total protein (TPROT)	g/l	biuret method	Weichselbaum, T.E., Amer. J. Clin. Path. 10, 40 (1946); Roche working instructions

Cholinesterase determination was carried out according to the recommendations of the EPA, 1996, and WHO, 1998.

3.8.2. Statistics of clinical pathology

Means and standard deviations of each test group were calculated for several parameters (see tables).

Further statistical analyses were performed according to following tables:

Parameter	Statistical test	Markers in the tables	References
Clinical pathology parameters	A non-parametric comparison of each dose group with the control was performed simultaneously using Steel´s test (two-sided) for the hypothesis of equal medians	* for $p \leq 0.05$ ** for $p \leq 0.01$	Steel R.G.D., Biometrics 15, 560-572 (1959), "A multiple comparison rank sum test: treatment versus control."

Due to technical reasons, on some tables the following markers are given:
* = 0.050 = * for $p \leq 0.05$
** = 0.010 = ** for $p \leq 0.01$

3.9. NEUROPATHOLOGY

3.9.1. Necropsy

3.9.2. Necropsy (animals not selected for perfusion fixation)

The animals not selected for perfusion fixation were sacrificed by decapitation under Isoflo®-anesthesia (Essex GmbH Munich). For determination of the cholinesterase, the brain of the exsanguinated animals was removed.

3.9.3. Necropsy (animals selected for perfusion fixation)

The five surviving animals per sex and test group that are selected for neuropathology, were deeply anesthetized (Narcoren®, about 4 ml/kg body weight) at the end of the study and sacrificed by perfusion fixation using a perfusion pump.

SOERENSEN's phosphate buffer served as rinsing solution and the fixation solution according to KARNOVSKY served as fixative (Karnovsky, 1965).

The sacrificed animals were necropsied and the visible organs assessed by gross pathology as thoroughly as possible for perfused animals. The organ/tissue samples listed in paragraphs below were carefully removed.

3.9.3.1. Weight parameters

Weight assessment of the brain (without olfactory bulb) was carried out on all perfused animals after removal of the brain but before any further preparation.

3.9.3.2. Organ / tissue preservation list

Additionally to organ/ tissues listed in paragraphs below, the following organs/tissues were preserved in neutral buffered 4% formaldehyde:

1. Brain (remaining material after trimming)
2. Spinal cord (parts of cervical and lumbar cord)

The remaining organ material and the animal body were also stored in neutral buffered 4% formaldehyde solution.

3.9.3.3. Plastic embedding, sectioning, staining and storage

The following samples were processed histotechnically according to the table below:

Organ samples from:	Test groups (dose)				
	0	1	2	3	4
	control	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
Peripheral nervous system:					
– Dorsal root ganglion, 3 of (C3-C6)	T5	P5	P5	P5	T5
– Dorsal root fiber (C3-C6)	T5	P5	P5	P5	T5
– Ventral root fiber (C3-C6)	T5	P5	P5	P5	T5
– Dorsal root ganglion, 3 of (L1-L4)	T5	P5	P5	P5	T5
– Dorsal root fiber (L1-L4)	T5	P5	P5	P5	T5
– Ventral root fiber (L1-L4)	T5	P5	P5	P5	T5
– Proximal sciatic nerve	T5	P5	P5	P5	T5
– Proximal tibial nerve (at knee)	T5	P5	P5	P5	T5
– Distal tibial nerve (at lower leg)	T5	P5	P5	P5	T5

METHODS/SCOPE OF EXAMINATIONS:

T = Plastic embedding (epoxy resin), semithin sectioning and staining with Azure II-Methylene blue-basic Fuchsin (AMbf)

P = Storage of fixed specimen in buffer solution

5 = all perfused animals per group and sex

The semithin sections were examined light-microscopically and assessed.

3.9.3.4. Paraffin embedding, sectioning, staining and preservation

The following organ samples were processed histotechnically according to the table below:

Organ samples from:	Test groups (dose)				
	0	1	2	3	4
	control	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
Brain (cross sections):		F5*	F5*	F5*	
– Frontal lobe	A5				A5
– Parietal lobe with diencephalon and hippocampus	A5				A5
– Midbrain with occipital and temporal Lobe	A5				A5
– Pons	A5				A5
– Cerebellum	A5				A5
– Medulla oblongata	A5				A5
Brain-associated organs/tissues					
– Eyes with retina and optical nerve	A5	F5	F5	F5	A5
Spinal cord (cross and longitudinal sections):					
– Cervical swelling (C3-C6)	A5	F5	F5	F5	A5
– Lumbar swelling (L1-L4)	A5	F5	F5	F5	A5
Peripheral nervous system:					
– Gasserian ganglia with nerve	A5	F5	F5	F5	A5
– Gastrocnemius muscle	A5	F5	F5	F5	A5

METHODS/SCOPE OF EXAMINATIONS:

A = Paraffin embedding (paraplast), sectioning and staining with hematoxylin-eosin (H & E)

F = Preservation in 4% formaldehyde

5 = all perfused animals per group and sex

* = in toto

The hematoxylin-eosin stained sections were examined light-microscopically and assessed.

3.9.4. Statistics of Neuropathology

Parameters	Statistical test	Markers in the tables	References
Weight parameters	Non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using the WILCOXON test for the hypothesis of equal medians	* for $p \leq 0.05$ ** for $p \leq 0.01$	HETTMANNSPERGER, T.P. (1984):Statistical Inference based on Ranks, John Wiley & Sons New York, 132-140. International Mathematical and Statistical Libraries, Inc., 2500 Park West Tower One, Houston, Texas 77042-3020, USA, nakl-1 - nakl-3 MILLER, R.G. (1981): Simultaneous Statistical Inference Springer-Verlag New York Inc., 165-167 NIJENHUIS, A. and S.W. WILF (1978): Combinatorial Algorithms, Academic Press, New York, 32-33

3.10. RETENTION OF RECORDS

GLP – relevant records and materials are stored at BASF Aktiengesellschaft for at least the period of time specified in the GLP principles. Details concerning responsibilities or locations of archiving can be seen from the respective SOPs and from the raw data.

No data will be withdrawn without the sponsors prior written consent.

4. RESULTS AND ASSESSMENT OF FINDINGS

Remark: Throughout the result sections, when intergroup differences are referred to as "significant" it implies that the differences have attained statistical significance ($p \leq 0.05$) when compared with the control group.

4.1. ANALYSES

4.1.1. Stability

The stability of the test substance in doubly distilled water over a period of 4 hours at room temperature was proven prior to the study. The recovery of the initial value was $\geq$96.5% (see Volume III).

4.1.2. Homogeneity/Concentration control analyses

Considering the low standard deviation in the homogeneity analysis, it can be concluded that Omethoate was distributed homogeneously in doubly distilled water.
The analytical concentration control values were 90.8 - 97.3% of the nominal concentrations. These results demonstrated also the correctness of the concentrations (details see Volume III).

4.1.3. Food analyses

On the basis of duration of use and the analytical findings with respect to chemical and microbiological contaminants the food was found to be suitable. Fed. Reg. Vol. 44, No. 91 of May 9, 1979, p. 27354 (EPA), served as a guideline for maximum tolerable chemical contaminants. The number of microorganisms did not exceed $5x10^5$/g food. Individual results are to be found in the archives of the Experimental Toxicology and Ecology of BASF Aktiengesellschaft. (Translation of the certificate of food analyses batch 52/02 see Volume III).

4.1.4. Drinking water analyses

On the basis of the analytical findings the drinking water was found to be suitable. German Drinking Water Regulation (Trinkwasserverordnung, Bundesgesetzblatt, December 5, 1990) served as a guideline for maximum tolerable contaminants. Individual results are to be found in the archives of the Experimental Toxicology and Ecology of BASF Aktiengesellschaft. (Translation of the certificate of water analyses see Volume III).

4.1.5. Bedding analyses

On the basis of the analytical findings the bedding was found to be suitable. Levels given in Lab. Animal, Nov. – Dec 1979, pp. 24 – 33, served as a guideline for maximum tolerable contaminants. Individual results are to be found in the archives of the Experimental Toxicology an Ecology of BASF Aktiengesellschaft. (Translation of the certificate of bedding analyses see Volume III). The batch(es) used in this study are covered with these analyses.

4.2. CLINICAL EXAMINATIONS

Summary tables of the results are given in the Appendix of VOLUME I; individual values are given in Part A of VOLUME II.

4.2.1. Mortality

No animal died during the study.

4.2.2. General clinical observations
(Tables IA-001 - IA-005)

Subset A (10 animals per sex and group):
In the high dose group, the following findings were seen during general clinical observations on day 0 about 2h after the test substance administration: 3 males and 3 females showed apathy (slight), 1 male showed visually increased respiration (slight), 1 female showed frequent chewing and 2 female animals showed tremor (slight).

Subset B and C (15 animals per sex and group; examination only on the days when no FOB was performed):
1 female of group 3 (0.35 mg/kg body weight) showed a skin lesion on day 15. This was clearly incidental. As the animals of subsets B and C were thoroughly examined during the FOBs (see below), the findings mentioned above for subset A are not further discussed in detail.

4.2.3. Food consumption
(Tables IA-006 - IA-007)

No substance-related findings were obtained.

4.2.4. Body weight data
(Tables IA-008 - IA-013)

No substance-related findings were obtained.

4.2.5. Functional observational battery (FOB)

The results are summarized in the tables 4-11. Only parameters affected/showing variations are reported, details are given in tables: IA-014 - IA-069.

Table 4: FOB Day –7, Males (for details see table IA-014 - IA-020)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	13	12	12	13	14
Posture	1	Animal is staying and moving	2	3	3	2	1
Impairment of gait	0	Animal is not walking during observation	13	12	12	13	14
Impairment of gait	1	No impairment of gait	2	3	3	2	1
OPEN FIELD OBSERVATIONS							
Feces	0	No defecation during observation period	11	6	8	7	8
Urine	0	No urination during observation period	7	10	11	7	12
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	10	10	10	13	10
Approach response	1	Approaching to object	5	5	5	2	5
Touch response	0	No reaction	15	15	14	15	15
Touch response	1	Orientation to the stimulus	0	0	1	0	0

Table 5: Day 0, Males (for details see table IA-021 - IA-027)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	13	12	12	9	15
Posture	1	Animal is staying and moving	2	3	3	6	0
Abnormal movements	4	frequent chewing	0	0	0	0	1
Impairment of gait	0	Animal is not walking during observation	13	12	12	9	15
Impairment of gait	1	No impairment of gait	2	3	3	6	0
OPEN FIELD OBSERVATIONS							
Behavior when removed from cage	2	Animals shows no resistance against the handling but appears indifferent	0	0	0	0	1
Fur	2	urine staining of anogenital region	0	0	0	0	2
Palpebral closure	1	eyelid(s) slight closure	0	0	0	1*)	0
Respiration	3	respiration accelerated	0	0	0	1	1
Respiration	4	respiration irregular	0	0	0	1	3
Tremors	1	sight tremors	0	0	0	0	8
Abnormal movements/ Stereotypy	4	frequent chewing	0	0	0	0	2
Impairment of gait	1	no impairment of gait	15	15	15	15	6
Impairment of gait	3	slight impairment of coordination, unsteady gait	0	0	0	0	9
Activity	1	reduced exploration of the area	0	1	2	0	3
Feces	0	No defecation during observation period	10	5	8	6	8
Feces	4	soft feces	0	0	0	0	2
Urine	0	No urination during observation period	7	9	6	8	4

*) Eyelid right

Table 5: Day 0, Males (for details see table IA-021 - IA-027) (continued)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	5	6	8	11	13
Approach response	1	Approaching to object	10	9	7	4	2
Touch response	0	No reaction	13	14	13	15	15
Touch response	1	Orientation to the stimulus	2	1	2	0	0
Pupillary reflex	1	retarded adaptation of the pupil to light	0	0	2	1	7
Pupillary reflex	2	no adaptation of the pupil to light, pupils permanently contracted	0	0	1	1	8

Table 6: Day 7, Males (for details see table IA-028 - IA-034)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	10	11	9	10	10
Posture	1	Animal is staying and moving	5	4	6	5	5
Impairment of gait	0	Animal is not walking during observation	10	11	9	10	10
Impairment of gait	1	No impairment of gait	5	4	6	5	5
OPEN FIELD OBSERVATIONS							
Posture	0	animal is sitting or lying	0	0	0	0	1
Posture	1	animal is staying and moving	15	15	15	15	14
Impairment of gait	0	animal is not walking during observation	0	0	0	0	1
Impairment of gait	1	no impairment of gait	15	15	15	15	14
Activity/ Arousal level	1	reduced exploration of the area	0	0	0	0	1
Feces	0	No defecation during observation period	10	9	7	10	4
Urine	0	No urination during observation period	11	8	7	6	4
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	7	9	6	8	8
Approach response	1	Approaching to object	8	6	9	7	7
Touch response	0	No reaction	14	15	13	15	13
Touch response	1	Orientation to the stimulus	1	0	2	0	2
Vocalization	1	very frequent vocalizations when touched	0	0	1	0	0

Table 7: Day 14, Males (for details see table IA-035 - IA-041)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	8	10	6	7	7
Posture	1	Animal is staying and moving	7	5	9	8	8
Impairment of gait	0	Animal is not walking during observation	8	10	6	7	7
Impairment of gait	1	No impairment of gait	7	5	9	8	8
OPEN FIELD OBSERVATIONS							
Feces	0	No defecation during observation period	13	11	10	8	7
Urine	0	No urination during observation period	11	9	6	11	9
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	6	5	6	8	6
Approach response	1	Approaching to object	9	10	9	7	9
Touch response	0	No reaction	13	12	14	14	15
Touch response	1	Orientation to the stimulus	2	3	1	1	0

Table 8: Day -7, Females (for details see table IA-042 - IA-048)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	11	11	11	9	7
Posture	1	Animal is staying and moving	4	4	4	6	8
Impairment of gait	0	Animal is not walking during observation	11	11	11	9	7
Impairment of gait	1	No impairment of gait	4	4	4	6	8
OPEN FIELD OBSERVATIONS							
Feces	0	No defecation during observation period	12	15	14	14	13
Urine	0	No urination during observation period	7	10	9	7	9
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	8	7	7	7	8
Approach response	1	Approaching to object	7	8	8	8	7
Touch response	0	No reaction	15	14	14	13	14
Touch response	1	Orientation to the stimulus	0	1	1	2	1

Table 9: Day 0, Females (for details see table IA-049 - IA-055)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	9	10	11	9	14
Posture	1	Animal is staying and moving	6	5	4	6	0
Posture	2	squatting posture	0	0	0	0	1
Impairment of gait	0	Animal is not walking during observation	9	10	11	9	15
Impairment of gait	1	No impairment of gait	6	5	4	6	0
OPEN FIELD OBSERVATIONS							
Fur	2	urine staining of anogenital region	0	0	0	0	1
Respiration	4	respiration irregular	0	0	0	0	2
Tremors	1	slight tremors	0	0	0	0	9
Abnormal movements/ Stereotypics	4	frequent chewing	0	0	0	0	2
Impairment of gait	1	no impairment of gait	15	15	15	14	2
Impairment of gait	2	stiff gait	0	0	0	0	1
Impairment of gait	3	slight impairment of co-ordination, unsteady gait	0	0	0	1	11
Impairment of gait	4	moderate impairment of co-ordination, shuffling gait	0	0	0	0	1
Activity/ Arousal level	1	reduced exploration of the area	0	0	0	0	2
Activity/ Arousal level	3	increased exploration of area, sudden or jerky movements	0	0	0	1	0
Feces	0	No defecation during observation period	15	12	13	12	15
Urine	0	No urination during observation period	11	13	11	8	7

Table 9: Day 0, Females (for details see table IA-049 - IA-055) (continued)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	7	4	7	9	9
Approach response	1	Approaching to object	8	11	8	6	6
Touch response	0	No reaction	13	13	15	15	15
Touch response	1	Orientation to the stimulus	2	2	0	0	0
Pupillary reflex	1	retarded adaptation of the pupil to light	0	0	2	2	9
Pupillary reflex	2	no adaptation of the pupil to light, pupils permanently contracted	0	0	0	0	5
Vocalization	1	very frequent vocalization when touched	0	0	1	0	0
Vocalization	2	vocalization always when touched	0	0	0	1	0

Table 10: Day 7, Females (for details see table IA-056 - IA-062)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	7	5	4	7	6
Posture	1	Animal is staying and moving	8	10	11	8	9
Impairment of gait	0	Animal is not walking during observation	7	5	4	7	6
Impairment of gait	1	No impairment of gait	8	10	11	8	9
OPEN FIELD OBSERVATIONS							
Feces	0	No defecation during observation period	14	14	13	13	15
Urine	0	No urination during observation period	6	8	7	8	9
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	7	9	9	8	6
Approach response	1	Approaching to object	8	6	6	7	9
Touch response	0	No reaction	13	12	12	12	12
Touch response	1	Orientation to the stimulus	2	3	3	3	3

Table 11: Day 14, Females (for details see table IA-063 - IA-069)

Observation-category	Ranking	Finding	No. of affected animals				
			0 mg/kg bw	0.2 mg/kg bw	0.25 mg/kg bw	0.35 mg/kg bw	5 mg/kg bw
HOME CAGE OBSERVATION							
Posture	0	Animal is sitting or lying	2	5	4	3	5
Posture	1	Animal is staying and moving	13	10	11	12	10
Impairment of gait	0	Animal is not walking during observation	2	5	4	3	5
Impairment of gait	1	No impairment of gait	13	10	11	12	10
OPEN FIELD OBSERVATIONS							
Feces	0	No defecation during observation period	15	15	15	14	15
Urine	0	No urination during observation period	9	10	9	7	9
SENSORIMOTOR TESTS/REFLEXES							
Approach response	0	No reaction	5	6	7	6	6
Approach response	1	Approaching to object	10	9	8	9	9
Touch response	0	No reaction	14	13	13	14	14
Touch response	1	Orientation to the stimulus	1	2	2	1	1

Assessment of results:

"Reduced exploration of the area" was seen in 2 males treated with 0.25 mg/kg bw and in 1 male treated with 0.2 mg/kg bw. This effect was also seen at the high dose level and is most likely a consequence of the impairment of motor activity at this dose level (see below). In contrast, as no impairment of motor activity was seen at the lower dose levels and as no clear dose-response relationship (no effect seen at 0.35 mg/kg bw) was observed, the "reduced exploration of the area" seen at the lower dose levels was assessed as being incidental.

Findings on day 0 (about 2 h after administration)

The following findings on day 0 were assessed as being treatment-related:

Test group 4 (5 mg/kg bw)

Home cage observation:
- 1 male showed frequent chewing
- 1 female showed squatting posture

Open field observations:
- 1 male showed no resistance against the handling but appears indifferent
- 2 males and 1 female showed urine staining of anogenital region
- 1 male showed accelerated respiration
- 3 males and 2 females showed irregular respiration
- 8 males and 9 females showed slight tremors
- 2 males and 2 females showed frequent chewing
- 1 female showed stiff gait
- 9 males and 11 female showed slight impairment of co-ordination, unsteady gait
- 1 female showed moderate impairment of co-ordination, shuffling gait
- 3 males and 2 females showed reduced exploration of the area
- 2 males showed soft feces

Sensorimotor tests/reflexes:
- 7 males and 9 females showed retarded adaptation of the pupil to light
- 8 males and 5 females showed no adaptation of the pupils to light, pupils permanently contracted

Test group 3 (0.35 mg/kg bw)

Open field observations:
- 1 male showed accelerated respiration
- 1 male showed irregular respiration
- 1 female showed slight impairment of co-ordination, unsteady gait

Sensorimotor tests/reflexes:
- 1 male and 2 females showed retarded adaptation of the pupil to light
- 1 male showed no adaptation of the pupils permanently contracted

Test group 2 (0.25 mg/kg bw)

Sensorimotor tests/reflexes:
- 2 males and 2 females showed retarded adaptation of the pupil to light
- 1 male showed no adaptation of the pupil to light, pupils permanently contracted

Test group 1 (0.2 mg/kg bw)

No effects

Findings on day 7 and day 14
All findings seen on day 7 and day 14 were assessed as being incidental and not treatment-related.

Feces, Rearing, Grip strength, Landing foot-splay test:
(Tables IA-070 - IA-079)

Rearing (see Table 12) was significantly decreased in high dose females on day 0. This was assessed as being treatment-related.

Table 12: Rearing

	Day 0		Day 7		Day 14	
	Male	Female	Male	Female	Male	Female
0 mg/kg bw	1.5	9.9	1.9	9.3	3.7	8.3
0.20 mg/kg bw	2.7	9.3	2.3	7.9	4.8	10.1
0.25 mg/kg bw	1.9	8.5	1.9	6.5	3.9	10.3
0.35 mg/kg bw	1.6	7.2	2.3	7.4	2.5	8.2
5.00 mg /kg bw	0.5	2.7**	1.7	6.3	2.9	8.7

* = $p \leq 0.05$; ** = $p \leq 0.01$

Grip strength of forelimbs (see Table 13) was significantly decreased in high dose females on day 0. This was assessed as being treatment-related.

Table 13: Grip strength of forelimbs

	Day 0		Day 7		Day 14	
	Male	Female	Male	Female	Male	Female
0 mg/kg bw	4.3	4.4	4.5	4.3	4.8	4.5
0.20 mg/kg bw	4.3	4.4	4.6	4.7	4.8	5.0
0.25 mg/kg bw	4.6	4.3	4.5	4.8	4.7	4.7
0.35 mg/kg bw	4.4	4.4	4.6	4.8	4.9	4.7
5.00 mg /kg bw	4.4	3.8*	4.5	4.6	4.6	4.5

* = $p \leq 0.05$; ** = $p \leq 0.01$

Grip strength of hindlimbs (see Table 14) was significantly decreased in high dose females on day 0. This was assessed as being treatment-related.

Table 14: Grip strength of hindlimbs

	Day 0		Day 7		Day 14	
	Male	Female	Male	Female	Male	Female
0 mg/kg bw	2.9	2.3	3.0	2.9	3.2	2.9
0.20 mg/kg bw	2.8	2.4	3.0	2.9	3.1	3.1
0.25 mg/kg bw	3.0	2.5	3.0	3.0	3.0	3.1
0.35 mg/kg bw	2.7	2.3	3.1	2.9	3.2	3.3
5.00 mg /kg bw	2.7	1.7**	3.0	2.7	3.0	2.8

* = $p \leq 0.05$; ** = $p \leq 0.01$

No significant deviations were seen concerning *feces and foot-splay test.*

4.2.6. Motor activity measurement
(Figures 3 - 10; Tables IA-080 - IA-095)

In high dose males and females, motor activity was clearly reduced on day 0. The summation of interval 1-12 (see Table 15) as well as the individual intervals 1-5 in males and intervals 1-6 in females were significantly lower than controls. This was assessed as being treatment-related.

Table 15: Motor activity summation of interval 1-12

	Day 0		Day 7		Day 14	
	Male	Female	Male	Female	Male	Female
0 mg/kg bw	172.4	225.2	193.4	205.3	213.4	218.4
0.20 mg/kg bw	206.3	219.5	236.4	203.7	233.3	213.6
0.25 mg/kg bw	181.5	235.5	194.3	236.7	229.9	214.0
0.35 mg/kg bw	202.6	246.1	213.7	236.5	230.9	209.5
5.00 mg /kg bw	99.9**	102.9**	211.1	211.4	235.5	211.7

* = $p \leq 0.05$; ** = $p \leq 0.01$

By contrast, the increased values (summation of interval 1-12) in groups 1, 3 and 4 males on day -7 (i.e., prior to treatment) were clearly incidental.

No effects were noted at day 7 or day 14.

4.3. CLINICAL PATHOLOGY

Summary tables of the results are given in the Appendix of Volume I; individual values are given in Part B of Volume II.

4.3.1. Enzymes
(Tables IB 1 – IB 8)

Remark on biological and toxicological significance of cholinesterase inhibition:
An average cholinesterase inhibition of more than 20% of the control has been usually used as the threshold level for abnormal cholinesterase values by various agencies (World Health Organization (1990), Office of Environmental Health Hazard Assessment Cal/ERA (1993), ACP Minutes (2000), GAGE (1967)). Therefore, in this study the inhibition of cholinesterases less than 20% of the control value is considered not to be a biologically and/or toxicologically significant effect.

Cholinesterase activities before dosing and 2.5 hours after test substance administration (results of subset A)

Before dosing (base-line values, see table 16)
Examinations of serum and erythrocyte cholinesterase activities before test substance administration revealed no significant differences between the control group and the treatment groups in either sex.

Table 16: Cholinesterase activities before dosing

Parameter	Test group 0 0 mg/kg bw	Test group 1 0.20 mg/kg bw	Test group 2 0.25 mg/kg bw	Test group 3 0.35 mg/kg bw	Test group 4 5.00 mg/kg bw
SCHE (males)	12.59	13.18 (5%)	12.76 (1%)	12.55 (0%)	13.33 (6%)
ECHE (males)	34.22	33.06 (-3%)	33.22 (-3%)	35.22(3%)	33.16 (-3%)
SCHE (females)	21.91	24.99 (14%)	25.53 (17%)	24.91 (14%)	24.50 (12%)
ECHE (females)	34.93	35.16 (1%)	36.52 (5%)	32.94 (-6%)	35.24 (1%)

SCHE = Serum cholinesterase (µkat/l serum)
ECHE = Erythrocyte cholinesterase (µkat/l erythrocytes)

2.5 hours after treatment (see table 17)

2.5 hours after test substance administration significantly decreased cholinesterase activities were found in serum, erythrocytes and brain of the high dose animals of either sex. Compared to untreated animals serum cholinesterase activities were reduced by 54% in the males and 41 % in the females, respectively. The decrease in erythrocyte cholinesterase activity was 77% in the high dose males and 75% in the high dose females and brain cholinesterase activities were reduced by about 80% in both sexes. Moreover, a slight, but statistically significant and biologically relevant inhibition in brain cholinesterase activity (-27%) was observed in the females of the 0.35 mg/kg bw group. No toxicologically relevant changes were seen in the other test groups.

Table 17: Cholinesterase activities 2.5 hours after test substance administration

Parameter	Test group 0 0 mg/kg bw	Test group 1 0.20 mg/kg bw	Test group 2 0.25 mg/kg bw	Test group 3 0.35 mg/kg bw	Test group 4 5.00 mg/kg bw
SCHE (males)	11.73	11.78 (0%)	11.56 (-1%)	10.69 (-9%)	5.41** (-54%)
ECHE (males)	31.86	31.51 (-1%)	27.85*(-13%)	26.76*(-16%)	7.22**(-77%)
BCHE (males)	3.87	3.62 (-6%)	3.57 (-8%)	3.14 (-19%)	0.75** (-81%)
SCHE (females)	28.65	27.73 (-3%)	29.86 (4%)	27.21 (-5%)	16.88*(-41%)
ECHE (females)	33.83	31.35 (-7%)	31.08 (-8%)	29.29 (-13%)	8.31**(-75%)
BCHE (females)	4.47	3.83 (-14%)	4.03 (-10%)	3.25*(-27%)	0.89**(-80%)

SCHE = Serum cholinesterase (µkat/l serum)
ECHE = Erythrocyte cholinesterase (µkat/l erythrocytes)
BCHE = Brain cholinesterase (µkat/g protein)
* = $p \leq 0.05$; ** = $p \leq 0.01$

Cholinesterase activities before dosing and 15 days after test substance administration (results of subset B)

Before dosing (base-line values see table 18)
Examinations of serum and erythrocyte cholinesterase activities before test substance administration revealed no significant differences between the control groups and the treatment groups in either sex.

Table 18: Cholinesterase activities before dosing

Parameter	Test group 0 0 mg/kg bw	Test group 1 0.20 mg/kg bw	Test group 2 0.25 mg/kg bw	Test group 3 0.35 mg/kg bw	Test group 4 5.00 mg/kg bw
SCHE (males)	12.00	11.35 (-5%)	12.13 (1%)	12.46 (4%)	13.14 (9%)
ECHE (males)	29.79	32.97 (11%)	33.18 (11%)	35.89 (20%)	34.61 (16%)
SCHE (females)	21.57	21.15 (-2%)	25.03 (16%)	24.83 (15%)	24.79 (15%)
ECHE (females)	37.63	36.22 (-4%)	32.94 (-12%)	36.51 (-3%)	35.65 (-5%)

SCHE = Serum cholinesterase (µkat/l serum)
ECHE = Erythrocyte cholinesterase (µkat/l erythrocytes)

15 days after treatment (see table 19)

15 days after test substance administration no toxicologically relevant effect was observed on serum, erythrocyte and brain cholinesterase activity in the treated animals of either sex.

Table 19: Cholinesterase activities 15 days after test substance administration

Parameter	Test group 0 0 mg/kg bw	Test group 1 0.20 mg/kg bw	Test group 2 0.25 mg/kg bw	Test group 3 0.35 mg/kg bw	Test group 4 5.00 mg/kg bw
SCHE (males)	10.83	10.03 (-7%)	11.30 (4%)	11.04 (2%)	11.73 (8%)
ECHE (males)	30.85	32.44 (5%)	30.58 (-1%)	30.23 (-2%)	28.42 (-8%)
BCHE (males)	3.05	3.04 (0%)	2.89 (-5%)	2.78 (-9%)	2.61 (-14%)
SCHE (females)	31.68	33.33 (5%)	37.18 (17%)	41.70 (32%)	37.04 (17%)
ECHE (females)	31.97	31.84 (0%)	31.59 (-1%)	32.64 (2%)	27.56**(-14%)
BCHE (females)	3.66	4.12 (13%)	3.30 (-10%)	3.60 (-2%)	3.41 (-7%)

SCHE = Serum cholinesterase (µkat/l serum)
ECHE = Erythrocyte cholinesterase (µkat/l erythrocytes)
BCHE = Brain cholinesterase (µkat/g protein)
* = $p \leq 0.05$; ** = $p \leq 0.01$

4.4. PATHOLOGY

Summary tables of the results are to be found in the Appendix of Volume I; individual tables are to be found in Part C of Volume II.

4.4.1. Weight parameters
(IC 1 - 4)

4.4.1.1. Absolute organ weights

There were no statistically significant changes noted.

4.4.1.2. Relative organ weights

There were no statistically significant changes noted.

4.4.2. Gross lesions
(IC 5 - 6)

There were no gross lesions recorded.

4.4.3. Histopathology
(IC 7 - 8)

A single "axonal degeneration" was recorded in the peripheral nerves for one control female, one top dose male and one top dose female. This finding is regarded as incidental or spontaneous in nature and not related to treatment.

5. DISCUSSION AND CONCLUSION

Omethoate was administered to groups of 25 male and 25 female Wistar rats as a single oral administration by gavage at dose levels of 0 (vehicle control), 0.2, 0.25, 0.35 and 5 mg/kg body weight.

FOB and motor activity measurement revealed clear substance-related effects at 5 mg/kg bw on the day of test substance administration (e.g., tremors, frequent chewing, lack of pupil reaction, reduced motor activity) in both sexes. These signs are typical for cholinesterase inhibitors and were reversible within one week after treatment. At 0.35 mg/kg bw few animals showed changes in respiration, impairment of co-ordination and effects on pupil reflex in parallel with a biologically relevant inhibition of brain cholinesterase. At 0.25 mg/kg bw no effects besides some changes with regard to pupil reflex were noted. The changes of pupil reflex were only noted in a few animals at 0.25 and 0.35 mg/kg bw, but without any dose-relationship. In parallel no biologically relevant cholinesterase inhibition or other relevant clinical signs like effects on respiration or impairment of co-ordination as observed at 0.35 mg/kg bw were noted at 0.25 mg/kg bw. The variability and the lack of reliability of such pupil effects is further demonstrated if the findings of the pre-test are taken into account. Under identical test conditions on such effects on pupil reflex were noted at a 20-times higher test dose of 5 mg/kg bw. In contrast, for other toxicologically relevant findings like cholinesterase inhibition or other clinical signs of toxicity, e.g. effects on respiration, the findings in the pre-tests and the main study are in good agreement. At 0.2 mg/kg bw, only one male animal showed a "reduced exploration of the area" which was assessed as being incidental and not treatment-related.

Regarding clinical pathology findings, the administration of 5 mg/kg bw produced marked decreases in serum cholinesterase (54 and 41% inhibition for males and females), erythrocyte cholinesterase (77 and 75% inhibition for males and females) and brain cholinesterase activities (81 and 80% inhibition for males and females) 2.5 hours after treatment. At this time interval a slight but biologically relevant inhibition (27%) of cholinesterase activity was also seen in the brain of the female rats having received 0.35 mg/kg body weight. No effects of biological concern (see remark under item 4.3.1) were seen in cholinesterase determinations of the lower dose groups although statistical differences to the control group were noted. In both sexes erythrocyte and brain cholinesterase activities were more inhibited than serum cholinesterase. 15 days after test substance administration cholinesterase examinations revealed no toxicologically relevant changes in all dose groups of both sexes. Thus, all findings seen at the 2.5-hour time interval were fully reversible within a treatment-free period of 15 days.

Neuropathologically, there were no treatment–related findings. The single occurrence of an "axonal degeneration" in the peripheral nerves of control and treated top dose animals is regarded as incidental or spontaneous in nature.

In conclusion, administration of 5 mg/kg bw caused abnormal clinical signs and a marked inhibition of cholinesterase activities in serum, erythrocytes and brain of male and female animals. At 0.35 mg/kg bw, a few animals showed abnormal clinical signs with regard to respiration, co-ordination and pupil reflex. At this dose level, a slight but biologically relevant decrease of brain cholinesterase activity was found in females.

No toxicologically relevant effects were observed in the animals of the 0.2 mg/kg bw and 0.25 mg/kg bw groups. Thus, the **no observed adverse effect level (NOAEL) in this study is 0.25 mg/kg bw.**

6. REFERENCES

Environmental Health Criteria 104:
"Principles for the Toxicological Assessment of Pesticide Residues in Food"
World Health Organization (WHO), Geneva, pp. 63-65 (1990)

JOWA, L. and HOWD, R.A.:
Draft of "Use of Cholinesterase Inhibition Estimates in Risk Assessment"
Office of Environmental Health Hazard Assessment
Cal/ERA (April 9, 1993)

ACP Minutes of the 276th Meeting on 18 May 2000
Agenda Item 4: Review of Chlorpyrifos-Methyl
The Pesticides Register, Issue 7, July/August 2000

GAGE, J.C.:"The Significance of Blood Cholinesterase Activity Measurements"
Residue Reviews, Vol. 18, 159-173 (1967)
Springer Verlag, Berlin, Heidelberg, New York

Karnovsky, M.J. (1965): A formaldehyde – glutaraldehyde fixative of high osmolality for use in electron microscopy. J. Cell Biol. 27, 137A

7. APPENDIX (FIGURES AND SUMMARY TABLES)

7.1. LIST OF THE ABBREVIATIONS IN TABLES IA

Food Cons.	=	food consumption
anm	=	animal
mg/kg bw	=	milligram per kilogram body weight
BW change	=	body weight change
G, g	=	weight in gram
M	=	mean
SD	=	standard deviation
N	=	number of animals for determining M and SD
p	=	significance level
Rear	=	rearing
Interr.	=	beam interrupts
Interv.	=	interval
%dev	=	percent deviation
FST	=	landing foot-splay test
GSF	=	grip strength forelimbs
GSH	=	grip strength hindlimbs
cm	=	centimeter
sum	=	summary
NC	=	not calculated

Abbreviations/ranking described in the tables of functional observational batteries are explained in Volume III: "Functional observational battery (FOB) Detailed description of examinations, ranking and documentation procedures".

7.2. LIST TO THE ABBREVIATIONS USED IN TABLES IB

CLINICAL PATHOLOGY:

SD	=	standard deviation
N	=	number of values
%dev	=	deviation in percent
SCHE	=	serum-cholinesterase
ECHE	=	erythrocyte-cholinesterase
BCHE	=	brain-cholinesterase
µkat/l E.	=	microkatal/liter erythrocytes
µkat/g P.	=	microkatal/gram protein

7.3. LIST TO THE ABBREVIATIONS USED IN TABLES IC

F	=	female animals
g	=	weight determination in grams
i1	=	test animals selected for perfusion fixation
M	=	male animals (under sex); mean value (on weight level)
mg/kg BW	=	milligram per kilogram body weight under dose level
n	=	number of values measured for the determination of mean value and standard deviation
NAD	=	number of animals without gross lesions
s	=	suspect weight (not included in the mean weights)
SD	=	standard deviation
%	=	percentage related to the reference weight in relative organ weight calculations

Codes for the status at necropsy:

1	=	planned sacrifice
2	=	sacrificed in a moribund state
3	=	spontaneous death

Codes used at finding level:

The codes are used for a grading system which takes into consideration either the severity or the number or the size of a microscopic finding.

	Severity	Number	Size
Grade 1	Minimal	Very few	Very small
Grade 2	Slight	Few	Small
Grade 3	Moderate	Moderate number	Moderate size
Grade 4	Marked; severe	Many	Large
Grade 5	Massive; extreme	Extensive number	Extensive size

Whenever a grading was not used, the microscopic finding was indicated to be present (P).

Figure 1


Body weight, males
300
280
260
240
220
200
180
160
140
120
100
grams
-7
0
7
14
days
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw

Figure 2


Body weight, females
200
190
180
170
160
150
140
130
120
110
100
grams
-7
0
7
14
days
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw

Figure 3


Motor activity measurement on day -7
males
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 4


Motor activity measurement on day 0
males
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 5


Motor activity measurement on day 7
males
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 6


Motor activity measurement on day 14
males
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 7


Motor activity measurement on day -7
females
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 8


Motor activity measurement on day 0
females
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 9


Motor activity measurement on day 7
females
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

Figure 10


Motor activity measurement on day 14
females
interrupts/animal/interval
interval
0 mg/kg bw
0.2 mg/kg bw
0.25 mg/kg bw
0.35 mg/kg bw
5 mg/kg bw
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12

OBSERVATIONS REPORT - INCIDENCE

Study: 20C0709/01098
Sex: Male

Treatment Group	0	1	2	3	4
Dose	GROUP 0	GROUP 1	GROUP 2	GROUP 3	GROUP 4
Animal Count	10	10	10	10	10
Apathy					
slight					
Incidence					3 (30%)
Observed					3
Mean onset (Days)					0
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (30%)
Observed	0	0	0	0	3
Mean onset (Days)					0
General observation					
Nothing abnormal detected					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	6 (60%)
Observed	10	10	10	10	6
Mean onset (Days)	0	0	0	0	0
TOTALS					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	6 (60%)
Observed	10	10	10	10	6
Mean onset (Days)	0	0	0	0	0
Visually increased respiration					
slight					
Incidence					1 (10%)
Observed					1
Mean onset (Days)					0
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (10%)
Observed	0	0	0	0	1
Mean onset (Days)					0
Sacrificed scheduled					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Observed	10	10	10	10	10
Mean onset (Days)	0	0	0	0	0
TOTALS					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Observed	10	10	10	10	10
Mean onset (Days)	0	0	0	0	0

OBSERVATIONS REPORT - INCIDENCE

Study: 20C0709/01098
Sex: Male

Treatment Group	0	1	2	3	4
Dose	GROUP 0	GROUP 1	GROUP 2	GROUP 3	GROUP 4
Animal Count	15	15	15	15	15
General observation					
Nothing abnormal detected					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	195	195	195	195	195
Mean onset (Days)	1	1	1	1	1
TOTALS					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	195	195	195	195	195
Mean onset (Days)	1	1	1	1	1
Sacrificed scheduled					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	15	15	15	15	15
Mean onset (Days)	15	15	15	15	15
TOTALS					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	15	15	15	15	15
Mean onset (Days)	15	15	15	15	15

OBSERVATIONS REPORT - INCIDENCE

Study: 20C0709/01098
Sex: Female

Treatment Group	0	1	2	3	4
Dose	GROUP 0	GROUP 1	GROUP 2	GROUP 3	GROUP 4
Animal Count	10	10	10	10	10
Apathy					
slight					
Incidence					3 (30%)
Observed					3
Mean onset (Days)					0
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (30%)
Observed	0	0	0	0	3
Mean onset (Days)					0
Frequent chewing					
Incidence					1 (10%)
Observed					1
Mean onset (Days)					0
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (10%)
Observed	0	0	0	0	1
Mean onset (Days)					0
General observation					
Nothing abnormal detected					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	5 (50%)
Observed	10	10	10	10	5
Mean onset (Days)	0	0	0	0	0
TOTALS					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	5 (50%)
Observed	10	10	10	10	5
Mean onset (Days)	0	0	0	0	0
Tremor					
slight					
Incidence					2 (20%)
Observed					2
Mean onset (Days)					0
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (20%)
Observed	0	0	0	0	2
Mean onset (Days)					0

Study: 20C0709/01098
Sex: Female

OBSERVATIONS REPORT - INCIDENCE

Treatment Group	0	1	2	3	4
Dose	GROUP 0	GROUP 1	GROUP 2	GROUP 3	GROUP 4
Animal Count	10	10	10	10	10
Sacrificed scheduled					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Observed	10	10	10	10	10
Mean onset (Days)	0	0	0	0	0
TOTALS					
Incidence	10 (100%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Observed	10	10	10	10	10
Mean onset (Days)	0	0	0	0	0

OBSERVATIONS REPORT - INCIDENCE

Study: 20C0709/01098
Sex: Female

Treatment Group	0	1	2	3	4
Dose	GROUP 0	GROUP 1	GROUP 2	GROUP 3	GROUP 4
Animal Count	15	15	15	15	15
General observation					
Nothing abnormal detected					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	195	195	195	194	195
Mean onset (Days)	1	1	1	1	1
TOTALS					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	195	195	195	194	195
Mean onset (Days)	1	1	1	1	1
Skin					
lesion					
Incidence				1 (7%)	
Observed				1	
Mean onset (Days)				15	
TOTALS					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)
Observed	0	0	0	1	0
Mean onset (Days)				15	
Sacrificed scheduled					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	15	15	15	15	15
Mean onset (Days)	15	15	15	15	15
TOTALS					
Incidence	15 (100%)	15 (100%)	15 (100%)	15 (100%)	15 (100%)
Observed	15	15	15	15	15
Mean onset (Days)	15	15	15	15	15

Study: 20C0709/01098

FOOD CONSUMPTION

	Food Cons. g/anm/day Day 0 D	Food Cons. g/anm/day Day 7 D	Food Cons. g/anm/day Day 14 D
Male, GROUP 0			
Mean	18.7	20.8	22.3
SD	0.9	1.0	1.2
N	15	15	15
%dev			
Male, GROUP 1			
Mean	18.9	20.9	22.0
SD	1.6	1.5	1.9
N	15	15	15
%dev	1.3	0.4	-1.3
Male, GROUP 2			
Mean	18.5	20.4	21.7
SD	0.9	1.1	1.2
N	15	15	15
%dev	-1.1	-1.7	-2.8
Male, GROUP 3			
Mean	18.7	20.6	22.0
SD	1.6	1.6	1.6
N	15	15	15
%dev	0.0	-1.0	-1.5
Male, GROUP 4			
Mean	18.5	20.3	22.2
SD	1.4	1.5	1.8
N	15	15	15
%dev	-0.8	-2.3	-0.5

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

FOOD CONSUMPTION

Study: 20C0709/01098

	Food Cons. g/anm/day Day 0 D	Food Cons. g/anm/day Day 7 D	Food Cons. g/anm/day Day 14 D
Female, GROUP 0			
Mean	14.7	15.8	16.5
SD	1.4	1.3	1.2
N	15	15	15
%dev			
Female, GROUP 1			
Mean	14.9	15.5	16.3
SD	1.2	0.8	0.8
N	15	15	15
%dev	1.5	-1.7	-0.9
Female, GROUP 2			
Mean	14.6	15.7	16.6
SD	1.1	1.1	1.3
N	15	15	15
%dev	-0.3	-0.2	0.8
Female, GROUP 3			
Mean	14.4	15.5	16.5
SD	1.6	1.0	1.0
N	15	15	15
%dev	-1.7	-1.8	0.3
Female, GROUP 4			
Mean	14.9	15.5	16.4
SD	1.6	1.3	1.5
N	15	15	15
%dev	1.2	-1.4	-0.5

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	Body Weight g Day 0 D
Male, GROUP 0	
Mean	189.9
SD	10.1
N	10
%dev	
Male, GROUP 1	
Mean	194.9
SD	6.9
N	10
%dev	2.6
Male, GROUP 2	
Mean	191.8
SD	9.9
N	10
%dev	1.0
Male, GROUP 3	
Mean	190.0
SD	10.2
N	10
%dev	0.0
Male, GROUP 4	
Mean	185.4
SD	17.7
N	10
%dev	-2.4

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

Study: 20C0709/01098

BODY WEIGHT

	Body Weight g Day -7 D	Body Weight g Day 0 D	Body Weight g Day 7 D	Body Weight g Day 14 D
Male, GROUP 0				
Mean	151.6	188.3	223.4	252.7
SD	5.1	5.2	8.3	11.6
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	153.8	191.9	226.3	254.0
SD	7.3	11.6	14.4	18.2
N	15	15	15	15
%dev	1.5	1.9	1.3	0.5
Male, GROUP 2				
Mean	153.0	190.4	224.0	252.5
SD	6.2	7.8	8.5	10.1
N	15	15	15	15
%dev	1.0	1.1	0.2	-0.1
Male, GROUP 3				
Mean	153.1	188.8	222.9	249.1
SD	8.6	11.4	14.3	17.2
N	15	15	15	15
%dev	1.0	0.3	-0.2	-1.4
Male, GROUP 4				
Mean	152.9	189.7	223.1	252.4
SD	4.8	7.8	11.3	15.5
N	15	15	15	15
%dev	0.9	0.7	-0.2	-0.1

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	Body Weight g Day 0 D
Female, GROUP 0	
Mean	142.4
SD	6.9
N	10
%dev	
Female, GROUP 1	
Mean	144.4
SD	11.2
N	10
%dev	1.4
Female, GROUP 2	
Mean	139.4
SD	8.4
N	10
%dev	-2.1
Female, GROUP 3	
Mean	138.5
SD	3.5
N	10
%dev	-2.7
Female, GROUP 4	
Mean	140.7
SD	6.7
N	10
%dev	-1.2

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

Study: 20C0709/01098

BODY WEIGHT

	Body Weight g Day -7 D	Body Weight g Day 0 D	Body Weight g Day 7 D	Body Weight g Day 14 D
Female, GROUP 0				
Mean	125.8	144.0	163.2	177.4
SD	6.6	11.6	14.4	14.4
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	125.9	145.9	161.4	174.0
SD	5.5	8.0	9.9	10.7
N	15	15	15	15
%dev	0.1	1.3	-1.1	-1.9
Female, GROUP 2				
Mean	125.7	145.1	163.4	175.9
SD	6.5	8.1	10.2	10.9
N	15	15	15	15
%dev	-0.1	0.8	0.2	-0.8
Female, GROUP 3				
Mean	124.8	144.7	161.0	175.3
SD	5.7	7.7	7.3	8.7
N	15	15	15	15
%dev	-0.8	0.5	-1.3	-1.2
Female, GROUP 4				
Mean	126.0	146.6	164.5	176.6
SD	5.0	6.3	10.0	12.6
N	15	15	15	15
%dev	0.2	1.8	0.8	-0.4

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

BODY WEIGHT CHANGE

Study: 20C0709/01098

	BW change g Day 7 D	BW change g Day 14 D
Male, GROUP 0		
Mean	35.1	64.3
SD	5.4	9.1
N	15	15
%dev		
Male, GROUP 1		
Mean	34.5	62.1
SD	4.2	8.3
N	15	15
%dev	-1.8	-3.5
Male, GROUP 2		
Mean	33.6	62.1
SD	3.9	6.4
N	15	15
%dev	-4.3	-3.5
Male, GROUP 3		
Mean	34.1	60.3
SD	4.4	7.7
N	15	15
%dev	-2.8	-6.2
Male, GROUP 4		
Mean	33.3	62.7
SD	4.6	9.0
N	15	15
%dev	-5.0	-2.6

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

BODY WEIGHT CHANGE

Study: 20C0709/01098

	BW change g Day 7 D	BW change g Day 14 D
Female, GROUP 0		
Mean	19.1	33.3
SD	6.2	6.0
N	15	15
%dev		
Female, GROUP 1		
Mean	15.5	28.1
SD	4.2	4.8
N	15	15
%dev	-18.9	-15.6
Female, GROUP 2		
Mean	18.3	30.7
SD	4.4	5.3
N	15	15
%dev	-4.4	-7.7
Female, GROUP 3		
Mean	16.3	30.6
SD	5.1	6.4
N	15	15
%dev	-14.7	-8.2
Female, GROUP 4		
Mean	17.9	30.0
SD	4.6	8.3
N	15	15
%dev	-6.6	-9.9

Key: D = Dunnett's test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	13	12	12	13	14
- animal is staying and moving	1	2	3	3	2	1
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	13	12	12	13	14
- no impairment of gait	1	2	3	3	2	1
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day -7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	15
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day -7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	15
- reduced exploration of the area	1	0	0	0	0	0
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	11	6	8	7	8
- Feces without abnormalities	1	4	9	7	8	7
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	0
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	7	10	11	7	12
- urine without abnormalities (some wet areas on the filter paper)	1	8	5	4	8	3
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day -7

male animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	10	10	10	13	10
- approaching to object	1	5	5	5	2	5
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	15	15	14	15	15
- orientation to the stimulus	1	0	0	1	0	0
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day -7

male animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	13	12	12	9	15
- animal is staying and moving	1	2	3	3	6	0
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	14
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	1
Impairment of gait						
- animal is not walking during observation	0	13	12	12	9	15
- no impairment of gait	1	2	3	3	6	0
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15		15	15	15

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 0

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	14
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	1
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	13
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	2
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 0

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	14	15
- eyelid(s) slight closure	1	0	0	0	1*)	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

*) eyelid right

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	13	11
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	1	1
- respiration irregular	4	0	0	0	1	3
Tremors						
- no tremors	0	15	15	15	15	7
- slight tremors	1	0	0	0	0	8
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	13
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	2
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	6
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	9
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 0

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	14	13	15	12
- reduced exploration of the area	1	0	1	2	0	3
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	10	5	8	6	8
- Feces without abnormalities	1	5	10	7	9	5
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	2
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	7	9	6	8	4
- urine without abnormalities (some wet areas on the filter paper)	1	8	6	9	7	11
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

BASF Project No. 20C0709/01098

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	5	6	8	11	13
- approaching to object	1	10	9	7	4	2
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	13	14	13	15	15
- orientation to the stimulus	1	2	1	2	0	0
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	12	13	0
- retarded adaptation of the pupil to light	1	0	0	2	1	7
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	1	1	8
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 0

male animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	10	11	9	10	10
- animal is staying and moving	1	5	4	6	5	5
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	10	11	9	10	10
- no impairment of gait	1	5	4	6	5	5
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	1
- animal is staying and moving	1	15	15	15	15	14
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	1
- no impairment of gait	1	15	15	15	15	14
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	14
- reduced exploration of the area	1	0	0	0	0	1
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	10	9	7	10	4
- Feces without abnormalities	1	5	6	8	5	11
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	2
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	11	8	7	6	4
- urine without abnormalities (some wet areas on the filter paper)	1	4	7	8	9	11
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	7	9	6	8	8
- approaching to object	1	8	6	9	7	7
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	14	15	13	15	13
- orientation to the stimulus	1	1	0	2	0	2
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 7

male animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	14	15	15
- very frequent vocalizations when touched	1	0	0	1	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	8	10	6	7	7
- animal is staying and moving	1	7	5	9	8	8
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	8	10	6	7	7
- no impairment of gait	1	7	5	9	8	8
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	5	15	15	15

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	15
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	15
- reduced exploration of the area	1	0	0	0	0	0
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	13	11	10	8	7
- Feces without abnormalities	1	2	4	5	7	8
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	2
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	11	9	6	11	9
- urine without abnormalities (some wet areas on the filter paper)	1	4	6	9	4	6
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	6	5	6	8	6
- approaching to object	1	9	10	9	7	9
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	13	12	14	14	15
- orientation to the stimulus	1	2	3	1	1	0
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	11	11	11	9	7
- animal is staying and moving	1	4	4	4	6	8
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	11	11	11	9	7
- no impairment of gait	1	4	4	4	6	8
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

FUNCTIONAL OBSERVATIONAL BATTERY day -7

female animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	15
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	15
- reduced exploration of the area	1	0	0	0	0	0
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	12	15	14	14	13
- Feces without abnormalities	1	3	0	1	1	2
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	0
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	7	10	9	7	9
- urine without abnormalities (some wet areas on the filter paper)	1	8	5	6	8	6
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day -7

female animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	8	7	7	7	8
- approaching to object	1	7	8	8	8	7
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	15	14	14	13	14
- orientation to the stimulus	1	0	1	1	2	1
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	9	10	11	9	14
- animal is staying and moving	1	6	5	4	6	0
- squatting posture	2	0	0	0	0	1
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	9	10	11	9	15
- no impairment of gait	1	6	5	4	6	0
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	14
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	1
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	13
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	2
Tremors						
- no tremors	0	15	15	15	15	6
- slight tremors	1	0	0	0	0	9
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	13
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	2
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	14	2
- stiff gait	2	0	0	0	0	1
- slight impairment of coordination, unsteady gait	3	0	0	0	1	11
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	1
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day 0

female animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	14	13
- reduced exploration of the area	1	0	0	0	0	2
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	1	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	15	12	13	12	15
- Feces without abnormalities	1	0	3	2	3	0
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	0
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	11	13	11	8	7
- urine without abnormalities (some wet areas on the filter paper)	1	4	2	4	7	8
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	7	4	7	9	9
- approaching to object	1	8	11	8	6	6
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	13	13	15	15	15
- orientation to the stimulus	1	2	2	0	0	0
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	13	13	1
- retarded adaptation of the pupil to light	1	0	0	2	2	9
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	5
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 0

female animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	14	14	15
- very frequent vocalizations when touched	1	0	0	1	0	0
- vocalizations always when touched	2	0	0	0	1	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	7	5	4	7	6
- animal is staying and moving	1	8	10	11	8	9
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	7	5	4	7	6
- no impairment of gait	1	8	10	11	8	9
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day 7

female animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	15
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	15
- reduced exploration of the area	1	0	0	0	0	0
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	14	14	13	13	15
- Feces without abnormalities	1	1	1	2	2	0
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	0
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	6	8	7	8	9
- urine without abnormalities (some wet areas on the filter paper)	1	9	7	8	7	6
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day 7

female animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	7	9	9	8	6
- approaching to object	1	8	6	6	7	9
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	13	12	12	12	12
- orientation to the stimulus	1	2	3	3	3	3
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day 7

female animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

HOME CAGE OBSERVATION	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Posture						
- animal is sitting or lying	0	2	5	4	3	5
- animal is staying and moving	1	13	10	11	12	10
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	2	5	4	3	5
- no impairment of gait	1	13	10	11	12	10
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0
Other findings	0	15	15	15	15	15

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour when removed from cage						
- animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- animal shows a slight resistance against the handling	1	0	0	0	0	0
- animal shows no resistance against the handling but appears indifferent	2	0	0	0	0	0
- animal is difficult to handle, it shows aggressiveness	3	0	0	0	0	0
- animal is very difficult to handle, it shows severe aggressiveness	4	0	0	0	0	0
Fur						
- nothing abnormal detected	0	15	15	15	15	15
- discolored fur	1	0	0	0	0	0
- urine staining of anogenital region	2	0	0	0	0	0
- piloerection	3	0	0	0	0	0
- alopecia	4	0	0	0	0	0
- reduced care on fur	5	0	0	0	0	0
Skin						
- nothing abnormal detected	0	15	15	15	15	15
- discolored skin	1	0	0	0	0	0
- reddening	2	0	0	0	0	0
- paleness	3	0	0	0	0	0
- dehydration (exsiccosis)	4	0	0	0	0	0
- hypothermia (skin is cold during handling)	5	0	0	0	0	0
- lesion(s)	6	0	0	0	0	0
- crust(s)	7	0	0	0	0	0
Salivation						
- no salivation	0	15	15	15	15	15
- slight salivation (area around the mouth is moist)	1	0	0	0	0	0
- moderate salivation (wet mouth)	2	0	0	0	0	0
- severe salivation (mouth very wet, wet paws)	3	0	0	0	0	0
Nose discharge						
- no discharge, dry nose	0	15	15	15	15	15
- clear discharge	1	0	0	0	0	0
- reddish discharge	2	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Lacrimation						
- no lacrimation	0	15	15	15	15	15
- slight lacrimation	1	0	0	0	0	0
- moderate lacrimation	2	0	0	0	0	0
- severe lacrimation	3	0	0	0	0	0
Eyes/Pupil size						
- nothing abnormal detected, pupils contracted at room light	0	15	15	15	15	15
- chromodacryorrhoe	1	0	0	0	0	0
- exophthalmos	2	0	0	0	0	0
- pupils dilated	3	0	0	0	0	0
- abnormal shape of pupils	4	0	0	0	0	0
- oblique eye posture	5	0	0	0	0	0
- opacity	6	0	0	0	0	0
- cataract	7	0	0	0	0	0
Posture						
- animal is sitting or lying	0	0	0	0	0	0
- animal is staying and moving	1	15	15	15	15	15
- squatting posture	2	0	0	0	0	0
- abdominal position	3	0	0	0	0	0
- abdominal position with splayed limbs	4	0	0	0	0	0
- lateral position	5	0	0	0	0	0
- oblique head posture	6	0	0	0	0	0
- opisthotonus	7	0	0	0	0	0
Palpebral closure						
- nothing abnormal detected	0	15	15	15	15	15
- eyelid(s) slight closure	1	0	0	0	0	0
- eyelid(s) half closure	2	0	0	0	0	0
- eyelid(s) permanent closure	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Respiration						
- nothing abnormal detected	0	15	15	15	15	15
- respiration labored	1	0	0	0	0	0
- gasping/respiratory sounds	2	0	0	0	0	0
- respiration accelerated	3	0	0	0	0	0
- respiration irregular	4	0	0	0	0	0
Tremors						
- no tremors	0	15	15	15	15	15
- slight tremors	1	0	0	0	0	0
- moderate tremors	2	0	0	0	0	0
- severe tremors	3	0	0	0	0	0
Convulsions						
- no convulsions	0	15	15	15	15	15
- slight convulsions	1	0	0	0	0	0
- moderate convulsions	2	0	0	0	0	0
- severe convulsions	3	0	0	0	0	0
Abnormal movements/Stereotypics						
- no abnormalities	0	15	15	15	15	15
- manege movements	1	0	0	0	0	0
- head shaking	2	0	0	0	0	0
- excessive cleaning	3	0	0	0	0	0
- frequent chewing	4	0	0	0	0	0
Impairment of gait						
- animal is not walking during observation	0	0	0	0	0	0
- no impairment of gait	1	15	15	15	15	15
- stiff gait	2	0	0	0	0	0
- slight impairment of coordination, unsteady gait	3	0	0	0	0	0
- moderate impairment of coordination, shuffling gait	4	0	0	0	0	0
- severe impairment of coordination, dragging of the hindlimbs	5	0	0	0	0	0
- severe impairment of coordination, with splayed limbs	6	0	0	0	0	0
- animal is unable to walk (abdominal or lateral position)	7	0	0	0	0	0

BASF Project No. 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY day 14

female animals

OPEN FIELD OBSERVATIONS	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Activity/Arousal level						
- Normal exploration of the area	0	15	15	15	15	15
- reduced exploration of the area	1	0	0	0	0	0
- Severe reduced exploration of the area, animal apathetic	2	0	0	0	0	0
- Increased exploration of the area, sudden or jerky movements	3	0	0	0	0	0
- Hyperactivity	4	0	0	0	0	0
Feces						
- no defecation during observation period	0	15	15	15	14	15
- Feces without abnormalities	1	0	0	0	1	0
- discolored feces	2	0	0	0	0	0
- crumbly feces	3	0	0	0	0	0
- soft feces	4	0	0	0	0	0
- muicid feces	5	0	0	0	0	0
- diarrhea	6	0	0	0	0	0
Urine						
- no urination during observation period	0	9	10	9	7	9
- urine without abnormalities (some wet areas on the filter paper)	1	6	5	6	8	6
- discoloration of urine	2	0	0	0	0	0
- polyuria (great wet areas on the filter paper)	3	0	0	0	0	0

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Approach response						
- no reaction	0	5	6	7	6	6
- approaching to object	1	10	9	8	9	9
- escape reaction	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
Touch response						
- no reaction	0	14	13	13	14	14
- orientation to the stimulus	1	1	2	2	1	1
- escape after touch	2	0	0	0	0	0
- aggressive reaction and attacking of object	3	0	0	0	0	0
- reaction to the stimulus but no ability to localize (e.g. turning to wrong side)	4	0	0	0	0	0
Vision						
- nothing abnormal detected (grasping with forelimbs)	0	15	15	15	15	15
- no grasping	1	0	0	0	0	0
Pupillary reflex						
- nothing abnormal detected, physiological adaptation of the pupil to light	0	15	15	15	15	15
- retarded adaptation of the pupil to light	1	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently contracted	2	0	0	0	0	0
- no adaptation of the pupil to light, pupils permanently dilated	3	0	0	0	0	0
Pinna reflex						
- immediate response to the stimulus	0	15	15	15	15	15
- no response to the stimulus	1	0	0	0	0	0
Audition						
- nothing abnormal detected, immediate normal response to the stimulus	0	15	15	15	15	15
- no response	1	0	0	0	0	0
- increased response	2	0	0	0	0	0
- hyperreaction	3	0	0	0	0	0
Coordination of movements						
- nothing abnormal detected, immediate righting response	0	15	15	15	15	15
- retarded righting response	1	0	0	0	0	0
- fails to turn into upright position, animal stays in lateral position	2	0	0	0	0	0
- no righting response, animal stays in dorsal position	3	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY day 14

female animals

SENSORIMOTOR TESTS/REFLEXES	Mean values Rank	Group 0 0 mg/kg bw N=15	Group 1 0.2 mg/kg bw N=15	Group 2 0.25 mg/kg bw N=15	Group 3 0.35 mg/kg bw N=15	Group 4 5 mg/kg bw N=15
Behaviour during handling						
- normal behavior, easy to handle, animal is tense, but it shows no resistance against handling	0	15	15	15	15	15
- very easy to handle, animal is limply hanging in the hand	1	0	0	0	0	0
- slightly difficult to handle, animal shows a slight resistance against handling	2	0	0	0	0	0
- difficult to handle, animal shows a severe resistance against handling	3	0	0	0	0	0
Vocalization						
- no or only sporadic vocalizations when touched	0	15	15	15	15	15
- very frequent vocalizations when touched	1	0	0	0	0	0
- vocalizations always when touched	2	0	0	0	0	0
- vocalization without touching	3	0	0	0	0	0
Pain perception						
- nothing abnormal detected, immediate response to the stimulus	0	15	15	15	15	15
- weak or retarded reaction to the stimulus	1	0	0	0	0	0
- no response to the stimulus	2	0	0	0	0	0
- hyperreaction to the stimulus	3	0	0	0	0	0
Other findings	0	15	15	15	15	15

	FECES N Day -7 k	FECES N Day 0 k	FECES N Day 7 k	FECES N Day 14 k
Male, GROUP 0				
Mean	0.9	1.1	0.7	0.1
SD	2.0	1.6	1.0	0.4
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	1.7	2.3	1.5	0.7
SD	1.8	2.1	1.6	1.5
N	15	15	15	15
%dev	78.6	105.9	130.0	450.0
Male, GROUP 2				
Mean	1.7	1.2	1.5	0.7
SD	1.9	1.7	1.6	1.0
N	15	15	15	15
%dev	78.6	5.9	120.0	400.0
Male, GROUP 3				
Mean	1.5	2.0	1.6	1.1
SD	2.0	2.1	1.5	1.3
N	15	15	15	15
%dev	64.3	76.5	140.0	700.0
Male, GROUP 4				
Mean	1.4	0.7	1.8	1.2
SD	2.0	0.8	1.7	1.4
N	15	15	15	15
%dev	50.0	-41.2	170.0	800.0

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	FECES N Day -7 k	FECES N Day 0 k	FECES N Day 7 k	FECES N Day 14 k
Female, GROUP 0				
Mean	0.5	0.0	0.2	0.0
SD	1.4	0.0	0.8	0.0
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	0.0	0.5	0.3	0.0
SD	0.0	1.1	1.0	0.0
N	15	15	15	15
%dev	-100.0	NC	33.3	NC
Female, GROUP 2				
Mean	0.3	0.2	0.2	0.0
SD	1.3	0.6	0.6	0.0
N	15	15	15	15
%dev	-37.5	NC	0.0	NC
Female, GROUP 3				
Mean	0.2	0.2	0.3	0.2
SD	0.8	0.4	0.9	0.8
N	15	15	15	15
%dev	-62.5	NC	66.7	NC
Female, GROUP 4				
Mean	0.2	0.0	0.1	0.0
SD	0.6	0.0	0.5	0.0
N	15	15	15	15
%dev	-62.5	NC	-33.3	NC

Key: NC = Not Calculable
k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	Rear Day -7 k	Rear Day 0 k	Rear Day 7 k	Rear Day 14 k
Male, GROUP 0				
Mean	3.9	1.5	1.9	3.7
SD	3.6	2.2	2.1	2.4
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	5.7	2.7	2.3	4.8
SD	3.9	4.4	2.7	2.4
N	15	15	15	15
%dev	44.1	73.9	20.7	30.9
Male, GROUP 2				
Mean	4.5	1.9	1.9	3.9
SD	3.2	3.2	1.7	3.5
N	15	15	15	15
%dev	13.6	21.7	-3.4	5.5
Male, GROUP 3				
Mean	4.2	1.6	2.3	2.5
SD	3.4	2.3	3.0	2.9
N	15	15	15	15
%dev	6.8	4.3	17.2	-30.9
Male, GROUP 4				
Mean	4.3	0.5	1.7	2.9
SD	4.4	0.8	1.9	3.0
N	15	15	15	15
%dev	8.5	-65.2	-13.8	-20.0

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	Rear Day -7 k	Rear Day 0 k	Rear Day 7 k	Rear Day 14 k
Female, GROUP 0				
Mean	8.6	9.9	9.3	8.3
SD	4.6	4.8	7.1	3.8
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	9.4	9.3	7.9	10.1
SD	4.3	8.8	5.0	4.3
N	15	15	15	15
%dev	9.3	-5.4	-15.0	21.8
Female, GROUP 2				
Mean	8.9	8.5	6.5	10.3
SD	4.4	5.0	4.2	7.1
N	15	15	15	15
%dev	3.1	-14.2	-30.0	25.0
Female, GROUP 3				
Mean	8.5	7.2	7.4	8.2
SD	3.1	4.2	5.1	5.0
N	15	15	15	15
%dev	-0.8	-27.0	-20.7	-0.8
Female, GROUP 4				
Mean	8.3	2.7**	6.3	8.7
SD	3.2	2.9	4.0	4.6
N	15	15	15	15
%dev	-3.9	-73.0	-32.1	5.6

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	GSF Newton Day -7 k	GSF Newton Day 0 k	GSF Newton Day 7 k	GSF Newton Day 14 k
Male, GROUP 0				
Mean	4.5	4.3	4.5	4.8
SD	0.4	0.5	0.3	0.4
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	4.4	4.3	4.6	4.8
SD	0.4	0.5	0.4	0.5
N	15	15	15	15
%dev	-2.7	0.8	3.0	-0.4
Male, GROUP 2				
Mean	4.4	4.6	4.5	4.7
SD	0.5	0.4	0.4	0.4
N	15	15	15	15
%dev	-3.7	6.0	1.2	-2.5
Male, GROUP 3				
Mean	4.6	4.4	4.6	4.9
SD	0.4	0.6	0.4	0.5
N	15	15	15	15
%dev	2.2	2.0	1.9	0.6
Male, GROUP 4				
Mean	4.5	4.4	4.5	4.6
SD	0.5	0.6	0.5	0.5
N	15	15	15	15
%dev	0.0	1.9	1.3	-4.1

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	GSF Newton Day -7 k	GSF Newton Day 0 k	GSF Newton Day 7 k	GSF Newton Day 14 k
Female, GROUP 0				
Mean	4.6	4.4	4.3	4.5
SD	0.5	0.4	0.7	0.8
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	4.4	4.4	4.7	5.0
SD	0.4	0.5	0.7	0.5
N	15	15	15	15
%dev	-3.1	-0.8	9.2	9.7
Female, GROUP 2				
Mean	4.4	4.3	4.8	4.7
SD	0.4	0.4	0.5	0.6
N	15	15	15	15
%dev	-3.5	-2.3	9.7	5.0
Female, GROUP 3				
Mean	4.5	4.4	4.8	4.7
SD	0.4	0.3	0.6	0.5
N	15	15	15	15
%dev	-2.0	1.1	11.1	4.1
Female, GROUP 4				
Mean	4.4	3.8*	4.6	4.5
SD	0.4	0.7	0.5	0.5
N	15	15	15	15
%dev	-3.4	-13.4	5.5	-0.7

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	GSH Newton Day -7 k	GSH Newton Day 0 k	GSH Newton Day 7 k	GSH Newton Day 14 k
Male, GROUP 0				
Mean	2.9	2.9	3.0	3.2
SD	0.5	0.4	0.4	0.4
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	3.1	2.8	3.0	3.1
SD	0.4	0.3	0.4	0.4
N	15	15	15	15
%dev	3.9	-4.8	0.9	-2.5
Male, GROUP 2				
Mean	2.9	3.0	3.0	3.0
SD	0.6	0.4	0.5	0.5
N	15	15	15	15
%dev	-0.5	1.4	0.0	-4.6
Male, GROUP 3				
Mean	3.1	2.7	3.1	3.2
SD	0.3	0.3	0.5	0.3
N	15	15	15	15
%dev	5.4	-6.6	3.3	1.5
Male, GROUP 4				
Mean	3.0	2.7	3.0	3.0
SD	0.2	0.6	0.4	0.3
N	15	15	15	15
%dev	3.2	-7.3	-0.9	-6.1

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	GSH Newton Day -7 k	GSH Newton Day 0 k	GSH Newton Day 7 k	GSH Newton Day 14 k
Female, GROUP 0				
Mean	2.7	2.3	2.9	2.9
SD	0.7	0.2	0.5	0.5
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	2.6	2.4	2.9	3.1
SD	0.6	0.5	0.5	0.5
N	15	15	15	15
%dev	-0.8	5.3	1.4	7.0
Female, GROUP 2				
Mean	2.7	2.5	3.0	3.1
SD	0.5	0.4	0.5	0.7
N	15	15	15	15
%dev	1.5	8.8	5.1	9.5
Female, GROUP 3				
Mean	2.5	2.3	2.9	3.3
SD	0.6	0.5	0.4	1.8
N	15	15	15	15
%dev	-6.8	0.6	1.2	14.2
Female, GROUP 4				
Mean	2.6	1.7**	2.7	2.8
SD	0.8	0.4	0.3	0.4
N	15	15	15	15
%dev	-2.8	-23.5	-4.8	-1.4

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	FS T cm Day -7 k	FS T cm Day 0 k	FS T cm Day 7 k	FS T cm Day 14 k
Male, GROUP 0				
Mean	9.2	10.0	10.0	10.0
SD	1.2	1.1	1.2	1.3
N	15	15	15	15
%dev				
Male, GROUP 1				
Mean	9.1	10.0	9.9	10.0
SD	1.0	1.2	0.9	1.3
N	15	15	15	15
%dev	-0.3	0.4	-1.4	-0.3
Male, GROUP 2				
Mean	9.4	10.6	10.2	10.3
SD	1.3	1.2	1.4	1.2
N	15	15	15	15
%dev	2.4	6.0	1.8	3.5
Male, GROUP 3				
Mean	9.5	10.3	10.6	10.3
SD	1.4	1.2	1.2	0.6
N	15	15	15	15
%dev	3.5	3.0	6.0	2.9
Male, GROUP 4				
Mean	9.0	10.1	10.7	10.3
SD	0.9	1.2	0.9	0.9
N	15	15	15	15
%dev	-1.2	0.7	6.8	3.6

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

	FS T cm Day -7 k	FS T cm Day 0 k	FS T cm Day 7 k	FS T cm Day 14 k
Female, GROUP 0				
Mean	9.1	9.4	9.1	9.5
SD	1.1	0.7	1.1	1.0
N	15	15	15	15
%dev				
Female, GROUP 1				
Mean	9.7	9.8	9.6	9.6
SD	1.5	1.3	0.9	0.9
N	15	15	15	15
%dev	6.5	3.7	5.6	1.6
Female, GROUP 2				
Mean	9.4	9.5	9.5	9.5
SD	1.5	1.4	1.4	1.4
N	15	15	15	15
%dev	3.4	0.6	4.4	0.4
Female, GROUP 3				
Mean	8.8	9.0	9.1	9.3
SD	1.2	1.1	1.4	1.3
N	15	15	15	15
%dev	-3.1	-4.7	0.1	-2.4
Female, GROUP 4				
Mean	9.5	9.1	9.4	9.6
SD	0.8	0.9	1.2	0.9
N	15	15	15	15
%dev	4.7	-3.6	3.4	0.8

Key: k = Kruskal-Wallis + Wilcoxon-test, Two-sided, * = 0.050, ** = 0.010
Experimental Unit = Animal

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	52.1	38.9	28.5	22.8	17.7	10.4	3.7	2.7	0.6
	SD	19.0	12.2	6.3	11.7	12.4	11.5	4.2	5.1	1.1
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	67.4	45.9	33.1	29.3	28.8	19.9	8.3	4.9	2.1
	SD	11.8	11.7	10.8	10.2	13.2	13.1	10.8	8.3	5.9
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	61.7	42.7	32.6	25.5	19.0	13.0	6.6	3.2	2.8
	SD	12.4	15.2	11.0	11.0	9.9	9.3	8.7	5.9	4.9
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	66.5	39.1	32.2	27.3	19.1	12.7	10.7	7.7	4.1
	SD	14.3	13.9	8.7	14.8	14.6	13.1	13.7	16.1	6.5
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	58.3	39.0	35.3	28.2	21.3	15.7	6.0	1.3	2.1
	SD	12.3	12.1	9.7	14.8	12.7	13.0	9.1	3.1	6.2
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	1.3	0.9	1.3	180.9
	SD	2.3	1.6	2.1	48.7
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	2.1	1.8	0.9	244.6 **
	SD	7.4	2.6	1.0	55.3
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	2.8	1.5	2.0	213.3
	SD	6.0	3.3	4.2	55.9
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	2.1	2.3	0.9	224.7 *
	SD	3.4	3.8	1.2	61.8
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	3.6	3.1	2.1	215.9 *
	SD	9.7	6.0	3.3	51.5
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	52.1	38.3	26.9	21.6	16.9	6.7	3.1	1.8	0.8
	SD	15.2	10.6	8.7	12.4	12.9	11.2	6.2	3.3	1.6
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	60.1	41.9	35.7	30.8	18.9	8.3	4.7	3.3	1.1
	SD	15.2	12.5	15.5	13.7	16.3	10.0	7.2	5.2	2.3
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	58.3	35.3	31.2	24.2	11.4	7.3	3.9	1.1	1.9
	SD	14.0	8.9	15.6	13.3	12.8	10.7	7.9	3.6	6.7
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	66.1 *	39.9	33.7	25.3	17.7	8.3	2.9	1.7	1.2
	SD	15.8	10.3	16.3	18.1	14.5	10.9	4.0	2.6	1.8
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	33.9 **	13.6 **	9.9 **	11.1 *	4.1 **	8.7	7.3	2.2	2.7
	SD	15.5	10.2	13.6	15.0	6.7	12.9	13.1	6.2	8.3
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	1.3	0.8	2.2	172.4
	SD	1.9	1.1	4.0	52.8
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	0.4	0.1	0.9	206.3
	SD	1.1	0.4	1.0	63.0
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	1.5	2.2	3.3	181.5
	SD	3.1	5.7	7.6	57.3
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	1.1	2.1	2.7	202.6
	SD	1.2	5.3	4.8	63.5
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	3.2	2.0	1.3	99.9 **
	SD	7.1	4.9	4.4	67.9
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	58.1	37.8	30.6	25.9	18.1	10.7	4.1	1.3	1.9
	SD	12.5	12.0	13.2	13.7	17.4	10.9	6.7	2.2	3.0
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	69.1	52.7 **	33.9	29.5	22.2	15.3	5.8	2.1	1.0
	SD	14.0	12.3	9.9	14.0	13.8	12.6	10.6	3.7	2.0
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	61.4	38.7	31.1	23.1	14.3	9.2	5.7	1.7	2.3
	SD	17.7	11.8	11.6	11.4	11.1	14.5	8.4	3.0	4.5
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	69.1	42.9	38.6	24.5	15.1	11.7	4.2	1.4	1.7
	SD	14.9	14.0	15.9	13.4	11.5	13.5	6.9	2.8	4.3
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	59.9	42.7	31.5	24.7	17.2	11.2	6.5	5.3	4.6
	SD	11.4	14.3	7.2	12.8	16.4	13.4	10.3	15.8	10.6
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY 7 PRINT DATE 18DEC02

M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	1.7	2.6	0.7	193.4
	SD	2.8	7.7	1.4	59.4
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	1.0	1.0	2.7	236.4
	SD	1.5	1.9	7.4	61.2
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	3.9	1.9	1.0	194.3
	SD	9.0	6.7	2.3	64.6
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	1.9	0.9	1.5	213.7
	SD	2.5	1.6	2.2	66.3
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	3.3	3.9	0.4	211.1
	SD	5.8	9.5	0.9	58.0
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY 14 PRINT DATE 18DEC02

M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	59.8	39.0	31.5	26.0	20.4	15.3	8.2	4.5	2.5
	SD	14.9	12.5	11.3	11.7	8.2	11.6	11.1	9.0	4.8
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	70.5	47.4	33.6	27.4	22.2	14.1	5.7	3.1	3.7
	SD	10.8	14.1	12.9	9.8	16.5	14.3	8.0	8.7	10.8
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	64.0	42.4	33.7	33.3	16.9	17.3	12.1	6.0	2.4
	SD	19.5	11.8	11.2	10.9	12.7	16.0	14.1	11.3	4.9
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	65.7	41.7	36.5	26.8	23.7	12.6	10.5	3.9	0.5
	SD	13.9	14.2	12.1	9.3	13.3	9.7	11.0	8.8	0.6
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	62.3	41.1	33.9	33.2	24.4	13.4	11.7	4.3	4.1
	SD	16.1	13.7	13.0	9.8	13.5	15.0	19.1	7.2	5.6
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	1.0	4.2	1.0	213.4
	SD	1.5	7.8	1.5	49.5
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	1.6	1.1	2.9	233.3
	SD	3.7	2.6	5.9	60.7
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	0.4	0.8	0.6	229.9
	SD	0.9	1.7	1.5	61.4
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	1.3	0.7	7.0	230.9
	SD	2.8	1.8	12.8	69.2
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	2.9	2.0	2.1	235.5
	SD	8.2	3.5	5.1	81.5
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	61.0	39.2	28.9	30.1	20.6	14.3	8.1	2.8	3.9
	SD	16.9	10.5	9.6	12.9	12.2	13.2	10.3	4.0	6.8
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	62.9	40.9	31.8	28.9	22.3	14.4	8.9	1.9	1.3
	SD	15.1	11.2	11.4	9.2	10.5	12.7	13.1	2.3	1.6
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	60.7	43.4	35.2	23.9	20.5	14.2	5.1	4.1	5.7
	SD	12.3	11.4	9.6	13.0	16.1	14.1	8.9	8.8	10.6
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	67.3	43.9	37.1	28.1	20.8	17.4	9.2	11.0	10.3
	SD	11.8	10.9	10.7	10.4	14.2	14.3	9.9	13.1	12.1
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	62.7	42.7	30.2	29.8	20.3	13.9	9.5	7.9	5.7
	SD	15.6	17.6	7.2	10.8	13.1	12.5	10.2	12.8	7.3
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

F E M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	2.3	2.2	0.9	214.2
	SD	3.3	3.8	1.2	51.5
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	0.9	0.7	1.1	216.1
	SD	1.5	0.9	1.6	55.1
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	4.9	2.3	4.4	224.5
	SD	9.0	3.5	9.6	69.1
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	7.4	4.4	2.5	259.3
	SD	9.5	8.5	5.8	46.8
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	11.8	7.1	2.3	243.9
	SD	17.8	12.3	4.4	57.9
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY 0 PRINT DATE 18DEC02

F E M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	65.5	38.1	32.6	26.3	17.4	13.8	6.3	5.3	5.6
	SD	10.7	9.2	8.3	11.9	12.8	11.9	7.6	8.8	12.3
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	64.4	36.7	31.1	21.0	17.8	17.9	11.9	5.2	2.4
	SD	13.8	16.7	9.9	10.6	9.7	12.6	13.0	7.6	5.1
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	63.2	41.1	29.2	22.7	25.1	19.9	11.0	4.5	3.1
	SD	9.9	10.1	12.8	12.2	11.5	12.1	12.5	5.8	9.0
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	67.3	39.1	35.5	27.7	20.5	13.7	12.7	4.9	4.4
	SD	12.9	10.9	9.5	11.6	12.9	11.5	13.4	6.3	6.3
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	37.2 **	14.4 **	5.9 **	6.9 **	4.9 **	4.4 *	4.2	4.1	2.1
	SD	9.5	7.4	8.2	8.5	5.2	5.8	8.2	8.0	4.0
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	5.1	5.1	4.1	225.2
	SD	11.8	9.3	7.3	65.5
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	0.5	4.5	6.1	219.5
	SD	1.1	8.1	9.7	61.8
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	4.1	5.2	6.4	235.5
	SD	9.8	7.9	10.3	66.2
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	3.9	10.3	5.9	246.1
	SD	6.2	13.4	11.9	55.1
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	2.5	8.7	7.5	102.9 **
	SD	5.5	10.6	6.0	22.9
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098 OMETHOATE

GROUP MEANS MOTOR ACTIVITY DAY 7 PRINT DATE 18DEC02

F E M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	61.3	37.3	30.3	20.3	18.9	10.8	8.3	6.8	4.4
	SD	10.2	9.3	12.8	12.7	14.7	11.9	8.9	10.4	9.5
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	59.4	39.4	25.8	26.3	21.5	11.7	8.1	2.6	1.1
	SD	16.7	12.4	9.6	10.6	12.7	13.8	9.5	5.1	2.1
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	62.1	39.7	32.7	27.1	18.1	14.8	9.6	6.9	8.5
	SD	12.7	8.0	11.2	15.8	11.9	14.5	11.6	9.8	11.3
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	58.9	37.5	29.7	26.4	21.5	17.6	12.1	11.9	8.1
	SD	13.0	10.0	11.7	13.2	13.3	11.6	10.8	14.9	11.3
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	60.3	40.7	29.1	27.3	23.8	9.1	5.5	3.5	2.2
	SD	15.4	11.3	9.4	10.9	12.3	7.1	6.5	6.1	5.7
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	2.7	3.0	1.1	205.3
	SD	5.2	7.4	2.4	50.8
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	0.7	4.0	3.1	203.7
	SD	2.1	9.9	7.8	55.1
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	4.5	3.5	9.2	236.7
	SD	8.0	8.1	13.6	73.2
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	4.4	3.1	5.3	236.5
	SD	6.4	5.8	7.7	59.5
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	4.3	2.7	3.0	211.4
	SD	8.7	5.5	5.7	36.7
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

		Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.	Interv. 9 Beam Interr.
GROUP 0										
0 MG/KG	M	66.3	41.3	33.1	23.9	16.5	10.1	7.5	4.3	4.5
	SD	15.7	11.4	13.2	14.6	16.5	11.3	9.4	7.9	8.4
	N	15	15	15	15	15	15	15	15	15
GROUP 1										
0.2 MG/KG	M	62.6	38.0	26.5	21.2	17.4	14.9	12.8	6.5	2.7
	SD	12.5	13.1	11.9	11.2	15.3	13.2	17.4	9.6	6.1
	N	15	15	15	15	15	15	15	15	15
GROUP 2										
0.25 MG/KG	M	59.5	37.3	33.5	29.0	21.1	11.7	10.9	6.8	2.0
	SD	10.5	14.7	11.6	12.7	13.9	12.8	16.2	15.8	3.3
	N	15	15	15	15	15	15	15	15	15
GROUP 3										
0.35 MG/KG	M	60.9	37.7	31.9	21.8	21.5	15.1	11.5	1.9	3.7
	SD	15.2	10.5	13.0	11.9	13.3	14.1	14.5	3.9	9.0
	N	15	15	15	15	15	15	15	15	15
GROUP 4										
5 MG/KG	M	60.4	41.4	28.2	23.1	21.9	14.1	9.4	6.6	4.3
	SD	15.9	12.4	10.9	11.4	12.0	12.0	9.8	7.2	6.1
	N	15	15	15	15	15	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

BASF
Project Number 20C0709/01098

OMETHOATE

GROUP MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

		Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.	Interv.1-12 Sum Interr.
GROUP 0					
0 MG/KG	M	5.5	4.3	1.0	218.4
	SD	13.0	8.1	1.5	75.0
	N	15	15	15	15
GROUP 1					
0.2 MG/KG	M	3.0	4.7	3.4	213.6
	SD	8.4	8.3	9.4	46.5
	N	15	15	15	15
GROUP 2					
0.25 MG/KG	M	0.3	0.3	1.5	214.0
	SD	0.8	0.6	3.3	65.6
	N	15	15	15	15
GROUP 3					
0.35 MG/KG	M	1.9	0.9	0.9	209.5
	SD	4.1	1.9	1.8	53.6
	N	15	15	15	15
GROUP 4					
5 MG/KG	M	1.7	0.6	0.0	211.7
	SD	5.9	1.7	0.0	64.0
	N	15	15	15	15

Kruskal-Wallis + Wilcoxon-tests (two-sided): * p<=0.05; ** p<=0.01 (Statistical unit = Animal)

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day -6 S	ECHE µkat/l E. Day -6 S
Male, GROUP 0		
Mean	12.59	34.22
SD	2.21	2.34
N	10	10
%dev		
Male, GROUP 1		
Mean	13.18	33.06
SD	1.76	4.29
N	10	10
%dev	4.69	-3.40
Male, GROUP 2		
Mean	12.76	33.22
SD	1.92	4.58
N	10	9
%dev	1.33	-2.92
Male, GROUP 3		
Mean	12.55	35.22
SD	1.87	3.09
N	10	10
%dev	-0.35	2.93
Male, GROUP 4		
Mean	13.33	33.16
SD	1.77	3.59
N	10	10
%dev	5.88	-3.10

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 0 S	ECHE µkat/l E. Day 0 S	BCHE µkat/g P. Day 0 S
Male, GROUP 0			
Mean	11.73	31.86	3.87
SD	1.74	3.38	0.70
N	10	10	10
%dev			
Male, GROUP 1			
Mean	11.78	31.51	3.62
SD	1.72	1.25	0.50
N	10	10	10
%dev	0.44	-1.10	-6.40
Male, GROUP 2			
Mean	11.56	27.85*	3.57
SD	1.71	2.24	0.76
N	10	10	10
%dev	-1.37	-12.57	-7.52
Male, GROUP 3			
Mean	10.69	26.76*	3.14
SD	1.46	3.23	0.83
N	10	10	10
%dev	-8.84	-16.00	-18.84
Male, GROUP 4			
Mean	5.41**	7.22**	0.75**
SD	1.14	1.04	0.20
N	10	10	10
%dev	-53.83	-77.34	-80.61

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day -6 S	ECHE µkat/l E. Day -6 S
Female, GROUP 0		
Mean	21.91	34.93
SD	5.89	4.76
N	10	10
%dev		
Female, GROUP 1		
Mean	24.99	35.16
SD	6.36	5.04
N	10	10
%dev	14.05	0.65
Female, GROUP 2		
Mean	25.53	36.52
SD	6.22	3.44
N	10	10
%dev	16.50	4.55
Female, GROUP 3		
Mean	24.91	32.94
SD	3.50	4.67
N	10	10
%dev	13.69	-5.70
Female, GROUP 4		
Mean	24.50	35.24
SD	5.82	5.15
N	10	10
%dev	11.81	0.89

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 0 S	ECHE µkat/l E. Day 0 S	BCHE µkat/g P. Day 0 S
Female, GROUP 0			
Mean	28.65	33.83	4.47
SD	9.95	6.14	0.81
N	10	10	10
%dev			
Female, GROUP 1			
Mean	27.73	31.35	3.83
SD	5.78	2.16	0.81
N	10	9	10
%dev	-3.24	-7.34	-14.39
Female, GROUP 2			
Mean	29.86	31.08	4.03
SD	8.95	4.29	0.50
N	10	10	10
%dev	4.19	-8.14	-10.01
Female, GROUP 3			
Mean	27.21	29.29	3.25*
SD	4.86	3.36	0.94
N	10	10	10
%dev	-5.05	-13.42	-27.43
Female, GROUP 4			
Mean	16.88*	8.31**	0.89**
SD	5.63	1.27	0.15
N	10	10	10
%dev	-41.09	-75.45	-80.20

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Week -1 S	ECHE µkat/l E. Week -1 S
Male, GROUP 0		
Mean	12.00	29.79
SD	1.74	7.29
N	10	10
%dev		
Male, GROUP 1		
Mean	11.35	32.97
SD	1.63	7.69
N	10	10
%dev	-5.43	10.65
Male, GROUP 2		
Mean	12.13	33.18
SD	1.35	4.71
N	10	10
%dev	1.04	11.37
Male, GROUP 3		
Mean	12.46	35.89
SD	0.94	4.65
N	10	10
%dev	3.83	20.45
Male, GROUP 4		
Mean	13.14	34.61
SD	1.78	3.99
N	10	10
%dev	9.45	16.17

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 15 S	ECHE µkat/l E. Day 15 S	BCHE µkat/g P. Day 15 S
Male, GROUP 0			
Mean	10.83	30.85	3.05
SD	1.84	4.28	1.09
N	10	9	10
%dev			
Male, GROUP 1			
Mean	10.03	32.44	3.04
SD	1.60	5.02	0.84
N	10	10	10
%dev	-7.36	5.17	-0.21
Male, GROUP 2			
Mean	11.30	30.58	2.89
SD	1.71	3.85	0.88
N	10	10	10
%dev	4.36	-0.88	-5.38
Male, GROUP 3			
Mean	11.04	30.23	2.78
SD	1.21	3.68	1.34
N	10	10	10
%dev	1.94	-2.00	-8.76
Male, GROUP 4			
Mean	11.73	28.42	2.61
SD	1.47	3.30	0.71
N	10	10	10
%dev	8.37	-7.89	-14.45

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Week -1 S	ECHE µkat/l E. Week -1 S
Female, GROUP 0		
Mean	21.57	37.63
SD	3.84	3.09
N	10	10
%dev		
Female, GROUP 1		
Mean	21.15	36.22
SD	5.89	5.59
N	10	10
%dev	-1.94	-3.74
Female, GROUP 2		
Mean	25.03	32.94
SD	6.51	5.68
N	10	10
%dev	16.05	-12.47
Female, GROUP 3		
Mean	24.83	36.51
SD	8.21	3.35
N	10	10
%dev	15.13	-2.98
Female, GROUP 4		
Mean	24.79	35.65
SD	6.69	4.35
N	10	10
%dev	14.92	-5.25

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 15 S	ECHE µkat/l E. Day 15 S	BCHE µkat/g P. Day 15 S
Female, GROUP 0			
Mean	31.68	31.97	3.66
SD	5.65	2.92	1.28
N	10	10	10
%dev			
Female, GROUP 1			
Mean	33.33	31.84	4.12
SD	11.08	1.67	0.63
N	10	9	10
%dev	5.20	-0.41	12.66
Female, GROUP 2			
Mean	37.18	31.59	3.30
SD	11.01	3.00	1.02
N	10	10	10
%dev	17.35	-1.20	-9.90
Female, GROUP 3			
Mean	41.70	32.64	3.60
SD	12.04	1.47	1.05
N	10	8	10
%dev	31.63	2.09	-1.66
Female, GROUP 4			
Mean	37.04	27.56**	3.41
SD	5.37	1.73	0.55
N	10	9	10
%dev	16.91	-13.81	-6.80

Key: S = Steel test, Two-sided, * p <= 0.050, ** p <= 0.010
Experimental Unit = Animal

ABSOLUTE WEIGHTS - MEAN VALUES (MALES)

Sacrifice group			I1				
Sex			M				
Dose group			0	1	2	3	4
Terminal body weight	g	M	249.06	265.48	244.58	250.6	253.26
		SD	8.245	10.939	13.032	27.117	18.964
		n	5	5	5	5	5
Brain	g	M	1.782	1.874	1.75	1.732	1.83
		SD	0.084	0.065	0.12	0.058	0.113
		n	5	5	5	5	5

* P <= 0.05 ** P <= 0.01 :Kruskal-Wallis-H- + Wilcoxon-Test
two-sided

ABSOLUTE WEIGHTS - MEAN VALUES (FEMALES)

Sacrifice group			I1				
Sex			F				
Dose group			0	1	2	3	4
Terminal body weight	g	M	171.16	179.56	170.2	177.72	188.36
		SD	19.801	12.464	13.54	13.962	9.99
		n	5	5	5	5	5
Brain	g	M	1.734	1.714	1.678	1.736	1.742
		SD	0.087	0.053	0.093	0.11	0.057
		n	5	5	5	5	5

* P <= 0.05 ** P <= 0.01 :Kruskal-Wallis-H- + Wilcoxon-Test
two-sided

RELATIVE WEIGHTS - MEAN VALUES (MALES)

Sacrifice group			I1				
Sex			M				
Dose group			0	1	2	3	4
Terminal body weight	%	M	100.0	100.0	100.0	100.0	100.0
		n	5	5	5	5	5
Brain	%	M	0.717	0.707	0.715	0.696	0.724
		SD	0.052	0.036	0.016	0.059	0.035
		n	5	5	5	5	5

* P <= 0.05 ** P <= 0.01 :Kruskal-Wallis-H- + Wilcoxon-Test
two-sided

RELATIVE WEIGHTS - MEAN VALUES (FEMALES)

Sacrifice group			I1				
Sex			F				
Dose group			0	1	2	3	4
Terminal body weight	%	M	100.0	100.0	100.0	100.0	100.0
		n	5	5	5	5	5
Brain	%	M	1.021	0.957	0.988	0.98	0.926
		SD	0.089	0.049	0.03	0.064	0.033
		n	5	5	5	5	5

* P <= 0.05 ** P <= 0.01 :Kruskal-Wallis-H- + Wilcoxon-Test
two-sided

INCIDENCE OF GROSS LESIONS

Sacrifice group	I1				
Sex	M				
Dose group	0	1	2	3	4
Animals in selected Group	5	5	5	5	5
NAD	5	5	5	5	5

INCIDENCE OF GROSS LESIONS

Sacrifice group	I1				
Sex	F				
Dose group	0	1	2	3	4
Animals in selected Group	5	5	5	5	5
NAD	5	5	5	5	5

INCIDENCE OF MICROSCOPIC FINDINGS

Sacrifice group	I1				
Sex	M				
Dose group	0	1	2	3	4
Animals in selected Group	5	5	5	5	5
Frontal lobe	5	.	.	.	5
Parietal lobe	5	.	.	.	5
Midbrain	5	.	.	.	5
Pons	5	.	.	.	5
Medulla oblongata	5	.	.	.	5
Cerebellum	5	.	.	.	5
Cervical cord	5	.	.	.	5
Lumbar cord	5	.	.	.	5
Cervical ganglia	5	.	.	.	5
Lumbar ganglia	5	.	.	.	5
Gasserian ganglia	5	.	.	.	5
Dorsal root, cerv.	5	.	.	.	5
Dorsal root, lumb.	5	.	.	.	5
Ventral root, cerv.	5	.	.	.	5
Ventral root, lumb.	5	.	.	.	5
Prox. sciatic nerve	5	.	.	.	5
- Axonal degeneration	.	.	.	.	.
Prox.tibial nerve	5	.	.	.	5
- Axonal degeneration	.	.	.	.	.
Distal tibial nerve	5	.	.	.	5
- Axonal degeneration	.	.	.	.	1
Eyes with opt. nerve	5	.	.	.	5
Gastrocnemius muscle	5	.	.	.	5

INCIDENCE OF MICROSCOPIC FINDINGS

Sacrifice group	I1				
Sex	F				
Dose group	0	1	2	3	4
Animals in selected Group	5	5	5	5	5
Frontal lobe	5	.	.	.	5
Parietal lobe	5	.	.	.	5
Midbrain	5	.	.	.	5
Pons	5	.	.	.	5
Medulla oblongata	5	.	.	.	5
Cerebellum	5	.	.	.	5
Cervical cord	5	.	.	.	5
Lumbar cord	5	.	.	.	5
Cervical ganglia	5	.	.	.	5
Lumbar ganglia	5	.	.	.	5
Gasserian ganglia	5	.	.	.	5
Dorsal root, cerv.	5	.	.	.	5
Dorsal root, lumb.	5	.	.	.	5
Ventral root, cerv.	5	.	.	.	5
Ventral root, lumb.	5	.	.	.	5
Prox. sciatic nerve	5	.	.	.	5
- Axonal degeneration	1	.	.	.	.
Prox.tibial nerve	5	.	.	.	5
- Axonal degeneration	.	.	.	.	1
Distal tibial nerve	5	.	.	.	5
- Axonal degeneration	.	.	.	.	.
Eyes with opt. nerve	5	.	.	.	5
Gastrocnemius muscle	5	.	.	.	5

STUDY TITLE

Report

Omethoate – Acute oral neurotoxicity study in Wistar rats
Single administration by gavage

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 20C0709/01098

VOLUME II OF III
(TABLES SECTION, INDIVIDUAL VALUES)

Confidentiality Statement
This report is property of the Dimethoate Task Force with its member companies BASF, Cheminova, and Isagro. This report (752 pages) should not be communicated to third parties, reproduced or published in any form without the proprietors´ explicit written authorization.

CONTENTS OF VOLUME II (TABLES SECTION; INDIVIDUAL VALUES)

Part B:
CLINICAL EXAMINATIONS (INDIVIDUAL VALUES)

Part C:
PATHOLOGY (INDIVIDUAL VALUES)

LIST OF ABBREVIATIONS USED IN TABLES IIA

No.	=	number
bw	=	body weight
MG, mg	=	milligram
KG, kg	=	kilogram
Rear	=	rearing
G, g	=	weight in gram
FST 1	=	landing foot-splay test, first value
FST 2	=	landing foot-splay test ,second value
cm	=	centimeter
GS F 1	=	grip strength forelimbs, first value
GS F 2	=	grip strength forelimbs, second value
GS H 1	=	grip strength hindlimbs, first value
GS H 2	=	grip strength hindlimbs, second value
Interr.	=	beam interrupts
Interv.	=	interval
N	=	number
M	=	male animals
F	=	female animals

Abbreviations/ranking described in the tables of functional observational batteries are explained in Volume III: "Functional observational battery (FOB) Detailed description of examinations, ranking and documentation procedures".

LIST OF ABBREVIATIONS USED IN TABLES IIB

CLINICAL PATHOLOGY:

SCHE	=	serum-cholinesterase
ECHE	=	erythrocyte-cholinesterase
BCHE	=	brain-cholinesterase
µkat/l E.	=	microkatal/liter erythrocytes
µkat/g P.	=	microkatal/gram protein

LIST OF ABBREVIATIONS USED IN TABLES IIC

F	=	female animals
g	=	weight determination in grams
I1	=	test animals selected for perfusion fixation
M	=	male animals (under sex); mean value (on weight level)
mg/kg BW	=	milligram per kilogram body weight under dose level
n	=	number of values measured for the determination of mean value and standard deviation
NAD	=	number of animals without gross lesions
s	=	suspect weight (not included in the mean weights)
SD	=	standard deviation
%	=	percentage related to the reference weight in relative organ weight calculations

Codes for the status at necropsy:

1	=	planned sacrifice
2	=	sacrificed in a moribund state
3	=	spontaneous death

Codes used at finding level:

The codes are used for a grading system which takes into consideration either the severity or the number or the size of a microscopic finding.

	Severity	Number	Size
Grade 1	Minimal	Very few	Very small
Grade 2	Slight	Few	Small
Grade 3	Moderate	Moderate number	Moderate size
Grade 4	Marked; severe	Many	Large
Grade 5	Massive; extreme	Extensive number	Extensive size

Whenever a grading was not used, the microscopic finding was indicated to be present (P).

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	0	7	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	14	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	17	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	19	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	23	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	32	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	33	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	45	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	46	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	51	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	0	65	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	68	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	69	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	0	70	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	75	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	86	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	93	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	97	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	102	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	105	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	222	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	226	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	228	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	238	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	0	239	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	1	1	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	3	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	5	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	15	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	25	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	30	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	35	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	37	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	41	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	42	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	1	53	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	59	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	60	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	1	63	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	79	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	84	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	88	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	95	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	100	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	101	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	216	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	219	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	220	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	231	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	1	233	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	2	2	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	22	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	29	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	34	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	36	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	38	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	43	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	44	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	48	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	52	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	2	55	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	62	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	76	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	2	77	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	78	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	81	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	90	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	94	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	96	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	99	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	213	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	215	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	218	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	224	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	2	237	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	3	4	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	8	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	10	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	11	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	16	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	18	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	24	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	28	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	47	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	50	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	3	56	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	57	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	72	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	3	73	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	74	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	83	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	85	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	91	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	103	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	106	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	221	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	225	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	227	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	230	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	3	232	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	4	9	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	12	Apathy, slight	0
			Sacrificed scheduled	0
M	4	13	Apathy, slight	0
			Sacrificed scheduled	0
M	4	20	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	21	Apathy, slight	0
			Sacrificed scheduled	0
M	4	26	Visually increased respiration, slight	0
			Sacrificed scheduled	0
M	4	27	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	31	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	40	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	49	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
M	4	54	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	58	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	64	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
M	4	66	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	71	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	82	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	87	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	92	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	98	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	104	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	214	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	217	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	229	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	235	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
M	4	236	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	0	109	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	110	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	120	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	125	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	126	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	128	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	129	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	144	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	152	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	157	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	0	162	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	173	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	180	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	0	181	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	184	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	194	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	198	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	201	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	202	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	211	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	243	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	244	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	261	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	264	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	0	266	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	1	108	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	116	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	118	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	130	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	131	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	136	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	143	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	145	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	149	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	150	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	1	161	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	167	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	170	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	1	175	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	185	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	186	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	188	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	193	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	209	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	212	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	241	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	242	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	245	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	246	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	1	257	General observation. Nothing abnormal detected	1-15
			Sacrificed scheduled	15

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	2	111	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	113	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	114	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	122	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	140	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	141	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	142	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	148	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	153	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	155	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	2	159	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	160	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	168	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	2	177	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	183	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	195	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	196	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	197	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	200	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	210	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	240	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	254	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	258	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	259	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	2	265	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Sex	Group	Animal	Observation	Days
F	3	112	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	115	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	119	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	134	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	137	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	138	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	146	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	151	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	154	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	156	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	3	163	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	171	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	174	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Study: 20C0709/01098

OBSERVATIONS REPORT - SUMMARY

Sex	Group	Animal	Observation	Days
F	3	176	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	179	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	190	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	191	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	192	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	203	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	204	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	248	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	250	General observation, Nothing abnormal detected	1-13
			Skin, lesion	15
			Sacrificed scheduled	15
F	3	255	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	260	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	3	263	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

Sex	Group	Animal	Observation	Days
F	4	107	Tremor, slight	0
			Sacrificed scheduled	0
F	4	117	Apathy, slight	0
			Sacrificed scheduled	0
F	4	121	Apathy, slight	0
			Tremor, slight	0
			Sacrificed scheduled	0
F	4	123	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	4	124	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	4	132	Apathy, slight	0
			Sacrificed scheduled	0
F	4	133	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	4	139	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	4	147	Frequent chewing	0
			Sacrificed scheduled	0
F	4	158	General observation, Nothing abnormal detected	0
			Sacrificed scheduled	0
F	4	164	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	165	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	166	General observation, Nothing abnormal detected	1-15

OBSERVATIONS REPORT - SUMMARY

Study: 20C0709/01098

Sex	Group	Animal	Observation	Days
F	4	166	Sacrificed scheduled	15
F	4	178	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	182	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	187	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	205	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	206	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	207	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	208	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	247	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	251	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	252	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	253	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15
F	4	262	General observation, Nothing abnormal detected	1-15
			Sacrificed scheduled	15

FOOD CONSUMPTION

Study: 20C0709/01098

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Male, GROUP 0			
75	19.1	20.6	22.8
65	19.8	22.5	24.0
70	17.3	18.5	20.1
68	19.7	21.4	22.4
69	17.3	19.8	21.5
102	18.8	21.3	22.8
105	17.6	21.7	23.9
86	18.3	20.8	22.7
93	18.7	21.0	23.5
97	18.4	21.5	21.6
239	17.6	19.3	20.8
222	19.5	21.6	22.3
226	18.7	20.3	20.7
228	20.3	21.3	22.6
238	18.8	20.3	22.7
Male, GROUP 1			
53	17.0	18.7	18.9
60	18.4	21.1	21.6
63	19.0	20.1	21.4
79	17.7	19.5	20.3
59	17.5	19.0	18.5
95	19.1	21.9	23.2
100	17.2	19.4	22.0
84	19.7	22.5	24.6
101	17.5	20.6	21.2
88	17.3	19.9	22.2
233	20.3	21.5	22.9
216	19.2	20.9	22.1
220	20.7	21.3	22.0
231	21.6	23.2	25.0
219	21.5	23.5	24.1

FOOD CONSUMPTION

Study: 20C0709/01098

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Male, GROUP 2			
77	16.9	18.4	19.5
78	17.8	20.4	21.5
55	19.4	21.7	23.2
62	19.5	22.0	23.5
76	18.7	21.2	22.1
81	19.2	21.9	22.8
99	17.9	21.0	22.2
94	18.5	21.2	22.8
90	16.6	19.5	20.8
96	17.8	20.5	22.0
215	17.9	18.6	19.7
237	19.0	20.2	21.5
218	19.1	20.2	21.3
213	19.7	19.6	20.9
224	18.7	20.2	21.3
Male, GROUP 3			
73	17.9	18.9	21.0
57	20.7	22.0	23.2
72	19.1	20.9	21.7
56	18.6	19.5	22.4
74	17.4	20.8	21.5
85	19.2	21.4	22.5
103	17.0	19.1	21.2
83	17.7	20.3	21.2
91	17.3	20.1	20.9
106	16.9	19.8	20.8
225	17.9	18.7	19.9
227	17.2	18.5	19.9
230	21.5	23.3	24.2
232	20.3	22.5	24.0
221	21.4	22.9	25.0

Study: 20C0709/01098

FOOD CONSUMPTION

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Male, GROUP 4			
66	16.8	18.6	19.4
64	18.6	20.7	22.2
54	17.3	19.2	21.4
71	16.1	17.4	19.4
58	17.9	20.0	21.4
92	18.0	21.1	22.9
104	18.3	21.8	23.8
87	19.5	21.6	24.1
98	18.4	19.9	22.1
82	20.3	22.6	25.3
229	18.0	18.9	20.8
236	18.5	19.5	20.5
235	20.4	21.6	24.0
217	21.5	22.4	24.4
214	18.2	19.3	21.1

FOOD CONSUMPTION

Study: 20C0709/01098

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Female, GROUP 0			
181	14.3	15.9	16.6
180	16.9	17.6	17.7
173	16.2	17.1	17.5
162	15.1	17.3	17.2
184	13.3	14.2	15.1
211	13.9	15.2	16.1
201	12.8	14.1	14.5
194	15.2	16.2	17.6
198	12.9	15.3	16.2
202	15.3	16.6	17.1
243	13.7	14.2	14.9
261	12.9	13.4	14.8
264	17.2	16.9	18.1
266	15.1	15.4	15.7
244	15.5	16.9	17.6
Female, GROUP 1			
167	14.5	15.2	16.8
161	15.2	15.6	16.6
170	12.9	13.9	15.1
175	14.5	15.2	16.2
185	13.7	14.5	15.1
193	13.9	15.2	15.8
186	14.8	15.6	17.0
212	13.7	14.9	16.0
209	15.5	17.2	17.6
188	15.1	16.4	17.1
241	15.1	15.1	15.5
242	15.9	15.8	15.8
246	15.9	15.2	16.4
245	15.1	15.4	16.1
257	18.0	16.8	17.4

Study: 20C0709/01098

FOOD CONSUMPTION

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Female, GROUP 2			
168	13.7	15.1	16.4
159	14.5	15.9	16.6
160	14.0	15.1	16.5
183	12.9	14.7	15.2
177	14.8	17.0	17.4
210	15.2	16.0	16.9
195	15.8	18.4	19.7
196	14.6	16.0	16.5
200	14.7	15.5	17.1
197	14.1	14.9	16.1
240	14.1	14.3	15.0
265	13.1	14.1	14.2
258	15.9	15.7	16.5
254	15.2	16.1	16.7
259	17.0	16.9	18.1
Female, GROUP 3			
163	12.9	14.5	15.8
176	14.7	15.7	15.7
174	11.6	15.8	16.8
179	14.4	15.8	16.2
171	13.2	13.4	14.5
204	12.7	15.1	16.0
203	15.2	16.6	17.6
192	14.0	15.7	16.2
191	14.2	15.6	17.5
190	14.6	15.0	16.4
263	13.7	14.6	15.7
248	15.2	15.5	16.5
255	15.1	14.8	16.4
260	17.9	17.7	18.5
250	17.3	16.3	17.5

FOOD CONSUMPTION

Study: 20C0709/01098

	Food Cons. g/anm/day Day 0	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14
Female, GROUP 4			
165	13.0	14.0	15.6
164	14.9	16.1	17.0
166	13.5	14.5	13.9
178	13.3	13.5	14.2
182	12.4	13.8	15.1
207	14.1	15.2	15.8
208	14.6	16.5	18.6
187	13.6	14.6	15.2
206	15.3	16.5	15.9
205	14.9	15.7	15.8
253	16.9	17.0	18.0
251	15.8	15.5	16.7
247	17.6	17.4	18.8
262	17.3	17.1	18.0
252	15.8	15.4	16.9

Body Weight
g
Day 0

Male, GROUP 0

23	212.7
46	187.8
17	188.7
45	184.7
19	193.0
51	190.8
7	178.3
33	197.8
14	177.2
32	188.4

Male, GROUP 1

3	200.7
35	204.2
1	200.8
5	195.1
30	194.6
37	180.2
25	187.9
42	198.0
15	193.1
41	194.6

Male, GROUP 2

43	206.0
22	190.6
2	197.2
48	173.4
34	199.6
38	183.6
52	197.0
29	195.7
36	180.4
44	194.7

Male, GROUP 3

10	199.9
4	180.7
8	187.7
16	200.2
50	183.2
47	182.6
28	198.3
24	200.5
11	171.8
18	195.2

Study: 20C0709/01098

	Body Weight g Day 0
Male, GROUP 4	
21	184.2
31	140.6
12	182.7
49	176.3
40	200.0
13	189.7
26	189.0
9	197.4
20	191.0
27	202.7

Study: 20C0709/01098

BODY WEIGHT

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Male, GROUP 0				
75	152.3	194.1	231.6	267.5
65	164.1	197.8	238.6	273.4
70	154.6	184.7	213.8	233.8
68	152.8	193.3	226.6	251.1
69	151.4	182.8	217.8	246.3
102	148.6	191.3	226.8	253.1
105	148.6	183.4	229.9	266.1
86	152.1	190.2	231.9	261.8
93	145.1	180.6	213.9	240.4
97	155.9	190.1	228.5	248.9
239	142.0	180.5	210.7	239.7
222	147.7	192.0	222.9	253.6
226	152.7	186.5	211.9	239.4
228	154.4	191.0	225.1	255.5
238	151.2	186.8	221.5	259.4
Male, GROUP 1				
53	151.8	183.7	217.6	237.7
60	159.3	194.2	227.1	251.9
63	160.1	194.2	228.7	257.0
79	151.4	187.3	218.7	242.0
59	144.9	174.3	199.8	217.5
95	153.8	193.2	231.2	262.5
100	142.2	176.8	211.1	242.4
84	164.8	215.3	258.8	292.3
101	145.4	178.6	212.9	238.7
88	146.2	184.3	217.6	248.2
233	155.4	191.9	228.8	255.6
216	148.3	192.4	231.1	257.9
220	158.6	199.8	228.5	254.9
231	162.3	207.4	241.7	277.4
219	162.4	204.9	241.5	273.5

BODY WEIGHT

Study: 20C0709/01098

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Male, GROUP 2				
77	152.6	185.4	216.6	245.1
78	157.4	198.2	233.9	260.6
55	162.8	201.3	234.2	261.9
62	159.6	192.2	225.8	251.7
76	148.1	184.7	224.7	250.7
81	158.6	199.7	233.0	265.9
99	145.3	180.3	218.7	250.9
94	150.9	189.1	228.1	262.1
90	146.1	183.4	217.2	247.0
96	153.0	191.4	229.4	262.5
215	148.6	182.7	209.3	233.1
237	141.8	177.5	207.1	232.6
218	157.0	193.6	223.5	250.7
213	160.1	199.6	229.9	256.4
224	153.7	196.8	228.1	256.2
Male, GROUP 3				
73	155.0	190.1	223.1	250.2
57	165.5	203.1	238.2	267.4
72	159.6	195.5	233.9	258.7
56	155.3	188.7	222.7	249.0
74	151.8	180.6	217.3	242.8
85	161.3	202.2	234.3	261.1
103	144.3	176.2	208.0	237.4
83	150.4	187.7	225.0	256.2
91	146.7	178.5	210.1	229.9
106	142.1	176.3	212.3	236.8
225	140.5	173.9	196.8	214.9
227	142.0	175.6	204.7	226.7
230	166.5	205.7	242.3	267.2
232	160.0	200.0	241.4	270.3
221	155.1	198.1	233.9	268.3

Study: 20C0709/01098

BODY WEIGHT

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Male, GROUP 4				
66	149.9	180.0	212.1	231.2
64	158.0	197.5	235.1	261.8
54	158.5	193.9	229.9	258.6
71	150.1	178.9	208.3	232.2
58	142.4	181.4	215.8	244.0
92	156.0	193.4	231.2	268.9
104	149.0	186.8	225.4	260.7
87	153.4	190.2	219.9	254.2
98	151.1	186.0	213.1	240.0
82	155.6	200.5	239.6	274.1
229	156.0	187.4	214.8	237.5
236	147.5	182.3	210.6	236.4
235	155.2	203.4	240.0	272.3
217	160.0	198.5	236.2	272.0
214	151.0	186.0	214.4	242.3

BODY WEIGHT

Study: 20C0709/01098

Body Weight g Day 0
Female, GROUP 0
144
110
128
109
157
152
129
126
120
125
Female, GROUP 1
143
150
108
145
131
149
118
136
130
116
Female, GROUP 2
111
141
140
142
155
153
114
148
113
122
Female, GROUP 3
138
115
146
119
134
156
137
154
112
151

134.4	
151.3	
145.1	
147.8	
133.1	
134.5	
149.5	
137.3	
147.2	
143.3	
127.6	
150.5	
144.8	
128.8	
144.9	
138.7	
148.2	
141.6	
153.7	
165.1	
127.2	
149.4	
142.8	
141.4	
130.2	
130.0	
148.7	
138.4	
149.6	
136.3	
137.3	
143.5	
139.8	
134.1	
137.7	
136.5	
144.4	
134.0	
137.9	
139.9	

BODY WEIGHT

Study: 20C0709/01098

	Body Weight g Day 0
Female, GROUP 4	
147	127.9
107	145.7
158	138.6
123	133.7
124	137.5
133	139.2
117	141.5
139	148.9
121	146.3
132	147.6

BODY WEIGHT

Study: 20C0709/01098

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Female, GROUP 0				
181	129.5	148.4	181.5	192.8
180	136.7	159.7	181.9	199.8
173	135.2	160.2	181.0	190.4
162	127.4	149.5	172.2	183.5
184	117.5	133.6	147.7	161.2
211	125.6	139.1	161.4	175.7
201	119.7	131.4	150.7	160.4
194	130.0	151.7	163.5	184.4
198	124.8	138.9	154.2	163.7
202	127.0	147.1	165.1	175.2
243	121.6	128.5	148.3	165.9
261	112.6	126.4	133.4	151.8
264	132.1	163.0	177.0	194.5
266	120.7	138.2	160.2	174.9
244	126.3	144.9	169.3	186.1
Female, GROUP 1				
167	129.3	149.1	162.9	175.6
161	126.7	148.7	168.0	179.8
170	119.1	138.1	149.2	159.6
175	125.5	148.8	163.0	174.2
185	118.5	136.9	149.2	165.5
193	122.4	136.7	150.7	157.0
186	132.5	150.6	172.2	182.4
212	122.1	140.5	147.5	166.9
209	132.5	155.5	167.5	180.5
188	127.7	146.5	163.5	175.5
241	123.8	144.9	160.2	166.8
242	128.8	146.4	169.5	182.9
246	119.8	141.3	156.8	172.2
245	123.1	138.3	158.0	171.1
257	137.3	166.1	182.8	200.2

Study: 20C0709/01098

BODY WEIGHT

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Female, GROUP 2				
168	124.6	149.6	167.4	178.6
159	128.5	150.6	167.5	173.7
160	120.8	138.8	152.2	170.8
183	120.0	136.8	149.5	163.7
177	124.2	150.8	173.9	186.2
210	127.5	150.9	170.0	181.9
195	133.6	150.6	176.7	189.5
196	134.1	146.9	175.0	185.7
200	128.2	144.3	161.6	176.9
197	129.7	146.9	164.3	170.4
240	118.1	131.0	150.9	162.7
265	111.0	128.6	144.1	155.7
258	129.4	146.6	163.5	174.1
254	122.2	145.8	161.2	171.5
259	133.4	158.7	173.4	196.6
Female, GROUP 3				
163	121.1	140.3	156.1	167.9
176	126.7	151.1	162.8	175.2
174	118.0	136.7	163.7	179.3
179	129.3	148.5	168.4	184.6
171	122.3	138.0	151.3	160.9
204	124.6	142.3	152.4	168.1
203	126.4	141.5	165.9	180.9
192	125.5	143.0	159.9	176.8
191	130.9	151.3	159.6	182.1
190	126.0	143.4	160.0	170.4
263	110.4	130.2	146.5	159.3
248	124.0	142.1	163.1	179.9
255	122.4	146.0	161.9	174.9
260	130.6	158.7	173.8	191.3
250	133.3	157.9	170.1	178.0

BODY WEIGHT

Study: 20C0709/01098

	Body Weight g Day -7	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14
Female, GROUP 4				
165	122.6	142.8	152.8	164.3
164	131.1	153.8	172.6	186.2
166	123.3	144.1	158.4	156.8
178	123.3	142.4	153.9	159.4
182	119.0	131.6	146.3	162.5
207	123.4	142.7	159.3	171.1
208	127.8	145.3	164.8	181.6
187	129.0	144.0	160.9	171.3
206	126.8	156.0	177.0	187.4
205	129.1	144.8	166.1	177.5
253	129.3	150.5	172.7	186.3
251	114.2	144.7	161.1	173.3
247	131.8	153.3	176.6	195.7
262	130.7	154.2	181.3	197.1
252	129.0	148.9	163.2	178.9

Omethoate

Table II A 37

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Posture	(0-7)	0	0	0	0	0	0	0	0	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	0	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	1	1	0	0	0	0	0	0	0	0
Urine	(0-3)	0	1	0	0	1	0	0	1	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Approach response	(0-3)	1	0	1	0	0	1	0	0	0	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 239	222	226	228	238
Posture	(0-7)	0	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 239	222	226	228	238
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	0	1	0	0
Urine	(0-3)	1	0	1	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 239	222	226	228	238
Approach response	(0-3)	0	0	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Posture	(0-7)	0	0	0	0	1	1	0	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	1	1	0	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	1	0	1	0	1	0	0	0	1	0
Urine	(0-3)	0	0	1	1	1	0	0	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Approach response	(0-3)	1	0	1	0	0	0	0	1	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 233	216	220	231	219
Posture	(0-7)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 233	216	220	231	219
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	1	1	1
Urine	(0-3)	0	1	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 233	216	220	231	219
Approach response	(0-3)	0	0	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Posture	(0-7)	1	0	0	0	0	0	1	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0	0	1	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	1	0	0	0	0	0	1
Urine	(0-3)	0	1	1	1	0	0	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Approach response	(0-3)	1	0	0	1	0	1	0	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 215	237	218	213	224
Posture	(0-7)	0	0	1	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 215	237	218	213	224
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	0	1	1
Urine	(0-3)	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 215	237	218	213	224
Approach response	(0-3)	0	0	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Posture	(0-7)	0	0	0	0	0	1	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	1	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Table II A 56

Individual values

Open field observations	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	1	1	0	0	0	0	0
Urine	(0-3)	0	1	0	1	1	1	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Approach response	(0-3)	0	0	1	0	0	0	0	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 225	227	230	232	221
Posture	(0-7)	1	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 225	227	230	232	221
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	1	1	1
Urine	(0-3)	0	0	1	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 225	227	230	232	221
Approach response	(0-3)	0	0	0	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Posture	(0-7)	0	0	0	1	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	1	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7 Individual values

Open field observations	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1	1	0	0	0	0
Urine	(0-3)	0	0	0	0	0	0	0	0	1	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Approach response	(0-3)	0	0	1	0	1	1	0	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 229	236	235	217	214
Posture	(0-7)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Table IIA 65

Individual values

Open field observations	Rank	Animal No. 229	236	235	217	214
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	0	1	0
Urine	(0-3)	0	1	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 229	236	235	217	214
Approach response	(0-3)	0	0	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Posture	(0-7)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	0	1	0	0	0	0	0
Urine	(0-3)	1	1	0	1	0	0	0	1	0	1

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Approach response	(0-3)	1	0	1	1	1	0	0	1	1	1
Touch response	(0-4)	0	0	0	0	0	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0 Individual values

Home cage observation	Rank	Animal No. 239	222	226	228	238
Posture	(0-7)	0	0	1	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 239	222	226	228	238
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	0	1	0	1
Urine	(0-3)	1	0	0	1	1

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0 Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 239	222	226	228	238
Approach response	(0-3)	0	1	0	1	1
Touch response	(0-4)	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 73

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Posture	(0-7)	0	0	0	0	0	0	1	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	1	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0 Individual values

Open field observations	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	1	0	0	0	0	0
Feces	(0-6)	1	0	1	1	1	0	1	1	0	0
Urine	(0-3)	0	1	1	1	1	0	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Approach response	(0-3)	1	1	0	1	0	0	0	0	1	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 233	216	220	231	219
Posture	(0-7)	1	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 233	216	220	231	219
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	1	0	1
Urine	(0-3)	0	1	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 233	216	220	231	219
Approach response	(0-3)	1	1	0	1	1
Touch response	(0-4)	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 79

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Posture	(0-7)	0	1	0	0	0	0	1	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0	0	1	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	1	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1	0	0	1	0	1
Urine	(0-3)	1	1	0	0	1	1	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Approach response	(0-3)	0	0	1	0	0	0	1	1	1	1
Touch response	(0-4)	0	0	1	0	0	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	1	0	0	2	1	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 215	237	218	213	224
Posture	(0-7)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 215	237	218	213	224
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	1
Feces	(0-6)	0	1	1	1	0
Urine	(0-3)	0	1	1	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 215	237	218	213	224
Approach response	(0-3)	0	0	1	1	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Posture	(0-7)	1	0	0	1	0	1	0	0	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	1	0	1	0	0	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0 Individual values

Open field observations	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	1*)	0	0	0	0	0	0
Respiration	(0-4)	0	0	4	0	3	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1	1	0	1	0	1
Urine	(0-3)	0	1	1	0	1	1	0	1	0	0

*) = eyelid right

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0 Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Approach response	(0-3)	1	0	0	0	0	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	2	0	0	0	0	0	1	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 225	227	230	232	221
Posture	(0-7)	0	0	0	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	1	1
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 225	227	230	232	221
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	1	1
Urine	(0-3)	0	0	1	0	1

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 225	227	230	232	221
Approach response	(0-3)	0	0	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Posture	(0-7)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	3	0	0	0	0	0	4	0	0	4
Tremors	(0-3)	0	0	0	0	0	0	1	1	1	1
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	3	3	1	3	1	1	3	3	1	3
Activity/Arousal level	(0-4)	1	0	0	1	0	0	0	0	0	0
Feces	(0-6)	0	1	1	0	1	1	4	0	0	0
Urine	(0-3)	1	1	1	0	1	1	0	1	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Approach response	(0-3)	0	1	0	0	0	0	0	0	0	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	1	2	1	2	2	1	2	2	1	1
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 229	236	235	217	214
Posture	(0-7)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	4	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 229	236	235	217	214
Behaviour when removed from cage	(0-4)	0	2	0	0	0
Fur	(0-5)	2	0	0	0	2
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	4	0
Tremors	(0-3)	1	1	1	0	1
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	4	0	0	4	0
Impairment of gait	(0-7)	3	1	3	1	3
Activity/Arousal level	(0-4)	0	0	1	0	0
Feces	(0-6)	1	0	4	0	0
Urine	(0-3)	0	1	1	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 229	236	235	217	214
Approach response	(0-3)	0	1	0	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	2	1	1	2	2
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Posture	(0-7)	0	0	1	1	0	0	0	1	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	1	0	0	0	1	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1	0	0	0	0	1
Urine	(0-3)	0	1	0	0	0	0	0	1	0	1

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Approach response	(0-3)	1	1	0	1	1	1	0	1	0	0
Touch response	(0-4)	0	0	0	0	0	1	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 239	222	226	228	238
Posture	(0-7)	0	0	0	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	1	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 239	222	226	228	238
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0
Urine	(0-3)	1	0	0	0	0

Omethoate

Table IIA 102

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 239	222	226	228	238
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 103

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Posture	(0-7)	0	0	1	0	0	0	1	0	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	0	0	1	0	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	1	1	1	0	0	0	1	1	1	0
Urine	(0-3)	0	1	1	1	1	0	0	0	0	0

Omethoate

Table IIA 105

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Approach response	(0-3)	0	0	0	1	1	0	1	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7 Individual values

Home cage observation	Rank	Animal No. 233	216	220	231	219
Posture	(0-7)	0	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 233	216	220	231	219
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	0	0	1
Urine	(0-3)	0	1	1	1	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 233	216	220	231	219
Approach response	(0-3)	0	1	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 109

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Posture	(0-7)	0	0	1	0	0	0	1	1	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	0	0	1	1	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	1	0	1	0	0	0	1	1
Urine	(0-3)	1	1	1	0	1	1	0	1	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Approach response	(0-3)	0	1	1	1	1	0	0	1	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	1	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7 Individual values

Home cage observation	Rank	Animal No. 215	237	218	213	224
Posture	(0-7)	1	0	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 215	237	218	213	224
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1
Urine	(0-3)	1	0	0	0	1

Omethoate

Table IIA 114

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 215	237	218	213	224
Approach response	(0-3)	1	0	1	1	0
Touch response	(0-4)	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 115

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Posture	(0-7)	0	1	0	1	0	1	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	1	0	1	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 116

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1	1	0	0	0	1
Urine	(0-3)	0	1	0	1	1	1	1	0	0	1

Omethoate

Table IIA 117

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Approach response	(0-3)	1	0	1	0	0	1	1	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 225	227	230	232	221
Posture	(0-7)	0	0	1	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 225	227	230	232	221
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	1	1	1	1
Urine	(0-3)	0	1	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 225	227	230	232	221
Approach response	(0-3)	0	0	0	1	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 121

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Posture	(0-7)	0	0	0	0	0	0	0	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	0	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	0	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	1	0	0	0	0
Feces	(0-6)	1	1	1	1	1	1	0	1	0	0
Urine	(0-3)	1	1	1	0	1	1	0	0	1	0

Omethoate

Table IIA 123

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Approach response	(0-3)	0	0	1	1	1	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 229	236	235	217	214
Posture	(0-7)	1	1	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 229	236	235	217	214
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	0	1	1	1
Urine	(0-3)	1	1	1	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 229	236	235	217	214
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14 Individual values

Home cage observation	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Posture	(0-7)	1	1	1	0	1	1	1	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	0	1	1	1	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	0	0	0	0	0	0	0
Urine	(0-3)	1	0	0	1	0	0	0	1	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 75	65	70	68	69	102	105	86	93	97
Approach response	(0-3)	0	1	1	1	0	1	1	0	1	1
Touch response	(0-4)	1	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14 Individual values

Home cage observation	Rank	Animal No. 239	222	226	228	238
Posture	(0-7)	0	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 239	222	226	228	238
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	1	0
Urine	(0-3)	1	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 239	222	226	228	238
Approach response	(0-3)	0	0	1	1	0
Touch response	(0-4)	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 133

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Posture	(0-7)	0	0	0	0	0	1	1	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	1	1	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	1	0	0	1	0	0	0
Urine	(0-3)	0	0	0	1	1	0	1	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 53	60	63	79	59	95	100	84	101	88
Approach response	(0-3)	0	1	1	0	1	1	1	1	0	1
Touch response	(0-4)	0	0	1	0	1	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 233	216	220	231	219
Posture	(0-7)	1	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 137

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 233	216	220	231	219
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1
Urine	(0-3)	0	1	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 233	216	220	231	219
Approach response	(0-3)	0	1	0	1	1
Touch response	(0-4)	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 139

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Posture	(0-7)	0	1	1	0	0	1	1	0	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	1	0	0	1	1	0	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1	0	0	0	0	1
Urine	(0-3)	1	1	0	0	1	1	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 77	78	55	62	76	81	99	94	90	96
Approach response	(0-3)	1	1	0	0	1	0	1	1	1	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 215	237	218	213	224
Posture	(0-7)	1	0	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	1
Other findings		0	0	0	0	0

Omethoate

Table IIA 143

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 215	237	218	213	224
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	1	0	0	1
Urine	(0-3)	1	1	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 215	237	218	213	224
Approach response	(0-3)	0	1	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Posture	(0-7)	1	0	0	1	1	1	0	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	1	1	1	0	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	1	1	0	0	0	1	1
Urine	(0-3)	1	0	0	0	1	1	1	0	0	0

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Table IIA 147

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 73	57	72	56	74	85	103	83	91	106
Approach response	(0-3)	0	1	0	0	1	0	0	1	1	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 225	227	230	232	221
Posture	(0-7)	1	1	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 225	227	230	232	221
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1
Urine	(0-3)	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 225	227	230	232	221
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Posture	(0-7)	0	1	0	0	1	1	1	1	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	1	1	1	1	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	1	1	1	0	0	1	1	0
Urine	(0-3)	0	1	0	0	1	1	0	1	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 66	64	54	71	58	92	104	87	98	82
Approach response	(0-3)	1	1	0	1	1	1	0	1	0	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 229	236	235	217	214
Posture	(0-7)	1	0	1	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 229	236	235	217	214
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1
Urine	(0-3)	0	0	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
male animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 229	236	235	217	214
Approach response	(0-3)	0	0	1	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Posture	(0-7)	0	0	0	0	0	0	0	1	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	1	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0	1	0	0	0	0
Urine	(0-3)	1	1	1	0	0	1	1	1	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Approach response	(0-3)	1	0	0	1	0	0	1	0	0	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 160

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 243	261	264	266	244
Posture	(0-7)	1	0	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 243	261	264	266	244
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0
Urine	(0-3)	0	0	1	1	0

Omethoate

Table IIA 162

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 243	261	264	266	244
Approach response	(0-3)	0	0	1	1	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 163

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Posture	(0-7)	0	0	0	0	1	0	0	0	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	1	0	0	0	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	1	0	1	0	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Approach response	(0-3)	1	0	1	0	0	0	0	1	1	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	1
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 241	242	246	245	257
Posture	(0-7)	0	0	1	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 241	242	246	245	257
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	0	1	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 241	242	246	245	257
Approach response	(0-3)	0	1	0	1	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Table IIA 169

Individual values

Home cage observation	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Posture	(0-7)	0	1	0	0	0	0	1	0	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0	0	1	0	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0	0	0	0	0	0
Urine	(0-3)	0	0	0	0	0	0	1	1	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Approach response	(0-3)	1	1	0	0	0	0	1	0	1	1
Touch response	(0-4)	0	1	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 240	265	258	254	259
Posture	(0-7)	0	0	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	1
Other findings		0	0	0	0	0

Omethoate

Table IIA 173

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 240	265	258	254	259
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	0	0	1

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 240	265	258	254	259
Approach response	(0-3)	0	1	1	1	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Posture	(0-7)	1	0	0	0	0	0	1	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0	0	1	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	0	0	0	1	0	1	1	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Approach response	(0-3)	0	1	0	0	0	1	1	1	1	0
Touch response	(0-4)	0	1	0	0	0	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 263	248	255	260	250
Posture	(0-7)	1	0	0	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	1	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 263	248	255	260	250
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	1
Urine	(0-3)	1	1	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 263	248	255	260	250
Approach response	(0-3)	1	1	1	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 181

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Home cage observation	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Posture	(0-7)	1	0	1	1	1	0	0	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	1	0	0	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	1	0	0	1	0	0	0	0	0
Urine	(0-3)	0	1	0	0	0	1	0	0	0	0

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Table IIA 183

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Approach response	(0-3)	0	1	0	0	1	1	1	0	0	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	1	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Table IIA 184

Individual values

Home cage observation	Rank	Animal No. 253	251	247	262	252
Posture	(0-7)	1	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Open field observations	Rank	Animal No. 253	251	247	262	252
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	0	1	1	1

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day -7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 253	251	247	262	252
Approach response	(0-3)	1	0	1	0	0
Touch response	(0-4)	1	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Posture	(0-7)	0	0	0	0	0	0	1	0	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	1	0	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	0	0	0	1	0	0	0	0

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 189

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Approach response	(0-3)	1	1	0	0	1	0	1	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 190

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 243	261	264	266	244
Posture	(0-7)	1	0	1	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 191

Individual values

Open field observations	Rank	Animal No. 243	261	264	266	244
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	0	1	0	1

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 243	261	264	266	244
Approach response	(0-3)	1	0	0	1	1
Touch response	(0-4)	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 193

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Posture	(0-7)	0	1	0	0	0	1	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	0	0	1	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 194

Individual values

Open field observations	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0	0	0	0	0	1
Urine	(0-3)	0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

Omethoate

Table IIA 195

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Approach response	(0-3)	1	1	1	0	1	0	1	1	0	1
Touch response	(0-4)	1	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table II A 196

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 241	242	246	245	257
Posture	(0-7)	0	0	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	1	1
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 197

Individual values

Open field observations	Rank	Animal No. 241	242	246	245	257
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	0	0	0	0
Urine	(0-3)	1	0	1	0	0

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 198

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 241	242	246	245	257
Approach response	(0-3)	1	0	1	1	1
Touch response	(0-4)	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 199

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Posture	(0-7)	1	0	0	0	0	0	0	0	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0	0	0	0	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 200

Individual values

Open field observations	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	1
Urine	(0-3)	0	0	0	0	0	0	1	1	1	0

Omethoate

Table IIA 201

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Approach response	(0-3)	1	1	0	0	1	0	1	1	0	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	1	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 202

Individual values

Home cage observation	Rank	Animal No. 240	265	258	254	259
Posture	(0-7)	0	0	1	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	1	1	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 203

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 240	265	258	254	259
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0
Urine	(0-3)	0	1	0	0	0

Omethoate

Table IIA 204

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 240	265	258	254	259
Approach response	(0-3)	0	1	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	1	0	0	1	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 205

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Posture	(0-7)	0	0	0	0	0	1	0	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	1	0	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 206

Individual values

Open field observations	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	3	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	3	0	0	0	0	0
Feces	(0-6)	1	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	0	0	0	0	0	0	0	1	1

Omethoate

Table IIA 207

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Approach response	(0-3)	0	0	1	0	0	1	0	1	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	1	1	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 263	248	255	260	250
Posture	(0-7)	1	1	0	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	1	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 263	248	255	260	250
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	1	0	1
Urine	(0-3)	0	1	1	1	1

Omethoate

Table IIA 210

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 263	248	255	260	250
Approach response	(0-3)	1	1	0	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	2	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 211

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Posture	(0-7)	0	0	0	0	0	0	0	0	0	2
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 212

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Open field observations	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	4	0	0	4	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	1	1	0	1	0	1
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	3	3	3	2	4	3	3	3	1	3
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	0	0	1	0	0	1	0	1

Omethoate

Table IIA 213

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Approach response	(0-3)	1	0	0	1	0	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	1	1	1	1	1	1	1	1	1
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 214

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Individual values

Home cage observation	Rank	Animal No. 253	251	247	262	252
Posture	(0-7)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 215

Individual values

Open field observations	Rank	Animal No. 253	251	247	262	252
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	2
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	1	1	1	1	1
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	4	0	0	4	0
Impairment of gait	(0-7)	3	3	1	3	3
Activity/Arousal level	(0-4)	0	1	0	0	1
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	1	1	1

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 0

Table IIA 216

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 253	251	247	262	252
Approach response	(0-3)	0	1	0	1	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	2	2	2	2	2
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Table IIA 217

Individual values

Home cage observation	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Posture	(0-7)	1	0	0	0	0	1	1	1	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	0	0	1	1	1	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	1	0	0	0	0	0	0	0
Urine	(0-3)	0	1	1	0	1	1	1	0	0	1

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Table IIA 219

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Approach response	(0-3)	0	0	0	1	1	0	1	1	0	1
Touch response	(0-4)	1	0	1	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 243	261	264	266	244
Posture	(0-7)	1	1	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 243	261	264	266	244
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 243	261	264	266	244
Approach response	(0-3)	0	1	1	1	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Posture	(0-7)	0	1	0	1	0	1	1	1	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	0	1	0	1	1	1	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	1	1	0	0	1	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Approach response	(0-3)	0	0	1	0	0	0	1	1	1	0
Touch response	(0-4)	0	0	1	0	1	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 241	242	246	245	257
Posture	(0-7)	0	1	1	1	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	1	1	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 241	242	246	245	257
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	1	0	0	0	0
Urine	(0-3)	1	1	0	0	1

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 241	242	246	245	257
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 229

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Posture	(0-7)	1	1	0	1	0	1	1	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	1	0	1	1	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	1	0	0	0	1
Urine	(0-3)	0	0	1	1	0	1	1	1	1	0

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Table IIA 2.31

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Approach response	(0-3)	0	0	0	0	0	1	0	1	1	1
Touch response	(0-4)	1	0	1	0	0	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	1	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 240	265	258	254	259
Posture	(0-7)	1	0	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	1
Other findings		0	0	0	0	0

Omethoate

Table IIA 233

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 240	265	258	254	259
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	0	0	1	0	1

Omethoate

Table IIA 234

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 240	265	258	254	259
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Posture	(0-7)	0	0	0	0	0	1	0	1	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	0	0	0	0	1	0	1	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	1	0	0	0	0	0	1	0	0	0
Urine	(0-3)	1	1	0	0	1	1	1	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Approach response	(0-3)	0	0	1	1	1	1	0	1	1	0
Touch response	(0-4)	1	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 263	248	255	260	250
Posture	(0-7)	1	0	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 263	248	255	260	250
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	0	0	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 263	248	255	260	250
Approach response	(0-3)	0	0	0	1	0
Touch response	(0-4)	0	0	1	1	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 241

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Posture	(0-7)	0	1	1	0	0	1	1	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	0	1	1	0	0	1	1	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	0	0	0	1	1	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Approach response	(0-3)	1	1	0	0	0	0	1	1	1	1
Touch response	(0-4)	0	1	0	0	1	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 244

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Home cage observation	Rank	Animal No. 253	251	247	262	252
Posture	(0-7)	1	0	1	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Open field observations	Rank	Animal No. 253	251	247	262	252
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	0	0	0	1	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 7

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 253	251	247	262	252
Approach response	(0-3)	0	1	0	1	1
Touch response	(0-4)	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Posture	(0-7)	1	0	0	1	1	1	1	1	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	0	1	1	1	1	1	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14 Individual values

Open field observations	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	1	1	1	0	1	0	1	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 0 0 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 181	180	173	162	184	211	201	194	198	202
Approach response	(0-3)	1	1	1	1	0	1	1	0	1	0
Touch response	(0-4)	0	0	0	0	0	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 250

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 243	261	264	266	244
Posture	(0-7)	1	1	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 243	261	264	266	244
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	0	1	0

Omethoate

BASF Project No. 20C0709/01098
Group 0 0 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 243	261	264	266	244
Approach response	(0-3)	1	0	1	1	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 253

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Posture	(0-7)	1	0	1	1	1	1	1	1	0	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	0	1	1	1	1	1	1	0	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	1	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 167	161	170	175	185	193	186	212	209	188
Approach response	(0-3)	1	0	1	1	0	1	1	1	0	0
Touch response	(0-4)	0	0	0	0	0	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 241	242	246	245	257
Posture	(0-7)	0	1	1	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	1	0	0
Other findings		0	0	0	0	0

BASF Project No. 20C0709/01098
Group 1 0.2 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 241	242	246	245	257
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	0	0	1

Omethoate

BASF Project No. 20C0709/01098

Group 1 0.2 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 241	242	246	245	257
Approach response	(0-3)	0	1	1	1	0
Touch response	(0-4)	0	1	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

Table IIA 259

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Posture	(0-7)	1	1	1	0	0	1	1	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	0	0	1	1	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	0	1	0	0	1	0	1	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 168	159	160	183	177	210	195	196	200	197
Approach response	(0-3)	0	1	1	1	0	1	0	1	0	1
Touch response	(0-4)	0	1	0	0	0	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

Omethoate

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Table IIA 262

Individual values

Home cage observation	Rank	Animal No. 240	265	258	254	259
Posture	(0-7)	0	1	1	1	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	0	1	1	1	1
Other findings		0	0	0	0	0

Omethoate

Table IIA 263

BASF Project No. 20C0709/01098
Group 2 0.25 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 240	265	258	254	259
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	0	0	0	0	1

Omethoate

Table IIA 264

BASF Project No. 20C0709/01098

Group 2 0.25 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 240	265	258	254	259
Approach response	(0-3)	0	1	1	0	0
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Posture	(0-7)	1	1	1	0	1	1	1	1	1	1
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	0	1	1	1	1	1	1
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	1	0	0	0	0	0	0	0	0	0
Urine	(0-3)	1	1	1	1	0	1	0	0	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14 Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 163	176	174	179	171	204	203	192	191	190
Approach response	(0-3)	1	0	1	1	0	1	0	1	1	1
Touch response	(0-4)	0	0	0	0	0	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 263	248	255	260	250
Posture	(0-7)	1	1	0	0	1
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	0	0	1
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 263	248	255	260	250
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	1	0	0	0

Omethoate

BASF Project No. 20C0709/01098

Group 3 0.35 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 263	248	255	260	250
Approach response	(0-3)	1	1	0	0	0
Touch response	(0-4)	0	0	1	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Posture	(0-7)	1	1	1	1	0	0	1	1	1	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	0	0	1	1	1	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 272

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Behaviour when removed from cage	(0-4)	0	0	0	0	0	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0	0	0	0	0	0
Urine	(0-3)	0	0	0	0	1	0	0	0	1	1

Omethoate

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 165	164	166	178	182	207	208	187	206	205
Approach response	(0-3)	1	0	1	1	0	0	1	1	1	0
Touch response	(0-4)	0	0	0	0	0	0	0	0	1	0
Vision	(0-1)	0	0	0	0	0	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0	0	0	0	0	0
Other findings		0	0	0	0	0	0	0	0	0	0

Omethoate

Table IIA 274

BASF Project No. 20C0709/01098

Group 4 5 mg/kg bw

female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Home cage observation	Rank	Animal No. 253	251	247	262	252
Posture	(0-7)	1	1	1	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	0	0
Other findings		0	0	0	0	0

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Open field observations	Rank	Animal No. 253	251	247	262	252
Behaviour when removed from cage	(0-4)	0	0	0	0	0
Fur	(0-5)	0	0	0	0	0
Skin	(0-7)	0	0	0	0	0
Salivation	(0-3)	0	0	0	0	0
Nose discharge	(0-2)	0	0	0	0	0
Lacrimation	(0-3)	0	0	0	0	0
Eyes/Pupil size	(0-7)	0	0	0	0	0
Posture	(0-7)	1	1	1	1	1
Palpebral closure	(0-3)	0	0	0	0	0
Respiration	(0-4)	0	0	0	0	0
Tremors	(0-3)	0	0	0	0	0
Convulsions	(0-3)	0	0	0	0	0
Abnormal movements/Stereotypics	(0-4)	0	0	0	0	0
Impairment of gait	(0-7)	1	1	1	1	1
Activity/Arousal level	(0-4)	0	0	0	0	0
Feces	(0-6)	0	0	0	0	0
Urine	(0-3)	1	0	1	0	1

Omethoate

BASF Project No. 20C0709/01098
Group 4 5 mg/kg bw
female animals

FUNCTIONAL OBSERVATIONAL BATTERY day 14

Individual values

Sensorimotor tests/reflexes	Rank	Animal No. 253	251	247	262	252
Approach response	(0-3)	1	1	0	0	1
Touch response	(0-4)	0	0	0	0	0
Vision	(0-1)	0	0	0	0	0
Pupillary reflex	(0-3)	0	0	0	0	0
Pinna reflex	(0-1)	0	0	0	0	0
Audition	(0-3)	0	0	0	0	0
Coordination of movements	(0-3)	0	0	0	0	0
Behaviour during handling	(0-3)	0	0	0	0	0
Vocalization	(0-3)	0	0	0	0	0
Pain perception	(0-3)	0	0	0	0	0
Other findings		0	0	0	0	0

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Male, GROUP 0				
75	1.0	0.0	0.0	0.0
65	3.0	4.0	2.0	1.0
70	0.0	0.0	0.0	0.0
68	0.0	4.0	3.0	0.0
69	0.0	2.0	2.0	0.0
102	0.0	0.0	0.0	0.0
105	0.0	0.0	0.0	0.0
86	0.0	0.0	0.0	0.0
93	0.0	0.0	0.0	0.0
97	0.0	0.0	1.0	0.0
239	7.0	1.0	0.0	0.0
222	0.0	0.0	0.0	0.0
226	3.0	4.0	2.0	0.0
228	0.0	0.0	0.0	1.0
238	0.0	2.0	0.0	0.0
Male, GROUP 1				
53	3.0	3.0	4.0	0.0
60	0.0	0.0	3.0	0.0
63	4.0	4.0	2.0	0.0
79	0.0	4.0	0.0	5.0
59	3.0	4.0	0.0	0.0
95	0.0	0.0	0.0	0.0
100	0.0	3.0	3.0	1.0
84	0.0	2.0	1.0	0.0
101	1.0	0.0	1.0	0.0
88	0.0	0.0	0.0	0.0
233	4.0	6.0	2.0	0.0
216	5.0	5.0	4.0	0.0
220	2.0	1.0	0.0	3.0
231	1.0	0.0	0.0	0.0
219	2.0	3.0	3.0	2.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Male, GROUP 2				
77	0.0	0.0	0.0	0.0
78	0.0	0.0	3.0	0.0
55	3.0	3.0	4.0	2.0
62	3.0	0.0	0.0	0.0
76	0.0	5.0	4.0	2.0
81	0.0	0.0	0.0	0.0
99	0.0	0.0	0.0	0.0
94	0.0	1.0	0.0	0.0
90	0.0	0.0	2.0	0.0
96	3.0	1.0	2.0	2.0
215	4.0	0.0	0.0	0.0
237	5.0	4.0	1.0	3.0
218	0.0	2.0	0.0	0.0
213	4.0	2.0	2.0	0.0
224	3.0	0.0	4.0	1.0
Male, GROUP 3				
73	0.0	0.0	0.0	0.0
57	0.0	4.0	3.0	3.0
72	3.0	0.0	0.0	0.0
56	3.0	6.0	3.0	3.0
74	1.0	2.0	3.0	3.0
85	0.0	3.0	2.0	0.0
103	0.0	0.0	0.0	0.0
83	0.0	2.0	0.0	0.0
91	0.0	0.0	0.0	1.0
106	0.0	6.0	1.0	2.0
225	1.0	0.0	5.0	0.0
227	4.0	0.0	3.0	0.0
230	6.0	2.0	1.0	3.0
232	1.0	2.0	2.0	0.0
221	4.0	3.0	1.0	1.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Male, GROUP 4				
66	0.0	0.0	2.0	0.0
64	7.0	1.0	2.0	3.0
54	0.0	2.0	2.0	3.0
71	2.0	0.0	3.0	4.0
58	3.0	2.0	3.0	3.0
92	1.0	1.0	1.0	0.0
104	0.0	1.0	0.0	0.0
87	0.0	0.0	6.0	1.0
98	0.0	0.0	0.0	1.0
82	0.0	0.0	0.0	0.0
229	3.0	1.0	4.0	0.0
236	3.0	0.0	0.0	0.0
235	0.0	2.0	2.0	1.0
217	2.0	0.0	1.0	0.0
214	0.0	0.0	1.0	2.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Female, GROUP 0				
181	0.0	0.0	0.0	0.0
180	0.0	0.0	0.0	0.0
173	5.0	0.0	3.0	0.0
162	0.0	0.0	0.0	0.0
184	0.0	0.0	0.0	0.0
211	1.0	0.0	0.0	0.0
201	0.0	0.0	0.0	0.0
194	0.0	0.0	0.0	0.0
198	0.0	0.0	0.0	0.0
202	0.0	0.0	0.0	0.0
243	0.0	0.0	0.0	0.0
261	0.0	0.0	0.0	0.0
264	2.0	0.0	0.0	0.0
266	0.0	0.0	0.0	0.0
244	0.0	0.0	0.0	0.0
Female, GROUP 1				
167	0.0	0.0	0.0	0.0
161	0.0	0.0	0.0	0.0
170	0.0	1.0	0.0	0.0
175	0.0	0.0	0.0	0.0
185	0.0	0.0	0.0	0.0
193	0.0	0.0	0.0	0.0
186	0.0	0.0	0.0	0.0
212	0.0	0.0	0.0	0.0
209	0.0	0.0	0.0	0.0
188	0.0	4.0	0.0	0.0
241	0.0	2.0	4.0	0.0
242	0.0	0.0	0.0	0.0
246	0.0	0.0	0.0	0.0
245	0.0	0.0	0.0	0.0
257	0.0	0.0	0.0	0.0

Study: 20C0709/01098

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Female, GROUP 2				
168	0.0	0.0	0.0	0.0
159	0.0	0.0	0.0	0.0
160	5.0	0.0	0.0	0.0
183	0.0	0.0	0.0	0.0
177	0.0	0.0	0.0	0.0
210	0.0	0.0	2.0	0.0
195	0.0	0.0	0.0	0.0
196	0.0	0.0	0.0	0.0
200	0.0	0.0	0.0	0.0
197	0.0	2.0	1.0	0.0
240	0.0	0.0	0.0	0.0
265	0.0	0.0	0.0	0.0
258	0.0	1.0	0.0	0.0
254	0.0	0.0	0.0	0.0
259	0.0	0.0	0.0	0.0
Female, GROUP 3				
163	0.0	1.0	3.0	3.0
176	0.0	0.0	0.0	0.0
174	0.0	0.0	0.0	0.0
179	0.0	0.0	0.0	0.0
171	0.0	0.0	0.0	0.0
204	0.0	0.0	0.0	0.0
203	0.0	0.0	2.0	0.0
192	0.0	0.0	0.0	0.0
191	0.0	0.0	0.0	0.0
190	0.0	0.0	0.0	0.0
263	0.0	0.0	0.0	0.0
248	0.0	0.0	0.0	0.0
255	0.0	1.0	0.0	0.0
260	0.0	0.0	0.0	0.0
250	3.0	1.0	0.0	0.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	FECES N Day -7	FECES N Day 0	FECES N Day 7	FECES N Day 14
Female, GROUP 4				
165	0.0	0.0	0.0	0.0
164	2.0	0.0	2.0	0.0
166	0.0	0.0	0.0	0.0
178	0.0	0.0	0.0	0.0
182	1.0	0.0	0.0	0.0
207	0.0	0.0	0.0	0.0
208	0.0	0.0	0.0	0.0
187	0.0	0.0	0.0	0.0
206	0.0	0.0	0.0	0.0
205	0.0	0.0	0.0	0.0
253	0.0	0.0	0.0	0.0
251	0.0	0.0	0.0	0.0
247	0.0	0.0	0.0	0.0
262	0.0	0.0	0.0	0.0
252	0.0	0.0	0.0	0.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Male, GROUP 0				
75	2.0	0.0	4.0	5.0
65	1.0	0.0	0.0	2.0
70	2.0	2.0	0.0	3.0
68	1.0	0.0	0.0	2.0
69	1.0	1.0	1.0	9.0
102	3.0	0.0	1.0	5.0
105	1.0	2.0	2.0	6.0
86	7.0	3.0	2.0	6.0
93	0.0	0.0	2.0	5.0
97	4.0	1.0	2.0	0.0
239	5.0	1.0	1.0	4.0
222	8.0	0.0	1.0	1.0
226	3.0	1.0	1.0	2.0
228	13.0	8.0	4.0	3.0
238	8.0	4.0	8.0	2.0
Male, GROUP 1				
53	2.0	0.0	2.0	2.0
60	4.0	7.0	3.0	7.0
63	10.0	0.0	2.0	7.0
79	3.0	1.0	1.0	3.0
59	3.0	0.0	0.0	2.0
95	15.0	16.0	0.0	5.0
100	5.0	0.0	5.0	6.0
84	1.0	0.0	1.0	8.0
101	3.0	1.0	2.0	2.0
88	7.0	1.0	7.0	7.0
233	3.0	1.0	0.0	3.0
216	9.0	3.0	9.0	9.0
220	5.0	1.0	0.0	5.0
231	11.0	2.0	1.0	3.0
219	4.0	7.0	2.0	3.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Male, GROUP 2				
77	0.0	0.0	6.0	3.0
78	3.0	1.0	2.0	1.0
55	0.0	0.0	1.0	1.0
62	3.0	0.0	0.0	5.0
76	5.0	0.0	0.0	1.0
81	5.0	1.0	0.0	4.0
99	3.0	6.0	2.0	14.0
94	6.0	1.0	3.0	4.0
90	12.0	0.0	2.0	5.0
96	6.0	1.0	4.0	3.0
215	2.0	12.0	2.0	1.0
237	7.0	2.0	2.0	1.0
218	5.0	2.0	0.0	5.0
213	8.0	2.0	1.0	8.0
224	2.0	0.0	3.0	2.0
Male, GROUP 3				
73	1.0	0.0	0.0	0.0
57	3.0	0.0	5.0	5.0
72	1.0	1.0	0.0	2.0
56	1.0	0.0	0.0	0.0
74	2.0	0.0	2.0	3.0
85	8.0	0.0	0.0	0.0
103	12.0	5.0	1.0	1.0
83	5.0	0.0	0.0	5.0
91	3.0	0.0	1.0	1.0
106	8.0	0.0	2.0	8.0
225	2.0	7.0	3.0	8.0
227	5.0	4.0	11.0	5.0
230	0.0	1.0	1.0	0.0
232	8.0	4.0	6.0	0.0
221	4.0	2.0	2.0	0.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Male, GROUP 4				
66	3.0	0.0	3.0	6.0
64	0.0	2.0	0.0	0.0
54	3.0	2.0	4.0	2.0
71	2.0	0.0	0.0	2.0
58	17.0	0.0	0.0	2.0
92	5.0	0.0	0.0	2.0
104	8.0	0.0	1.0	7.0
87	1.0	2.0	1.0	1.0
98	4.0	0.0	0.0	2.0
82	5.0	0.0	6.0	11.0
229	1.0	0.0	3.0	4.0
236	3.0	1.0	0.0	1.0
235	3.0	0.0	1.0	1.0
217	9.0	1.0	3.0	3.0
214	0.0	0.0	3.0	0.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Female, GROUP 0				
181	2.0	9.0	11.0	5.0
180	1.0	4.0	1.0	4.0
173	4.0	6.0	4.0	8.0
162	8.0	6.0	6.0	9.0
184	3.0	8.0	5.0	5.0
211	5.0	16.0	15.0	9.0
201	9.0	9.0	5.0	8.0
194	13.0	8.0	11.0	8.0
198	8.0	10.0	11.0	8.0
202	10.0	10.0	1.0	7.0
243	13.0	7.0	20.0	6.0
261	13.0	20.0	24.0	19.0
264	13.0	10.0	0.0	9.0
266	12.0	19.0	13.0	14.0
244	15.0	6.0	13.0	5.0
Female, GROUP 1				
167	6.0	4.0	6.0	5.0
161	5.0	10.0	5.0	11.0
170	7.0	6.0	2.0	12.0
175	3.0	7.0	6.0	9.0
185	3.0	0.0	4.0	13.0
193	9.0	12.0	2.0	19.0
186	10.0	11.0	14.0	15.0
212	16.0	4.0	12.0	6.0
209	10.0	6.0	11.0	10.0
188	13.0	4.0	12.0	12.0
241	11.0	3.0	0.0	6.0
242	9.0	24.0	11.0	14.0
246	18.0	19.0	18.0	10.0
245	11.0	30.0	9.0	4.0
257	10.0	0.0	7.0	5.0

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Female, GROUP 2				
168	4.0	7.0	5.0	10.0
159	9.0	12.0	5.0	17.0
160	7.0	0.0	7.0	4.0
183	6.0	9.0	1.0	4.0
177	15.0	8.0	5.0	3.0
210	15.0	13.0	2.0	5.0
195	8.0	2.0	3.0	4.0
196	5.0	2.0	10.0	10.0
200	8.0	12.0	7.0	14.0
197	4.0	5.0	2.0	7.0
240	8.0	11.0	12.0	7.0
265	19.0	18.0	17.0	14.0
258	10.0	11.0	7.0	26.0
254	10.0	12.0	7.0	23.0
259	5.0	5.0	8.0	7.0
Female, GROUP 3				
163	10.0	6.0	4.0	3.0
176	7.0	8.0	11.0	2.0
174	10.0	5.0	7.0	18.0
179	3.0	11.0	5.0	1.0
171	6.0	9.0	6.0	8.0
204	12.0	14.0	12.0	10.0
203	8.0	2.0	1.0	7.0
192	14.0	6.0	14.0	4.0
191	12.0	11.0	14.0	14.0
190	5.0	1.0	8.0	4.0
263	7.0	15.0	2.0	13.0
248	8.0	7.0	2.0	5.0
255	8.0	2.0	6.0	10.0
260	12.0	5.0	2.0	12.0
250	6.0	6.0	17.0	12.0

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	Rear Day -7	Rear Day 0	Rear Day 7	Rear Day 14
Female, GROUP 4				
165	6.0	6.0	6.0	10.0
164	6.0	0.0	7.0	7.0
166	6.0	3.0	3.0	0.0
178	5.0	5.0	2.0	14.0
182	4.0	0.0	5.0	4.0
207	5.0	0.0	8.0	10.0
208	11.0	1.0	9.0	9.0
187	5.0	4.0	12.0	12.0
206	12.0	5.0	5.0	14.0
205	10.0	0.0	5.0	5.0
253	14.0	10.0	13.0	18.0
251	11.0	2.0	2.0	10.0
247	9.0	3.0	13.0	8.0
262	11.0	1.0	4.0	5.0
252	9.0	0.0	1.0	5.0

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Male, GROUP 0				
75	5.4	3.0	4.4	5.0
65	5.0	5.0	4.2	4.0
70	4.8	4.2	4.4	4.2
68	4.2	4.8	4.6	4.2
69	4.0	4.0	4.6	5.4
102	4.6	4.0	4.8	5.0
105	5.0	4.4	4.4	5.0
86	4.0	4.8	5.0	4.2
93	4.6	4.8	5.0	5.2
97	4.0	4.6	4.0	4.2
239	5.0	4.6	3.8	4.0
222	5.0	4.2	4.2	5.8
226	4.0	5.0	4.6	5.2
228	4.0	4.0	5.2	4.8
238	4.6	3.6	4.0	5.0
Male, GROUP 1				
53	4.8	4.0	4.4	4.0
60	4.2	5.0	5.2	5.6
63	5.2	3.8	4.0	4.8
79	4.8	3.8	4.8	4.8
59	5.2	4.2	4.2	4.4
95	4.0	4.4	4.6	4.0
100	4.2	4.6	4.6	4.0
84	4.2	4.6	4.0	4.6
101	4.6	4.8	4.0	5.0
88	4.0	4.0	4.6	4.4
233	3.8	4.0	5.0	5.6
216	3.8	4.8	4.8	5.4
220	4.2	5.0	4.4	5.2
231	4.8	5.2	5.4	5.0
219	3.8	3.8	4.4	5.4

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Male, GROUP 2				
77	3.4	4.8	4.6	5.2
78	3.8	5.0	4.0	4.8
55	4.8	4.2	5.2	4.0
62	4.6	3.8	3.6	4.0
76	4.6	4.2	4.2	4.0
81	5.2	4.2	4.4	4.0
99	5.0	4.8	4.0	5.0
94	4.0	5.0	4.4	5.4
90	4.2	4.6	4.8	4.2
96	4.0	4.0	4.8	4.6
215	4.0	4.4	4.6	5.2
237	4.0	4.8	4.0	4.8
218	4.2	5.2	4.8	4.6
213	4.6	4.6	4.8	5.2
224	4.2	4.0	5.2	5.4
Male, GROUP 3				
73	5.2	4.2	4.2	4.8
57	4.8	4.0	4.8	4.0
72	4.0	3.8	4.2	4.0
56	4.0	4.0	5.0	4.6
74	5.0	4.0	4.2	5.0
85	4.8	5.8	4.4	4.6
103	5.0	4.2	5.4	4.8
83	5.0	5.0	4.8	4.6
91	4.0	4.8	4.8	5.2
106	5.0	4.0	4.2	4.6
225	4.4	5.0	4.2	5.0
227	4.8	4.2	4.6	5.2
230	4.2	5.4	5.0	5.8
232	5.0	4.0	4.0	6.0
221	4.2	4.0	5.0	4.8

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Male, GROUP 4				
66	6.0	3.8	4.4	4.0
64	5.2	4.6	4.6	5.6
54	5.0	5.8	5.0	4.0
71	3.8	4.0	4.0	4.0
58	4.0	4.8	5.2	5.0
92	4.2	4.8	4.8	4.6
104	4.6	5.2	4.2	5.0
87	4.2	4.4	4.2	4.4
98	4.6	3.8	4.0	5.0
82	4.4	4.6	4.0	4.0
229	4.2	4.8	4.4	5.0
236	4.0	4.0	4.4	5.0
235	3.8	4.8	4.6	4.6
217	5.0	4.4	5.4	5.2
214	4.8	4.0	5.2	5.0

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Female, GROUP 0				
181	4.8	4.2	4.8	4.2
180	4.8	4.8	5.6	5.4
173	4.6	4.6	4.0	5.0
162	4.0	5.2	5.6	5.6
184	4.0	5.4	4.4	4.8
211	5.0	4.4	4.2	3.4
201	4.2	4.0	3.6	3.4
194	5.8	4.6	4.4	5.0
198	4.0	4.4	3.4	3.6
202	4.8	3.6	3.4	3.0
243	5.0	4.0	4.8	5.0
261	5.2	4.0	4.2	5.0
264	4.0	4.0	4.2	4.6
266	4.0	5.2	4.6	5.4
244	4.4	4.0	4.0	5.0
Female, GROUP 1				
167	4.4	4.6	4.8	4.4
161	4.0	4.2	5.8	5.0
170	5.0	5.0	5.6	5.0
175	3.8	3.8	3.8	4.8
185	4.4	4.2	5.0	5.2
193	4.4	5.0	4.8	3.8
186	4.8	4.0	4.0	4.4
212	4.0	4.0	6.0	5.6
209	4.4	5.0	3.8	5.2
188	5.0	4.2	4.8	4.4
241	3.8	4.6	5.0	5.0
242	4.8	4.0	4.8	5.4
246	4.6	5.0	4.6	5.4
245	4.4	3.6	4.2	5.2
257	4.6	3.8	5.0	5.0

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Female, GROUP 2				
168	4.0	4.4	4.4	3.6
159	5.6	4.4	5.6	5.6
160	4.0	4.6	5.2	5.0
183	4.2	3.8	5.4	4.8
177	3.8	4.2	4.8	5.6
210	4.2	4.0	4.6	4.2
195	4.4	3.8	4.8	4.6
196	3.8	5.0	4.6	4.2
200	4.0	4.2	4.8	5.4
197	4.0	4.8	4.8	3.6
240	4.8	4.8	4.6	5.0
265	4.6	4.0	5.0	5.0
258	4.8	4.6	4.0	5.2
254	4.2	3.6	3.6	4.4
259	4.8	4.2	4.4	4.8
Female, GROUP 3				
163	4.8	5.0	6.0	5.0
176	4.2	4.8	5.0	4.6
174	4.0	4.2	5.6	4.0
179	4.2	4.4	4.0	5.4
171	4.2	4.4	5.0	4.6
204	4.2	4.6	3.8	4.2
203	4.6	4.0	4.6	4.0
192	4.6	3.8	4.4	5.2
191	4.8	4.4	5.6	5.4
190	3.8	4.6	4.0	4.0
263	4.8	4.0	4.0	4.8
248	4.6	5.0	4.4	4.6
255	5.0	4.6	5.2	5.0
260	4.6	4.8	5.4	5.0
250	4.6	4.0	5.2	5.2

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS F 1 Newton Day -7	GS F 1 Newton Day 0	GS F 1 Newton Day 7	GS F 1 Newton Day 14
Female, GROUP 4				
165	4.2	3.6	5.0	4.8
164	4.8	4.6	5.4	5.2
166	4.0	3.0	4.4	4.4
178	4.2	3.6	5.2	5.4
182	4.0	3.0	4.0	4.0
207	4.2	3.2	5.0	4.8
208	4.0	3.6	4.6	3.6
187	5.0	2.8	3.6	3.6
206	5.0	4.6	4.8	3.6
205	4.2	4.0	4.8	4.6
253	4.6	3.4	4.6	4.6
251	4.8	5.0	5.2	4.6
247	5.0	4.6	5.0	4.2
262	3.8	3.4	4.0	5.0
252	4.0	4.0	4.6	5.0

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Male, GROUP 0				
75	5.8	3.0	5.0	5.0
65	4.6	4.8	4.0	4.4
70	4.6	4.4	5.0	4.8
68	3.6	4.6	4.4	4.2
69	4.8	4.4	4.4	5.2
102	4.2	4.2	4.6	5.4
105	4.6	4.6	4.0	5.2
86	4.2	4.2	4.6	4.8
93	4.4	4.6	4.6	4.8
97	4.6	4.0	4.4	4.6
239	4.6	4.0	3.6	4.6
222	4.6	4.6	4.8	5.4
226	3.8	5.2	4.4	4.8
228	4.2	4.2	4.8	5.2
238	4.8	3.4	4.4	5.2
Male, GROUP 1				
53	5.0	4.0	4.2	4.8
60	4.0	5.0	5.0	5.6
63	4.8	3.8	4.6	4.4
79	5.4	3.4	4.6	4.8
59	5.0	3.8	4.0	4.4
95	4.4	3.8	4.4	4.6
100	4.0	3.8	4.2	3.8
84	4.0	4.2	4.2	4.4
101	4.4	5.2	4.6	5.0
88	4.0	4.2	4.6	4.4
233	4.6	4.4	5.4	5.2
216	3.6	4.4	5.2	5.2
220	4.6	4.8	4.4	4.6
231	4.4	5.2	5.8	5.4
219	4.2	4.2	4.6	5.4

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Male, GROUP 2				
77	3.2	4.6	5.0	5.0
78	4.0	4.2	4.8	4.0
55	5.0	4.4	5.4	4.8
62	4.2	4.2	4.0	4.2
76	4.4	4.8	4.4	4.4
81	5.8	4.4	4.4	4.8
99	4.8	5.0	4.0	4.6
94	4.4	5.2	3.8	5.0
90	4.4	4.8	4.4	4.4
96	4.4	4.4	4.6	4.6
215	4.4	4.8	4.6	5.0
237	3.8	5.0	4.6	5.2
218	4.6	5.0	5.0	5.0
213	4.0	4.8	4.2	5.0
224	4.6	3.8	5.2	4.8
Male, GROUP 3				
73	4.8	3.8	4.0	4.8
57	4.6	3.6	4.4	4.4
72	4.2	4.0	4.0	3.8
56	4.6	4.8	4.8	5.0
74	5.2	4.4	4.8	5.2
85	5.4	5.6	4.8	4.4
103	4.8	3.6	5.4	5.0
83	5.0	4.4	4.4	4.8
91	3.8	4.2	4.4	4.8
106	4.6	4.2	4.0	5.0
225	4.2	5.2	4.4	4.6
227	4.4	4.4	4.4	5.0
230	4.8	5.2	4.8	5.4
232	4.8	3.8	4.6	5.8
221	4.0	4.2	4.8	4.6

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Male, GROUP 4				
66	5.8	3.2	4.0	3.8
64	5.0	4.0	4.8	5.8
54	5.2	6.0	5.2	4.2
71	4.0	3.8	3.4	3.8
58	4.2	4.2	5.0	5.2
92	4.2	4.4	5.0	4.8
104	4.8	4.8	4.0	4.4
87	4.2	4.4	4.2	4.4
98	4.8	3.2	4.6	4.4
82	4.8	4.4	3.8	4.0
229	3.8	4.2	4.4	4.6
236	4.6	4.0	4.8	5.0
235	4.2	5.0	4.4	4.0
217	4.0	4.2	5.2	5.0
214	4.2	4.0	4.8	5.0

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Female, GROUP 0				
181	5.2	4.2	4.4	4.0
180	4.0	5.0	5.8	5.6
173	4.2	4.2	4.0	4.8
162	4.2	4.8	5.6	5.4
184	4.6	4.8	4.8	4.6
211	5.2	4.2	4.0	3.6
201	4.8	4.2	3.2	3.6
194	5.2	4.2	3.8	4.4
198	3.4	4.2	3.6	3.8
202	4.0	4.0	3.2	3.2
243	5.2	4.6	4.8	4.6
261	5.4	3.8	4.0	5.0
264	4.4	4.0	4.8	4.8
266	4.2	5.0	4.6	5.4
244	4.6	4.2	4.4	4.4
Female, GROUP 1				
167	4.8	4.6	4.6	4.4
161	4.0	4.2	5.6	4.8
170	5.2	5.2	5.8	5.4
175	3.8	3.6	4.0	5.0
185	4.8	4.8	4.8	6.0
193	4.8	4.6	4.8	3.8
186	4.0	4.0	3.8	4.8
212	4.4	4.0	5.6	6.0
209	4.2	5.2	3.8	4.8
188	4.8	4.0	4.6	4.6
241	4.0	5.2	4.8	5.0
242	4.8	4.0	4.8	5.4
246	4.2	4.6	4.4	4.8
245	4.0	3.8	3.8	4.8
257	4.8	4.0	5.0	5.4

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Female, GROUP 2				
168	4.6	4.8	4.2	3.2
159	5.4	4.0	5.0	5.8
160	4.4	4.6	5.6	5.2
183	4.8	3.6	5.8	5.2
177	3.8	4.0	5.2	5.4
210	4.4	4.4	4.8	4.0
195	4.4	4.2	5.2	4.8
196	4.0	5.2	4.6	4.4
200	4.4	4.0	4.8	4.8
197	4.2	4.4	4.8	4.2
240	4.8	4.4	5.0	4.6
265	4.8	4.4	4.4	4.8
258	4.4	4.2	4.4	5.6
254	4.4	4.2	3.8	4.6
259	4.4	4.0	4.6	4.8
Female, GROUP 3				
163	5.0	4.8	5.8	5.4
176	4.0	4.4	4.4	4.2
174	4.2	3.8	5.4	4.4
179	4.0	4.4	4.6	5.2
171	4.6	4.4	5.2	4.2
204	4.0	5.2	3.8	4.0
203	4.4	4.2	5.0	4.0
192	4.2	4.4	4.8	4.6
191	5.0	4.4	5.8	5.6
190	3.4	4.4	4.4	4.0
263	5.0	4.0	4.0	4.6
248	4.8	5.2	4.8	5.2
255	5.0	4.4	4.6	5.2
260	4.8	4.4	4.8	4.8
250	5.0	4.2	5.0	4.8

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	GS F 2 Newton Day -7	GS F 2 Newton Day 0	GS F 2 Newton Day 7	GS F 2 Newton Day 14
Female, GROUP 4				
165	5.0	3.4	4.6	4.2
164	2.6	4.6	5.0	5.0
166	4.2	2.6	4.0	4.0
178	4.8	3.8	4.8	4.8
182	5.0	3.0	3.8	4.4
207	5.0	3.4	5.2	4.6
208	4.0	3.8	4.0	3.2
187	4.8	2.8	3.6	4.0
206	5.0	4.6	5.0	3.6
205	4.0	4.2	4.2	4.4
253	4.8	4.0	5.2	5.2
251	4.8	5.2	5.0	4.8
247	4.8	4.4	4.6	5.2
262	4.0	4.2	4.0	4.6
252	4.0	3.8	4.2	5.2

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Male, GROUP 0				
75	2.4	2.6	3.2	3.4
65	2.4	3.4	3.4	3.2
70	2.4	2.6	2.8	3.4
68	2.0	2.2	3.2	3.8
69	3.0	3.0	3.6	3.4
102	3.4	3.2	3.0	3.6
105	3.8	3.2	2.4	3.4
86	3.0	3.6	3.8	3.0
93	3.2	3.0	3.4	3.4
97	2.8	3.2	3.6	3.4
239	3.6	2.2	2.6	3.0
222	2.6	2.8	3.0	3.0
226	3.4	3.6	2.4	3.0
228	2.6	3.0	2.8	2.8
238	3.4	1.8	2.0	2.6
Male, GROUP 1				
53	3.4	2.2	3.6	3.2
60	2.6	3.0	3.4	3.8
63	3.0	2.6	2.6	3.2
79	3.8	2.6	3.8	3.6
59	3.4	2.8	2.8	3.0
95	3.0	2.8	3.2	2.4
100	2.8	2.6	3.2	3.2
84	3.2	3.0	3.2	3.2
101	3.6	3.4	3.8	4.0
88	3.2	3.6	3.2	3.2
233	3.2	2.6	2.0	3.0
216	3.0	3.0	2.4	3.0
220	2.4	2.8	3.0	2.0
231	2.8	2.2	3.0	3.0
219	3.2	2.4	2.6	2.6

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Male, GROUP 2				
77	2.0	3.0	3.2	4.0
78	2.2	3.8	3.4	3.2
55	2.4	2.8	3.4	3.0
62	3.6	3.0	2.8	3.0
76	3.6	3.2	2.8	3.0
81	3.6	3.2	3.6	2.6
99	3.8	3.6	3.6	3.6
94	3.4	2.8	2.4	4.0
90	2.4	2.6	3.6	3.0
96	3.0	3.4	3.8	3.2
215	3.0	2.2	3.0	2.8
237	2.6	2.6	3.0	3.0
218	2.4	3.2	2.6	2.0
213	3.0	2.6	2.4	2.6
224	3.2	2.6	2.0	3.4
Male, GROUP 3				
73	3.0	2.8	2.8	3.6
57	3.2	2.4	3.8	3.4
72	3.0	3.0	2.8	3.0
56	2.8	3.0	3.8	3.2
74	3.6	2.6	3.6	3.6
85	3.6	3.0	3.0	4.0
103	3.0	3.2	3.8	3.6
83	3.4	2.8	3.6	3.6
91	2.8	2.4	3.2	3.2
106	3.4	3.6	3.2	3.4
225	2.4	2.6	2.4	2.8
227	2.8	2.8	3.0	3.0
230	3.2	2.8	2.8	3.4
232	3.0	2.2	2.0	3.2
221	3.0	2.6	2.8	3.0

Study: 20C0709/01098

FUNCTIONAL OBSERVATIONAL BATTERY

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Male, GROUP 4				
66	3.0	3.0	2.4	3.0
64	3.2	2.6	3.2	3.8
54	3.0	3.8	3.0	3.4
71	2.6	3.0	2.8	3.0
58	3.4	2.6	3.2	3.2
92	3.4	3.2	3.0	3.2
104	3.2	3.4	3.2	3.0
87	3.4	3.2	3.2	3.0
98	3.0	2.6	3.4	2.6
82	3.2	2.4	2.4	3.2
229	2.8	2.4	3.2	2.8
236	2.6	2.8	2.0	3.0
235	2.8	1.8	3.0	2.6
217	3.2	2.6	3.2	3.2
214	2.8	2.0	3.0	2.8

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Female, GROUP 0				
181	2.4	1.8	2.2	2.8
180	2.6	2.0	3.6	3.6
173	2.2	2.0	2.8	2.8
162	2.8	2.2	3.8	3.4
184	2.8	2.4	3.6	3.2
211	3.2	2.2	3.4	3.0
201	3.6	2.2	2.2	3.0
194	4.2	2.6	3.6	3.4
198	3.0	2.6	2.8	2.6
202	3.4	2.4	2.8	2.8
243	2.4	2.0	2.6	3.0
261	2.2	2.2	2.6	2.0
264	2.0	2.2	3.0	2.4
266	1.4	2.6	2.2	2.8
244	1.2	2.0	2.4	2.4
Female, GROUP 1				
167	2.6	1.6	3.2	3.0
161	2.8	2.2	3.4	3.2
170	2.4	2.2	3.4	3.4
175	2.2	1.8	3.0	3.4
185	3.0	1.6	2.2	4.2
193	3.4	2.6	3.4	3.4
186	2.4	1.8	3.2	3.0
212	3.6	3.0	3.2	3.8
209	3.8	2.8	2.6	3.2
188	3.8	3.4	4.0	3.4
241	2.0	2.0	2.6	2.6
242	2.2	2.2	2.8	2.8
246	1.8	2.0	2.2	2.4
245	2.4	3.0	3.0	2.4
257	2.2	2.8	2.0	2.6

Study: 20C0709/01098

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Female, GROUP 2				
168	3.4	2.2	2.8	2.8
159	3.0	2.6	3.6	4.6
160	3.0	2.4	3.4	4.2
183	2.8	2.2	3.2	3.6
177	2.0	1.8	3.0	3.2
210	2.8	2.0	2.2	3.0
195	2.8	2.6	4.0	3.2
196	3.0	2.6	2.8	3.6
200	3.2	3.6	3.6	4.0
197	3.6	3.2	4.2	3.2
240	2.4	2.6	3.0	2.8
265	2.0	2.0	2.6	2.2
258	1.8	2.8	3.0	2.4
254	2.4	2.4	2.2	2.0
259	2.0	3.0	3.0	2.0
Female, GROUP 3				
163	2.4	2.6	4.0	3.0
176	2.8	2.2	2.4	2.8
174	2.8	2.4	3.2	3.2
179	2.0	1.8	2.6	3.0
171	2.0	1.2	2.6	2.2
204	3.4	3.2	3.0	3.0
203	3.2	2.2	2.6	3.0
192	3.2	2.6	2.6	3.6
191	3.0	3.2	3.2	3.4
190	2.4	2.2	3.2	2.2
263	1.4	2.2	2.2	2.0
248	1.0	2.2	3.0	2.8
255	2.4	2.4	3.0	2.2
260	1.8	2.0	3.4	2.8
250	2.0	2.6	3.2	9.5

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	GS H 1 Newton Day -7	GS H 1 Newton Day 0	GS H 1 Newton Day 7	GS H 1 Newton Day 14
Female, GROUP 4				
165	3.4	2.4	3.0	3.0
164	3.2	1.2	2.6	3.4
166	2.4	1.0	2.6	2.8
178	2.6	1.2	3.2	3.0
182	2.4	1.2	2.6	2.6
207	3.4	1.8	2.4	3.0
208	3.2	1.6	3.2	3.4
187	2.4	2.0	2.6	2.8
206	4.0	1.8	2.8	2.8
205	3.0	1.6	3.4	3.6
253	2.2	2.0	2.2	2.4
251	1.0	2.2	3.0	2.2
247	2.4	2.0	2.8	2.4
262	1.4	1.8	2.4	2.4
252	2.0	2.4	2.2	2.2

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Male, GROUP 0				
75	2.4	2.4	3.0	3.2
65	2.4	3.4	3.2	3.8
70	2.6	3.2	3.0	3.2
68	2.4	2.8	3.6	3.2
69	3.6	3.2	3.2	3.2
102	3.2	3.0	2.8	4.2
105	3.4	3.2	2.6	3.2
86	3.4	3.4	3.4	3.2
93	3.0	3.0	3.0	3.0
97	3.0	3.0	3.2	3.2
239	3.2	2.4	2.4	2.6
222	2.6	2.6	3.0	3.2
226	3.0	3.0	2.8	3.2
228	2.4	3.4	3.2	2.4
238	3.6	2.4	2.4	2.2
Male, GROUP 1				
53	3.8	2.8	3.4	3.0
60	2.4	2.8	3.6	3.6
63	3.4	2.8	2.4	3.6
79	3.2	2.2	3.8	3.4
59	3.0	2.6	2.8	3.4
95	3.2	3.2	3.4	2.8
100	3.0	2.4	2.8	3.0
84	2.8	3.2	3.0	3.2
101	3.2	3.0	3.2	3.8
88	3.0	3.4	3.0	2.8
233	3.4	3.0	2.6	2.8
216	2.6	2.4	3.0	2.8
220	2.0	2.8	2.8	2.4
231	3.0	2.6	2.8	2.8
219	3.0	2.8	2.4	3.2

Study: 20C0709/01098

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Male, GROUP 2				
77	1.8	3.0	2.8	3.8
78	2.4	3.4	3.6	3.0
55	2.4	3.2	3.0	2.8
62	3.4	2.8	3.0	2.6
76	3.8	3.6	3.2	3.4
81	3.6	3.2	3.4	2.8
99	3.4	3.2	3.2	3.6
94	3.2	3.2	2.6	3.4
90	2.4	2.4	3.4	2.8
96	2.8	3.2	3.6	3.0
215	3.4	2.4	2.8	2.8
237	2.4	2.4	2.8	2.6
218	2.0	3.4	2.2	2.4
213	3.4	2.8	2.4	2.4
224	3.2	2.2	2.4	3.2
Male, GROUP 3				
73	3.4	2.8	2.6	3.2
57	3.4	2.2	3.6	2.8
72	3.4	2.6	2.6	3.2
56	3.0	2.6	4.0	3.4
74	3.0	2.8	3.4	3.8
85	3.2	3.0	3.4	3.8
103	3.4	2.8	3.6	3.0
83	3.6	3.2	3.8	3.6
91	3.0	2.2	3.4	2.6
106	3.2	3.4	3.0	3.2
225	2.2	2.8	2.6	2.2
227	3.0	2.4	3.0	2.8
230	3.0	2.6	2.8	3.2
232	2.8	2.0	2.2	2.8
221	3.2	2.8	2.4	3.2

Study: 20C0709/01098

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Male, GROUP 4				
66	2.8	2.4	2.4	2.6
64	3.8	3.2	3.4	4.0
54	3.0	4.0	3.4	3.4
71	2.8	2.8	2.4	2.8
58	3.0	2.6	3.4	3.0
92	3.0	3.6	3.0	2.8
104	3.2	3.0	3.2	2.8
87	3.0	3.0	3.4	3.4
98	2.6	2.4	3.4	2.4
82	3.2	2.0	2.6	3.0
229	2.8	2.6	3.2	2.4
236	3.0	2.2	2.2	2.8
235	3.0	1.6	2.8	2.8
217	3.2	2.6	3.6	3.0
214	3.0	2.0	2.6	2.6

Study: 20C0709/01098

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Female, GROUP 0				
181	3.0	2.0	2.0	2.6
180	2.2	1.8	3.0	3.8
173	2.8	2.4	3.4	3.0
162	3.2	2.2	3.6	3.6
184	2.4	2.4	3.8	2.8
211	3.6	2.4	3.2	2.6
201	3.0	2.4	2.0	2.8
194	4.2	3.0	3.2	3.6
198	2.4	2.8	2.6	2.6
202	3.4	2.0	2.8	2.8
243	2.4	2.4	2.4	3.4
261	2.6	2.4	2.4	2.2
264	2.2	2.0	3.0	2.0
266	1.6	2.2	2.6	2.6
244	1.6	2.4	3.0	2.6
Female, GROUP 1				
167	3.4	1.8	3.0	2.8
161	2.4	2.2	3.0	3.4
170	2.4	2.4	3.6	3.0
175	2.0	1.6	2.6	3.8
185	2.6	2.0	2.8	3.8
193	3.2	2.4	3.2	3.2
186	2.8	1.8	3.0	2.8
212	3.2	2.8	3.4	3.8
209	3.6	3.0	2.8	3.6
188	3.2	3.6	3.6	3.0
241	1.8	2.6	3.0	2.0
242	2.0	2.4	2.4	2.6
246	1.6	2.4	2.6	2.0
245	2.2	3.0	2.4	2.8
257	2.4	2.8	2.2	2.8

Study: 20C0709/01098

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Female, GROUP 2				
168	3.4	1.8	2.6	2.8
159	3.4	2.4	3.2	4.8
160	3.2	2.2	3.0	4.2
183	2.6	2.6	3.0	3.0
177	2.6	2.0	3.2	3.4
210	2.2	1.8	2.8	2.8
195	3.4	2.2	3.6	3.2
196	3.0	2.4	3.4	3.4
200	2.8	3.2	3.4	3.8
197	3.4	3.0	3.8	3.2
240	2.6	2.8	2.4	2.8
265	2.4	2.2	2.4	2.6
258	1.6	2.6	2.6	2.8
254	2.0	2.2	2.2	2.2
259	2.4	2.8	2.8	2.6
Female, GROUP 3				
163	2.6	2.6	4.0	3.2
176	2.4	1.8	2.8	3.0
174	3.2	2.2	4.0	3.0
179	3.0	1.6	2.0	2.6
171	2.4	1.2	2.6	2.6
204	3.6	3.0	2.6	3.4
203	3.0	2.6	2.8	2.8
192	3.6	2.2	3.0	3.2
191	3.0	3.2	3.2	3.6
190	2.2	2.4	2.6	2.6
263	1.6	2.6	2.8	2.6
248	1.4	2.2	2.8	3.0
255	2.2	2.0	2.8	2.2
260	2.2	2.0	2.8	2.4
250	2.4	2.0	2.6	9.5

Study: 20C0709/01098

	GS H 2 Newton Day -7	GS H 2 Newton Day 0	GS H 2 Newton Day 7	GS H 2 Newton Day 14
Female, GROUP 4				
165	3.6	1.8	3.6	3.2
164	3.2	1.0	2.6	3.0
166	2.6	1.2	2.0	3.0
178	2.8	1.4	2.8	3.2
182	2.4	0.8	2.2	2.8
207	3.0	1.4	2.8	2.6
208	3.0	1.6	3.2	3.2
187	2.0	1.8	2.6	3.0
206	3.8	2.2	2.6	2.6
205	3.4	1.8	3.2	3.4
253	2.0	2.4	2.8	2.6
251	1.2	2.0	3.0	2.6
247	2.6	2.4	2.6	2.8
262	1.6	2.2	3.0	2.6
252	1.6	2.0	2.4	2.4

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Male, GROUP 0				
75	8.7	9.8	9.4	10.5
65	6.6	8.0	7.2	8.3
70	9.1	10.3	11.3	12.3
68	9.4	8.9	9.8	10.6
69	10.6	10.0	11.5	11.3
102	8.2	8.9	10.8	8.2
105	9.5	11.4	11.8	12.3
86	10.4	11.2	11.5	11.0
93	10.5	11.6	11.9	9.6
97	8.6	9.4	8.9	8.0
239	10.1	9.6	9.1	9.1
222	7.7	11.6	9.6	9.8
226	10.0	10.3	9.0	9.1
228	7.2	9.2	8.9	8.3
238	10.5	11.7	9.6	9.8
Male, GROUP 1				
53	7.5	9.0	10.8	9.5
60	8.7	9.8	9.2	9.0
63	8.7	7.4	9.1	9.7
79	9.3	12.2	12.3	11.2
59	9.2	9.6	10.0	10.3
95	8.0	10.5	8.5	9.0
100	9.6	9.5	8.4	9.2
84	11.0	11.3	11.0	11.8
101	7.6	9.6	10.0	8.0
88	8.3	11.2	9.8	11.8
233	10.7	10.4	10.4	9.4
216	10.5	11.7	10.6	11.0
220	9.0	7.9	9.4	7.7
231	8.6	10.1	10.0	9.5
219	9.4	9.6	8.7	8.9

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Male, GROUP 2				
77	6.4	9.7	6.9	9.3
78	10.0	11.2	12.6	13.2
55	7.7	9.9	9.5	9.0
62	9.5	11.3	9.8	9.7
76	9.5	10.5	10.5	9.4
81	11.0	12.8	11.3	11.3
99	11.3	10.9	11.5	12.4
94	9.6	9.2	9.7	9.0
90	9.6	9.0	10.0	10.3
96	8.4	9.4	9.5	9.7
215	10.0	11.3	11.5	9.9
237	7.6	8.9	7.6	9.5
218	9.2	11.0	11.5	9.8
213	8.2	13.8	10.9	12.0
224	9.6	9.2	8.8	10.2
Male, GROUP 3				
73	7.8	10.0	11.3	10.0
57	10.1	10.7	10.3	10.7
72	8.9	8.3	9.3	9.8
56	7.4	10.0	9.0	10.0
74	8.2	9.7	10.5	10.0
85	11.0	10.0	10.5	9.8
103	11.7	11.2	10.9	10.0
83	10.0	12.3	12.3	9.5
91	9.4	10.0	9.2	10.0
106	9.4	8.4	9.7	9.7
225	11.1	12.2	11.5	11.3
227	8.3	8.3	12.1	10.5
230	7.3	11.2	12.2	11.5
232	9.7	11.6	10.8	9.7
221	10.4	9.9	8.6	9.3

FUNCTIONAL OBSERVATIONAL BATTERY

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Male, GROUP 4				
66	8.2	10.2	11.0	10.5
64	8.7	10.5	11.3	10.3
54	8.2	11.0	11.0	10.7
71	9.0	10.2	11.3	10.8
58	9.0	8.2	11.0	9.2
92	8.0	8.5	8.9	8.8
104	8.0	8.7	10.0	10.5
87	9.6	9.5	10.8	11.1
98	9.6	10.7	12.6	11.7
82	9.4	9.4	9.3	10.1
229	10.4	9.2	10.6	8.9
236	8.3	13.3	11.3	10.7
235	9.3	11.5	10.8	10.6
217	10.3	9.0	10.7	10.5
214	9.8	9.5	9.7	9.4

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Female, GROUP 0				
181	7.2	9.2	10.3	10.0
180	6.4	8.0	7.0	8.7
173	10.2	10.5	10.6	11.0
162	9.0	8.8	9.1	9.2
184	9.6	9.6	9.1	10.2
211	8.5	9.1	9.3	8.5
201	9.9	10.6	9.5	8.2
194	9.2	10.0	8.2	8.7
198	9.6	9.2	8.8	9.8
202	8.6	8.0	8.0	7.5
243	10.4	9.1	10.9	10.6
261	9.9	9.4	7.6	9.1
264	9.5	9.5	8.2	9.4
266	9.4	10.0	9.2	11.4
244	7.7	9.8	8.4	9.2
Female, GROUP 1				
167	8.7	8.2	7.7	9.0
161	11.3	11.6	11.2	11.3
170	10.4	11.6	10.0	10.5
175	9.7	10.3	10.6	9.8
185	8.7	10.2	11.0	11.2
193	10.2	10.4	9.5	9.3
186	10.4	9.5	10.2	8.0
212	10.1	10.0	9.2	9.7
209	9.2	10.0	8.5	8.7
188	10.1	7.8	9.2	9.7
241	12.7	11.6	9.8	9.7
242	10.5	8.7	9.7	7.9
246	6.5	7.4	8.4	9.3
245	7.5	9.4	9.2	9.7
257	7.6	8.6	9.0	9.1

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Female, GROUP 2				
168	8.4	7.5	8.0	8.0
159	12.8	10.4	9.7	11.3
160	9.2	10.0	10.0	9.6
183	7.6	8.6	8.5	8.0
177	10.0	11.0	10.2	11.3
210	8.3	9.5	10.2	8.5
195	8.4	8.1	8.4	10.0
196	12.1	11.3	12.3	10.2
200	7.3	6.8	7.0	7.0
197	9.5	8.7	8.5	10.2
240	9.7	11.1	9.4	10.0
265	8.4	8.0	8.6	7.0
258	9.5	12.3	12.5	11.3
254	7.5	9.0	7.9	7.6
259	10.0	9.7	9.0	11.3
Female, GROUP 3				
163	10.3	10.0	10.6	9.2
176	8.2	8.4	7.0	7.8
174	9.4	10.3	11.7	12.0
179	7.0	8.5	9.1	8.5
171	8.0	8.1	6.8	9.2
204	8.0	10.5	11.0	11.0
203	8.0	8.6	9.3	7.8
192	6.2	7.2	7.9	8.5
191	9.6	10.6	10.2	9.7
190	7.8	8.2	7.5	8.2
263	8.7	9.8	8.5	9.6
248	10.6	9.0	7.4	8.7
255	9.7	8.9	9.8	7.7
260	8.5	8.4	9.9	9.5
250	10.2	8.7	9.4	9.8

Study: 20C0709/01098

	FST 1 cm Day -7	FST 1 cm Day 0	FST 1 cm Day 7	FST 1 cm Day 14
Female, GROUP 4				
165	8.6	9.5	8.4	9.5
164	9.3	8.0	10.2	10.0
166	9.6	10.2	10.2	10.5
178	9.6	9.2	9.2	8.7
182	8.4	7.6	7.0	7.8
207	8.3	7.5	8.2	8.0
208	9.2	8.5	9.2	8.6
187	8.2	10.0	9.0	10.5
206	10.0	10.2	8.2	9.4
205	9.3	8.2	8.3	9.6
253	10.2	9.6	10.2	9.8
251	9.2	8.7	9.7	10.2
247	11.5	9.4	11.3	10.6
262	9.7	10.4	11.5	9.3
252	10.2	9.4	9.3	10.1

Study: 20C0709/01098

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Male, GROUP 0				
75	9.1	9.4	9.7	10.1
65	7.4	7.4	8.0	9.0
70	8.9	10.0	10.8	11.8
68	9.0	9.4	9.5	10.3
69	10.9	9.5	10.7	12.0
102	7.4	8.3	10.0	8.5
105	9.0	10.9	11.9	11.6
86	9.7	11.7	11.3	11.9
93	10.9	11.2	11.4	10.0
97	8.3	9.6	8.8	8.9
239	9.6	9.2	10.2	9.3
222	8.7	10.9	10.0	9.9
226	9.4	9.7	8.8	8.6
228	8.0	9.6	8.2	9.1
238	11.2	11.2	10.2	10.3
Male, GROUP 1				
53	8.0	9.4	10.5	10.1
60	9.2	9.4	9.0	9.8
63	8.0	8.2	8.8	9.5
79	9.7	12.5	11.5	11.9
59	9.8	10.4	9.8	10.0
95	8.3	9.8	9.0	9.9
100	10.0	10.6	9.2	10.0
84	10.8	11.0	10.5	12.3
101	8.2	9.1	9.6	7.9
88	8.6	11.3	10.5	12.4
233	11.5	9.7	9.6	9.8
216	9.2	11.7	11.1	11.4
220	8.2	8.6	10.0	8.4
231	8.3	9.8	9.2	9.7
219	9.9	9.7	9.2	9.5

Study: 20C0709/01098

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Male, GROUP 2				
77	7.0	10.3	7.7	9.7
78	9.6	11.5	12.2	12.9
55	8.0	9.5	9.1	10.0
62	9.6	11.5	10.0	10.5
76	10.0	10.0	9.5	10.2
81	11.9	11.9	11.5	10.9
99	12.4	11.4	12.0	11.5
94	9.5	10.0	10.2	8.6
90	9.7	10.0	10.2	11.2
96	8.0	10.1	10.2	10.1
215	10.5	10.8	10.9	9.5
237	8.8	9.3	8.3	8.8
218	9.8	12.1	11.1	10.0
213	9.1	12.0	11.5	11.8
224	9.6	9.4	9.1	9.5
Male, GROUP 3				
73	7.3	10.2	11.2	11.0
57	9.8	10.3	11.9	11.3
72	8.4	8.6	8.5	10.6
56	8.0	9.9	9.0	9.9
74	8.5	9.7	9.6	10.0
85	10.8	10.2	10.3	10.0
103	11.4	10.9	11.4	9.4
83	11.2	11.5	12.5	10.5
91	9.6	10.0	9.5	10.4
106	9.3	9.2	9.9	10.3
225	12.0	11.5	10.8	10.0
227	8.9	9.1	11.6	11.0
230	7.8	11.7	12.7	12.1
232	9.6	12.4	11.3	10.1
221	11.0	9.8	9.5	9.7

Study: 20C0709/01098

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Male, GROUP 4				
66	8.5	10.2	10.5	9.8
64	9.0	10.4	11.3	10.7
54	7.8	11.8	10.8	9.8
71	8.5	10.5	11.5	11.5
58	8.6	9.0	10.6	9.0
92	7.5	8.7	9.0	9.3
104	7.5	9.5	10.4	11.2
87	9.7	10.3	10.4	10.5
98	10.4	11.3	12.4	12.4
82	9.5	9.5	9.9	10.4
229	9.6	8.4	10.9	8.3
236	8.8	12.9	11.4	10.9
235	8.7	11.0	10.2	11.3
217	11.0	9.7	11.1	11.2
214	10.4	9.5	9.5	10.1

Study: 20C0709/01098

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Female, GROUP 0				
181	6.6	10.0	10.5	10.7
180	7.2	8.4	7.2	8.6
173	10.7	11.1	11.3	11.2
162	9.5	9.2	8.8	8.5
184	9.1	10.2	10.0	10.5
211	8.9	9.3	10.5	8.9
201	10.2	10.5	9.7	8.6
194	9.2	9.2	8.3	9.2
198	9.4	9.0	8.8	9.0
202	8.3	8.2	7.8	7.8
243	9.9	8.8	10.4	10.8
261	10.6	9.6	7.9	9.2
264	10.3	9.3	9.1	9.8
266	9.0	10.2	10.0	10.7
244	8.2	9.2	9.0	9.4
Female, GROUP 1				
167	9.0	8.6	8.4	9.2
161	11.1	11.7	11.5	11.5
170	11.0	11.4	10.3	10.3
175	9.0	9.7	10.1	10.0
185	9.3	11.0	10.6	11.5
193	10.4	10.5	9.0	9.4
186	10.6	10.2	11.0	8.5
212	9.5	10.2	9.1	10.1
209	9.6	9.6	8.7	9.2
188	9.8	8.4	9.6	9.0
241	13.6	11.8	10.7	9.9
242	9.8	9.5	9.4	8.4
246	7.4	7.6	8.5	9.9
245	8.4	10.1	9.0	9.4
257	7.8	7.9	9.7	9.7

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Female, GROUP 2				
168	8.7	8.3	8.6	8.3
159	13.4	10.2	9.8	11.0
160	8.8	9.8	9.8	10.3
183	8.3	8.4	8.7	8.2
177	9.4	10.6	11.3	11.5
210	8.7	9.7	11.0	9.2
195	7.9	8.3	8.9	10.0
196	11.9	11.0	11.7	10.7
200	7.7	7.0	7.9	7.5
197	10.4	9.3	8.7	10.6
240	10.4	10.6	10.0	9.3
265	9.2	8.5	9.1	7.9
258	10.2	12.0	11.6	10.7
254	8.2	8.5	8.1	8.2
259	9.5	10.4	10.2	10.9
Female, GROUP 3				
163	11.0	9.9	10.5	10.0
176	8.7	8.0	7.5	8.0
174	9.2	11.2	11.2	12.6
179	7.5	8.3	8.8	8.3
171	8.9	8.1	7.1	9.7
204	7.3	10.2	11.3	11.5
203	7.6	8.8	9.3	7.8
192	7.1	7.0	8.3	8.1
191	9.9	10.2	10.2	10.2
190	8.4	8.2	8.0	8.5
263	9.4	10.4	8.3	8.8
248	9.5	8.9	7.9	8.9
255	10.4	8.5	9.1	7.9
260	7.8	8.9	10.4	10.1
250	10.8	8.0	9.7	10.0

Study: 20C0709/01098

	FST 2 cm Day -7	FST 2 cm Day 0	FST 2 cm Day 7	FST 2 cm Day 14
Female, GROUP 4				
165	8.4	10.0	9.1	9.2
164	9.7	8.0	10.0	10.3
166	10.2	10.5	10.3	10.7
178	8.9	8.8	9.8	9.5
182	8.9	7.5	6.9	8.2
207	8.6	7.8	8.0	8.0
208	9.5	9.3	9.4	8.2
187	8.6	9.6	9.3	10.2
206	9.8	9.8	9.2	8.9
205	8.5	8.3	8.3	9.6
253	11.0	8.4	9.5	10.1
251	10.3	9.6	10.4	10.5
247	9.3	9.7	10.9	11.4
262	11.3	9.5	12.3	9.6
252	10.7	9.6	9.5	9.8

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	75	77	27	40	12	4	0	1	2
	65	30	34	28	12	13	0	0	1
	70	55	42	27	12	24	10	4	0
	68	39	34	14	16	2	0	0	1
	69	61	56	31	15	5	0	1	1
	102	74	57	28	34	15	22	14	19
	105	31	33	23	38	16	3	0	0
	86	66	19	31	30	17	12	3	0
	93	52	38	28	20	26	19	1	1
	97	24	47	25	26	28	10	9	0
	239	37	28	25	30	21	15	7	6
	222	76	36	37	22	48	32	5	0
	226	35	51	35	44	31	32	8	8
	228	47	25	24	1	6	1	1	1
	238	78	56	31	30	9	0	1	1
	M	52.1	38.9	28.5	22.8	17.7	10.4	3.7	2.7
	SD	19.0	12.2	6.3	11.7	12.4	11.5	4.2	5.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	53	71	49	37	13	14	27	16	2
	60	80	46	24	31	37	24	9	0
	63	54	29	41	31	22	34	0	0
	79	80	79	20	37	9	23	3	0
	59	62	37	31	26	33	36	0	0
	95	50	33	28	35	13	23	7	2
	100	74	37	18	10	15	4	0	0
	84	65	45	39	35	25	27	15	19
	101	63	47	20	27	41	10	0	0
	88	57	40	49	39	46	0	0	0
	233	62	51	21	35	45	19	13	10
	216	54	42	41	23	39	13	28	15
	220	93	48	50	19	26	2	0	0
	231	76	56	43	49	47	45	33	25
	219	70	50	35	30	20	12	0	0
	M	67.4	45.9	33.1	29.3	28.8	19.9	8.3	4.9
	SD	11.8	11.7	10.8	10.2	13.2	13.1	10.8	8.3
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	77	48	58	38	36	26	30	32	21
	78	59	31	26	22	5	0	0	0
	55	49	27	17	0	0	2	14	2
	62	64	65	53	34	19	11	2	0
	76	64	44	36	16	13	27	0	0
	81	58	30	32	20	20	14	9	12
	99	83	56	35	31	24	4	1	0
	94	89	50	29	30	34	22	10	3
	90	66	62	32	38	27	4	0	0
	96	60	21	27	13	18	14	9	1
	215	70	50	40	26	3	3	0	0
	237	66	52	43	34	25	12	12	6
	218	53	47	45	36	29	13	1	1
	213	45	24	9	14	19	17	0	2
	224	51	23	27	32	23	22	9	0
	M	61.7	42.7	32.6	25.5	19.0	13.0	6.6	3.2
	SD	12.4	15.2	11.0	11.0	9.9	9.3	8.7	5.9
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	73	72	32	20	22	3	0	0	0
	57	80	48	31	26	28	25	23	7
	72	73	74	29	51	47	13	4	3
	56	82	36	42	20	13	0	1	4
	74	49	61	43	1	0	11	34	14
	85	59	25	31	14	20	17	1	2
	103	89	34	41	45	42	15	0	1
	83	61	30	22	23	22	39	36	2
	91	47	27	30	19	26	10	15	5
	106	71	27	29	8	2	0	0	0
	225	74	50	19	24	2	5	0	0
	227	45	41	45	36	29	40	32	64
	230	46	29	38	29	6	4	4	2
	232	77	40	39	47	24	12	2	10
	221	72	32	24	45	23	0	8	1
	M	66.5	39.1	32.2	27.3	19.1	12.7	10.7	7.7
	SD	14.3	13.9	8.7	14.8	14.6	13.1	13.7	16.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	66	62	44	33	24	17	2	0	0
	64	54	27	36	1	35	21	0	0
	54	32	38	16	32	16	6	0	3
	71	75	48	45	59	35	44	30	1
	58	74	37	28	31	12	3	1	0
	92	47	53	31	19	30	24	21	12
	104	62	61	49	32	42	21	0	0
	87	47	18	35	31	32	26	16	0
	98	63	45	55	42	0	0	0	0
	82	44	33	28	19	12	25	4	2
	229	59	22	29	26	32	31	1	0
	236	66	39	39	36	8	12	8	0
	235	74	54	40	37	6	0	2	1
	217	63	37	37	34	27	10	3	1
	214	52	29	28	0	16	10	4	0
	M	58.3	39.0	35.3	28.2	21.3	15.7	6.0	1.3
	SD	12.3	12.1	9.7	14.8	12.7	13.0	9.1	3.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	75	3	2	2	2
	65	0	7	1	2
	70	0	2	0	1
	68	0	0	0	2
	69	3	1	0	8
	102	0	0	0	0
	105	0	0	0	0
	86	0	0	1	3
	93	2	6	1	1
	97	0	0	0	0
	239	0	2	0	0
	222	0	0	6	0
	226	0	0	0	0
	228	1	0	2	0
	238	0	0	1	1
	M	0.6	1.3	0.9	1.3
	SD	1.1	2.3	1.6	2.1
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	53	23	0	0	1
	60	0	0	0	0
	63	0	1	1	0
	79	0	0	1	2
	59	0	0	0	2
	95	0	0	3	1
	100	0	0	1	2
	84	4	1	2	3
	101	0	0	2	0
	88	0	0	0	0
	233	0	0	10	1
	216	1	0	2	0
	220	1	1	1	0
	231	3	29	4	1
	219	0	0	0	0
	M	2.1	2.1	1.8	0.9
	SD	5.9	7.4	2.6	1.0
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	77	18	24	9	0
	78	0	0	0	16
	55	2	4	1	2
	62	0	0	0	0
	76	0	2	0	0
	81	7	0	0	0
	99	3	0	0	1
	94	0	0	0	0
	90	1	2	0	0
	96	0	1	0	0
	215	1	3	10	2
	237	0	0	0	6
	218	2	0	1	0
	213	0	2	1	3
	224	8	4	0	0
	M	2.8	2.8	1.5	2.0
	SD	4.9	6.0	3.3	4.2
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	73	3	3	2	0
	57	18	13	0	1
	72	1	0	0	1
	56	0	0	0	2
	74	1	4	4	0
	85	6	3	2	2
	103	1	3	1	1
	83	0	0	0	1
	91	0	1	1	2
	106	0	0	0	0
	225	1	0	9	0
	227	21	1	3	4
	230	3	3	13	0
	232	4	0	0	0
	221	2	0	0	0
	M	4.1	2.1	2.3	0.9
	SD	6.5	3.4	3.8	1.2
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	66	24	38	24	13
	64	1	3	5	3
	54	0	0	1	0
	71	0	1	0	0
	58	1	0	0	0
	92	0	2	2	1
	104	4	0	0	0
	87	0	0	0	0
	98	0	0	1	3
	82	1	5	2	3
	229	0	0	3	0
	236	0	0	4	3
	235	0	0	2	2
	217	0	5	2	2
	214	0	0	0	2
	M	2.1	3.6	3.1	2.1
	SD	6.2	9.7	6.0	3.3
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	75	59	29	22	13	7	4	1	0
	65	50	49	14	19	11	0	0	0
	70	60	40	36	42	33	2	0	1
	68	51	26	13	8	0	1	0	0
	69	50	54	29	6	21	0	0	0
	102	83	45	27	26	41	19	5	1
	105	47	53	14	19	20	0	0	0
	86	75	41	41	39	25	15	18	2
	93	42	35	28	40	12	5	2	3
	97	35	27	34	16	8	0	0	0
	239	31	35	30	23	6	2	1	3
	222	59	51	35	21	26	11	0	2
	226	27	40	35	29	35	41	18	13
	228	62	26	25	23	8	0	1	2
	238	51	23	21	0	0	0	0	0
	M	52.1	38.3	26.9	21.6	16.9	6.7	3.1	1.8
	SD	15.2	10.6	8.7	12.4	12.9	11.2	6.2	3.3
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	53	66	37	26	35	30	10	3	0
	60	68	47	38	18	10	0	0	1
	63	51	57	59	36	46	23	17	18
	79	80	34	31	38	3	0	0	0
	59	32	22	25	0	0	0	0	0
	95	65	35	33	39	21	20	3	4
	100	48	57	44	37	2	0	0	0
	84	68	33	48	30	5	0	0	1
	101	60	35	34	23	9	0	0	0
	88	61	55	27	28	19	0	0	0
	233	49	50	73	46	35	17	15	9
	216	35	38	13	31	13	26	18	6
	220	79	63	17	54	33	11	0	2
	231	83	42	35	37	50	18	14	9
	219	57	23	32	10	8	0	0	0
	M	60.1	41.9	35.7	30.8	18.9	8.3	4.7	3.3
	SD	15.2	12.5	15.5	13.7	16.3	10.0	7.2	5.2
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	77	88	39	57	25	34	34	29	14
	78	60	34	8	22	0	0	0	0
	55	65	41	19	0	0	0	0	0
	62	63	33	44	9	22	13	4	1
	76	69	47	10	28	8	0	0	0
	81	51	28	32	32	17	27	4	0
	99	42	31	46	46	16	4	1	1
	94	72	29	28	45	36	5	14	0
	90	62	49	18	32	25	15	3	0
	96	70	22	14	4	0	1	3	0
	215	33	30	50	26	1	0	0	0
	237	44	35	47	32	9	9	0	0
	218	47	44	25	28	2	1	0	0
	213	53	21	29	14	0	0	0	0
	224	56	47	41	20	1	0	0	0
	M	58.3	35.3	31.2	24.2	11.4	7.3	3.9	1.1
	SD	14.0	8.9	15.6	13.3	12.8	10.7	7.9	3.6
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	73	65	54	24	25	20	32	6	2
	57	56	44	32	36	33	4	3	0
	72	80	53	65	44	21	33	9	9
	56	89	30	42	30	2	0	1	0
	74	68	36	2	0	0	0	0	0
	85	75	28	26	6	3	0	1	1
	103	91	51	36	69	39	4	0	0
	83	38	37	43	36	18	14	0	0
	91	64	37	24	14	19	6	0	0
	106	70	48	59	15	2	0	0	1
	225	68	32	44	17	20	6	0	0
	227	54	37	28	33	47	10	12	3
	230	35	18	13	0	4	0	3	0
	232	66	47	27	32	28	14	8	5
	221	72	47	41	23	9	2	0	4
	M	66.1	39.9	33.7	25.3	17.7	8.3	2.9	1.7
	SD	15.8	10.3	16.3	18.1	14.5	10.9	4.0	2.6
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	66	19	8	4	2	5	4	0	0
	64	34	11	7	4	0	0	0	0
	54	49	5	0	7	13	0	0	0
	71	64	37	29	7	0	0	0	0
	58	44	3	0	0	0	0	1	0
	92	46	25	39	34	17	32	23	0
	104	24	8	13	29	0	27	31	1
	87	49	31	36	49	18	33	38	23
	98	34	18	0	10	0	0	0	0
	82	32	10	0	0	0	20	0	0
	229	16	1	9	0	0	15	0	0
	236	18	14	0	18	0	0	0	0
	235	9	10	0	6	8	0	16	9
	217	46	12	9	0	0	0	0	0
	214	25	11	2	0	0	0	0	0
	M	33.9	13.6	9.9	11.1	4.1	8.7	7.3	2.2
	SD	15.5	10.2	13.6	15.0	6.7	12.9	13.1	6.2
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	75	2	2	2	15
	65	0	0	0	0
	70	0	6	2	3
	68	0	0	0	4
	69	0	0	1	0
	102	1	3	1	1
	105	0	0	0	0
	86	0	0	0	0
	93	0	0	0	0
	97	0	0	1	0
	239	0	2	0	6
	222	1	2	1	1
	226	6	0	0	0
	228	2	4	4	2
	238	0	0	0	1
	M	0.8	1.3	0.8	2.2
	SD	1.6	1.9	1.1	4.0
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	53	0	0	0	0
	60	1	4	0	0
	63	0	0	0	2
	79	0	0	0	2
	59	0	0	0	0
	95	0	1	0	3
	100	0	0	0	0
	84	0	0	1	2
	101	0	0	0	0
	88	0	0	0	1
	233	7	0	0	0
	216	6	0	0	1
	220	0	0	0	0
	231	2	0	0	2
	219	0	1	1	1
	M	1.1	0.4	0.1	0.9
	SD	2.3	1.1	0.4	1.0
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	77	26	1	0	0
	78	0	11	19	27
	55	0	0	0	0
	62	1	0	0	0
	76	0	1	0	15
	81	0	0	13	0
	99	0	0	0	1
	94	0	0	0	0
	90	2	3	0	4
	96	0	0	0	1
	215	0	0	0	1
	237	0	6	0	0
	218	0	0	0	0
	213	0	0	1	0
	224	0	0	0	0
	M	1.9	1.5	2.2	3.3
	SD	6.7	3.1	5.7	7.6
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY 0 PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	73	3	1	21	15
	57	1	3	0	7
	72	0	0	1	0
	56	0	0	0	12
	74	6	2	0	0
	85	0	0	0	2
	103	0	0	0	0
	83	4	1	0	0
	91	0	0	0	0
	106	1	1	2	1
	225	1	1	3	3
	227	0	2	2	0
	230	0	0	0	0
	232	2	4	1	0
	221	0	1	1	0
	M	1.2	1.1	2.1	2.7
	SD	1.8	1.2	5.3	4.8
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	66	6	7	0	0
	64	0	23	0	0
	54	0	17	0	0
	71	0	0	0	0
	58	0	0	1	0
	92	0	0	0	0
	104	0	0	0	17
	87	0	0	0	0
	98	0	1	0	1
	82	0	0	3	0
	229	2	0	8	0
	236	32	0	0	0
	235	0	0	18	1
	217	0	0	0	0
	214	0	0	0	0
	M	2.7	3.2	2.0	1.3
	SD	8.3	7.1	4.9	4.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	75	56	57	49	30	52	15	24	0
	65	46	53	28	53	10	0	0	4
	70	58	48	50	18	23	1	9	0
	68	51	37	37	34	1	0	0	7
	69	77	45	36	49	36	28	0	0
	102	56	46	42	36	28	7	8	0
	105	66	34	7	10	9	26	8	0
	86	78	41	34	34	45	27	9	4
	93	49	17	18	19	22	22	3	0
	97	56	41	19	10	0	0	0	0
	239	58	32	18	14	2	0	0	2
	222	57	24	18	23	8	7	0	0
	226	61	22	37	29	33	6	0	0
	228	29	24	21	9	0	3	0	2
	238	73	46	45	20	3	19	0	0
	M	58.1	37.8	30.6	25.9	18.1	10.7	4.1	1.3
	SD	12.5	12.0	13.2	13.7	17.4	10.9	6.7	2.2
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	53	77	39	43	21	14	2	0	0
	60	82	50	37	14	36	20	1	2
	63	89	56	41	63	26	15	39	14
	79	89	77	31	44	1	0	0	0
	59	50	39	23	22	1	0	0	6
	95	78	43	18	28	28	17	10	1
	100	54	48	19	4	17	30	0	0
	84	79	59	48	43	25	33	13	4
	101	66	51	39	24	34	22	0	1
	88	64	64	28	28	35	30	1	0
	233	70	41	25	20	14	13	7	0
	216	71	73	48	34	43	10	15	1
	220	40	62	30	28	33	4	0	2
	231	63	50	42	38	26	34	1	1
	219	65	38	37	31	0	0	0	0
	M	69.1	52.7	33.9	29.5	22.2	15.3	5.8	2.1
	SD	14.0	12.3	9.9	14.0	13.8	12.6	10.6	3.7
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	77	103	59	44	34	22	17	24	11
	78	86	39	27	22	12	1	0	1
	55	51	22	9	28	0	0	0	0
	62	61	48	42	30	14	3	2	4
	76	69	46	29	0	1	0	3	3
	81	51	31	23	33	31	24	3	4
	99	47	48	37	36	7	52	20	1
	94	70	29	18	27	19	6	0	0
	90	65	26	20	28	23	0	0	0
	96	36	28	17	14	1	0	0	0
	215	60	33	45	17	19	11	4	0
	237	48	43	38	27	8	1	0	0
	218	78	51	33	35	23	22	3	0
	213	47	25	41	14	1	1	7	1
	224	49	53	44	2	33	0	20	0
	M	61.4	38.7	31.1	23.1	14.3	9.2	5.7	1.7
	SD	17.7	11.8	11.6	11.4	11.1	14.5	8.4	3.0
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	73	61	46	55	31	9	8	0	0
	57	64	56	50	41	20	42	9	0
	72	107	52	67	53	33	37	26	1
	56	86	71	32	33	10	1	1	0
	74	77	42	18	2	0	0	3	0
	85	65	22	23	12	8	5	0	9
	103	53	31	22	36	29	13	0	0
	83	58	36	38	14	22	24	1	0
	91	57	28	31	14	9	21	9	0
	106	58	52	50	17	0	0	1	0
	225	72	22	22	20	10	9	1	0
	227	66	39	47	32	17	7	2	0
	230	54	38	19	14	0	0	1	2
	232	87	52	49	29	29	8	9	7
	221	72	57	56	20	30	0	0	2
	M	69.1	42.9	38.6	24.5	15.1	11.7	4.2	1.4
	SD	14.9	14.0	15.9	13.4	11.5	13.5	6.9	2.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	66	58	50	17	37	28	30	18	0
	64	73	43	27	10	4	0	0	7
	54	66	51	28	11	0	1	2	12
	71	77	55	36	44	28	24	7	0
	58	58	78	40	12	0	0	0	0
	92	41	40	38	18	4	14	7	0
	104	71	54	22	43	43	13	0	0
	87	57	39	40	44	24	10	16	0
	98	63	51	31	22	3	1	2	0
	82	41	28	38	11	25	4	1	0
	229	46	32	37	36	28	35	37	61
	236	52	37	31	22	19	35	8	0
	235	58	32	23	26	3	0	0	0
	217	63	21	27	14	0	0	0	0
	214	74	30	37	20	49	1	0	0
	M	59.9	42.7	31.5	24.7	17.2	11.2	6.5	5.3
	SD	11.4	14.3	7.2	12.8	16.4	13.4	10.3	15.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	75	0	0	0	1
	65	3	1	3	0
	70	0	0	0	0
	68	4	9	30	4
	69	0	7	1	0
	102	5	2	0	4
	105	0	0	0	0
	86	9	1	0	0
	93	1	1	4	1
	97	0	0	0	0
	239	0	0	0	0
	222	0	0	0	0
	226	0	0	0	0
	228	7	4	1	0
	238	0	0	0	0
	M	1.9	1.7	2.6	0.7
	SD	3.0	2.8	7.7	1.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	53	0	0	0	0
	60	3	1	2	2
	63	0	0	7	29
	79	0	0	0	0
	59	0	0	0	0
	95	7	3	2	6
	100	0	0	0	0
	84	3	1	0	0
	101	0	0	0	0
	88	0	0	0	0
	233	0	0	0	0
	216	0	3	0	0
	220	2	4	1	2
	231	0	3	3	2
	219	0	0	0	0
	M	1.0	1.0	1.0	2.7
	SD	2.0	1.5	1.9	7.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	77	16	0	0	0
	78	0	0	0	0
	55	0	0	0	0
	62	8	4	3	5
	76	0	4	0	1
	81	0	13	0	0
	99	0	0	0	0
	94	0	0	0	0
	90	0	0	0	0
	96	0	0	0	0
	215	0	0	0	0
	237	1	0	0	0
	218	4	34	26	1
	213	5	3	0	8
	224	0	0	0	0
	M	2.3	3.9	1.9	1.0
	SD	4.5	9.0	6.7	2.3
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	73	0	0	0	0
	57	1	1	0	1
	72	0	0	0	0
	56	1	8	3	6
	74	0	0	0	3
	85	2	2	0	0
	103	0	4	1	0
	83	3	0	0	0
	91	0	0	0	0
	106	0	0	0	0
	225	0	0	0	0
	227	1	3	2	1
	230	1	6	0	6
	232	0	2	5	2
	221	17	3	3	4
	M	1.7	1.9	0.9	1.5
	SD	4.3	2.5	1.6	2.2
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	66	0	4	16	0
	64	2	0	1	0
	54	36	13	35	3
	71	0	0	0	1
	58	0	0	0	0
	92	0	0	0	0
	104	0	0	0	0
	87	0	0	3	0
	98	0	0	0	0
	82	0	2	2	2
	229	24	9	1	0
	236	0	0	0	0
	235	5	19	0	0
	217	0	0	0	0
	214	2	2	0	0
	M	4.6	3.3	3.9	0.4
	SD	10.6	5.8	9.5	0.9
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	75	49	32	38	24	18	0	0	0
	65	42	62	40	48	30	18	1	0
	70	48	40	17	29	27	18	15	1
	68	72	58	58	20	15	0	0	0
	69	66	47	39	37	15	18	3	3
	102	72	32	30	27	26	9	27	24
	105	61	34	32	18	29	22	0	0
	86	79	21	37	26	23	26	27	1
	93	41	37	33	12	28	8	0	1
	97	39	31	34	14	9	0	0	0
	239	52	33	27	37	25	23	5	1
	222	90	38	33	33	20	32	24	28
	226	66	36	22	40	21	31	21	9
	228	56	24	9	20	20	24	0	0
	238	64	60	24	5	0	0	0	0
	M	59.8	39.0	31.5	26.0	20.4	15.3	8.2	4.5
	SD	14.9	12.5	11.3	11.7	8.2	11.6	11.1	9.0
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	53	58	61	55	42	38	18	8	0
	60	66	50	20	24	27	38	13	1
	63	89	74	50	31	51	34	18	6
	79	92	76	32	18	41	10	0	0
	59	76	42	22	20	0	0	0	0
	95	78	23	37	38	22	2	0	1
	100	63	38	39	26	3	0	4	2
	84	67	44	41	35	35	16	0	1
	101	71	48	27	15	27	1	0	0
	88	81	40	30	39	14	0	2	34
	233	68	36	54	24	34	38	21	1
	216	57	37	24	36	13	12	0	0
	220	69	47	18	23	0	15	1	1
	231	64	52	40	32	28	27	19	0
	219	58	43	15	8	0	0	0	0
	M	70.5	47.4	33.6	27.4	22.2	14.1	5.7	3.1
	SD	10.8	14.1	12.9	9.8	16.5	14.3	8.0	8.7
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	77	85	31	32	25	19	32	16	16
	78	71	42	23	20	5	8	32	35
	55	45	57	33	21	11	34	34	0
	62	53	47	56	32	10	13	8	0
	76	48	45	25	28	26	0	0	0
	81	49	50	44	25	20	17	0	0
	99	92	70	45	51	33	34	33	6
	94	91	34	30	46	50	25	33	28
	90	69	37	23	49	8	2	0	0
	96	75	32	33	24	6	0	0	0
	215	63	23	35	42	20	49	16	5
	237	23	39	19	38	1	32	1	0
	218	68	45	25	29	7	0	7	0
	213	48	33	29	24	18	14	1	0
	224	80	51	53	46	20	0	0	0
	M	64.0	42.4	33.7	33.3	16.9	17.3	12.1	6.0
	SD	19.5	11.8	11.2	10.9	12.7	16.0	14.1	11.3
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	73	61	51	44	23	35	12	20	6
	57	74	53	43	18	35	26	26	34
	72	91	63	56	31	51	23	24	0
	56	83	51	64	13	30	6	1	3
	74	60	54	31	38	30	14	3	0
	85	44	25	23	19	19	1	27	0
	103	63	43	41	32	25	11	2	0
	83	59	26	22	30	17	7	1	2
	91	63	19	37	17	2	3	0	0
	106	51	36	37	38	6	0	0	0
	225	69	43	38	35	14	23	1	0
	227	70	43	31	26	25	18	4	0
	230	52	37	29	35	30	17	7	0
	232	90	61	30	36	31	28	18	5
	221	56	21	21	11	5	0	24	9
	M	65.7	41.7	36.5	26.8	23.7	12.6	10.5	3.9
	SD	13.9	14.2	12.1	9.3	13.3	9.7	11.0	8.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	66	59	38	18	33	24	23	19	13
	64	65	27	27	24	8	0	0	0
	54	52	35	36	6	6	13	0	12
	71	98	75	65	42	24	3	0	0
	58	74	46	15	26	1	1	1	0
	92	39	40	40	39	32	28	22	0
	104	63	35	40	33	33	4	0	0
	87	43	26	26	32	38	48	27	2
	98	72	44	41	33	30	0	2	0
	82	39	24	21	32	20	18	0	0
	229	71	59	46	46	54	26	61	19
	236	79	28	30	36	28	1	0	0
	235	50	51	24	35	20	0	0	1
	217	69	41	36	47	32	32	43	18
	214	62	47	44	34	16	4	0	0
	M	62.3	41.1	33.9	33.2	24.4	13.4	11.7	4.3
	SD	16.1	13.7	13.0	9.8	13.5	15.0	19.1	7.2
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	75	0	0	29	4
	65	0	0	0	0
	70	1	5	1	3
	68	0	0	0	0
	69	7	1	7	0
	102	18	3	4	2
	105	0	0	0	0
	86	1	1	14	0
	93	3	1	3	0
	97	0	0	0	0
	239	2	1	1	1
	222	5	0	3	0
	226	0	3	1	0
	228	0	0	0	4
	238	0	0	0	1
	M	2.5	1.0	4.2	1.0
	SD	4.8	1.5	7.8	1.5
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	53	0	0	0	0
	60	0	1	2	0
	63	0	0	0	0
	79	0	0	0	0
	59	0	0	0	0
	95	7	2	10	19
	100	0	1	3	15
	84	4	5	1	3
	101	0	0	0	0
	88	42	14	1	2
	233	0	0	0	0
	216	0	0	0	3
	220	0	0	0	0
	231	0	1	0	0
	219	2	0	0	1
	M	3.7	1.6	1.1	2.9
	SD	10.8	3.7	2.6	5.9
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	77	0	0	0	0
	78	18	0	0	1
	55	0	2	0	0
	62	0	0	4	0
	76	4	0	5	6
	81	6	0	0	1
	99	0	0	0	0
	94	6	3	0	0
	90	0	0	3	0
	96	0	0	0	0
	215	0	0	0	0
	237	0	0	0	0
	218	0	0	0	0
	213	2	1	0	1
	224	0	0	0	0
	M	2.4	0.4	0.8	0.6
	SD	4.9	0.9	1.7	1.5
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	73	0	0	0	0
	57	0	0	0	6
	72	1	0	0	32
	56	0	10	0	1
	74	0	0	0	0
	85	2	1	0	0
	103	1	1	0	0
	83	1	5	1	0
	91	1	0	0	1
	106	0	2	1	0
	225	0	0	0	0
	227	0	0	7	26
	230	0	0	0	0
	232	1	0	1	36
	221	0	0	0	3
	M	0.5	1.3	0.7	7.0
	SD	0.6	2.8	1.8	12.8
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	66	11	0	2	0
	64	5	0	0	0
	54	2	0	0	1
	71	0	0	0	0
	58	2	0	0	1
	92	4	5	5	3
	104	1	0	5	0
	87	4	0	0	0
	98	2	2	3	3
	82	0	3	0	1
	229	10	32	13	20
	236	0	0	0	0
	235	1	0	1	0
	217	20	0	1	1
	214	0	1	0	2
	M	4.1	2.9	2.0	2.1
	SD	5.6	8.2	3.5	5.1
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	181	41	33	25	42	35	13	1	13
	180	72	32	31	25	14	30	27	2
	173	45	39	21	17	0	0	1	1
	162	79	46	38	34	23	20	0	2
	184	57	52	30	9	0	0	1	0
	211	58	28	28	30	16	20	4	4
	201	23	43	18	16	8	0	0	0
	194	46	22	5	57	34	42	17	0
	198	74	32	45	41	23	4	0	0
	202	68	28	29	25	26	23	12	2
	243	84	58	36	27	22	7	1	2
	261	78	52	35	24	43	32	30	0
	264	62	36	29	25	15	2	0	0
	266	72	49	38	50	23	8	12	6
	244	56	38	25	29	27	14	16	10
	M	61.0	39.2	28.9	30.1	20.6	14.3	8.1	2.8
	SD	16.9	10.5	9.6	12.9	12.2	13.2	10.3	4.0
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	167	67	42	16	13	21	3	0	4
	161	57	32	29	27	35	15	19	0
	170	85	70	42	46	29	35	46	4
	175	57	41	44	26	27	2	1	2
	185	65	26	27	25	14	24	3	0
	193	45	33	22	28	30	23	17	6
	186	47	32	48	38	22	14	0	1
	212	32	44	15	40	22	29	8	1
	209	68	29	22	20	1	0	0	0
	188	83	49	34	35	32	5	0	0
	241	78	50	53	25	22	23	20	1
	242	82	37	23	29	15	5	1	0
	246	58	35	37	27	17	4	0	1
	245	62	42	32	16	7	0	0	2
	257	57	52	33	39	40	34	19	7
	M	62.9	40.9	31.8	28.9	22.3	14.4	8.9	1.9
	SD	15.1	11.2	11.4	9.2	10.5	12.7	13.1	2.3
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	168	50	57	29	29	3	4	0	0
	159	47	25	50	39	62	46	24	31
	160	77	47	23	13	33	0	0	0
	183	72	27	46	48	31	32	11	14
	177	73	51	29	28	20	27	1	1
	210	50	37	17	4	0	0	0	13
	195	48	44	28	3	0	0	0	0
	196	47	51	39	37	11	15	0	0
	200	53	28	38	7	27	11	3	0
	197	67	51	41	20	28	22	7	0
	240	55	61	28	32	16	17	27	0
	265	57	51	47	29	16	23	0	0
	258	82	30	42	26	7	0	1	0
	254	75	46	30	22	29	16	0	1
	259	58	45	41	22	24	0	3	2
	M	60.7	43.4	35.2	23.9	20.5	14.2	5.1	4.1
	SD	12.3	11.4	9.6	13.0	16.1	14.1	8.9	8.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	163	78	42	25	31	26	20	20	12
	176	56	40	39	27	5	4	0	36
	174	59	33	49	22	35	27	15	30
	179	70	65	53	24	20	0	14	23
	171	89	63	50	13	25	11	0	0
	204	61	37	46	17	31	33	13	20
	203	49	29	29	14	24	20	1	0
	192	66	62	28	41	53	29	34	2
	191	92	43	33	27	0	0	0	1
	190	60	43	31	34	3	36	0	0
	263	60	39	20	48	30	30	15	30
	248	68	40	29	37	9	39	13	7
	255	66	37	31	18	24	7	5	1
	260	62	38	50	39	7	0	0	0
	250	74	47	43	29	20	5	8	3
	M	67.3	43.9	37.1	28.1	20.8	17.4	9.2	11.0
	SD	11.8	10.9	10.7	10.4	14.2	14.3	9.9	13.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	165	34	29	25	12	33	4	9	0
	164	48	45	34	39	33	8	3	0
	166	55	20	22	27	27	18	26	31
	178	70	62	35	33	24	15	4	1
	182	81	83	40	51	4	0	2	3
	207	51	31	25	17	24	27	26	8
	208	48	26	22	18	4	1	0	0
	187	48	55	39	24	38	29	23	43
	206	79	47	29	17	0	0	1	0
	205	59	37	33	31	13	0	1	1
	253	83	40	24	35	22	11	0	16
	251	70	26	38	36	15	17	9	1
	247	63	50	18	42	38	36	18	6
	262	87	63	39	36	27	33	20	7
	252	65	26	30	29	3	10	0	1
	M	62.7	42.7	30.2	29.8	20.3	13.9	9.5	7.9
	SD	15.6	17.6	7.2	10.8	13.1	12.5	10.2	12.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	181	21	11	15	0
	180	4	0	0	0
	173	3	3	0	0
	162	2	2	2	2
	184	0	0	3	4
	211	9	1	2	1
	201	0	0	0	0
	194	0	0	0	0
	198	0	0	1	0
	202	0	2	2	2
	243	1	7	1	1
	261	0	0	0	0
	264	0	2	2	1
	266	0	0	0	2
	244	18	6	5	0
	M	3.9	2.3	2.2	0.9
	SD	6.8	3.3	3.8	1.2
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	167	1	2	2	0
	161	0	0	2	2
	170	4	0	0	0
	175	4	0	2	1
	185	1	5	0	0
	193	0	0	0	0
	186	0	0	0	0
	212	0	2	0	1
	209	3	0	2	1
	188	0	1	0	6
	241	1	0	0	3
	242	1	0	1	1
	246	4	0	0	0
	245	1	3	1	0
	257	0	0	0	2
	M	1.3	0.9	0.7	1.1
	SD	1.6	1.5	0.9	1.6
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY -7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	168	0	2	0	2
	159	33	31	11	28
	160	0	0	3	0
	183	0	8	0	0
	177	2	4	2	1
	210	21	19	9	0
	195	0	0	2	1
	196	1	0	0	0
	200	6	0	0	2
	197	0	0	1	0
	240	22	9	0	0
	265	0	0	5	0
	258	0	0	0	28
	254	0	0	0	2
	259	1	0	1	2
	M	5.7	4.9	2.3	4.4
	SD	10.6	9.0	3.5	9.6
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	163	11	14	0	0
	176	27	31	13	7
	174	8	1	1	1
	179	3	0	0	0
	171	1	1	0	3
	204	23	1	1	0
	203	32	21	26	22
	192	16	14	0	0
	191	0	0	0	0
	190	0	7	1	4
	263	30	15	21	0
	248	3	4	0	0
	255	0	2	3	1
	260	0	0	0	0
	250	0	0	0	0
	M	10.3	7.4	4.4	2.5
	SD	12.1	9.5	8.5	5.8
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY -7 PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	165	0	0	3	1
	164	2	0	0	1
	166	22	11	6	0
	178	0	0	0	0
	182	0	12	1	0
	207	15	4	0	3
	208	0	0	1	0
	187	7	15	3	0
	206	8	64	0	2
	205	8	33	27	5
	253	0	2	3	3
	251	18	28	40	17
	247	4	2	0	0
	262	0	0	1	2
	252	2	6	22	0
	M	5.7	11.8	7.1	2.3
	SD	7.3	17.8	12.3	4.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	181	59	28	24	30	10	20	5	13
	180	63	36	39	32	9	12	1	0
	173	75	21	36	35	19	5	8	0
	162	62	49	41	25	26	36	9	0
	184	49	41	29	8	3	0	0	0
	211	68	43	26	29	15	2	0	0
	201	58	33	27	38	12	13	2	0
	194	93	37	24	28	51	30	29	17
	198	56	43	43	9	8	17	8	3
	202	65	46	46	10	10	19	14	0
	243	71	48	37	48	29	31	10	17
	261	64	48	38	10	0	0	4	27
	264	57	22	32	28	19	16	0	0
	266	78	33	31	35	23	6	0	2
	244	64	44	16	29	27	0	5	0
	M	65.5	38.1	32.6	26.3	17.4	13.8	6.3	5.3
	SD	10.7	9.2	8.3	11.9	12.8	11.9	7.6	8.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	167	64	32	44	16	7	0	0	0
	161	76	24	28	41	26	34	28	11
	170	96	83	48	29	19	36	45	23
	175	60	33	36	7	0	0	1	3
	185	59	24	31	20	20	13	0	0
	193	57	32	33	14	15	0	0	1
	186	82	39	30	20	6	25	10	0
	212	46	22	37	23	27	29	17	7
	209	61	42	27	15	28	19	11	0
	188	66	39	32	18	28	27	19	0
	241	77	66	43	28	7	1	0	0
	242	48	30	22	29	25	19	16	0
	246	48	26	23	19	29	16	6	18
	245	69	29	10	0	20	23	3	2
	257	57	29	22	36	10	27	22	13
	M	64.4	36.7	31.1	21.0	17.8	17.9	11.9	5.2
	SD	13.8	16.7	9.9	10.6	9.7	12.6	13.0	7.6
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	168	67	52	22	32	27	20	1	0
	159	71	45	53	20	41	42	33	15
	160	66	34	7	0	31	22	0	0
	183	61	58	42	28	26	25	2	0
	177	71	49	26	26	36	21	11	1
	210	58	32	34	28	16	14	13	15
	195	69	38	30	34	25	26	8	2
	196	82	57	18	12	2	36	24	0
	200	62	48	14	10	18	9	3	10
	197	60	41	15	14	21	7	19	5
	240	42	42	35	39	29	12	2	2
	265	69	28	40	35	47	26	39	13
	258	49	27	25	38	29	34	10	5
	254	54	34	45	18	15	1	0	0
	259	67	32	32	7	13	4	0	0
	M	63.2	41.1	29.2	22.7	25.1	19.9	11.0	4.5
	SD	9.9	10.1	12.8	12.2	11.5	12.1	12.5	5.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	163	77	27	21	38	0	2	0	0
	176	62	34	30	36	26	11	30	7
	174	78	42	33	17	30	9	21	0
	179	87	66	54	29	37	0	1	2
	171	88	53	48	4	1	4	2	1
	204	59	33	30	30	28	36	31	16
	203	73	33	31	13	22	7	1	4
	192	81	42	42	39	20	29	32	17
	191	55	29	34	34	32	21	3	3
	190	63	38	41	37	24	24	2	11
	263	62	38	49	30	27	21	30	0
	248	54	38	23	38	4	2	1	0
	255	43	31	29	34	22	21	23	0
	260	62	54	34	29	0	0	1	0
	250	66	29	34	8	34	19	13	13
	M	67.3	39.1	35.5	27.7	20.5	13.7	12.7	4.9
	SD	12.9	10.9	9.5	11.6	12.9	11.5	13.4	6.3
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	181	1	1	0	1
	180	1	0	0	0
	173	0	0	0	0
	162	4	3	2	22
	184	0	0	0	1
	211	33	32	25	19
	201	0	0	0	12
	194	0	0	0	0
	198	0	0	2	1
	202	1	2	3	2
	243	38	36	25	3
	261	6	0	2	0
	264	0	0	18	0
	266	0	2	0	1
	244	0	0	0	0
	M	5.6	5.1	5.1	4.1
	SD	12.3	11.8	9.3	7.3
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	167	0	0	0	8
	161	5	0	0	0
	170	15	0	0	0
	175	2	1	1	2
	185	0	0	0	3
	193	0	0	0	18
	186	0	0	0	28
	212	0	0	2	0
	209	0	0	2	0
	188	0	4	4	2
	241	0	0	21	26
	242	0	0	23	0
	246	14	1	15	5
	245	0	1	0	0
	257	0	0	0	0
	M	2.4	0.5	4.5	6.1
	SD	5.1	1.1	8.1	9.7
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	168	0	18	17	0
	159	0	0	0	30
	160	0	0	0	1
	183	3	0	2	8
	177	0	1	3	19
	210	0	0	0	0
	195	0	0	0	0
	196	5	0	3	0
	200	0	0	0	1
	197	0	0	0	0
	240	3	0	12	7
	265	35	35	16	0
	258	0	7	24	27
	254	0	0	0	0
	259	0	0	1	3
	M	3.1	4.1	5.2	6.4
	SD	9.0	9.8	7.9	10.3
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	163	0	10	21	45
	176	0	2	0	0
	174	0	0	2	3
	179	1	10	20	3
	171	15	5	0	12
	204	9	4	0	0
	203	0	0	0	9
	192	17	22	42	16
	191	14	0	1	0
	190	2	5	2	0
	263	0	0	25	0
	248	1	0	23	1
	255	0	0	18	0
	260	0	0	0	0
	250	7	0	0	0
	M	4.4	3.9	10.3	5.9
	SD	6.3	6.2	13.4	11.9
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 0

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	165	4	17	13	7
	164	0	0	0	0
	166	8	2	0	3
	178	0	0	0	4
	182	0	1	0	11
	207	1	0	20	12
	208	0	0	0	23
	187	1	0	23	7
	206	1	2	1	2
	205	0	0	4	6
	253	3	15	15	4
	251	0	0	28	11
	247	0	0	24	15
	262	14	1	3	4
	252	0	0	0	4
	M	2.1	2.5	8.7	7.5
	SD	4.0	5.5	10.6	6.0
	N	15	15	15	15

BASF
Project Number 20C0709/01098 OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS MOTOR ACTIVITY DAY 7 PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	181	62	22	28	32	27	0	0	9
	180	49	41	39	18	35	10	18	1
	173	68	17	43	14	3	2	0	0
	162	74	48	39	31	37	32	7	18
	184	65	36	27	14	19	17	0	0
	211	58	41	43	38	35	22	13	0
	201	71	37	30	22	14	11	14	0
	194	70	35	0	0	0	0	14	25
	198	56	39	37	4	0	0	23	5
	202	47	39	25	23	36	9	24	5
	243	55	33	33	35	29	37	10	33
	261	75	56	43	29	1	0	0	6
	264	50	42	37	33	27	9	1	0
	266	72	39	24	12	21	13	0	0
	244	47	34	7	0	0	0	0	0
	M	61.3	37.3	30.3	20.3	18.9	10.8	8.3	6.8
	SD	10.2	9.3	12.8	12.7	14.7	11.9	8.9	10.4
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	167	85	41	27	19	30	1	0	0
	161	59	49	11	35	18	6	13	0
	170	88	62	32	55	29	50	14	1
	175	67	28	22	34	20	16	15	0
	185	71	47	24	37	19	1	1	1
	193	63	48	15	21	2	24	0	0
	186	39	32	36	29	24	16	23	9
	212	59	34	18	27	14	0	0	0
	209	53	45	33	18	33	2	0	0
	188	63	47	32	16	37	5	0	0
	241	63	44	10	16	4	0	0	0
	242	33	28	21	16	20	17	19	18
	246	69	34	38	24	20	14	12	7
	245	30	9	27	25	5	0	0	0
	257	49	43	41	22	48	24	25	3
	M	59.4	39.4	25.8	26.3	21.5	11.7	8.1	2.6
	SD	16.7	12.4	9.6	10.6	12.7	13.8	9.5	5.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	168	78	40	49	37	20	7	10	0
	159	55	46	48	57	38	36	43	25
	160	75	31	10	2	0	8	19	5
	183	78	53	49	20	30	26	0	0
	177	55	37	31	34	8	0	1	1
	210	60	28	29	14	12	0	1	24
	195	50	37	26	55	16	31	15	26
	196	66	45	26	34	20	21	10	11
	200	55	33	31	9	0	0	2	1
	197	83	41	47	33	27	32	17	3
	240	56	38	31	19	14	0	0	0
	265	67	52	35	33	14	32	12	5
	258	45	26	21	9	14	26	14	0
	254	41	42	30	25	18	0	0	2
	259	68	46	28	25	41	3	0	0
	M	62.1	39.7	32.7	27.1	18.1	14.8	9.6	6.9
	SD	12.7	8.0	11.2	15.8	11.9	14.5	11.6	9.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	163	53	20	27	40	9	5	12	2
	176	60	32	40	27	41	32	20	45
	174	56	36	30	30	29	22	24	38
	179	66	21	18	3	0	18	21	2
	171	71	38	53	56	38	14	0	6
	204	49	36	20	33	25	15	6	18
	203	50	35	24	17	13	28	15	29
	192	70	43	20	34	24	3	20	3
	191	73	54	25	11	1	3	36	15
	190	59	46	39	29	40	14	0	0
	263	66	48	36	21	14	38	6	0
	248	23	25	9	20	12	31	15	18
	255	52	45	28	15	19	21	7	3
	260	74	38	28	39	23	0	0	0
	250	62	46	48	21	34	20	0	0
	M	58.9	37.5	29.7	26.4	21.5	17.6	12.1	11.9
	SD	13.0	10.0	11.7	13.2	13.3	11.6	10.8	14.9
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	165	51	33	36	18	12	15	8	2
	164	83	46	35	38	22	21	19	5
	166	27	28	25	15	14	5	1	0
	178	73	56	32	26	35	13	7	14
	182	66	58	8	40	3	11	1	0
	207	46	30	21	25	28	11	7	19
	208	75	57	41	11	21	0	0	0
	187	47	39	30	24	30	19	14	11
	206	71	54	39	30	43	15	15	0
	205	61	39	21	27	0	0	0	0
	253	67	27	27	37	24	8	0	1
	251	81	27	38	43	28	14	0	0
	247	51	35	18	18	25	3	10	0
	262	52	36	26	14	36	2	1	0
	252	53	45	39	43	36	0	0	0
	M	60.3	40.7	29.1	27.3	23.8	9.1	5.5	3.5
	SD	15.4	11.3	9.4	10.9	12.3	7.1	6.5	6.1
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	181	20	7	6	2
	180	0	1	1	0
	173	0	0	0	0
	162	0	0	0	0
	184	0	0	0	0
	211	0	0	0	0
	201	0	0	0	0
	194	0	0	0	0
	198	1	3	4	2
	202	0	0	0	0
	243	31	10	3	9
	261	14	0	1	0
	264	0	2	1	3
	266	0	0	0	1
	244	0	18	29	0
	M	4.4	2.7	3.0	1.1
	SD	9.5	5.2	7.4	2.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	167	0	1	2	0
	161	0	0	0	0
	170	0	0	0	0
	175	4	1	0	0
	185	0	0	0	0
	193	3	0	4	0
	186	0	8	37	25
	212	0	0	15	19
	209	0	0	0	0
	188	0	0	0	0
	241	1	0	0	0
	242	7	0	2	2
	246	1	0	0	1
	245	0	0	0	0
	257	0	0	0	0
	M	1.1	0.7	4.0	3.1
	SD	2.1	2.1	9.9	7.8
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	168	0	0	6	40
	159	15	27	0	0
	160	3	0	0	0
	183	0	0	31	17
	177	0	0	1	2
	210	27	8	0	0
	195	13	0	0	1
	196	25	4	0	0
	200	0	4	1	29
	197	0	19	10	22
	240	8	3	0	0
	265	32	0	1	0
	258	3	0	0	25
	254	1	1	1	2
	259	0	2	1	0
	M	8.5	4.5	3.5	9.2
	SD	11.3	8.0	8.1	13.6
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	163	0	0	0	0
	176	20	13	16	21
	174	25	13	18	12
	179	20	5	0	0
	171	0	13	4	9
	204	3	0	0	9
	203	31	4	2	0
	192	19	18	3	0
	191	0	0	3	22
	190	0	0	0	0
	263	0	0	0	2
	248	4	0	0	4
	255	0	0	0	0
	260	0	0	0	0
	250	0	0	0	0
	M	8.1	4.4	3.1	5.3
	SD	11.3	6.4	5.8	7.7
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

PRINT DATE 18DEC02

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 7

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	165	2	0	1	2
	164	0	1	2	1
	166	5	29	15	16
	178	0	0	0	0
	182	0	9	17	17
	207	22	3	0	0
	208	0	0	0	0
	187	4	0	0	0
	206	0	0	0	0
	205	0	0	0	5
	253	0	20	0	0
	251	0	0	0	0
	247	0	0	4	4
	262	0	0	1	0
	252	0	2	1	0
	M	2.2	4.3	2.7	3.0
	SD	5.7	8.7	5.5	5.7
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 0									
0 MG/KG	181	45	31	48	23	0	2	0	0
	180	85	46	43	40	44	27	18	10
	173	29	34	8	20	0	2	4	0
	162	85	64	48	25	4	0	1	0
	184	59	35	36	0	0	0	0	0
	211	58	40	32	33	38	21	22	27
	201	78	41	20	8	15	6	3	0
	194	75	30	16	24	33	8	0	0
	198	70	60	14	0	0	0	0	0
	202	79	27	41	9	1	0	0	1
	243	75	51	49	44	20	32	26	4
	261	65	33	28	36	10	26	4	0
	264	72	32	36	45	44	10	15	16
	266	69	54	39	29	22	2	1	0
	244	50	42	39	22	17	15	18	7
	M	66.3	41.3	33.1	23.9	16.5	10.1	7.5	4.3
	SD	15.7	11.4	13.2	14.6	16.5	11.3	9.4	7.9
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 1									
0.2 MG/KG	167	41	57	31	23	4	3	0	0
	161	43	51	19	26	22	14	18	34
	170	65	47	7	0	2	29	62	11
	175	76	60	50	12	0	0	0	17
	185	84	43	19	31	21	19	0	0
	193	52	28	18	11	28	1	0	0
	186	68	38	17	47	11	0	0	0
	212	53	23	24	24	32	21	34	5
	209	69	13	25	17	0	38	22	8
	188	64	44	28	12	1	0	0	0
	241	61	44	23	20	8	28	14	0
	242	57	35	19	18	15	9	0	0
	246	76	32	27	24	38	33	14	13
	245	75	30	46	35	33	7	7	0
	257	55	25	44	18	46	21	21	10
	M	62.6	38.0	26.5	21.2	17.4	14.9	12.8	6.5
	SD	12.5	13.1	11.9	11.2	15.3	13.2	17.4	9.6
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 2									
0.25 MG/KG	168	54	47	16	40	28	0	1	0
	159	64	56	47	34	42	36	61	5
	160	50	45	35	27	15	0	0	0
	183	54	37	44	27	18	5	6	1
	177	66	39	26	39	9	0	2	1
	210	52	28	29	20	27	35	10	0
	195	61	26	17	44	33	6	8	1
	196	66	43	55	41	24	13	9	0
	200	45	20	42	10	1	2	1	27
	197	81	53	28	19	7	0	0	7
	240	70	50	24	29	38	20	0	0
	265	66	57	46	54	29	24	23	58
	258	67	8	34	20	8	20	22	2
	254	54	30	23	18	38	15	21	0
	259	42	21	36	13	0	0	0	0
	M	59.5	37.3	33.5	29.0	21.1	11.7	10.9	6.8
	SD	10.5	14.7	11.6	12.7	13.9	12.8	16.2	15.8
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 3									
0.35 MG/KG	163	56	47	15	15	30	0	0	0
	176	68	41	61	37	41	27	15	2
	174	32	25	19	21	0	4	0	0
	179	67	39	38	30	18	0	0	0
	171	79	39	24	2	0	5	0	0
	204	45	27	29	31	28	40	27	0
	203	39	34	27	21	24	44	35	15
	192	67	47	34	19	34	28	42	0
	191	75	27	29	1	0	0	0	5
	190	45	28	19	23	25	8	13	2
	263	73	45	43	31	29	16	1	0
	248	62	24	36	7	18	18	23	2
	255	53	35	18	19	12	16	16	2
	260	73	61	34	30	36	10	0	0
	250	80	46	52	40	27	11	0	0
	M	60.9	37.7	31.9	21.8	21.5	15.1	11.5	1.9
	SD	15.2	10.5	13.0	11.9	13.3	14.1	14.5	3.9
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 1 Beam Interr.	Interv. 2 Beam Interr.	Interv. 3 Beam Interr.	Interv. 4 Beam Interr.	Interv. 5 Beam Interr.	Interv. 6 Beam Interr.	Interv. 7 Beam Interr.	Interv. 8 Beam Interr.
GROUP 4									
5 MG/KG	165	38	29	6	10	1	8	4	0
	164	78	53	32	21	11	8	23	0
	166	40	22	17	0	23	0	3	0
	178	77	55	22	19	12	0	0	0
	182	96	53	28	35	25	32	16	17
	207	57	41	30	28	25	29	6	18
	208	55	46	47	19	33	6	0	12
	187	51	27	15	26	5	15	26	3
	206	64	61	29	41	27	15	0	0
	205	44	38	32	9	16	0	0	0
	253	58	24	29	30	16	16	4	7
	251	74	35	37	40	36	9	27	12
	247	59	36	22	20	24	37	14	6
	262	49	51	31	20	46	27	14	19
	252	66	50	46	28	28	9	4	5
	M	60.4	41.4	28.2	23.1	21.9	14.1	9.4	6.6
	SD	15.9	12.4	10.9	11.4	12.0	12.0	9.8	7.2
	N	15	15	15	15	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 0					
0 MG/KG	181	2	1	2	3
	180	5	0	0	0
	173	0	0	0	0
	162	2	31	22	4
	184	0	0	0	0
	211	14	0	15	2
	201	4	0	0	0
	194	0	2	1	1
	198	0	0	2	1
	202	0	1	0	0
	243	1	0	1	4
	261	0	0	0	0
	264	0	1	0	0
	266	31	43	22	0
	244	9	4	0	0
	M	4.5	5.5	4.3	1.0
	SD	8.4	13.0	8.1	1.5
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 1					
0.2 MG/KG	167	0	0	0	0
	161	2	0	0	0
	170	15	0	0	0
	175	0	0	0	0
	185	0	0	0	0
	193	0	9	17	14
	186	0	0	26	0
	212	2	4	2	1
	209	0	0	0	0
	188	1	0	0	0
	241	0	0	0	0
	242	0	0	2	1
	246	20	32	17	0
	245	0	0	6	35
	257	0	0	0	0
	M	2.7	3.0	4.7	3.4
	SD	6.1	8.4	8.3	9.4
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 2					
0.25 MG/KG	168	0	0	0	0
	159	0	0	0	0
	160	0	0	0	4
	183	0	0	0	5
	177	0	0	0	0
	210	0	0	0	0
	195	4	0	1	0
	196	0	0	0	0
	200	9	1	1	2
	197	7	0	1	0
	240	0	0	2	12
	265	8	0	0	0
	258	0	3	0	0
	254	0	0	0	0
	259	2	0	0	0
	M	2.0	0.3	0.3	1.5
	SD	3.3	0.8	0.6	3.3
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 3					
0.35 MG/KG	163	0	0	1	6
	176	5	3	0	0
	174	0	0	0	0
	179	0	0	1	0
	171	0	0	0	1
	204	8	16	0	0
	203	0	1	0	3
	192	0	0	0	0
	191	35	1	0	0
	190	0	2	6	3
	263	0	0	0	0
	248	1	0	5	0
	255	5	3	0	0
	260	0	0	0	0
	250	1	2	0	1
	M	3.7	1.9	0.9	0.9
	SD	9.0	4.1	1.9	1.8
	N	15	15	15	15

BASF
Project Number 20C0709/01098

OMETHOATE

INDIVIDUAL DATA LISTING WITH MEANS

MOTOR ACTIVITY DAY 14

PRINT DATE 18DEC02

F E M A L E S

	Animal No.	Interv. 9 Beam Interr.	Interv.10 Beam Interr.	Interv.11 Beam Interr.	Interv.12 Beam Interr.
GROUP 4					
5 MG/KG	165	0	0	0	0
	164	0	0	0	0
	166	0	0	0	0
	178	0	0	0	0
	182	12	0	0	0
	207	10	0	3	0
	208	0	0	0	0
	187	0	0	0	0
	206	0	0	0	0
	205	0	0	0	0
	253	14	0	0	0
	251	17	0	0	0
	247	8	0	6	0
	262	3	23	0	0
	252	1	3	0	0
	M	4.3	1.7	0.6	0.0
	SD	6.1	5.9	1.7	0.0
	N	15	15	15	15

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day -6	ECHE µkat/l E. Day -6
Male, GROUP 0		
23	13.26	31.43
46	12.52	33.59
17	12.61	36.79
45	13.43	32.38
19	18.05	31.32
51	10.47	37.60
7	11.99	34.72
33	10.42	32.21
14	12.45	36.40
32	10.70	35.75
Male, GROUP 1		
3	14.15	30.61
35	15.82	25.05
1	12.77	30.79
5	14.55	35.98
30	12.63	37.19
37	10.54	33.74
25	10.42	38.42
42	13.76	29.88
15	14.70	37.72
41	12.46	31.18
Male, GROUP 2		
43	13.37	36.90
22	13.42	55.48*
2	13.11	41.24
48	10.26	28.29
34	14.59	33.33
38	10.23	31.62
52	11.56	34.56
29	15.74	33.91
36	14.35	25.45
44	10.94	33.67

Key: * = Outlier

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day -6	ECHE µkat/l E. Day -6
Male, GROUP 3		
10	11.34	38.35
4	11.82	36.87
8	12.91	35.16
16	15.39	34.93
50	14.85	36.21
47	13.00	37.53
28	11.66	29.44
24	12.28	31.12
11	8.79	33.60
18	13.42	39.02
Male, GROUP 4		
21	10.58	33.09
31	12.38	28.53
12	13.55	29.18
49	10.81	29.34
40	14.77	32.90
13	13.16	35.75
26	12.51	40.41
9	14.82	33.11
20	15.54	34.48
27	15.18	34.79

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 0	ECHE µkat/l E. Day 0	BCHE µkat/g P. Day 0
Male, GROUP 0			
23	12.07	34.30	4.56
46	11.60	32.58	3.60
17	11.55	28.70	4.95
45	13.27	30.20	3.87
19	15.84	32.68	2.68
51	9.98	38.11	4.18
7	10.87	29.36	3.15
33	10.06	27.41	3.44
14	11.17	35.53	4.53
32	10.84	29.73	3.68
Male, GROUP 1			
3	13.04	33.89	3.46
35	13.39	31.27	3.94
1	11.38	32.61	3.18
5	14.03	30.59	3.49
30	11.13	31.72	3.77
37	9.77	31.37	4.14
25	8.71	32.77	2.59
42	10.93	30.05	4.34
15	13.38	30.49	3.56
41	12.01	30.34	3.72
Male, GROUP 2			
43	12.38	27.50	4.09
22	13.23	28.41	4.05
2	11.92	29.06	3.59
48	9.02	29.17	3.59
34	13.11	31.86	4.09
38	9.52	25.57	4.43
52	10.69	27.60	3.28
29	13.73	28.46	3.95
36	12.37	23.41	2.80
44	9.67	27.48	1.89
Male, GROUP 3			
10	10.20	24.90	2.92
4	10.03	21.38	4.48
8	11.04	28.93	3.13
16	13.31	33.12	3.68
50	13.13	27.31	3.71
47	9.76	23.73	3.58
28	10.21	26.88	2.65
24	10.11	25.13	1.35
11	8.70	27.70	2.84
18	10.40	28.54	3.03

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 0	ECHE µkat/l E. Day 0	BCHE µkat/g P. Day 0
Male, GROUP 4			
21	3.77	6.73	0.73
31	5.65	8.14	0.92
12	4.64	6.10	0.40
49	4.66	7.59	0.90
40	5.56	8.01	0.71
13	4.97	6.10	1.02
26	4.77	8.22	0.82
9	7.03	7.59	0.65
20	7.54	5.45	0.46
27	5.55	8.27	0.88

Study: 20C0709/01098

	SCHE µkat/l Day -6	ECHE µkat/l E. Day -6
Female, GROUP 0		
144	16.85	37.88
110	21.20	31.16
128	23.76	27.45
109	20.39	34.07
157	19.93	35.79
152	35.36	36.97
129	27.18	30.29
126	14.54	32.55
120	18.28	40.10
125	21.61	43.02
Female, GROUP 1		
143	18.73	33.76
150	26.81	31.54
108	18.35	30.00
145	21.09	32.51
131	27.37	41.15
149	24.61	43.84
118	38.21	34.53
136	22.28	40.03
130	32.18	35.68
116	20.25	28.52
Female, GROUP 2		
111	25.93	38.28
141	23.83	35.80
140	27.35	35.45
142	23.30	36.95
155	16.38	38.76
153	17.61	41.70
114	28.63	38.53
148	35.24	29.75
113	22.61	37.72
122	34.38	32.23
Female, GROUP 3		
138	22.27	28.88
115	27.77	35.14
146	17.26	38.83
119	25.54	28.84
134	26.56	32.08
156	26.39	35.25
137	26.53	28.60
154	23.56	26.42
112	29.83	35.29
151	23.39	40.05

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day -6	ECHE µkat/l E. Day -6
Female, GROUP 4		
147	21.36	45.52
107	16.18	29.70
158	16.21	39.19
123	33.26	32.46
124	28.91	38.42
133	28.74	30.50
117	30.08	30.82
139	22.46	39.44
121	25.67	33.48
132	22.11	32.85

Study: 20C0709/01098

	SCHE µkat/l Day 0	ECHE µkat/l E. Day 0	BCHE µkat/g P. Day 0
Female, GROUP 0			
144	18.25	34.21	5.16
110	23.03	30.28	4.84
128	34.34	27.36	2.63
109	19.47	24.73	4.50
157	28.84	37.59	5.25
152	50.23	36.75	4.21
129	37.02	33.33	4.51
126	19.57	30.47	3.67
120	25.08	46.29	5.02
125	30.71	37.30	4.93
Female, GROUP 1			
143	27.25	31.75	4.42
150	27.57	27.23	3.94
108	20.17	30.45	4.14
145	23.83	31.93	4.18
131	30.61	33.12	3.79
149	24.53	32.76	4.15
118	38.48	33.89	3.87
136	25.93	28.76	4.11
130	35.98	32.25	4.11
116	22.92	20.63*	1.58
Female, GROUP 2			
111	26.53	30.31	4.69
141	34.87	22.05	4.91
140	32.37	36.83	4.26
142	22.25	36.15	3.83
155	18.01	28.18	3.95
153	16.11	31.60	3.72
114	44.58	34.23	3.23
148	34.02	31.10	4.07
113	33.07	31.58	3.59
122	36.74	28.73	4.00

Key: * = Outlier

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 0	ECHE µkat/l E. Day 0	BCHE µkat/g P. Day 0
Female, GROUP 3			
138	31.18	29.33	4.05
115	28.45	32.44	4.18
146	17.81	35.72	3.62
119	29.02	28.28	3.70
134	32.28	22.85	4.05
156	29.85	28.36	3.08
137	30.92	29.88	1.64
154	20.05	28.19	3.58
112	24.89	30.56	2.95
151	27.62	27.29	1.61
Female, GROUP 4			
147	12.53	10.27	1.00
107	10.74	9.23	1.04
158	7.53	8.64	0.62
123	21.06	7.96	0.81
124	20.11	10.17	1.13
133	23.49	7.49	0.89
117	24.96	6.89	0.77
139	16.82	6.63	0.91
121	14.71	8.22	0.76
132	16.84	7.57	0.92

Study: 20C0709/01098

	SCHE µkat/l Week -1	ECHE µkat/l E. Week -1
Male, GROUP 0		
75	13.75	20.07
65	11.24	18.40
70	11.27	33.22
68	11.92	34.61
69	12.49	21.80
102	10.24	39.80
105	14.83	29.05
86	9.72	31.37
93	10.49	33.83
97	14.09	35.80
Male, GROUP 1		
53	9.91	35.56
60	10.49	33.30
63	11.86	36.15
79	13.28	33.15
59	8.25	40.26
95	11.26	40.51
100	10.29	17.01
84	13.36	26.40
101	12.15	26.38
88	12.67	40.96
Male, GROUP 2		
77	13.40	34.93
78	14.86	34.38
55	11.63	37.71
62	12.18	28.45
76	11.12	37.89
81	11.18	32.26
99	10.05	22.17
94	11.53	34.86
90	12.65	33.71
96	12.69	35.47
Male, GROUP 3		
73	11.01	36.49
57	11.98	35.29
72	12.85	35.54
56	12.24	32.19
74	13.78	36.83
85	11.80	37.20
103	13.77	45.27
83	13.22	37.05
91	12.46	26.51
106	11.53	36.50

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Week -1	ECHE µkat/l E. Week -1
Male, GROUP 4		
66	11.08	37.48
64	13.66	35.74
54	10.98	31.56
71	13.63	27.45
58	15.47	34.68
92	13.45	38.71
104	13.16	40.41
87	16.32	36.72
98	12.01	30.88
82	11.62	32.49

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 15	ECHE µkat/l E. Day 15	BCHE µkat/g P. Day 15
Male, GROUP 0			
75	12.51	30.45	2.08
65	10.54	32.00	2.12
70	10.59	29.59	3.16
68	10.25	39.46	1.46
69	11.03	25.90	2.84
102	8.94	35.69	2.32
105	13.77	28.34	3.91
86	8.12		3.36
93	9.35	27.62	4.75
97	13.17	28.61	4.51
Male, GROUP 1			
53	8.83	41.07	2.22
60	10.26	31.93	4.76
63	10.20	34.74	2.36
79	12.36	36.25	3.87
59	6.75	31.26	3.13
95	10.41	33.82	3.02
100	9.01	25.07	3.61
84	11.60	33.68	2.20
101	9.61	23.91	2.26
88	11.27	32.71	3.03
Male, GROUP 2			
77	13.91	34.79	2.56
78	13.23	30.75	3.32
55	12.41	29.09	4.09
62	12.44	30.02	1.86
76	9.68	33.20	2.76
81	9.56	31.94	2.15
99	8.90	29.05	4.04
94	10.10	24.96	3.89
90	10.88	25.06	1.93
96	11.88	36.92	2.26
Male, GROUP 3			
73	10.63	29.75	5.11
57	9.56	27.75	1.80
72	11.57	29.60	3.07
56	11.24	25.37	1.49
74	13.27	30.20	4.95
85	10.98	38.58	3.13
103	11.89	33.44	1.57
83	11.90	27.66	1.85
91	9.97	31.58	1.86
106	9.36	28.40	3.01

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Day 15	ECHE µkat/l E. Day 15	BCHE µkat/g P. Day 15
Male, GROUP 4			
66	9.54	27.98	2.63
64	12.48	31.03	2.24
54	11.57	30.22	2.52
71	12.85	30.88	3.37
58	13.41	30.09	1.44
92	12.06	27.99	1.73
104	12.96	32.50	3.31
87	12.69	23.58	2.20
98	10.43	22.28	3.34
82	9.34	27.62	3.32

ENZYMES

Study: 20C0709/01098

	SCHE µkat/l Week -1	ECHE µkat/l E. Week -1
Female, GROUP 0		
181	17.94	40.87
180	26.46	35.40
173	20.73	37.40
162	28.42	39.88
184	19.04	37.70
211	22.64	40.97
201	22.27	33.88
194	19.66	36.26
198	15.66	32.66
202	22.86	41.28
Female, GROUP 1		
167	16.44	39.04
161	28.77	33.17
170	20.05	34.19
175	16.31	37.69
185	25.05	40.94
193	24.10	37.23
186	14.91	22.06
212	15.81	37.95
209	18.46	38.81
188	31.60	41.12
Female, GROUP 2		
168	19.02	35.77
159	30.04	32.00
160	21.45	42.17
183	40.11	23.31
177	19.42	38.00
210	24.44	25.31
195	19.39	36.03
196	23.58	34.56
200	28.72	31.77
197	24.12	30.45
Female, GROUP 3		
163	30.55	37.69
176	32.22	38.22
174	17.91	38.95
179	35.04	28.36
171	23.19	36.59
204	14.75	36.74
203	31.96	36.12
192	15.51	35.59
191	15.79	35.57
190	31.40	41.22

Study: 20C0709/01098

	SCHE µkat/l Week -1	ECHE µkat/l E. Week -1
Female, GROUP 4		
165	35.69	32.52
164	22.22	35.34
166	34.55	27.23
178	30.87	41.95
182	18.91	34.79
207	24.80	35.18
208	16.21	42.23
187	19.81	36.73
206	23.08	36.62
205	21.71	33.92

Study: 20C0709/01098

	SCHE µkat/l Day 15	ECHE µkat/l E. Day 15	BCHE µkat/g P. Day 15
Female, GROUP 0			
181	23.04	37.11	3.69
180	32.50	31.93	5.58
173	27.99	28.13	1.81
162	41.67	29.34	2.96
184	24.10	32.28	1.57
211	32.51	32.02	4.42
201	34.96	29.89	4.42
194	32.25	32.30	4.40
198	30.79	36.55	4.60
202	37.01	30.16	3.15
Female, GROUP 1			
167	23.20	32.92	5.08
161	43.55	29.23	4.59
170	26.10	24.17*	4.11
175	27.56	32.60	4.26
185	26.45	31.12	4.49
193	57.98	29.74	3.63
186	25.72	32.86	3.90
212	26.96	30.80	3.98
209	34.86	34.04	2.76
188	40.90	33.23	4.43
Female, GROUP 2			
168	31.26	32.97	2.21
159	48.42	26.75	3.99
160	25.76	36.57	1.92
183	25.64	27.03	2.07
177	24.61	34.29	4.92
210	45.54	30.49	4.18
195	30.55	32.71	4.09
196	38.50	31.42	3.59
200	54.21	31.37	3.06
197	47.30	32.27	2.94

Key: * = Outlier

Study: 20C0709/01098

	SCHE µkat/l Day 15	ECHE µkat/l E. Day 15	BCHE µkat/g P. Day 15
Female, GROUP 3			
163	46.01	33.47	3.85
176	48.36	34.45	4.33
174	24.17	16.18*	4.49
179	45.96	19.55*	2.08
171	40.74	31.06	1.50
204	28.13	34.40	3.58
203	67.53	31.27	3.22
192	36.00	31.02	4.71
191	36.49	32.03	4.16
190	43.64	33.43	4.06
Female, GROUP 4			
165	42.70	26.60	2.88
164	37.57	26.15	3.53
166	35.30	9.38*	2.94
178	39.85	29.35	3.67
182	39.59	27.18	3.72
207	36.96	27.08	3.61
208	25.55	30.15	2.79
187	36.23	27.67	4.56
206	32.25	24.69	3.56
205	44.40	29.15	2.86

Key: * = Outlier

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 0

	Term. body weight g	Brain g
M	249.06	1.782
SD	8.245	0.084
n	5	5
222	254.2	1.68
226	240.1	1.79
228	255.8	1.72
238	255.2	1.83
239	240.	1.89

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 1

	Term. body weight	Brain
	g	g
M	265.48	1.874
SD	10.939	0.065
n	5	5
216	261.3	1.79
219	276.7	1.83
220	253.4	1.88
231	277.4	1.95
233	258.6	1.92

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 2

	Term. body weight	Brain
	g	g
M	244.58	1.75
SD	13.032	0.12
n	5	5
213	256.6	1.9
215	228.2	1.6
218	246.5	1.78
224	257.2	1.81
237	234.4	1.66

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 3

	Term. body weight	Brain
	g	g
M	250.6	1.732
SD	27.117	0.058
n	5	5
221	272.9	1.77
225	216.4	1.65
227	226.	1.71
230	267.6	1.8
232	270.1	1.73

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 4

	Term. body weight	Brain
	g	g
M	253.26	1.83
SD	18.964	0.113
n	5	5
214	244.6	1.71
217	273.2	1.85
229	237.8	1.77
235	274.3	2.01
236	236.4	1.81

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 0

	Term. body weight	Brain
	g	g
M	171.16	1.734
SD	19.801	0.087
n	5	5
243	158.4	1.72
244	185.4	1.76
261	144.9	1.6
264	193.7	1.75
266	173.4	1.84

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 1

	Term. body weight	Brain
	g	g
M	179.56	1.714
SD	12.464	0.053
n	5	5
241	170.8	1.7
242	182.5	1.73
245	172.5	1.74
246	171.8	1.63
257	200.2	1.77

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 2

	Term. body weight	Brain
	g	g
M	170.2	1.678
SD	13.54	0.093
n	5	5
240	160.8	1.6
254	173.1	1.68
258	177.6	1.77
259	186.8	1.77
265	152.7	1.57

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 3

	Term. body weight	Brain
	g	g
M	177.72	1.736
SD	13.962	0.11
n	5	5
248	180.5	1.77
250	181.9	1.9
255	178.3	1.7
260	193.	1.71
263	154.9	1.6

ABSOLUTE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 4

	Term. body weight	Brain
	g	g
M	188.36	1.742
SD	9.99	0.057
n	5	5
247	198.5	1.83
251	175.7	1.72
252	180.6	1.68
253	190.1	1.72
262	196.9	1.76

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 0

	Term. body weight	Brain
	%	%
M	100.	0.717
SD		0.052
n	5	5
222	100.	0.661
226	100.	0.746
228	100.	0.672
238	100.	0.717
239	100.	0.788

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 1

	Term. body weight %	Brain %
M	100.	0.707
SD		0.036
n	5	5
216	100.	0.685
219	100.	0.661
220	100.	0.742
231	100.	0.703
233	100.	0.742

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 2

	Term. body weight	Brain
	%	%
M	100.	0.715
SD		0.016
n	5	5
213	100.	0.74
215	100.	0.701
218	100.	0.722
224	100.	0.704
237	100.	0.708

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 3

	Term. body weight %	Brain %
M	100.	0.696
SD		0.059
n	5	5
221	100.	0.649
225	100.	0.762
227	100.	0.757
230	100.	0.673
232	100.	0.641

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex M
Dose group 4

	Term. body weight	Brain
	%	%
M	100.	0.724
SD		0.035
n	5	5
214	100.	0.699
217	100.	0.677
229	100.	0.744
235	100.	0.733
236	100.	0.766

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 0

	Term. body weight %	Brain %
M	100.	1.021
SD		0.089
n	5	5
243	100.	1.086
244	100.	0.949
261	100.	1.104
264	100.	0.903
266	100.	1.061

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 1

	Term. body weight %	Brain %
M	100.	0.957
SD		0.049
n	5	5
241	100.	0.995
242	100.	0.948
245	100.	1.009
246	100.	0.949
257	100.	0.884

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 2

	Term. body weight %	Brain %
M	100.	0.988
SD		0.03
n	5	5
240	100.	0.995
254	100.	0.971
258	100.	0.997
259	100.	0.948
265	100.	1.028

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group	I1	
Sex	F	
Dose group	3	
	Term. body weight	Brain
	%	%
M	100.	0.98
SD		0.064
n	5	5
248	100.	0.981
250	100.	1.045
255	100.	0.953
260	100.	0.886
263	100.	1.033

RELATIVE WEIGHTS - INDIVIDUAL VALUES

Sacrifice group I1
Sex F
Dose group 4

	Term. body weight %	Brain %
M	100.	0.926
SD		0.033
n	5	5
247	100.	0.922
251	100.	0.979
252	100.	0.93
253	100.	0.905
262	100.	0.894

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	0
Animal	222

General Information
Sex : Male
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal 226

General Information
Sex : Male
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal 228

General Information
Sex : Male
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal 238

General Information
Sex : Male
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	0
cont. Animal	238

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	239

General Information

Sex	: Male
Dose group	: 0 (0 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/11/2002
	15 days after start of exposure
	15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	1
Animal	216

General Information
Sex : Male
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	219

General Information
Sex : Male
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	220

General Information
Sex : Male
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	231

General Information
Sex : Male
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

	Sacrifice group	I1
	Sex	M
	Dose group	1
cont.	Animal	231

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

	Animal	233

General Information

Sex	: Male
Dose group	: 1 (0,2 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/11/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	2
Animal	213

General Information
Sex : Male
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 215

General Information
Sex : Male
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 218

General Information
Sex : Male
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 224

General Information
Sex : Male
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	2
cont. Animal	224

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	237

General Information

Sex	: Male
Dose group	: 2 (0,25 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/11/2002
	15 days after start of exposure
	15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	3
Animal	221

General Information
Sex : Male
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 225

General Information
Sex : Male
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 227

General Information
Sex : Male
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 230

General Information
Sex : Male
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

	Sacrifice group	I1
	Sex	M
	Dose group	3
cont.	Animal	230

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

	Animal	232

General Information

Sex	: Male
Dose group	: 3 (0,35 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/11/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	4
Animal	214

General Information
Sex : Male
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	217

General Information
Sex : Male
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	229

General Information
Sex : Male
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
Distal tibial nerve (calf muscle branches)
- Axonal degeneration, grade 1.
All other organs examined without microscopic findings

Animal	235

General Information
Sex : Male
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/11/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	M
Dose group	4
cont. Animal	235

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	236

General Information

Sex	: Male
Dose group	: 4 (5 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/11/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	0
Animal	243

General Information
Sex : Female
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal 244

General Information
Sex : Female
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
Prox. sciatic nerve
- Axonal degeneration, grade 1.
All other organs examined without microscopic findings

Animal 261

General Information
Sex : Female
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal 264

General Information
Sex : Female
Dose group : 0 (0 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

	Sacrifice group	I1
	Sex	F
	Dose group	0
cont.	Animal	264

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

	Animal	266

General Information

Sex	: Female
Dose group	: 0 (0 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/12/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	1
Animal	241

General Information

Sex : Female
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	242

General Information

Sex : Female
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	245

General Information

Sex : Female
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	246

General Information

Sex : Female
Dose group : 1 (0,2 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	1
cont. Animal	246

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	257

General Information

Sex	: Female
Dose group	: 1 (0,2 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/12/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	2
Animal	240

General Information
Sex : Female
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 254

General Information
Sex : Female
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 258

General Information
Sex : Female
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal 259

General Information
Sex : Female
Dose group : 2 (0,25 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

	Sacrifice group	I1
	Sex	F
	Dose group	2
cont.	Animal	259

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

	Animal	265

General Information

Sex	: Female
Dose group	: 2 (0,25 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/12/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	3
Animal	248

General Information

Sex : Female
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	250

General Information

Sex : Female
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	255

General Information

Sex : Female
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	260

General Information

Sex : Female
Dose group : 3 (0,35 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	3
cont. Animal	260

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

Animal	263

General Information

Sex	: Female
Dose group	: 3 (0,35 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/12/2002
	15 days after start of exposure
	15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
No microscopic examination required.

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	4
Animal	247

General Information
Sex : Female
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	251

General Information
Sex : Female
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	252

General Information
Sex : Female
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	253

General Information
Sex : Female
Dose group : 4 (5 mg/kg)
Sacrifice group : Perfusion fixation
Necropsy status : Planned sacrifice
Date of death : Dec/12/2002
15 days after start of exposure
15 days after end of exposure

SINGLE ANIMAL SHEET

Sacrifice group	I1
Sex	F
Dose group	4
cont. Animal	253

Macroscopy
Animal without particular findings.

Microscopy
All organs examined without pathologic findings.

Animal	262

General Information

Sex	: Female
Dose group	: 4 (5 mg/kg)
Sacrifice group	: Perfusion fixation
Necropsy status	: Planned sacrifice
Date of death	: Dec/12/2002 15 days after start of exposure 15 days after end of exposure

Macroscopy
Animal without particular findings.

Microscopy
Proximal tibial nerve (at the knee)
- Axonal degeneration, grade 1.
All other organs examined without microscopic findings

STUDY TITLE

Report

Omethoate – Acute oral neurotoxicity study in Wistar rats
Single administration by gavage

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 20C0709/01098

VOLUME III OF III
(SUPPLEMENT)

Confidentiality Statement
This report is property of the Dimethoate Task Force with its member companies BASF, Cheminova, and Isagro. This report (752 pages) should not be communicated to third parties, reproduced or published in any form without the proprietors' explicit written authorization.

CONTENTS OF VOLUME III (SUPPLEMENT)

weg141

Functional Observational Battery (FOB): Detailed description of examinations, ranking and documentation procedures

The following describes in detail the scope of examinations and the ranking of the findings.

HOME CAGE OBSERVATIONS:

Posture

The posture of the animals is examined for any abnormal findings.

Ranking:
0 animal is sitting or lying
1 animal is staying and moving
2 squatting posture
3 abdominal position
4 abdominal position with splayed limbs
5 lateral position
6 oblique head posture
7 opisthotonus

Tremors

Any tremors are documented.

Ranking:
0 no tremors
1 slight tremors
2 moderate tremors
3 severe tremors

Convulsions

If convulsions are seen, the severeness is assessed. If possible, also the type of convulsions, i.e. clonic (alternate muscular contraction and relaxation in rapid succession) or tonic (characterized by continuous tension) is documented.

Ranking:
0 no convulsions
1 slight convulsions
2 moderate convulsions
3 severe convulsions

Abnormal movements

Any abnormal movement or bizarre behaviour is documented.

Ranking:
0 no abnormalities
1 manege movements
2 head shaking
3 excessive cleaning
4 frequent chewing

Impairment of gait

Any abnormal movement or bizarre behavior is documented.

Ranking:
0 animal is not walking during observation
1 no impairment of gait
2 stiff gait
3 slight impairment of coordination, unsteady gait
4 moderate impairment of coordination, shuffling gait
5 severe impairment of coordination, dragging of the hindlimbs
6 severe impairment of coordination, with splayed limbs
7 animal is unable to walk (abdominal or lateral position)

Other findings

Ranking:
0 no other findings
* If findings appear which are not included in this grading system, they are described

OPEN FIELD OBSERVATIONS

Behavior when removed from cage

The animal is removed from the home cage, and the reaction is documented.

Ranking:
0 animal is tense, but it shows no resistance against handling
1 animal shows a slight resistance against the handling
2 animal shows no resistance against the handling but appears indifferent
3 animal is difficult to handle, it shows aggressiveness
4 animal is very difficult to handle, it shows severe aggressiveness

Fur

The fur of the animals is examined for any abnormal signs.

Ranking:
0 nothing abnormal detected
1 discolored fur
2 urine staining of anogenital region
3 Piloerection
4 Alopecia
5 reduced care on fur

Skin

The visible parts of the skin (e.g. nose) are examined for any abnormal signs.

Ranking:
0 nothing abnormal detected
1 discolored skin
2 reddening
3 paleness
4 Dehydration (exsiccosis)
5 Hypothermia (skin is cold during handling)
6 lesion(s)
7 crust(s)

Salivation

The area around the mouth is examined for signs of discharge; if possible, also the color of discharge is documented.

Ranking:
0 no salivation
1 slight salivation (area around the mouth is moist)
2 moderate salivation (wet mouth)
3 severe salivation (mouth very wet, wet paws)

Nose discharge

Any discharge is documented.

Ranking
0 no discharge, dry nose
1 clear discharge
2 reddish discharge

Lacrimation

Any lacrimation or secretion of pigmented tears is documented. If possible, also the color of the tears is assessed.

Ranking:
0 no lacrimation
1 slight lacrimation
2 moderate lacrimation
3 severe lacrimation

Eyes/Pupilsize

Ranking:
0 Nothing abnormal detected, pupils contracted at room light
1 Chromodacryorrhoe
2 Exophthalmus
3 Pupils dilated
4 Abnormal shape of pupils
5 Oblique eye posture
6 Opacity
7 Cataract

Posture

The posture of the animals is examined for any abnormal findings.

Ranking:
0 animal is sitting or lying
1 animal is staying and moving
2 squatting posture
3 abdominal position
4 Abdominal position with splayed limbs
5 lateral position
6 oblique head posture
7 Opisthotonus

Palpebral closure

The level of eyelid closure is examined. Usually, the eyelids of rats are completely opened (except winking).

Ranking:
0 nothing abnormal detected
1 eyelid(s) slight closure
2 eyelid(s) half closure
3 eyelid(s) permanent closure

Respiration

The respiration is examined for any abnormalities.

Ranking:
0 nothing abnormal detected
1 respiration labored
2 gasping/respiratory sounds
3 respiration accelerated
4 respiration irregular

Tremors

Any tremors are documented.

Ranking:
0 no tremors
1 slight tremors
2 moderate tremors
3 severe tremors

Convulsions

If convulsions are seen, the severeness is assessed. If possible, also the type of convulsions, i.e. clonic (alternate muscular contraction and relaxation in rapid succession) or tonic (characterized by continuous tension) is documented.

Ranking:
0 no convulsions
1 slight convulsions
2 moderate convulsions
3 severe convulsions

Abnormal movements/stereotypy

Any abnormal movements or bizarre behavior are documented

Ranking:
0 no abnormalities
1 manege movements
2 head shaking
3 excessive cleaning
4 frequent chewing

Impairment of gait

If any impairment of gait is observed, the type and severeness is documented. Different types of gait impairment are ataxia (irregularity of muscular action), paralysis (loss of motor function) and paresis (slight or incomplete paralysis). If possible, also the affected limbs (forelimbs, hindlimbs) are documented.

Ranking:
0 animal is not walking during observation
1 no impairment of gait
2 stiff gait
3 slight impairment of coordination, unsteady gait
4 moderate impairment of coordination, shuffling gait
5 severe impairment of coordination, dragging of the hindlimbs
6 severe impairment of coordination, with splayed limbs
7 animal is unable to walk (abdominal or lateral position)

Activity/Arousal level

The activity of the animals in the open field and the arousal level is examined for any deviation from normal.

Ranking:
0 Normal exploration of the area
1 reduced exploration of the area
2 Severe reduced exploration of the area, animal apathetic
3 Increased exploration of the area, sudden or jerky movements
4 Hyperactivity

Feces excreted during the observation period

The appearance and consistency of the feces are described. The number of scybala is documented separately.

Ranking:
0 no defecation during observation period
1 Feces without abnormalities
2 discolored feces
3 crumbly feces
4 soft feces
5 muicid feces
6 diarrhea

Urine excreted during the observation period

The amount and color of the urine is described.

Ranking:
0 no urination during observation period
1 urine without abnormalities (some wet areas on the filter paper)
2 discoloration of urine
3 polyuria (great wet areas on the filter paper)

Number of rearings

In the open field, the animals usually rear several times in order to explore the new environment. A rear is counted, if both forelimbs are removed from the floor. The number of rearings is counted within a 2 minute observation period.

Ranking:
- (number)

SENSORY-MOTORIC TEST/REFLEXES

Approach response

A stick is approached slowly to the head of the animal. Normal reaction of the animal is to approach to the object or to ignore the object.

Ranking:
0 no reaction
1 approaching to object
2 reaction
3 aggressive reaction and attacking of object

Touch Response

The animal is touched with a stick along the flank. Normal reaction is to orientate to the stimulus or to ignore the stimulus.

Ranking:
0 no reaction
1 orientation to the stimulus
2 escape after touch
3 aggressive reaction and attacking of object
4 reaction to the stimulus but no ability to localize (e.g. turning to wrong side)

Vision ("visual placing response")

The animal is held on the tail and moved slowly towards the wire cover of a cage. Normal reaction of the animal is to stretch the forelimbs in order to grasp the object.

Ranking:
0 nothing abnormal detected (grasping with forelimbs)
1 no grasping

Pupillary reflex

The capacity of the pupils to adapt to darkness and to light is examined. The animals are put into a dark box for about 10 seconds and the pupils are examined using an electric torch. Normally, the pupil dilates in the dark and contracts immediately in the light.

Ranking:
0 nothing abnormal detected, physiological adaptation of the pupil to light
1 retarded adaptation of the pupil to light
2 no adaptation of the pupil to light, pupils permanently contracted
3 no adaptation of the pupil to light, pupils permanently dilated

Pinna reflex

The pinna of the animal is touched with a small bristle. Normally, the animals jerks the pinna or head immediately after the stimulus.

Ranking:
0 immediate response to the stimulus
1 no response to the stimulus

Audition ("startle response")

The animal is exposed to a sharp, electrically produced noise and the reaction to the sound is tested. Normally the animal shows a startle response (e.g. moving the ears, jerking, jumping backwards).

Ranking:
0 nothing abnormal detected, immediate normal response to the stimulus
1 no response
2 increased response
3 hyperreaction

Coordination of movements ("righting response")

The animal is turned into dorsal position and released. Normal reaction is that the animal immediately turns to an upright position.

Ranking:
0 nothing abnormal detected, immediate righting response
1 retarded righting response
2 fails to turn into upright position, animal stays in lateral position
3 no righting response, animal stays in dorsal position

Behavior during handling

Ranking:
0 normal behavior, easy to handle, animal is tense, but it shows no resistance against handling
1 very easy to handle, animal is limply hanging in the hand
2 slightly difficult to handle, animal shows a slight resistance against handling
3 difficult to handle, animal shows a severe resistance against handling

Vocalization

Ranking:
0 No or only sporadic vocalizations when touched
1 very frequent vocalizations when touched
2 vocalizations always when touched
3 vocalization without touching

Pain perception ("tail pinch")

The tip of the tail is squeezed with a forceps. Normally the animals responds to the stimulus, e.g. it moves away.

Ranking:
0 nothing abnormal detected, immediate response to the stimulus
1 weak or retarded reaction to the stimulus
2 no response to the stimulus
3 hyperreaction to the stimulus

Other findings

Ranking:
0 no other findings
* If findings appear which are not included in this grading system, they are described

Grip strength of forelimbs and hindlimbs

Measurement of grip strength is performed according to the method described by Meyer et al. 1979 (Neurobehavioral Toxicology, 1, 233-236):

The animal is brought into a position that forelimbs/hindlimbs are able to grip the metal bar of a newtonmeter. Then the animal is pulled gently backwards until it releases the grid. The average of two measurements is taken for each hindlimbs and forelimbs.

Documentation:
- (number)

Landing foot splay test

The animal is held about 30 cm above and dropped onto a flat area covered with putty. This results in clearly visible footprints. The distance between the fourth digits of the left and right hindlimb is measured. The average of two measurements is taken for each rat.

Documentation:
- (number)

GENERAL REMARK:

Details of localization or color, or detailed descriptions of findings (e.g. tonic or clonic convulsions) are be described using an abbreviation (letter or a combination of letters), if they are not given already in the SOP.

Annex 4

Analytical results
Kliba 3433 flour & pellets maintenance diet for mice/rats/hamsters
Batch No.: 52/02 Date of manufacture: July. 15, 2002 Analytical report of: July. 16, 2002, Aug. 09,2002 and July. 27, 2002

Corresponds to the quality criteria of the testing facility:

[x] Yes [ ] No

Remarks:

Mr. Rath
Signed: Aug. 19, 2002
(Signature/date)
(One signature is sufficient.)

Remarks of the Study Director in the case of deviations :

RCC

Linking science to progress

RCC Ltd
Environmental Chemistry &
Pharmanalytics Division
Zelgliweg 1
CH-4452 Itingen
Switzerland
Phone: +41 61 975 11 11
Fax: +41 61 971 52 66

ANALYTICAL TEST REPORT

RCC Study 842160
16.07.02

Prepared for	PROVIMI KLIBA AG 4303 Kaiseraugst
Attention of	Dr. Isler
Materials tested	KLIBA-NAFAG 3433, Batch 52/02 vom 15.07.02
Test performed	AAS, GC, GC-MS, HPLC
Test results	See attached Table 1
Submitted	E. Dettwiler
Issued by	K. Biedermann

.....
July 26, 2002/bon

Invoice address: RCC Ltd
Zelgliweg 1
CH-4452 Itingen
Switzerland

Phone: +41 (0)61 975 11 11
Fax: +41 (0)61 971 52 84
www.rcc.ch

RCC
Linking science to progress

RCC Ltd
Environmental Chemistry &
Pharmanalytics Division
Zelgliweg 1
CH-4452 Itingen
Switzerland
Phone: +41 61 975 11 11
Fax: +41 61 971 52 66

ATTACHMENT

RCC Study 842160
16.07.02

Table 1 - Test Results

KLIBA-NAFAG 3433,
Batch 52/02 vom 15.07.02

PARAMETER	ASSAY LEVEL mg/kg	LIMIT* mg/kg
Aflatoxins (B1, B2, G1, G2), total	< 0.001	0.005
Estrogens (DES, Hexestrol, Dienestrol), total	< 0.001	0.001
Lindane	0.007	0.02
Heptachlor	< 0.005	0.02
Malathion	< 0.5	2.5
DDT, total	< 0.025	0.100
Dieldrin	< 0.005	0.02
Cadmium	0.04	0.160
Arsenic	< 0.15	1.0
Lead	< 0.25	1.5
Mercury	< 0.05	0.1
Selenium	< 0.15	0.6
Copper	12	----
PCBs	< 0.025	0.05
Nitrosamines (DMN, DEN, NPIP, NMORPH), total	< 0.002	0.010

< 0.001 = less than 0.001 milligram per kilogram
* = USP EPA, Federal Register, Vol. 44, No. 91, May 9, 1979

Translation

PROVIMI
KLIBA

Bulletin No.: 66666

Laboratory

PROVIMI KLIBA SA

Date of receipt: July 24,2002
from: Dr. Dorothee ISLER

4303 KAISERAUGST

Name of sample:
1) Mice/Rat maintenance"GLP" 3433 Batch 52/02
2) Production Code: 0207011
3) Production Date: July 15, 2002

Control no.:
66666-1

RESULT	UNIT	
Moisture	%	11.3
Protein	%	18.4
Fiber	%	4.0
Ash	%	5.6
Fat	%	4.4
Calcium	%	1.18
Phosphorus	%	0.76
Magnesium	%	0.19
Potassium	%	0.83
Sodium	%	0.18

Penthalaz, Aug. 09,2002
(Signed)

PROVIMI KLIBA SA 4303 KAISERAUGST – Tel.: 061 816 16 16

Translation

RCC
Linking science to progress

RCC Ltd
Biotechnology &
Animal Breeding Division
Wölferstrasse 4
CH-4414 Füllinsdorf
Switzerland

Phone: 41/61.906.42.42
Fax: 41/61.901.25.65

Dr. Isler
PROVIMI KLIBA AG
4303 Kaiseraugst, Switzerland

MICROBIOLOGICAL ANALYSIS CERTIFICATE

Name of sample: Feed No.: 3433, rat/mouse maintenance "GLP"
BA: 52/02

Project:	842254		
Date of manufacture:	July 15, 2002	**Date of receipt:**	July 18, 2002
Beginning of analysis:	July 22, 2002	**End of analysis:**	July 27, 2002

Method: Petrifilm

Microbiological analysis

	Result	Detection limit
Total bacterial count (CASO; 3d/30°C)	2×10^3 CFU/g	10 CFU/g
Clostridia (TSC 2x1d/37°C)	N CFU/g	in 1 g
Yeasts (YGC; 5d/20°C)	<100 CFU/g	100 CFU/g
Molds (YGC; 5d/20°C)	<100 CFU/g	100 CFU/g
Enterobacteriaceae (VRBD; 1d/37°C)	*6×10^2 CFU/g	10 CFU/g
Escherichia coli (LST 2d/37°C; BGB, PW 2d/44°C)	N CFU/g (ml)	10 CFU/g
Salmonella sp. (Rappaport 2d/42°C, BPLS 1d/37°C) (Transia Card, ELISA)	Nf. CFU/25 g	in 25 g

Key: CFU = Colony Forming Units
N = not tested
Nf = not found
*Pantoea spp./E.coli not found

(Signed)
Dr. G. Menne

(Signed)
Dr. M. Claros

TRANSLATION

Mr. Wolf
ZHT/ B- Z 470

October 11, 2002
GUE/PW – A 727
Mr. Sahler
Phone: 94536
Fax. 78533

RE.: BACTERIOLOGICAL WATER ANALYSIS

Sampling date: October 08, 2002
Sample no.: no. 1-1735/02 e

Marking	E.coli in 100 ml	coliform germs in 100 ml	colony nos. in 1 ml at 20°C	colony nos. in 1 ml at 36°C	pH-value
No. 104/2	0	0	0	0	7,65
No. 104/3	0	0	2	0	7,74
No. 104/8	0	0	0	0	9,02
No. 104/12	0	0	0	2	8,03
No. 104/15	0	0	0	0	8,76
No. 104/16	0	0	0	2	7,88
No. 104/17	no sampling				
No. 104/18	no sampling				
No. 104/19	no sampling				
No. 104/21	no sampling				

From the bacteriological viewpoint no objection against using the water as drinking water.

Mr. Sahler (Energieversorgung/Energierohrnetze)

No. 104/2	Z470, drinking water container	1. ground floor, west	room AU-07
No. 104/3	Z470, drinking water container	2. ground floor	room BU-07
No. 104/8	Z470, demineralized water (KKS-system)	ground floor	room AU-04
No. 104/12	Z470, drinking water/blended water container		
No. 104/15	Z470, demineralized water	ground floor	room BU-07
No. 104/16	Z470, drinking water/blended water container	ground floor	room BU-07
No. 104/17	Z470, drinking water, bidistillation system	3. floor	room C3-15
No. 104/18	Z470, drinking water, bidistillation system	ground floor	room CU-07
No. 104/19	Z470, drinking water, bidistillation system	3. floor	room C3-01
No. 104/21	Z470, Milli-Q system	2. floor	room C2-11

Drinking water BASF Ludwigshafen

Receipt

Name of sample			Lu-Parkinsel	Lu-Maudach	Frankenthal
			C6	U405	Z561
Sample No.			20030648	20030647	20030646
Sampler			GUE/PC	GUE/PC	GUE/PC
Sampling		Date	Nov. 12. 2002	Nov. 12. 2002	Nov. 12. 2002
Name and indication		**Unit**			
Odor, qualitatively		**	1	1	1
Coloration, qualitatively		**	1	1	1
Turbidity, qualitatively		**	1	1	1
Sediment, qualitatively		**	1	1	1
Coloration (spectr. abs. coeff. 436n)		1/m	0.1	0.2	0.1
Turbidity (spectr. var. coeff.)		TE/F	0.11	0.22	0.19
Substances removable by filtration		mg/l	<1	<1	<1
Water temperature		°C	14	14	14
Spectr. abs. coeff. (254nm)		1/m	4.0	5.7	4.9
Electr. Conductivity at 25°C		uS/cm	700	460	570
pH at 25°C					
pH at water temperature			7.2	7.6	7.7
Acid capacity up to pH = 4.3		mmol/l	6.4	3.8	5.4
Acid capacity up to pH = 8.2		mmol/l	0.66	0.19	0.17
Hardness	(Ca+Mg)	mmol/l	3.2	1.7	2.4
Calcium	(Ca)	mg/l	101	57	78
Magnesium	(Mg)	mg/l	17	7.5	11
Sodium	(Na)	mg/l	24	29	26
Potassium	(K)	mg/l	1.8	2.4	2.5
Ammonium	(NH4)	mg/l	<0.05	<0.05	<0.05
Iron, total	(Fe)	mg/l	0.02	0.03	0.03
Iron, dissolved	(Fe)	mg/l			
Manganese, total	(Mn)	mg/l	<0.05	<0.05	<0.05
Copper	(Cu)	mg/l	0.002	<0.001	0.001
Zinc	(Zn)	mg/l			
Aluminum	(Al)	mg/l			
Antimony	(Sb)	mg/l			
Arsenic	(As)	mg/l			
Barium	(Ba)	mg/l			
Lead	(Pb)	mg/l			
Cadmium	(Cd)	mg/l			
Chromium	(Cr)	mg/l			
Mercury	(Hg)	mg/l			
Selenium	(Se)	mg/l			
Nickel	(Ni)	mg/l			
Silver	(Ag)	mg/l			
Hydrogencarbonate	(HCO3)	mg/l	390	232	329
Chloride	(Cl)	mg/l	18	18	15
Fluoride	(F)	mg/l	0.11	0.21	0.18
Sulfate	(SO4)	mg/l	32	22	14
Sulfide	(S)	mg/l	<0.005	<0.005	<0.005
Nitrate	(NO3)	mg/l	1.9	2.6	2.3
Nitrite	(NO2)	mg/l	<0.005	<0.005	<0.005
Phosphate, ortho	(PO4)	mg/l	<0.2	<0.2	<0.2
Silicate	(SiO2)	mg/l	21	16	16
Cyanide, total	(CN)	mg/l			
Borate	(B)	mg/l			

Continued on Sheet 2

** 1 = not detectable
2 = detectable
3 = strongly detectable

BASF

Power plant and water chemistry — Dec.12, 2002

GUE/PC - K118 — Sheet 2

Drinking water BASF Ludwigshafen

Receipt

Name of sample			Lu-Parkinsel	Lu-Maudach	Frankenthal
			C6	U405	Z561
Sample No.			20030648	20030647	20030646
Sampling		Date	Nov. 12. 2002	Nov. 12. 2002	Nov. 12. 2002
Name and indication		**Unit**			
Oxygen	(O2)	mg/l	5.7	5.3	6.4
Carbon dioxide	(CO2)	mg/l	29	8	7
Chlorine, free	(Cl2)	mg/l	<0.03	<0.03	<0.03
Colony count at 30°C, semiquant.		1/ml			
Colony count at 36°C, semiquant.		## 1/ml	<100	<100	n.s
E. coli/colif. bacteria at 36°C		## 1/ml	<1	<1	n.s
DOC: dissolved org. carbon	(C)	mg/l	1.5	2.0	2.0
Phenol index	(C6H6O)	ug/l			
AOX: adsorb. org. halogens	(Cl)	ug/l	<10	<10	<10
POX: purgeable org. halogens	(Cl)	ug/l			
Total organ. bound halogens	(Cl)	ug/l	<1	<1	<1
1,1,1-trichloroethane	(C2H3Cl3)	ug/l	<0.1	<0.1	<0.1
Trichloroethene	(C2HCl3)	ug/l	<0.1	<0.1	<0.1
Tetrachloroethene	(C2Cl4)	ug/l	<0.1	<0.1	<0.1
Dichloromethane	(CH2Cl2)	ug/l	<0.1	<0.1	<0.1
Tetrachloromethane	(CCl4)	ug/l	<0.1	<0.1	<0.1
Dibromochloromethane	(CHBr2Cl)	ug/l	<0.1	<0.1	<0.1
Dichlorobromomethane	(CHBrCl2)	ug/l	<0.1	<0.1	<0.1
Tribromomethane	(CHBr3)	ug/l	<0.1	<0.1	<0.1
Trichloromethane	(CHCl3)	ug/l	<0.1	<0.1	<0.1

Remarks: Values within the usual range of variation.
No exceeding of statutory limit or guide values.

Cc	GUE/PW A607, ESP/TL L719, MEP/HC O820, MEP/LV A412, GUE/W Z561, ZH/TE Z470 SWFt (by fax), TWL (by fax)		
Head of laboratory	Spengler / Brünn	Plant engineer	Wied
Phone	54216 / 56387	Phone	56058
Signature	(Signed)		(Signed)

Measured value taken over from GUE/PW (n.s. = no sample taken by GUE/PW)

Power plant and water chemistry
GUE/PC – K 118

Oct. 29, 2002

Toxicology Z470
Receipt of drinking water

Name of sample			Z470 TOX 1
Sample No.			20028823
Sampler			GUE/PC
Sampling		Date	Oct. 23, 2002
		Time	08:00
Name and indication		Unit	
Odor, qualitatively		**	1
Coloration, qualitatively		**	1
Turbidity, qualitatively		**	1
Sediment, qualitatively		**	1
Water temperature		°C	17.1
Electr. conductivity at 25°C		µS/cm	560
pH at 25°C			7.7
pH at water temperature			
Acid capacity up to pH = 4.3		mmol/l	5.4
Hardness	(Ca+Mg)	mmol/l	2.4
Calcium	(Ca)	mg/l	78
Magnesium	(Mg)	mg/l	11
Sodium	(Na)	mg/l	27.1
Lead	(Pb)	mg/l	<0.001
Hydrogencarbonate	(HCO3)	mg/l	329
Chloride	(Cl)	mg/l	16
Bromide	(Br)	mg/l	<0.2
Sulfate	(SO4)	mg/l	14
Nitrate	(NO3)	mg/l	2.2
Phosphate, ortho	(PO4)	mg/l	<0.2
Silicate, dissolved	(SiO2)	mg/l	15.0
Colony count at 30°C, semiquant.		1/ml	100
DOC: dissolved org. carbon	(C)	mg/l	1.8

Remarks: DOC corresponds to TOC

cc	Meisterei ZH/T Z470		
Head of laboratory	Spengler / Brünn	Plant engineer	Wied
Phone	54216 / 56387	Phone	56058
Signature			

** 1 = not detectable
2 = detectable
3 = strongly detectable

ssniff
Spezialdiäten GmbH

ssniff Spezialdiäten GmbH • Ferd.-Gabriel-Weg 16 • D-59494 Soest

BASF Aktiengesellschaft
Attn. Dr. Mellert
ZHT Z470
Karl-Bosch-Str. 38

D-67056 Ludwigshafen

October 24, 2002
Re: 10571-bd Br

Test results for bedding

Dear Dr. Mellert,

Enclosed please find the test results of the animal bedding:

1. From Kiel LUFA of July 01, 2002 and October 09, 2002
2. From Aulendorf State Investigating Office of June 24, 2002 and Sep. 26, 2002

Very truly yours
ssniff
Spezialdiäten GmbH

(Signed)
p.p. H. Brinkmann

Enclosure

Translation

J. RETTENMAIER & SÖHNE

Fibers designed by Nature

Holzmühle 1
D-73494 Rosenberg Germany
Phone: +49 - (0) 79 67 / 152-0
Telefax: +49 - (0) 79 67 / 152-222
e-mail: info@jrs.de
www.jrs.de

J.RETTENMAIER & SÖHNE • D-73494 Rosenberg • Holzmühle 1

State Veterinary Investigating Office
Aulendorf
Dr. Bracknies
Löwenbreitestraße 18/20

88326 Aulendorf

Our reference: eh/1
Phone: 079 67/152-228

Holzmühle, September 16, 2002

Bacteriological investigation of test animal bedding

Dear Dr. Bracknies,

A sample of test animal bedding granules is enclosed. Please

1) Analyze the bacterial and fungal floras including mycobacteria
2) Determine the fungal and bacterial counts quantitatively.

The material should be referred to as test animal bedding with batch Nos.

0510121001 to 0510121231
0510021001 to 0510021231
0210521001 to 0210521231
0300621001 to 0300621231
0210121001 to 0210121231
0210221001 to 0210221231
0330021001 to 0330021231
0301721001 to 0301721231
0510521001 to 0510521231
0090221001 to 0090221231
0510321001 to 0510321231
0300121001 to 0300121231
0512021001 to 0512021231
0320121001 to 0320121231
0510921001 to 0510921231

We will settle the invoice as soon as we receive your findings.

Thank you very much in advance for your prompt attention.

Very truly yours

(Signed)
Erna Heilmann

Translation

Aulendorf State Veterinary Investigating Office
Diagnostics Center

State Veterinary Investigating Office, Postfach 11 27, 88321 Aulendorf

J. Rettenmaier & Söhne GmbH & Co. KG
Faserstoffwerk
Holzmühle 1

73494 Rosenberg

Aulendorf, Sep. 26. 2002
Phone (0 75 25) 9 42- 238
Person in charge: Br/bn
Reference: B 3102-02

Reference: Investigation of 1 sample: Test animal bedding granules
Sender: J. Rettenmaier & Söhne in 73494 Rosenberg

Date of sampling: September 16, 2002
Date of receipt: September 19, 2002
Beginning of investigation: September 19, 2002

Preliminary report: Bedding granules about 500 g
Test animal bedding from batches: see Annex 1 (copy of the application)

Amount of homogenate examined from the amount of batch sent
Sample weight: 5 g in 45 ml physiological saline

Results of bacteriology:(see PP003BA01)

Sample:	1
Name of sample:	Test animal bedding

Finding	Type of investigation	Result	Explanation
Total bacterial count	Bacterial count; pour-plate method	<25 CFU/g	Aerobic spore-forming bacteria
Enterobacteriaceae	Bacterial count; streaking out	<2 CFU/g	No growth
Enterococci	Bacterial count; streaking out	<25 CFU/g	No growth
Staphylococci	Bacterial count; streaking out	<50 CFU/g	(Blood agar) no growth
Pseudomonadaceae	Bacterial count; streaking out	<25 CFU/g	No growth
Total fungal count	Bacterial count; streaking out	100 CFU/g	moulds
Yeasts	Bacterial count; streaking out	<25 CFU/g	No growth
Salmonellae	Tetrathionate accumulation	Negative	In 25 g
Shigellae	Selenite accumulation	Negative	In 25 g
Clostridia perfringens	Liver-liver broth (anae.) MPN method	Negative	In 1 g

Test procedures used: PV044BA01; PV038BA01; PV020BA01; PV021BA01

The test for mycobacteria has not yet been completed. You will be informed by separate mail.

(Signed)
Dr. S. Bracknies OVR

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025:2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980.00)

Freigabe QS
Release QA
(GV-SOLAS)

LUFA – ITL Gutenbergstr. 75-77, 24116 Kiel

RETTENMAIER & SÖHNE
GMBH & CO
HOLZMÜHLE 1

73494 ROSENBERG

Translation

First result ofJul. 01,2002
Date: Aug. 06, 2002
Customer no.: 21751

Test result
No. of analyses: 28085

Order no.:	35563
Date of receipt.	Jun. 13, 2002
Name of sample:	Test animal bedding, combined sample from batch Nos.: 0510120701-0510120930, 0510020701-0510020930, 0210520701-0210520930, 0300620701-0300620930, 0210120701-0210120930, 0210220701-0210220930, 0330020701-0330020930, 0300720701-0301720930, 0510520701-0510520930, 0090220701-0090220930, 0510320701-0510320930, 0300120701-0300120930, 0512020701-0512020930, 0320120701-0320120930, 0510920701-0510920930,
Product identification	Jun. 10, 2002
Packaging:	Plastic bag
Stamp/seal.	Without

Parameter	value unit	Substance method
borum	6,94 mg/kg	OS EN ISO 11885
selenium	< 0,1 mg/kg	OS VDLUFA III 11.6.1
lead	0,31 mg/kg	OS §35 LMBG L00.00-19
cadmium	0,08 mg/kg	OS §35 LMBG L00.00-19
mercury	< 0,01 mg/kg	OS §35 LMBG L00.00-19
arsenic	< 0,1 mg/kg	OS analog §35 LMBG L00.00-19
Organochlorpestizide		
Aldrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the Institute.

Landwirtschaftliche Untersuchungs- und Forschungsanstalt
Institut fürTiergesundheit und Lebensmittelqualität GmbH

LUFA-ITL

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025:2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980.00)

Test result
No. of analyses: 28085

Untersuchungsparameter	Wert Einheit	Substanz Methode
Dieldrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Endrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
gamma-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
oxy-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-endosulfan	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
beta-endosulfan	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
endosulphansulphate	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
HCB (hexachlorbenzene)	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
beta-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
delta-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
epsilon-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
gamma-HCH (lindane)	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
cis-heptachlor epoxide	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Heptachlor	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
trans-heptachlor epoxide	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDD	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDE	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDT	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDD	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDE	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDT	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Methoxychlor	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Quintozene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Tecnazene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Tetradifone	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Nitrofene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Phosphoric esters		
Bromophos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Bromophos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorfenvinphos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorpyriphos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the Institute.

Landwirtschaftliche Untersuchungs- und Forschungsanstalt
Institut für Tiergesundheit und Lebensmittelqualität GmbH

LUFA-ITL

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025 2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980 00)

First result of Jul. 01,2002
Date: Aug. 06.2002
Customer no.: 21751

Test result

No. of analyses: 28085

Untersuchungsparameter	Wert Einheit	Substanz Methode
Chlorpyriphos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorthion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Diazinon	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Dichlorvos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Dimethoate	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Ethion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Fenitrothion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Fenthion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Malathion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Mecarbam	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Methidathion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Parathion (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Parathion (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Pirimiphos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Pirimiphos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Profenofos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Sulfotep	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34

Key: substance: OS = original substance, TS = dry substance; n.b. = not determinable

LUFA – ITL, Dr. Wehage, Tel. 0431/1228-220

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the Institute.

Eingetragen
im AG Kiel
HRB 5796

Geschäftsführer
Dr. Paul Wimmer

Commerzbank AG Kiel
BLZ 210 400 10
Kto: 720 40 50

Ein Institut der
AGROLAB-
Gruppe

Translation

Aulendorf State Veterinary Investigating Office
Diagnostics Center
Postfach 11 27 88321 Aulendorf
Phone (0 75 25) 9 42-0
Löwenbreitestr. 18/20 88326 Aulendorf
Fax (0 75 25) 9 42-200

State Veterinary Investigating Office, Postfach 11 27, 88321 Aulendorf

J. Rettenmaier & Söhne GmbH & Co. KG
Faserstoffwerk
Holzmühle 1

73494 Rosenberg

Aulendorf, Jun. 24, 2002
Phone (0 75 25) 9 42- 238
Person in charge: Br/bn
Reference 20024008628
Laboratory no.: B 2382-02

Reference: Investigation of 1 sample: Test animal bedding granules
Sender: J. Rettenmaier & Söhne GmbH + Co. in 73494 Rosenberg

Date of sampling: June 03, 2002
Date of receipt: June 11, 2002
Beginning of investigation: June 11, 2002

Preliminary report: Test animal bedding from batches: see Annex 1 (copy of the application)

Results of bacteriology:(see PP003BA01)

Sample:	001
Name of sample:	Test animal bedding

Finding	Type of investigation	Result	Explanation
Acid-proof rod	Ziehl-Neelson colouring		
Bacteria	direct culture aerobic		
Bacteria	direct culture aerobic		
Total bacterial count	Bacterial count; pour-plate method	about 500 CFU/g	aerobic spore-forming bacteria
coliform germs	Bacterial count; pour-plate method	<2 CFU/g	Enterobacteriaceae
Pseudomonadaceae	Bacterial count; streaking out	<25 CFU/g	No growth
Enterococci	Bacterial count; streaking out	<25 CFU/g	No growth
Total fungal count	Bacterial count; streaking out	<25 CFU/g	No growth.
Total yeast count	Bacterial count; streaking out	<25 CFU/g	No growth.
Salmonellae	Tetrathionate accumulation	Negative	In 15 g
Clostridium	Clostridium accumulation	Negative	In 1 g
Shigellae	Accumulation anaerobic	Negative	In 15 g

Test procedures used: PV044BA01; PV038BA01; PV020BA01; PV023BA01

The test for mycobacteria has not yet been completed. You will be informed by separate mail.

(Signed)
Dr. S. Bracknies

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025:2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980.00)

Freigabe QS
Release QA
(GV-SOLAS)

LUFA – ITL Gutenbergstr. 75-77, 24116 Kiel

RETTENMAIER & SÖHNE
GMBH & CO
HOLZMÜHLE 1

73494 ROSENBERG

Translation

Date: Oct. 09, 2002
Customer no.: 21751
page 1 of 3

Test result
No. of analyses: 56926

Order no.: 58336
Date of receipt. Sep. 20, 2002
Name of sample: Test animal bedding, combined sample from batch Nos.: 0510121001-0510121241, 0510021001-0510021231, 0210521001-0210521231, 0300621001-0300621231, 0210121001-0210121231, 0210221001-0210221231, 0330021001-0330021231, 0301721001-0301721231, 0510521001-0510521231, 0090221001-0090221231, 0510321001-0510321231, 0300121001-0300121231, 0512021001-0512021231, 0320121001-0320121231, 0510921001-0510921231
Packaging: Plastic bag
Stamp/seal. Without

Parameter	value unit	Substance method
borum	47,0 mg/kg	OS EN ISO 11885
selenium	< 0,1 mg/kg	OS VDLUFA III 11.6.1
lead	0,32 mg/kg	OS §35 LMBG L00.00-19
cadmium	0,11 mg/kg	OS §35 LMBG L00.00-19
mercury	< 0,02 mg/kg	OS §35 LMBG L00.00-19
arsenic	< 0,2 mg/kg	OS analog §35 LMBG L00.00-19
Organochlorpestizide		
Aldrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Dieldrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Endrin	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
gamma-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
oxy-chlordane	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-endosulfan	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
beta-endosulfan	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the Institute.

Landwirtschaftliche Untersuchungs- und Forschungsanstalt
Institut fürTiergesundheit und Lebensmittelqualität GmbH

LUFA-ITL

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025:2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980.00)

Date: Oct. 09,2002
Customer no.: 21751

Test result

No. of analyses: 56926

Untersuchungsparameter	Wert Einheit	Substanz Methode
endosulphansulphate	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
HCB (hexachlorbenzene)	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
alpha-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
beta-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
delta-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
epsilon-HCH	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
gamma-HCH (lindane)	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
cis-heptachlor epoxide	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Heptachlor	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
trans-heptachlor epoxide	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDD	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDE	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
o,p-DDT	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDD	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDE	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
p,p-DDT	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Methoxychlor	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Quintozene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Tecnazene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Tetradifone	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Nitrofene	< 0,005 mg/kg	OS analog §35 LMBG L00.00-34
Phosphoric esters		
Bromophos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Bromophos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorfenvinphos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorpyriphos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorpyriphos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Chlorthion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Diazinon	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Dichlorvos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Dimethoate	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Ethion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the Institute.

Landwirtschaftliche Untersuchungs- und Forschungsanstalt
Institut fürTiergesundheit und Lebensmittelqualität GmbH

LUFA-ITL

Gutenbergstr. 75-77
D-24116 Kiel
Tel.: 0431/1228-0

eMail: zentrale@lufa-itl.de
Internet: www.lufa-itl.de
Fax: 0431/1228-498

DAR Deutscher Akkreditierungs Rat
Nach DIN EN ISO/IEC 17025 2000
durch die DAP akkreditiertes
Prüflaboratorium (DAP-PL-2980.00)

Date: Oct. 09,2002
Customer no.: 21751

Test result

No. of analyses: 56926

Untersuchungsparameter	Wert Einheit	Substanz Methode
Fenitrothion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Fenthion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Malathion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Mecarbam	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Methidathion	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Parathion (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Parathion (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Pirimiphos (-ethyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Pirimiphos (-methyl)	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Profenofos	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34
Sulfotep	< 0,01 mg/kg	OS analog §35 LMBG L00.00-34

Key: substance: OS = original substance, TS = dry substance; n.b. = not determinable

LUFA – ITL, Dr. Wehage, Tel. 0431/1228-220

The test results refer exclusively to the sample investigated. Extracts of any publication or reproduction of the test reports require the permission of the institute.

Eingetragen
im AG Kiel
HRB 5796

Geschäftsführer
Dr. Paul Wimmer

Commerzbank AG Kiel
BLZ 210 400 10
Kto: 720 40 50

Ein Institut der
AGROLAB-
Gruppe

Test substance data sheet
(TSDS Omethoate batch 676-BSe-74B)

Omethoate

DTF-Dimethoate Task Force
DOC. NO.: 134-009
BASF, Cheminova, Isagro

SCC
SCIENTIFIC CONSULTING COMPANY

The following data serve for save and proper handling of the test substance. Data marked with * are required for the conduct of GLP studies.

All data is strictly confidential !

The study(ies) has (have) to be conducted according to the following guidelines:
OECD: ☐ yes ☐ no U.S.-EPA (FIFRA): ☐ yes ☐ no EU: ☐ yes ☐ no

The study(ies) has (have) to be conducted in compliance with the following GLP regulations:
OECD: ☐ yes ☐ no U.S.-EPA (FIFRA): ☐ yes ☐ no EU/D-ChemG: ☐ yes ☐ no Others: local/national

1. General Data

1.1	* Sponsor	:	Dimethoate Task Force Wotanstraße 39 ~~D-68305 Mannheim, Germany~~ Phone: +49-(0)-621-742900
1.2	Monitoring	:	SCC Scientific Consulting Company Chemisch-Wissenschaftliche Beratung GmbH Mikroforum Ring 1, D-55234 Wendelsheim, Germany Phone (++49)-6703-919-0 - Fax (++49)-6703-919-191 EMAIL: scc@scc-gmbh.de
1.3	Reference substance	:	Omethoate
1.4	* Reference substance name to be used in the protocol/final report	:	Omethoate
1.5	* Batch Number	:	676-BSe-74B
1.6	* Quantity available	:	see shipping documents
1.7	* Expiry date	:	10/2004

2. PHYSICAL-CHEMICAL DATA

2.1	* Aspect of the test substance at room temperature	:	Pale yellow; liquid
2.2	Type of formulation	:	n.r.
2.3	Chemical name(s) of a.i.(s) (CAS No.)	:	O,O-Dimethyl S-[2-(methylamino)-2-oxoethyl] phosphorothioate (1113-02-6)
2.4	Structural formula(s)	:	
2.5	Molecular weight(s)/molecular formula(s)	:	213.2/ $C_5H_{12}NO_4PS$
2.6	* Content/Purity/Concentration	:	96.5% w/w
2.7	Method of analysis	:	^{31}P-NMR
2.8	* Certificate of analysis	:	see 8.
2.9	* Information on inerts/composition of the test substance	:	n.r.
2.10	Melting point/boiling point	:	n.r./ decomposes at 135°C
2.11	Relative density	:	1.32 (20°C)
2.12	Vapour pressure	:	$2.5 * 10^{-5}$ mm Hg (20°C)
2.13	Water solubility	:	soluble
2.14	Solubility in organic solvents	:	soluble in acetone, ethanol and ether; slightly soluble in hydrocarbons; practically insoluble in light petroleum
2.15	pH (% solution/suspension/emulsion)	:	unknown
2.16	* Stability of the test substance when stored according to 5.	:	min. 3 years

SCC

3. * SAFETY DATA FOR HANDLING, TRANSPORT AND STORAGE

		YES	NO	UNKNOWN
toxic, harmful	:	X		
irritant	:		X	
highly flammable	:		X	
explosive	:			X
classification	:	T,N; R21-25-50;		

4. IF REQUIRED FOR THE STUDY(IES)

4.1	Appropriate solvent/suspension medium	:	according to the relevant guidelines and testing requirements
4.2	Protection of test substance preparation from light required	:	see point 8
~~4.3~~	~~* Containers~~	:	~~appropriate laboratory equipment~~
4.4	* The test substance is stable for at least 2 hours in water	:	yes
	polyethylene glycol (PEG)	:	unknown
	carboxymethylcellulose (CMC)	:	unknown
	dimethylsulphoxide (DMSO)	:	unknown
	organic solvents	:	yes
4.5	If no stability data is provided:		
	stability data will be supplied	:	no
	stability data will be ordered separately	:	no
	no stability test is required (not in compliance with GLP)	:	no

5. * STORAGE (1)

5.1	Temperature	:	in deep freezer (below –18°C)
5.2	Light protection	:	yes

(1) = Different storage conditions which may be/are indicated in the Certificate of Analysis have to be disregarded as the harmonised storage conditions of this data sheet apply in agreement with DTF.

6. WASTE DISPOSAL

6.1	Return to	:	please contact SCC (see 1.2)
6.2	Destruction method	:	appropriate incineration plant

7. PRODUCT CLASSIFICATION

☐ Pharmaceutical ☒ Agrochemical ☐ industrial Chemical ☐ Others

8. ADDITIONAL INFORMATION

Certificate of analysis: Signed by Hinz (CHEMINOVA) 02.11.2001 (see enclosure; 1 p.)

Handling:
* Protect from direct sunlight
* Do no heat/warm up above 25°C
* Do not apply alkaline and strongly acidic conditions

This data sheet is based on information given by the sponsor (see 1.1).

Date: 15.1.2002 Signature: .....

SCC Scientific Consulting Company Chemisch-Wissenschaftliche Beratung GmbH, Mikroforum Ring 1, D-55234 Wendelsheim, Germany

CHEMINOVA

Cheminova A/S
P.O. Box 9
DK-7620 Lemvig
Denmark

Phone (+45) 96 90 96 90
Fax (+45) 96 90 96 91
www.cheminova.com
CVR-No. DK 12 76 00 43

BATCH ANALYTICAL CERTIFICATE

01/0709-41
16.9.02

ARTICLE IDENTIFICATION

Article Name: Omethoate

Reg. Dept. Code: -

Manufacturer: BAYER AG

Batch No.: 676-BSe-743

Origin of Production: Commercial [X]; Pilot plant [ ]; Laboratory [X];

PHYSICAL PROPERTIES

Technical Product [X]; Preparation of technical Product [ ]; Analytical Standard [ ]; Liquid [X]; Solid [ ]; Colour: Pale yellow

Recommended Storage Conditions

Ambient temperature in the dark ____
In refrigerator ..... ____
In deep freezer X

Additional Comments: Below -25°C

Expiry Date:
The article is stable at least 3 years from date of analysis/last date of reanalysis when stored at recommended conditions.

ACTIVE INGREDIENT IDENTIFICATION

Common Name/ISO-Name: Omethoate

CAS-Name: O,O-Dimethyl S-[2-(methylamino)-2-oxoethyl] phosphorothioate

CAS No.: 1113-02-6

Structural Formula:



Empirical Formula: $C_5H_{12}NO_4PS$

Molecular Weight: 213.2

Identified by means of:

NMR [X]; IR [ ]; UV [ ]; MS [ ]; Other Methods:

ANALYTICAL DATA

Certified Purity/Content of a.i.: 96.5% w/w
Analytical Method: ^{31}P-NMR
Analytical Report (incl. amendments): TEM 036-02

Date of analysis/ reanalysis (yymmdd)	011023				
-for article stored at -	Cheminova A/S				

GLP-COMPLIANCE

The identification and determination of purity/content of active ingredient were performed at Cheminova Agro A/S and conducted in accordance with FIFRA Good Laboratory Practice Standards, 40 CFR Part 160 and the OECD Principles of Good Laboratory Practices. All raw data, documentation, records, study plans, test articles, reference samples, and report are retained in the GLP archives of Cheminova A/S, Denmark.

Date: November 2 2001

Signature: Barbara Hinz
Barbara Hinz

Stability of Omethoate in Doubly Distilled Water

1. PROJECT AND TEST SUBSTANCE INFORMATION

Project No.:	20C0709/01098
Test substance:	Omethoate
Batch No.:	676-BSe-74B

2. SAMPLE DATA

2.1. STABILITY ANALYSIS

Vehicle:	doubly distilled water
Nominal concentration:	0.5 g/100ml
Storage conditions of the samples during the stability test period:	at ambient temperature

3. MATERIAL AND METHODS

3.1. SAMPLE PREPARATION FOR ANALYSIS

The samples were diluted with methanol. Aliquots of the dilutions were used for HPLC-analysis.

3.2. ANALYTICAL METHOD

HPLC with external calibration

Column:	Nucleosil 50-5-C8 ec , 250 x 3 mm
Eluant:	900 ml Doubly distilled water + 100 ml Methanol + 1 ml acetic acid
Flow rate:	0.7 ml/min
Detection:	UV, 196 nm

4. RESULTS AND DISCUSSION

4.1. ANALYSIS OF STABILITY

The results obtained for the stability analysis of Omethoate in doubly distilled water are summarized in the following table:

Time after starting [h]	Analytical value (nominal concentration: 0.5 g/100 ml)			% of initial value
	Sample I [g/100 ml]	Sample II [g/100 ml]	Mean [g/100 ml]	
0	0.489	0.486	0.488	100.0
1	0.476	0.479	0.478	98.0
2	0.482	0.482	0.482	98.8
3	0.479	0.480	0.480	98.4
4	0.468	0.473	0.471	96.5

The analyses demonstrated the stability of Omethoate in doubly distilled water over a period of 4 hours under the conditions chosen (storage at ambient temperature) as the recovery of the initial value was >= 96.5 %.

Dr. Lan Ma
(Head of analytical laboratory)

5. September 2003
Date
(dd/mm/yyyy)

Note: The data given are part of Project 20C0709/01098 which was performed in compliance with GLP and the results were audited by the QAU.

Concentration control analysis and analysis of the homogeneity of Omethoate in Doubly Distilled Water

1. PROJECT AND TEST SUBSTANCE INFORMATION

Project No.:	20C0709/01098
Test substance:	Omethoate
Batch No.:	676-BSe-74B

2. SAMPLE DATA

2.1. CONCENTRATION CONTROL ANALYSIS AND ANALYSIS OF THE HOMOGENEITY

Vehicle:	doubly distilled water
Storage conditions of the samples until analysis:	freezer

3. MATERIAL AND METHODS

3.1. SAMPLE PREPARATION FOR ANALYSIS

Aliquots of the samples were used for HPLC-analysis.

3.2. ANALYTICAL METHOD

HPLC with external calibration

Column:	Nucleosil 50-5-C8 ec , 250 x 3 mm
Eluant:	900 ml Doubly distilled water + 100 ml Methanol + 1 ml acetic acid
Flow rate:	0.7 ml/min
Detection:	UV, 196 nm

4. RESULTS AND DISCUSSION

4.1. CONCENTRATION CONTROL ANALYSIS AND ANALYSIS OF HOMOGENEITY

The results obtained for the homogeneity and concentration control analysis of Omethoate in doubly distilled water are summarized in the following table:

Date of sampling: October 21, 2002

Date of sample preparation: October 21, 2002

Date of receipt of sample in analytical laboratory: October 21, 2002

Date of analytical determination: January 18 & 20, 2003

Sample No.	Nominal concen-tration [g/100ml]	Analytical concentration [g/100ml]			% of nominal concentration		
		Sample I	Sample II	Mean		Mean	SD
2	0	n.d.	n.d.	n.d.	---	---	---
3	0,004	0.00389	0.00389	0.00389	97.3	96.8	0.7
4	0,004	0.00385	0.00391	0.00388	97.0		
5	0,004	0.00385	0.00383	0.00384	96.0		
6	0,005	0.00485	0.00484	0.00485	97.0	---	---
7	0,007	0.00658	0.00660	0.00659	94.1	---	---
8	0,100	0.09147	0.09054	0.09101	91.0	91.1	0.3
9	0,100	0.09118	0.09157	0.09138	91.4		
10	0,100	0.09075	0.09080	0.09078	90.8		

n.d. = non-detectable

Considering the low standard deviation in the homogeneity analysis, it can be concluded that Omethoate was distributed homogeneously in doubly distilled water.
The mean values of Omethoate in doubly distilled water were found to be in the range of 91.1 – 96.8 % of the nominal concentration.
These results demonstrated the correctness of the concentrations of Omethoate in doubly distilled water.

Ma Lan
Dr. Lan Ma
(Head of analytical laboratory)

5 September 2003
Date
(dd/mm/yyyy)

Note: The data given are part of Project 20C0709/01098 which was performed in compliance with GLP and the results were audited by the QAU.

Positive Control Studies for Neurotoxicity

In several positive control studies, behavioral and neuropathological sequelae of substances with nervous system effects were evaluated using Functional Observational Batteries (FOB), Motor Activity Measurements and Neuropathology. Clinical signs of peripheral neuropathy (e.g. ataxia, limb weakness), central neuropathy (e.g. tremors) and autonomic signs (e.g. salivation) could be shown. Histopathologically, changes in the peripheral nervous system (e.g. Wallerian-like degeneration) and central nervous system (e.g. neuronal necrosis) were seen. The motor activity device could show both increased and decreased activity. The interobserver reliability of the technicians performing FOBs was proven. Thus, the ability of the methods used to detect signs of neurotoxicity was demonstrated. Summaries of the following studies are attached:

Kaufmann, W. and B. Hildebrand, 1993, "Study of the Neurotoxicity of 3,3'-Iminodipropionitrile in Conjunction with the 'Functional Observational Battery' in Rats", Laboratory Project ID 99S0120/89004, BASF Reg. Doc. No. 1993/1000494, MRDI 45540501

Mellert, W., 2001, "Carbaryl – Positive Control Study for Neurotoxicity, Single Intraperitoneal Administration, to Wistar Rats", Lab. Project ID 99C0378/94027, BASF Reg. Doc. No. 2001/1017344, MRDI 45540502

Mellert, W., 2001, Carbaryl, Nomifensin, and Diazepam – Positive Control Study for Neurotoxicity in Wistar Rats", Lab. Project ID 99C0378/94068, BASF Reg. Doc. No. 2001/1017345, MRDI 45540503

Mellert, W., 2001, "Carbaryl – Positive Control Study for Neurotoxicity, Single Intraperitoneal Administration", Lab. Project ID 99C0378/94052, BASF Reg. Doc. No. 2001/1017346, MRDI 45540504

Mellert, W., 2001, "Carbaryl – Positive Control Study for Neurotoxicity, Single Intraperitoneal Administration, to Wistar Rats", Lab. Project ID 99C0378/94077, BASF Reg. Doc. No. 2001/1017347, MRDI 45540505

Mellert, W., W. Kaufmann, and B. van Ravenzwaay, 2001. "Acrylamide – Positive Control Study for Neurotoxicity, Repeated Oral Administration by Gavage", Lab. Project ID 99C0259/89112, BASF Reg. Doc. No. 2001/1017348, MRDI 45540506

Mellert, W., 2001, "Trimethyltinchloride – Positive Control Study for Neurotoxicity in Wistar Rats", Lab. Project ID 99S0228/93025, BASF Reg. Dec. No. 2001/1017349. MRDI 45540507

Mellert, W., W. Kaufmann and B. van Ravenzwaay, 2002. "Acrylamide - Positive Control Study for Neurotoxicity, Repeated Oral Administration by Gavage", Lab. Project ID 99C0803/00066, BASF Reg. Doc. No. 2002/1011461 (acrylamide): MRDI 45833904

Kaspers, U.,2002 "Carbaryl (1-Naphthylmethylcarbamat) - Positive control study for Neurotoxicity, Single oral administration", Lab. Project ID 99S0378/94078, BASF Reg. Doc. No. 2002/1011460 (carbaryl): MRDI 45833903

BASF
Abteilung Toxikologie
Department of Toxicology

D-W6700 Ludwigs-
hafen, FRG

Confidential

wk-kb; 1014
APR 3 0 1993

REPORT

Study of the neurotoxicity of

3,3'-IMINODIPROPIONITRILE

in conjunction with the
"Functional Observational Battery"
in rats

Administration 1 x i.p.
followed by a 4-week observation
period without test substance ad-
ministration

Project No.: 99S0120/89004

VOLUME I of IV
REPORT SECTION

Testing facility:

BASF Aktiengesellschaft
Department of Toxicology
D-W6700 Ludwigshafen/Rhein, FRG

Dieses Dokument enthält Betriebs- und Geschäftsgeheimnisse der BASF. Es ist Eigentum der BASF und darf nur zu dem von BASF vorgesehenen Zweck verwendet werden. Jede andere oder darüber hinausgehende Verwendung, Verwertung, Weitergabe, Vervielfältigung oder Veröffentlichung bedarf der Einwilligung der BASF.

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF.

1. SUMMARY

3,3'-Iminodipropionitrile (2 g/kg body weight) was administered once intraperitoneally to 10 Wistar rats (5 male, 5 female animals). For comparison, one group of untreated animals (5 male and 5 female animals) served as control they received aqua bidest. (2 g/kg body weight) once intraperitoneally. The application volume was 1,96 ml/kg body weight.

The body weights were determined at the beginning and at the end of the study.

The state of health was checked each day.

Exact clinical examinations were carried out in all animals once at the beginning of the study and daily as of March 2, 1989.

The neurofunction of all animals was observed once prior to the start of the study, at 1, 6, 24 and 48 hours after the administration of IDPN and then 7, 14, 21 and 28 days after the administration. Four ophthalmological examinations were carried out.

At the end of the study, the animals were sacrificed using two different methods. (Details see Pathology Report.)

It can be stated that the single administration of 2 g/kg body weight **3,3'-Iminodipropionitrile** followed by a 4-week observation period without test substance administration led to the following findings:

Clinical examinations
- decreased body weight in both sexes
- special neurotoxic symptoms after 24 hours until the end of the study for example: Ataxia (walking backwards, circling movement etc.) in the female animals
- special neurotoxic symptoms after 48 hours until the end of the study in both sexes
- reduction of the grip strength of the fore- and hind limbs in both sexes
- corneal opacities of different grades of severity
- blood lacunas in the iris
- anisocoria
- hematobulbus

Pathology
- axonal atrophy in the distal segments of peripheral nerves in the tibial, sural and sciatic nerves
- intraocular hemorrhages
- retinal degeneration with atrophy
- degeneration and atrophy of the optic nerve

Confidential

wm0795

STUDY TITLE

Report

Carbaryl – Positive control study for neurotoxicity
Single intraperitoneal administration to Wistar rats

DATA REQUIREMENT

EPA-FIFRA Neurotoxicity Screening Battery

AUTHOR

Dr. W. Mellert (Study Director)

STUDY COMPLETED ON

August 09, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0378/94027

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Carbaryl was administered to groups of 6 male Wistar rats as a single intraperitoneal administration at dose levels of 0; 10, and 30 mg/kg body weight. The vehicle was a 0.9% NaCl solution with 2% Cremophor EL®, and the administration volume was 5 ml/kg body weight. Functional Observational Batteries were performed on day 0 (starting about 20 minutes after administration of the test substance to the latest animal) and on day 8 (without additional treatment).

All observers participating the study detected treatment-related abnormal clinical signs (among others e.g. squatting position, tremors, frequent chewing (indicative for beginning of slight salivation), impairment of gait, reduced rearing). These findings are typical for the mode of action of Carbaryl.

This study therefore fulfilled the criteria for a positive control study according to the test guidelines. The interobserver reliability was demonstrated.

STUDY TITLE

Report

Carbaryl
Nomifensin
Diazepam

Positive control study for neurotoxicity in Wistar rats

DATA REQUIREMENT

EPA-FIFRA Neurotoxicity Screening Battery

AUTHOR

Dr. W. Mellert (Study Director)

STUDY COMPLETED ON

August 09, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0378/94068

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Carbaryl was administered to groups of 6 male Wistar rats as a single intraperitoneal administration at dose levels of 0; 10 and 30 mg/kg body weight. The vehicle was a 0.9% NaCl solution with 2% Cremophor EL®, and the administration volume was 5 ml/kg body weight. A Functional Observational Batteries was performed on day 0 (starting about 20 minutes after administration of Carbaryl to the latest animal).

After recovery of about 3 weeks, **Nomifensin** was administered oral by gavage to groups of 20 male animals at doses of 0 and 10 mg/kg body weight on 2 days. The vehicle was Aqua bidest. and the administration volume was 10 ml/kg body weight. Due to technical failures, motor activity was determined after the second administration, only.

After further recovery of about 1 week, **Diazepam** was administered intraperitoneally to groups of 20 male animals at doses of 0 and 3 mg/kg body weight on 2 days. The administration volume was 0.6 ml/kg body weight. Motor activity was determined on both days of treatment.

All observers participating the study detected treatment-related abnormal clinical signs, e.g. abdominal position, tremors, frequent chewing (indicative for beginning of salivation), ataxia and/or reduced rearing. These findings are typical for the mode of action of Carbaryl. This study therefore fulfilled the criteria for a positive control study according to the test guidelines. The interobserver reliability was demonstrated.

After administration of Nomifensin, motor activity was statistically significantly increased, whereas after administration of Diazepam motor activity was statistically significantly decreased. The ability of the measurement device to detect an increase as well a decrease in motor activity was therefore demonstrated.

wm0796

STUDY TITLE

Report

Carbaryl – Positive control study for neurotoxicity
Single intraperitoneal administration

DATA REQUIREMENT

EPA-FIFRA Neurotoxicity Screening Battery

AUTHOR

Dr. W. Mellert (Study Director)

STUDY COMPLETED ON

August 09, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0378/94052

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Carbaryl was administered twice (day 0 and day 7) to groups of 6 male Wistar rats as a single intraperitoneal administration at dose levels of 0; 10, and 30 mg/kg body weight. The vehicle was a 0.9% NaCl solution with 2% Cremophor EL®, and the administration volume was 5 ml/kg body weight. Functional Observational Batteries were performed, starting each time about 20 minutes after administration of the test substance to the latest animal.

All observers participating the study detected treatment-related abnormal clinical signs (among others: tremors, salivation). These findings are typical for the mode of action of Carbaryl (effects on the autonomic nervous system).

This study therefore fulfilled the criteria for a positive control study according to the test guidelines. The interobserver reliability was demonstrated.

Confidential

wm0791

STUDY TITLE

Report

Carbaryl – Positive control study for neurotoxicity
Single intraperitoneal administration to Wistar rats

DATA REQUIREMENT

EPA-FIFRA Neurotoxicity Screening Battery

AUTHOR

Dr. W. Mellert (Study Director)

STUDY COMPLETED ON

August 09, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0378/94077

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Carbaryl was administered to groups of 2 male and 2 female Wistar rats as a single intraperitoneal administration.

According to the protocol, dose levels of 0; 10, and 30 mg/kg body weight were intended. After reviewing the raw data it became obvious, that 15 mg/kg body weight instead of 30 mg/kg were administered. However, as the expected abnormal clinical signs were detected, this did not affect the validity of this positive control study. Due to technical reasons, in the tables still the intended dose level of 30 mg/kg body weight is given.

The vehicle was a 0.9% NaCl solution with 2% Cremophor EL®, and the administration volume was 5 ml/kg body weight. A Functional Observational Battery (FOB) was performed starting about 20 minutes after administration of the test substance to the latest animal.

All observers participating the study detected treatment-related abnormal clinical signs such as abdominal position, tremors, frequent chewing (indicative for beginning of slight salivation), impairment of gait, changes in behaviour during handling, and reduced rearing. These findings are typical for the mode of action of Carbaryl (effects on the autonomic nervous system).

This study therefore fulfilled the criteria for a positive control study according to the test guidelines. The interobserver reliability was demonstrated.

STUDY TITLE

Report

Acrylamide – Positive control study for neurotoxicity
Repeated oral administration by gavage

DATA REQUIREMENT

EPA-TSCA: § 798.6050
EPA-FIFRA Neurotoxicity Screening Battery

AUTHORS

Dr. W. Mellert (Study Director)
Dr. W. Kaufmann
Dr. B. van Ravenzwaay

STUDY COMPLETED ON

August 13, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0259/89112

VOLUME I OF II

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties requires the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Acrylamide was administered by gavage as an aqueous solution to groups of 10 male and 10 female Wistar rats at doses of 0 and 40 mg/kg body weight for 2 weeks (11 administrations). Body weight was determined once during the acclimatization period, at the start of the administration period (day 0), and on days 7 and 14. A check for dead or moribund animals was made usually twice a day (Mondays to Fridays) and once a day (Saturdays, Sundays and on public holidays). Before and after each test substance administration the animals were checked for clinical signs. Functional observational batteries were conducted before the start of the administration period and on days 1, 7 and 14. Motor activity measurements were conducted before the start of the administration period and on days 0, 1, 7 and 14. At the end of the administration period 5 animals per sex and test group were fixed by in situ perfusion and subjected to neuropathological examinations.

The following substance-related findings were obtained:

General clinical examinations:

- decreased body weight in males on day 14
- decreased body weight change in males on day 7 and 14
- slight to severe ataxia, splay of the toes of the hindlimbs and/or splay of hindlimbs in both sexes

Functional observational batteries:

- slight to severe ataxia, splay of the toes of the hindlimbs and/or broad stepping gait in both sexes
- decreased activity and reduced tail pinch reaction (one male, only)
- decreased grip strength of fore- und hindlimbs in both sexes
- increased reaction time in the hot-plate test in males
- increased values of the landing foot splay test in both sexes

Pathology:

Brain weight:
- statistically significantly decrease of absolute weights in males (6.5%)
- tendency of decrease of absolute weights in females (6.2%)

Cerebellar cortex:
- selective Purkinje cell necrosis
- vacuolation of molecular layer

Lumbar spinal ganglia:
- cytoplasmic remodeling in spinal ganglion cells which resembles chromatolysis

Peripheral nerves (sciatic, tibial, sural and plantar nerves):
- Wallerian-like axonal degeneration

Intramuscular nerves (gastrocnemic muscle):
- neurofilament accumulation in some nerve fibers

Neuromuscular junction (gastrocnemic muscle):
- neurofilament accumulation and decrease in or loss of synaptic vesicles
- swelling of synaptic terminals

Additionally, a single nerve cell in the midbrain (mesencephalic trigeminal nucleus region) of one treated male animal showed neuronal necrosis which is seen as probably compound-related.

In conclusion, typical acrylamide-type lesions were seen during clinical examinations, FOB and histopathology even after the relatively short duration of the study, demonstrating the sensitivity of the examination methods used.

STUDY TITLE

Report

Trimethyltinchloride

Positive control study for neurotoxicity in Wistar rats

DATA REQUIREMENT

EPA-FIFRA Neurotoxicity Screening Battery

AUTHORS

Dr. W. Mellert (Study Director)

STUDY COMPLETED ON

September 25, 2001

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99S0228/93025

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Trimethyltinchloride was administered to groups of 5 male Wistar rats as a single intraperitoneal administration at dose levels of 0; 6; 9 and 12 mg/kg body weight. The vehicle was a 0.9% NaCl solution and the administration volume was 10 ml/kg body weight. Functional Observational Batteries were performed daily on study days –1, 0, 1, 2, 5, 6, 7, 8, 9, 12, 13 and 14. Interobserver reliability was explicitly tested on day 5. Motor Activity measurements were performed on study days –1, 0, 1, 7 and 14. As 2 animals of the high dose group 3 died on study days 6 and 8, the remaining animals of this group were sacrificed prematurely by perfusion fixation on day 8.

Treatment-related and dose-dependent abnormal clinical signs were observed such as ataxia, tremors, convulsions, reduced grip strength, increased values in foot spread test, and increased values in motor activity (probably also related to tremors and convulsions of the animals).

Histopathology revealed several treatment-related neuropathological findings in the olfactory bulb (e.g. neuronal necrosis), the frontal and parietal lobe (e.g. hydrocephalus internus), in midbrain with cortex cerebri (e.g. neuronal necrosis), pons with cerebellar cortex, midcerebellum and medulla oblongata with cerebellar cortex (e.g. Purkinje cell necrosis), cervical and lumbar cord (e.g. chromatolysis of alpha-motor neurons), cervical ganglia (e.g. axonal degeneration), lumbar ganglia (e.g. vacuolar degeneration), and peripheral nerves (e.g. axonal degeneration).

These findings are typical for the mode of action of Trimethyltinchloride. This study therefore fulfilled the criteria for a positive control study according to the test guidelines. The interobserver reliability was demonstrated.

klu088

STUDY TITLE

Report

ACRYLAMIDE – Positive control study for neurotoxicity
Repeated oral administration by gavage

DATA REQUIREMENT

U.S. EPA OPPTS 870.6200

AUTHORS

Dr. W. Mellert (Study Director)
Dr. W. Kaufmann
Dr. B. van Ravenzwaay

STUDY COMPLETED ON

April 02, 2002

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99C0803/00066

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

VOLUME I OF III
(REPORT SECTION AND SUMMARY TABLES)

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority.

1. SUMMARY

Acrylamide was administered to groups of 10 male and 10 female Wistar rats by gavage at dose levels of 0 (vehicle control), 10, 20 and 30 mg/kg body weight/day [mg/kg bw/d]. The vehicle used was aqua bidest. and the administration volume was 10 ml/kg body weight. Due to severe clinical symptoms and mortality at 30 mg/kg bw/d, all remaining animals of this group were sacrificed prematurely after about 3 weeks of treatment. The other groups were treated for 4 weeks.

Body weight was determined weekly. The animals were examined for clinical signs of toxicity or mortality at least once a day. The animals were checked for clinical signs once a day. Functional observational batteries (FOBs) and motor activity measurements were conducted before the start of the administration period and on days 7, 14, 21 and 28. Five animals per sex and dose were fixed by in situ perfusion and subjected to neuropathological examinations. The remaining animals were sacrificed under CO_2-anesthesia without any further examinations.

The following substance-related findings were obtained:

30 mg/kg body weight

- 3 males and 2 females died prematurely
- decreased body weights and body weight change in males and females
- abnormal clinical signs, e.g., impairment of gait, retarded righting response, abdominal position, splay of hindlimbs, anogenital region smeared with urine and/or piloerection in both sexes.
- decreased rearing in males and females
- decreased grip strength of forelimbs in females
- decreased grip strength of hindlimbs in males and females
- increased values of foot splay in males and females
- decreased motor activity values (total movement distance and rearing) in males and females
- decreased brain weights in males (- 9 %) and females (- 8 %)

Cerebellum:

- Multiple Purkinje cell necrosis in the cerebellar cortex of males and females
- Vacuolations of the molecular layer in the cerebellar cortex of males and females

Cervical ganglia:

- Cytoplasmic remodeling of sensory ganglion cells in males and females

Lumbar ganglia:

- Cytoplasmic remodeling of sensory ganglion cells in males and females

Proximal sciatic nerve:

- Minimal to slight Wallerian – like axonal degeneration in males and females

Proximal tibial nerve:
- Minimal to moderate Wallerian – like axonal degeneration in males and females
- Fiber atrophy in males and females

Distal tibial nerve:
- Slight to severe Wallerian – like axonal degeneration in males and females
- Fiber atrophy in males and females

20 mg/kg body weight
- decreased body weight and body weight change in females
- abnormal clinical signs, e.g., slight to severe impairment of gait, retarded righting response, abdominal position, splay of hindlimbs, anogenital region smeared with urine and/or piloerection in both sexes.
- decreased rearing in males and females
- decreased grip strength of hindlimbs in males and females
- increased values of foot splay in males and females
- decreased motor activity values (total movement distance and rearing) in males and females

Cerebellum:
- Multiple Purkinje cell necrosis in the cerebellar cortex of males and females
- Vacuolations of the molecular layer in the cerebellar cortex of males and females

Cervical ganglia:
- Cytoplasmic remodeling of sensory ganglion cells in males and females

Lumbar ganglia:
- Cytoplasmic remodeling of sensory ganglion cells in males and females

Proximal sciatic nerve:
- Minimal Wallerian – like axonal degeneration in males
- Minimal to slight Wallerian – like axonal degeneration in females

Proximal tibial nerve:
- Minimal to moderate Wallerian – like axonal degeneration in males and females
- Fiber atrophy in males and females

Distal tibial nerve:
- Slight and moderate Wallerian – like axonal degeneration in males
- Slight to severe Wallerian – like axonal degeneration in females
- Fiber atrophy in males and females

10 mg/kg body weight

- decreased body weight change in females
- decreased rearing in females
- increased values of foot splay in males and females

Cerebellum:

- Single nerve cell necrosis in the granular layer of the cerebellar cortex in one female

Lumbar ganglia:

- Cytoplasmic remodeling of sensory ganglion cells in males and females

In conclusion, typical acrylamide-type lesions were seen dose-dependently during FOB, Motor activity measurement, and histopathology. This study fulfills therefore the criteria of a positive control study for neurotoxicity.

sge0149

STUDY TITLE

Report

Carbaryl (1-Naphthylmethylcarbamat) – Positive control study for neurotoxicity
Single oral administration

DATA REQUIREMENT

OPPTS 870.6200 Neurotoxicity Screening Battery
U.S.EPA Health Effects Test Guidelines

AUTHOR

Dr. U. Kaspers (Study Director)

STUDY COMPLETED ON

September 12, 2002

PERFORMING LABORATORY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

LABORATORY PROJECT IDENTIFICATION

Project No.: 99S0378/94078

SPONSOR

BASF Aktiengesellschaft
67056 Ludwigshafen/Rhein, Germany

This document contains manufacturing and trade secrets of BASF. It is the property of BASF and may be used only for that purpose for which it was intended by BASF. Every other or additional use, exploitation, reproduction, publication or submission to other parties require the written permission of BASF, with the exception of regulatory agencies acting within the limits of their administrative authority

1. SUMMARY

Carbaryl (1-Naphthylmethylcarbamat) was administered to groups of 10 male Wistar rats as a single oral administration at dose levels of 0 and 200 mg/kg body weight. The vehicle was doubly distilled water with 2% Cremophor EL®, and the administration volume was 5 ml/kg body weight. Functional Observational Batteries were performed, starting each time 1 hour after administration of the test substance to the last animal.

For technical reasons, the dose groups were split into each 5 animals per examination.

All observers participating the present study detected treatment-related abnormal clinical signs like tremor, salivation, lacrimation, impairment of gait, etc. These effects on the autonomic nervous system are typical findings for the mode of action of Carbaryl (1-Naphthylmethylcarbamat). Moreover, the interobserver reliability was demonstrated.

Therefore, according to the test guidelines this study fulfilled the criteria for a positive control study.

ra0327e

TRANSLATION

PROTOCOL

Omethoate

Acute neurotoxicity study in Wistar rats;
single administration by gavage

TEST GUIDELINES

OPPTS 870.6200
OECD 424

TEST FACILITY

Experimental Toxicology and Ecology
BASF Aktiengesellschaft
D-67056 Ludwigshafen/Rhein, Germany

PROJECT NUMBER:

20C0709/01098

SPONSOR:

Dimethoate Task Force (DTF)
c/o P. Hofmann
Wotanstr. 39
D-68305 Mannheim, Germany

LABORATORY INTERNAL ABBREVIATION:

OME

1. ORGANIZATION

1.1. SIGNATURES

	Name	Signature / Date
Study Director:	Dr. Mellert	Signed: Oct. 2, 2002
Clinical Pathology:	Dr. Deckardt	Signed: Sep. 26, 2002
Pathology:	Dr. Kaufmann	Signed: Sep. 26, 2002
Quality Assurance:	Mr. Hajok	Signed: Oct. 7, 2002
Management:	Dr. van Ravenzwaay	Signed: Oct. 7, 2002

Sponsor:	Dimethoate Task Force (DTF) c/o P. Hofmann Wotanstr. 39 D-68305 Mannheim, Germany	Signed: Sep. 26, 2002
Study monitor:	SCC Scientific Consulting Company Chemisch-Wissenschaftliche Beratung GmbH Mikroforum Ring 1 D-55234 Wendelsheim, Germany Phone: +49 (0) 6734 919 0 Fax: +49 (0) 6734 919 191 Email: scc@scc-gmbh.de	

2. GENERAL INFORMATION

2.1. AIM OF THE STUDY

The aim of the study is to determine a possible neurotoxicity of the test substance after a single oral administration by gavage to Wistar rats. Moreover, the effects of cholinesterase in serum, erythrocytes and brain will be determined.

2.2. FIXING OF THE DOSES / CONCENTRATIONS

On request of the sponsor, dose levels of 0, 0.2, 0.25, 0.35 and 5 mg/kg body weight will be tested.

2.3. TEST GUIDELINES

- EPA Health Effects Test Guidelines; OPPTS 870.6200; Neurotoxicity Screening Battery
- OECD Guideline 424: Neurotoxicity study in rodents

2.4. GOOD LABORATORY PRACTICE

The study will be carried out in accordance with the OECD Principles of Good Laboratory Practice and the GLP provisions of the German Chemicals Act. The investigations described below will be carried out in accordance with the Standard Operating Procedures (SOPs) unless reasons for using a different procedure have been given and approved in the protocol or in amendments to the protocol. Unplanned deviations from the protocol will be documented immediately, communicated to the sponsor and have to be countersigned by the Study Director. All planned deviations from the protocol must be confirmed by the Sponsor beforehand and documented in an amendment to the protocol.

2.5. RETENTION OF RECORDS

All GLP-relevant documents and materials will be retained (15 years) at BASF Aktiengesellschaft at least for the period of time specified in the GLP regulations. Details on the responsibility and site of archiving can be seen from the specific SOPs or from the raw data. After expiration of the above indicated storage time period the sponsor must be consulted and in writing indicate the future of the stored raw data and material.

3. MATERIALS AND METHODS

3.1. TEST SUBSTANCE

Name of test substance:	Omethoate
GV/T test substance No.:	01/0709-1
CAS No.:	1113-02-6
IUPAC name:	O,O-Dimethyl-S-[2-(methylamino)-2-oxoethyl] phosphorothioate
Batch No.:	676-BSe-74B
Production date:	Unknown
Expiry date:	10/2004 (Cheminova certificate)
Physical state/ Appearance:	Liquid/ pale yellow, (Cheminova certificate)
Purity:	96.5% (Cheminova certificate)
Homogeneity:	Homogeneous on account of the high purity
Stability:	Until 10/2004 (Cheminova certificate)
Storage conditions:	Freezer (≤ -18°C), light protection
Precautions:	The usual safety precautions in handling chemicals must be observed. For preparation of test substance mixtures dust masks ≥ P2 must be worn; the test substance is a cholinesterase inhibitor.

The analyses of the test substance were carried out by Cheminova Agro A/S, Lemvig, Denmark.

3.2. ANIMALS

3.2.1. Selection of animals

Species:	Rat
Strain:	CrlGlxBrlHan:WI
Supplier:	Charles River Deutschland GmbH Sandhofer Weg 7 D-97633 Sulzfeld
Sex:	Males and females
Age when supplied:	32 – 37 days
Age at the beginning of the administration period:	49(±1) days
Reason for the selection:	The rat is a frequently used laboratory animal, and there is comprehensive experience with this animal species. Moreover, the rat has been proposed as a suitable animal species by the OECD and the EPA for this type of study. Wistar rats will be used as all positive control data were performed with this strain.
Randomization:	The male and female rats will be allocated randomly to the dose groups before the first neurofunction tests on the basis of their weight. The list of randomization instructions will be compiled with a computer. A deviation of 10% in the initial body weight between the groups is acceptable. For FOB and measurement of motor activity new randomization plans will be compiled.
Animal identification:	Ear tattoo as animal no.; the animals will be tattooed in a consecutive sequence when supplied before randomization.

3.2.2. Housing conditions

Animal facility:	Non-barrier animal house
Air conditions:	Temperature 20-24°C; humidity 30-70% Any deviations will be documented.
Number of air changes/hour:	10
Illumination period:	12 hours light from 6:00 to 18:00 hours; 12 hours darkness from 18:00 to 6:00 hours
Type of cage:	Wire cages, type DK-III, Becker & Co., Castrop-Rauxel, Germany For measurement of motor activity, Polycarbonate cages (floor area about 800 cm^2) supplied by EHRET, Emmendingen, Germany will be used
No. of animals per cage:	1
Bedding in the polycarbonate cages:	SSNIFF (type 3/4)
Type of diet:	Ground Kliba rat/mouse/hamster maintenance diet supplied by Provimi Kliba SA, Kaiseraugst (Switzerland), ad libitum
Watering:	Drinking water ad libitum
Acclimatization:	During the acclimatization period the animals will be accustomed to the environmental conditions of the study and to the diet. The acclimatization period has to last at least 5 days before the start of the study.

3.3. DOSE GROUPS

The dose groups are split into 3 subsets.

- Subset A: Animals for Cholinesterase determination before administration and on day 0 about 2.5h after administration.
- Subset B: Animals for Cholinesterase determination before administration and on day 15.
- Subset C: Animals for perfusion fixation

Males:

Dose group / Subset Color of the cage cards	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / A 0 / B 0 / C grey	0[2)]	10 10 5		1 – 10 11 – 20 21 – 25
1 / A 1 / B 1 / C grey with a blue dot	0.2	10 10 5		26 – 35 36 – 45 46 – 50
2 / A 2 / B 2 / C grey with a green dot	0.25	10 10 5		51 – 60 61 – 70 71 – 75
3 / A 3 / B 3 / C grey with a yellow dot	0.35	10 10 5		76 – 85 86 – 95 96 – 100
4 / A 4 / B 4 / C grey with a red dot	5	10 10 5		101 – 110 111 – 120 121 – 125

1) = To guarantee the impartiality of the investigator in the FOB, the animals that have already been ear tattooed will be allocated to the individual dose groups at randomization before the first neurofunction tests. The exact allocation of the animals to the dose groups can be seen from an amendment to the protocol.

2) = vehicle control: doubly distilled water

Females:

Dose group / Subset Color of the cage cards	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / A 0 / B 0 / C grey	0[2)]	10 10 5		126 – 135 136 – 145 146 – 150
1 / A 1 / B 1 / C grey with a blue dot	0.2	10 10 5		151 – 160 161 – 170 171 – 175
2 / A 2 / B 2 / C grey with a green dot	0.25	10 10 5		176 – 185 186 – 195 196 – 200
3 / A 3 / B 3 / C grey with a yellow dot	0.35	10 10 5		201 – 210 211 – 220 221 – 225
4 / A 4 / B 4 / C grey with a red dot	5	10 10 5		226 – 235 236 – 245 246 – 250

1) = To guarantee the impartiality of the investigator in the FOB, the animals that have already been ear tattooed will be allocated to the individual dose groups at randomization before the first neurofunction tests. The exact allocation of the animals to the dose groups can be seen from an amendment to the protocol.

2) = vehicle control: doubly distilled water

3.4. TEST SUBSTANCE PREPARATION AND ADMINISTRATION

Route of administration:	Oral administration by gavage using 3 or 5 ml syringes (Becton Dickinson & Co., U.S.A.)
Administration frequency:	Single administration
Form of preparation:	Solution
Carrier:	Doubly distilled water
Volume to be administered:	**5 ml/kg** body weight
Preparation:	Details on the technical procedure will be laid down in a description of the method and reported correspondingly.
Reason for the selection of the route of administration:	The oral administration of a substance has proved useful in numerous studies for discovering potential toxicological risks.

3.5. ANALYSIS

The analyses of the test substance preparations will be/were carried out at the laboratory Analytical Chemistry, Experimental Toxicology and Ecology of BASF Aktiengesellschaft.

3.5.1. Stability

The stability of the test substance in doubly distilled water over a period of 4 hours was verified before the start of the study.

3.5.2. Homogeneity/Concentration control analyses

A homogeneity analysis of the high and low dose and a concentration control analysis of the mid doses will be made at the start of the study. The homogeneity analyses served also as concentration control.

3.5.3. Methods of analysis

Details on the methods used have been/will be fixed by the analytical laboratory.

3.5.4. Feed analysis

The feed used in the study will be assayed for chemical and microbial contaminants. Fed. Reg. Vol. 44, No. 91 of May. 09, 1979, p 27354 (EPA), will serve as the guideline for maximum tolerable contaminants. According to recommendations of the GV-SOLAS, the total amount of bacteria must not exceed 10^5 per g feed.
A certificate of analysis translated to English will be added to the report.

3.5.5. Drinking water analysis

The drinking water is regularly assayed for chemical contaminants both by the municipal authorities of Frankenthal and by the Power Plant & Water Chemistry Department of BASF Aktiengesellschaft as well as for bacteria by a contract laboratory. The German Drinking Water Regulation of Dec. 05, 1990 will serve as the guideline for maximum tolerable contaminants.
A certificate of analysis translated to English will be added to the report.

3.5.6. Bedding analysis

The bedding is regularly assayed for contaminants (chlorinated hydrocarbons and heavy metals). The values given in Lab Animal, Nov.–Dec. 1979, pp 24–33, will serve as the guideline for maximum tolerable contaminants. A certificate of analysis translated to English will be added to the report.

3.6. TIME SCHEDULE

Due to the high number of animals, subset C first started after termination of subsets A and B and subset B is divided in 2 parts per sex (first 5 animals and second 5 animals per sex and dose).

Subset A (males)	Subset A (females)	Phase of study / examination	Day of study
Oct., 08, 2002	Oct., 08, 2002	Experimental starting date: arrival of the animals and start of acclimatization period. Age of the animals: 35(±1) days 34(±1) days	-14 -15
Oct., 16, 2002	Oct., 17, 2002	Blood sampling	-6
Oct., 22, 2002	Oct., 23, 2002	Test substance administration, **blood sampling and necropsy[1] about 2.5h after administration**	0

1 = Before necropsy no fasting period

Subset B (males, part 1)	Subset B (females, part 1)	Subset B (males, part 2)	Subset B (females, part 2)	Phase of study / examination	Day of study
Oct., 08, 2002	Oct., 08, 2002	Oct., 08, 2002	Oct., 08, 2002	Arrival of the animals and beginning of the experimental phase: Age of the animals: 36(±1) days 35(±1) days 34(±1) days 33(±1) days	 -13 -14 -15 -16
Oct., 14, 2002	Oct., 15, 2002	Oct., 16, 2002	Oct., 17, 2002	FOB1; M1/M2 FOB2; M3/M4 FOB3; M5/M6 FOB4; M7/M8	-7
Oct., 18, 2002	Oct., 18, 2002	Oct., 18, 2002	Oct., 18, 2002	Blood sampling	-3 -4 -5 -6
Oct., 21, 2002	Oct., 22, 2002	Oct., 23, 2002	Oct., 24, 2002	Test substance administration	0
Oct., 21, 2002	Oct., 22, 2002	Oct., 23, 2002	Oct., 24, 2002	FOB5; M9/M10 FOB6; M11/M12 FOB7; M13/M14 FOB8; M15/M16	0
Oct., 28, 2002	Oct., 29, 2002	Oct., 30, 2002	Oct., 31, 2002	FOB9; M17/M18 FOB10; M19/M20 FOB11; M21/M22 FOB12; M23/M24	7
Nov. 04, 2002	Nov. 05, 2002	Nov. 06, 2002	Nov. 07, 2002	FOB13; M25/M26 FOB14; M27/M28 FOB15; M29/M30 FOB16; M31/M32	14
Nov. 05, 2002	Nov. 06, 2002	Nov. 07, 2002	Nov. 08, 2002	Blood sampling and necropsy[1]	15

1 = Before necropsy no fasting period
FOB = Functional observational battery
M = Measurement of motor activity
1 ... 32 = Identification No. of the specific examination

Subset C (males)	Subset C (females)	Phase of study / examination	Study day
Nov. 12, 2002	Nov. 12, 2002	Arrival of the animals Age of the animals: 35(±1) days 34(±1) days	 -14 –15
Nov. 19, 2002	Nov. 20, 2002	FOB17; M33 FOB18; M34	-7
Nov. 26, 2002	Nov. 27, 2002	Test substance administration	0
Nov. 26, 2002	Nov. 27, 2002	FOB19; M35 FOB20; M36	0
Dec. 03, 2002	Dec. 04, 2002	FOB21; M37 FOB22; M38	7
Dec. 10, 2002	Dec. 11, 2002	FOB23; M39 FOB24; M40	14
Dec. 11, 2002	Dec. 12, 2002	Perfusion fixation[1]	15
Dec. 2002 – April 2003		Evaluation and reporting	
April 2003		Expected end of the experimental phase of the study; draft report to QAU	
May 2003		Final report	

1 = Before necropsy no fasting period

FOB = Functional observational battery
M = Measurement of motor activity
17... 40 = Identification No. Of the specific examination

3.7. CLINICAL EXAMINATIONS

3.7.1. Mortality

A check for moribund and dead animals will be made twice daily from Mondays to Fridays and once daily on Saturdays, Sundays and public holidays.

3.7.2. Clinical signs

Each animals will be checked daily for any clinically abnormal signs. Abnormalities and changes will be documented for each animal.

3.7.3. Functional observational battery (FOB)

The FOB will be carried out in all animals of **subsets B and C** on days –7, 0 (**about 2 hours after administration**), 7 and 14. The examinations will generally start at about 10:00 hours.

The examinations will be carried out by specially trained staff who have carried out positive control studies as part of their training. The findings that are observed will, as far as possible, be graded according to their intensity on the basis of an index of findings or will be described in detail.

In order to guarantee the blind status of the observer, the cages are randomly distributed in the racks at least 30 minutes before the examinations, and the cage labels (indicating the dose group) are turned. Thus only the animal number, but not the allocation of the animals to the different dose groups can be identified by the observer. Moreover, the examinations are carried out in randomized order. The findings and values obtained are documented by another technician knowing the identification of the animals.

3.7.3.1. Home cage observation

The animals are observed in their closed home cages (for about 10 – 30s); any disturbing activities (touching the cage or rack, noise) will be avoided during these examinations in order not to influence the behavior of the animals. Besides all other overt abnormal findings, special attention will be paid to:

1. posture
2. tremor
3. convulsions
4. abnormal movements
5. impairment of gait

3.7.3.2. Open field observation

The animals are transferred to a standard arena (50 x 50 cm with sides of 25 cm high) and observed for at least 2 minutes. Following parameters will be examined:

1. behavior when removed from cage
2. fur
3. skin
4. salivation
5. nose discharge
6. lacrimation
7. eyes/pupil size
8. posture
9. palpebral closure
10. respiration
11. tremors
12. convulsions
13. abnormal movements/stereotypies
14. impairment of gait
15. activity/arousal level
16. feces (number of fecal pellets/appearance/consistency) within two minutes
17. urine (volume/color) within two minutes
18. number of rearings within two minutes

3.7.3.3. Sensory-motor tests / Reflex tests

The animals are removed from the open field and subjected to following sensory-motor or reflex tests:

1. approach response
2. touch response
3. vision (visual placing response)
4. pupillary reflex
5. pinna reflex
6. audition (startle response)
7. coordination of movements (righting response)
8. behavior during handling
9. vocalization
10. pain perception (tail pinch)
11. grip strength of forelimbs
12. grip strength of hindlimbs
13. landing foot-splay test

3.7.4. Measurement of motor activity (MA)

MA measurement will be carried out in all animals of **subsets B and C** on days –7, 0, 7 and 14 immediately after the FOB. MA will be measured using the Multi-Varimex system supplied by Columbus Instruments Int. Corp., Ohio, U.S.A. For this purpose, the animals will be placed in polycarbonate cages for the time of measurement. 4 beams will be allocated per cage (placed on the longer side of the cage at a height of about 5 cm and at equal distances of about 10 cm). The number of beam interrupts will be counted over 12 intervals for 5 minutes. The sequence at which the animals are placed in the polycarbonate cages will be selected at random. On account of the measuring variant "staggered", the starting time will vary by the time which is needed to place the animals in the cages. For each animal, measurement will start individually when the 1st beam is interrupted and will end exactly 1 hour later. The animals will be given no feed or water during the measurements. Measurement will be carried out in the dark.

3.7.5. Food consumption

Check should be done at least at the time feed exchanges takes place.

3.7.6. Drinking water consumption

Daily visual check within the general observation.

3.7.7. Body weight

Once weekly and additionally on the FOB days for the relevant animals; body weight gain as compared with day 0 will be calculated as body weight change.

3.7.8. Statistics of clinical examinations

Means and standard deviations will be calculated. In addition, the following statistical analyses will be carried out:

Parameter	Statistical test
Body weights, body weight change, food consumption	DUNNETT
Feces, rearing, grip strength forelimbs, grip strength hind´-limbs, landing foot-splay test, motor activity	KRUSKAL-WALLIS and WILCOXON

3.8. CLINICAL PATHOLOGY (SUBSETS A AND B)

Blood samples will be taken from non fasted animals by puncturing the retroorbital venous plexus before start of treatment and before necropsy. **Blood sampling and necropsy of the animals of subset A will be done about 2.5h after test substance administration**. The animals of Subset A will For blood sampling the animals will be anaesthetized using Isoflo® (Essex GmbH München, Germany) as anaesthesia. The samples were analyzed in a randomized sequence. The randomization list will be compiled with a computer. The following parameters will be examined in all animals:

3.8.1. Clinical pathology/chemistry

1. Hematocrit
2. Erythrocyte cholinesterase (modified Ellman method with DTNA)
3. Serum cholinesterase (Ellman method with DTNB)
4. Brain cholinesterase (Ellman method with DTNB), (sampling at necropsy)

Cholinesterase determination will be carried out according to the recommendations of the EPA 1996, and WHO 1998.

For determination of serum cholinesterase, blood samples will be collected in Serum Gel tubes without anticoagulant and transferred under ice cooling into the clinical-pathology laboratory. To separate the serum, the samples will be centrifuged for 2 minutes (3,000 x g, 4 °C). The serum cholinesterase activity will be determined within about 2 hours after blood sampling.

For determination of Erythrocyte cholinesterase 50 µl blood will be pipetted in 2.5 ml ice-cold isotonic sodium chloride and mixed immediately. Subsequently the samples will be transferred under ice cooling to the laboratory. The erythrocytes will be isolated by centrifugation (3,000 x g, 4 °C, 15 minutes). The supernatant will be discarded and the retained red blood cells will be lysated with Triton-buffer (0.1% Triton) for 1 hour under continuous ice cooling. The hemolysate will be analysed for cholinesterase activity within about 3 hours after blood sampling.

For determination of brain cholinesterase the left hemisphere of the brain will be sampled under ice cooling and stored at approximately -80 °C till analysis. After thawing the samples about 0.2 g cortex will be separated from the truncus cerebri and homogenised in Triton-buffer (0.75%) under ice cooling. After centrifugation (1,500 x g, 4 °C, 5 minutes) the cholinesterae activity and protein content will be measured in the supernatant at the same day. Cortex is chosen for brain cholinesterase determination on recommendaation of OPPTS as this region is rich in cholinergic neurons ("Science Policy on The Use of Data on Cholinesterase Inhibition for Risk Assessments of Organophosphorus and Carbamate Pesticides", Office of Pesticide Programs, US Environmental Protection Agency, Washington DC 20460, USA)

3.8.2. Statistics of clinical Pathology

Means and standard deviations will be calculated. In addition, the following statistical analyses will be carried out:

Parameter	Statistical test
Blood examinations and brain cholinesterase	KRUSKAL-WALLIS and WILCOXON test

3.9. PATHOLOGY (SUBSET C)

3.9.1. Neuropathology (subsets C)

The animals of subset C will be subjected to deep anesthesia (Narcoren®, about 4 ml/kg body weight) and sacrificed by perfusion fixation using a perfusion pump. SOERENSEN phosphate buffer will be used as a rinsing solution and a fixation solution according to KARNOVSKY will be used as a fixative (Karnovsky, 1965).

The animals fixed by perfusion will be necropsied with regard to the question of neuropathology, and the visible organs or organ sections will be assessed by gross pathology as accurately as is possible after a perfusion fixation.

3.9.1.1. Weight determinations

The following organ/tissue will be weighed after its removal but before each further preparation:

1. Brain (without olfactory bulb)

3.9.1.2. Organ/Tissue preservation list

In addition to the buffer storage or preservation of the organ specimens listed in 3.9.1.3. and 3.9.1.4., the following organs/tissues will be preserved in neutrally buffered 4% formaldehyde solution:

1. Brain (remaining material after trimming)
2. Spinal cord (sections from cervical and lumbar cords)
3. All gross lesions

The remaining animal body will be stored in neutrally buffered 4% formaldehyde solution.

3.9.1.3. Buffer storage, plastic embedding*, cutting and staining

The following organ specimens will be removed after perfusion and processed histotechnically according to the table below:

Organ specimens from:	Dose groups				
	0	1	2	3	4
Peripheral nervous system:	T5	P5	P5	P5	T5
• Spinal ganglia (3 from C3–C6)	T5	P5	P5	P5	T5
• Dorsal spinal root filaments (C3-C6)	T5	P5	P5	P5	T5
• Ventral spinal root filaments (C3-C6)	T5	P5	P5	P5	T5
• Spinal ganglia (3 from lumbosacral region L1-L4)	T5	P5	P5	P5	T5
• Dorsal spinal root filaments (L1-L4)	T5	P5	P5	P5	T5
• Ventral spinal root filaments (L1-L4)	T5	P5	P5	P5	T5
• Proximal sciatic nerve	T5	P5	P5	P5	T5
• Tibial nerve (on the knee)	T5	P5	P5	P5	T5
• Tibial nerve (nerve branches in the tibia)	T5	P5	P5	P5	T5

METHODS:

P = Storage in buffer solution

T = Plastic embedding and preparation of stained semithin sections

SCOPE OF EXAMINATIONS:

5 = All animals from the group fixed by perfusion

The semithin sections will be examined by light microscopy and assessed. Further examinations will depend on the results of the study obtained, especially on the presence of neurofunctional disorders or neuropathological changes.

* Epoxide embedding

3.9.1.4. Specimen preservation, Paraplast embedding, cutting and staining

Organ specimens from:	Dose groups				
	0	1	2	3	4
Central nervous system:					
Brain (cross sections):		F5*	F5*	F5*	
• Prosencephalon with frontal lobe	A5				A5
• Diencephalon with parietal lobe and hippocampus	A5				A5
• Mesencephalon with occipital lobe and temporal lobe	A5				A5
• Pons	A5				A5
• Cerebellum	A5				A5
• Medulla oblongata	A5				A5
• Eyes with retina and optic nerve	A5	F5	F5	F5	A5
Spinal cord (cross and longitudinal sections):					
• Cervical cord (C3–C6, cross section in the region of the largest diameter)	A5	F5	F5	F5	A5
• Lumbar cord (L1–L4, cross section in the region of the largest diameter)	A5	F5	F5	F5	A5
Peripheral nervous system:					
• G. trigeminale with part of nerve (both ganglia)	A5	F5	F5	F5	A5
• M. gastrocnemius (longitudinal and cross sections)	A5	F5	F5	F5	A5
All gross lesions	A2	A2	A2	A2	A2

METHODS:

F = Preservation in buffered 4% formaldehyde solution

F* = Preservation in toto

A = Paraplast embedding, cutting and staining with hematoxylin-eosin (HE)

SCOPE OF EXAMINATIONS:

5 = All animals fixed by perfusion per group and sex

2 = All animals affected from the group fixed by perfusion

The HE-stained Paraplast sections will be examined by light microscopy and assessed.

Further examinations (e.g. special stains) will depend on the results of the study obtained, especially on the presence of neurofunctional disorders or neuropathological changes.

3.9.1.5. Procedure in the case of neuropathological findings

In the case of neuropathological findings, the affected localizations will be processed histotechnically, examined by light microscopy and assessed in the other dose groups. All localizations with neuropathological findings will be coded and examined again by light microscopy without knowing the animal No. or the dose group. The frequency and severity of neuropathological alterations will be assessed. The presence of a dose-response relationship will be investigated in particular. A photodocumentation of representative, treatment-related neuropathological alterations will be compiled.

3.9.2. Pathology (subsets A and B)

The animals will be sacrificed by decapitation under Isoflo® (Essex GmbH München, Germany) anaesthesia. The brain will be removed for determination of brain cholesterase. No further examinations are performed.

3.9.3. Statistics of pathology

Means and standard deviations will be calculated. In addition, the following statistical analyses will be carried out:

Parameter	Statistical test
Brain weight	KRUSKAL-WALLIS and WILCOXON

3.9.4. References

Karnovsky, M.J. (1965): A formaldehyde – glutaraldehyde fixative of high osmolality for use in electron microscopy. J. Cell Biol. 27, 137A

BASF Aktiengesellschaft
Produktsicherheit
Chemikalienrecht, Toxikologie und Ökologie

BASF

TRANSLATION

Project number

ra0334a

20C0709/01098

Omethoate; Acute neurotoxicity study in Wistar rats; single administration by gavage

Amendment No. 1 to the study protocol

Pt 3.3. DOSE GROUPS

As mentioned in the protocol, following the exact allocation of the animals to the dose groups of subsets A and B. The allocation of subset C will be given in an addition amendment.

Signed: Dr. Mellert, Oct. 11, 2002

Male animals

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / A	0 (control)	10	23	1
			46	2
			17	3
			45	4
			19	5
			51	6
			7	7
			33	8
			14	9
			32	10
0 / B		10	75	11
			65	12
			70	13
			68	14
			69	15
			102	16
			105	17
			86	18
			93	19
			97	20
1 / A	0,2	10	3	26
			35	27
			1	28
			5	29
			30	30
			37	31
			25	32
			42	33
			15	34
			41	35
1 / B		10	53	36
			60	37
			63	38
			79	39
			59	40
			95	41
			100	42
			84	43
			101	44
			88	45

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
2 / A	0,25	10	43	51
			22	52
			2	53
			48	54
			34	55
			38	56
			52	57
			29	58
			36	59
			44	60
2 / B		10	77	61
			78	62
			55	63
			62	64
			76	65
			81	66
			99	67
			94	68
			90	69
			96	70
3 / A	0,35	10	10	76
			4	77
			8	78
			16	79
			50	80
			47	81
			28	82
			24	83
			11	84
			18	85
3 / B		10	73	86
			57	87
			72	88
			56	89
			74	90
			85	91
			103	92
			83	93
			91	94
			106	95

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
4 / A	5	10	21	101
			31	102
			12	103
			49	104
			40	105
			13	106
			26	107
			9	108
			20	109
			27	110
4 / B		10	66	111
			64	112
			54	113
			71	114
			58	115
			92	116
			104	117
			87	118
			98	119
			82	120

Female animals

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / A	0 (control)	10	144	126
			110	127
			128	128
			109	129
			157	130
			152	131
			129	132
			126	133
			120	134
			125	135
0 / B		10	181	136
			180	137
			173	138
			162	139
			184	140
			211	141
			201	142
			194	143
			198	144
			202	145
1 / A	0,2	10	143	151
			150	152
			108	153
			145	154
			131	155
			149	156
			118	157
			136	158
			130	159
			116	160
1 / B		10	167	161
			161	162
			170	163
			175	164
			185	165
			193	166
			186	167
			212	168
			209	169
			188	170

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
2 / A	0,25	10	111	176
			141	177
			140	178
			142	179
			155	180
			153	181
			114	182
			148	183
			113	184
			122	185
2 / B		10	168	186
			159	187
			160	188
			183	189
			177	190
			210	191
			195	192
			196	193
			200	194
			197	195
3 / A	0,35	10	138	201
			115	202
			146	203
			119	204
			134	205
			156	206
			137	207
			154	208
			112	209
			151	210
3 / B		10	163	211
			176	212
			174	213
			179	214
			171	215
			204	216
			203	217
			192	218
			191	219
			190	220

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
4 / A	5	10	147	226
			107	227
			158	228
			123	229
			124	230
			133	231
			117	232
			139	233
			121	234
			132	235
4 / B		10	165	236
			164	237
			166	238
			178	239
			182	240
			207	241
			208	242
			187	243
			206	244
			205	245

BASF Aktiengesellschaft
Produktsicherheit
Chemikalienrecht, Toxikologie und Ökologie

BASF

TRANSLATION

Project number ra0334b

20C0709/01098

Omethoate; Acute neurotoxicity study in Wistar rats; single administration by gavage

Amendment No. 2 to the study protocol

Pt 3.3. DOSE GROUPS

As mentioned in the protocol, following the exact allocation of the animals to the dose groups of subset C will be given in an addition amendment.

Signed: Dr. Mellert, Nov. 15, 2002

Male animals

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / C	0 (Kontrolle)	5	239 222 226 228 238	21 22 23 24 25
1 / C	0,2	5	233 216 220 231 219	46 47 48 49 50
2 / C	0,25	5	215 237 218 213 224	71 72 73 74 75
3 / C	0,35	5	225 227 230 232 221	96 97 98 99 100
4 / C	5	5	229 236 235 217 214	121 122 123 124 125

Female animals

Dose group / Subset	Dose in mg/kg body weight	Number of animals	Animal No.[1)]	Cage No.
0 / C	0 (Kontrolle)	5	243 261 264 266 244	146 147 148 149 150
1 / C	0,2	5	241 242 246 245 257	171 172 173 174 175
2 / C	0,25	5	240 265 258 254 259	196 197 198 199 200
3 / C	0,35	5	263 248 255 260 250	221 222 223 224 225
4 / C	5	5	253 251 247 262 252	246 247 248 249 250

TRANSLATION

Project number ra0334c

20C0709/01098

Omethoate; Acute neurotoxicity study in Wistar rats; single administration by gavage

Amendment No. 3 to the study protocol

Pt 3.6. STUDY SCHEDULE

Due to technical reasons the Motor Activity measurements of **Subset C** will be divided in two single measurements on the respective day of the study.

Subset C (males)	**Subset C (females)**	**Phase of study / examination**	**Study day**
Nov. 19, 2002	Nov. 20, 2002	FOB17; M33/M34 FOB18; M35/M36	-7
Nov. 26, 2002	Nov. 27, 2002	Test substance administration	0
Nov. 26, 2002	Nov. 27, 2002	FOB19; M37/M38 FOB20; M39/M40	0
Dec. 03, 2002	Dec. 04, 2002	FOB21; M41/M42 FOB22; M43/M44	7
Dec. 10, 2002	Dec. 11, 2002	FOB23; M45/M46 FOB24; M47/M48	14

FOB = Functional observational battery
M = Measurement of motor activity
17... = Identification No. Of the specific examination
48

Signed: Dr. Mellert, Nov. 18, 2002

BASF Aktiengesellschaft
Produktsicherheit
Chemikalienrecht, Toxikologie und Ökologie

BASF

TRANSLATION

Project number ra0334d

20C0709/01098

Omethoate; Acute neurotoxicity study in Wistar rats; single administration by gavage

Amendment No. 4 to the study protocol

Pt 3.8.2. Statistics of clinical Pathology

In order to apply the statistical method preferably used by the sponsor, the Steel's test was taken for statistical analysis of the cholinesterase values instead of the Kruskal-Wallis test with Wilcoxon test.

Signed: Dr. Mellert, Dec. 1, 2003